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Preface to “Diet and Metabolic Dysfunction” 
The fundamental importance of diet in the pathophysiology of metabolic syndrome is well 
acknowledged and may be crucial in the determination of cardiovascular risk and the development of 
cardiovascular complications. The contributions presented here provide an updated systematic 
overview examining, in detail, the functional role of different diets and dietary components in 
maintaining glucose homeostasis and preventing long-term complications. The two books  
encompass 40 peer-reviewed articles, both in the basic research field (book 1) and in the clinical 
scenario (book 2), written by worldwide renowned experts. Intriguingly, one of the assets of the 
present books is in the melting pot of researchers involved in this project, literally working in all 
continents, with contributions from United States, Canada, Mexico, Argentina, Italy, Ireland, Spain, 
Sweden, Austria, Liechtenstein, Germany, Japan, Korea, China, Hong Kong, Taiwan, Malaysia,  
Saudi Arabia, South-Africa, Nigeria, and Australia. These books include both evidence-based original 
research and state-of-the-art reviews and meta-analyses of the scientific literature. There are articles 
investigating different dietary regimens and articles focusing on specific nutrients. In particular, 
studies on the following topics are presented: omega-3 fatty acids, barley, honey, capsaicin, 
magnesium, selenium, fructose, vanillic acid, glutamine, histidine, isoleucine and valine, quercetin, 
rutin, naringin, red ginseng, epigallocatechin gallate (a component of green tea), cudrania tricuspidata 
fruits, aloe vera, and probiotics and prebiotics. This collection of papers shows that the selection of 
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Abstract: Calorie restriction (CR) via manipulating dietary carbohydrates has attracted increasing
interest in the prevention and treatment of metabolic syndrome. There is little consensus about
the extent of carbohydrate restriction to elicit optimal results in controlling metabolic parameters.
Our study will identify a better carbohydrate-restricted diet using rat models. Rats were fed with
one of the following diets for 12 weeks: Control diet, 80% energy (34% carbohydrate-reduced)
and 60% energy (68% carbohydrate-reduced) of the control diet. Changes in metabolic parameters
and expressions of adiponectin and peroxisome proliferator activator receptor γ (PPARγ) were
identified. Compared to the control diet, 68% carbohydrate-reduced diet led to a decrease in
serum triglyceride and increases inlow density lipoprotein-cholesterol (LDL-C), high density
lipoprotein-cholesterol (HDL-C) and total cholesterol; a 34% carbohydrate-reduced diet resulted in a
decrease in triglycerides and an increase in HDL-cholesterol, no changes however, were shown in
LDL-cholesterol and total cholesterol; reductions in HOMA-IR were observed in both CR groups.
Gene expressions of adiponectin and PPARγ in adipose tissues were found proportionally elevated
with an increased degree of energy restriction. Our study for the first time ever identified that a
moderate-carbohydrate restricted diet is not only effective in raising gene expressions of adiponectin
and PPARγ which potentially lead to better metabolic conditions but is better at improving lipid
profiles than a low-carbohydrate diet in rats.
Keywords: dietary intervention; metabolic syndrome; adiponectin; peroxisome proliferator activator
receptor γ; dietary carbohydrate restriction; rats
1. Introduction
Metabolic syndrome (MetS) is a collection of medical conditions that can lead to obesity, diabetes,
cardiovascular disease and hypertension. The prevalence of MetS is on a rapid rise due to the shifted
paradigm of diet and lifestyle and thus has afflicted many people worldwide. It is well known that
calorie restriction (CR) improves some markers of MetS [1–3], such as blood pressure, blood glucose
and plasma cholesterol, as demonstrated in a number of animal models, and humans [3,4].
Besides functioning as primary energy storage reservoirs, adipose tissue also acts as an endocrine
organ secreting numerous protein hormones into the circulation [5]. It was reported that a reduction in
White Adipose Tissue (WAT) via CR is likely to change the levels of its secreted hormones. Among
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all the WAT depots, Visceral Adipose Tissue (VAT) is closely related in particular to MetS and thus
is a pathogenic fat depot [6]. The VAT compartment secretes adipokines and cytokines that are
predisposed to the development of metabolic traits [7]. Adiponectin is an adipokine and mainly
expressed in adipose tissues. Adiponectin has been shown as an insulin-sensitive hormone that
participates in the regulation of glucose and lipid metabolism. It was found that adiponectin levels
rise during CR [8].
Several elements are capable of modulating adiponectin gene expression, most notably peroxisome
proliferator activator receptor γ (PPAR-γ) [9], which is expressed in adipose tissues. A response element
of PPARγ was discovered on the promoter of adiponectin gene [10]. Treatment with PPARγ agonists
induced adiponectin synthesis during adiponeogenesis [11–13]. PPARγ can also be upregulated by CR
through its antioxidative action [14,15].
The beneficial effect of CR on prevention and treatment of MetS has been widely recognized.
The optimal CR diet, however, remains to be identified. Among all the CR diets, CR via manipulating
dietary carbohydrate content has attracted increasing interest due to its effectiveness on weight loss,
glycemic control, insulin sensitivity and the management of cardiovascular risk factors [16]. However,
there is little consensus about the extent of dietary carbohydrate restriction to elicit the optimal result
in controlling metabolic parameters. In the present study, 12-week CR by varying dietary carbohydrate
content (80% or 60% energy (34% or 68% carbohydrate reduction) of the control diet) was employed
in Wistar rats to investigate the changes in metabolic parameters and expressions of adiponectin and
PPARγ. The results of the study will provide a new perspective and new scientific evidence for the
prevention and treatment of MetS.
2. Experimental Section
2.1. Animals and Diets
Thirty-six male Wistar rats (two months old, body weight 240–260 g) were obtained from a local
supplier for laboratory animals (Laboratory Animal Center of Hubei Province; Wuhan, China). Rats
were housed individually under laboratory conditions (12 h day and night lighting cycle, 22 ◦C ± 2 ◦C,
50% ± 10% humidity). All experimental protocols were reviewed and approved by Tongji Medical
College Council of Animal Care Committee. Rats were randomly assigned into three different groups,
ad libitum group (AL group; n = 12), calorie restriction group 1 (CR1 group; n = 12) and calorie
restriction group 2 (CR2 group; n = 12). All rats had ad libitum access to drinking water.
Rat chow diets were prepared based on the Association of Official Analytical Chemists (AOAC)
and AIN-93G formulas to meet the nutrient and energy requirements for the growth and development
of rats [17]. Rats were fed with these diets for 12 weeks. AL group had ad libitum access to the feed
whereas CR1 and CR2 group were maintained on a CR regimen with daily access to 80% and 60%
of the calorie intake of AL group, respectively (Table 1). Starch was the only nutrient reduced from
diets to achieve calorie restriction for CR1 and CR2 groups whereas the amount of other nutrients
provided were at the same level as those in the AL group to ensure sufficient nutrients were provided to
maintain normal growth of rats. As starch constitutes 58.5% (w/w) of the control diet, 80% and 60% CR
correspond to 34% and 68% carbohydrate reduction in CR1 and CR2 group, respectively. The amount
of feed consumed by each rat was recorded daily and body weights of rats were monitored weekly.
At the end of the 12-week study, rats fasted for 10 h overnight and blood samples were collected.
Rats were then sacrificed by decapitation. Serum samples were obtained from all blood samples
promptly after blood collection and stored at −80 ◦C. The peri-epididymal and perirenal adipose
tissues were obtained, weighed and frozen immediately in liquid nitrogen prior to storage at −80 ◦C.
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Table 1. Composition of rat chow diet *.
Components
AL Group CR1 Group a CR2 Group b
g/kg Diet % Energy g/0.8 kg Diet % Energy g/0.6 kg Diet % Energy
Casein 200.0 20.2 200.0 25.2 200.0 33.8
Vitamin mix ** 10.0 - 10.0 - 10.0 -
Mineral mix ** 35.0 - 35.0 - 35.0 -
Sucrose 50.0 5.0 50.0 6.3 50.0 8.4
Corn starch 585.0 58.9 385.0 48.6 185.0 31.2
Fiber 50.0 - 50.0 - 50.0 -
Lipid 70.0 15.9 70.0 19.9 70.0 26.6
Total amount (g) 1000.0 100.0 800.0 100.0 600.0 100.0
Total Calorie/kg diet (Kcal) 3970.0 3170.0 2370.0
Energy ratio (%)
Protein/Total 20 25 34
Carbohydrate/Total 64 55 40
Lipid/Total 16 20 26
* Abbreviations: AL: ad libitum; CR: calorie restriction; ** The composition of vitamin and mineral mix can be
referred to AIN-93G; a CR1 group was provided with 80% of ad libitum intake based on AL group; b CR2 group
was provided with 60% of ad libitum intake based on AL group.
2.2. Biochemical Measurements
Commercial ELISA kit (R & D Systems, Minneapolis, MN, USA) was used to measure serum
adiponectin at the baseline and at the end of the study. Fasting blood glucose, fasting serum insulin,
serum total cholesterol, fasting triglyceride and serum high density lipoprotein cholesterol (HDL-C)
were determined by enzymatic colorimetric analysis using commercialized kits purchased from
BioSino Bio-technology and Science Inc., Beijing, China. All the measurements were performed
using an automatic enzymatic analyser (BioTek SpectraMax M2, Winooski, VT, USA). Triglyceride
level was measured using glycerol-3-phosphate oxidase-p-aminophenazone (GPO-PAP) method.
Total cholesterol was determined using cholesterol oxidase-p-aminophenazone (CHOD-PAP) method.
After precipitation of very-low-density lipoprotein (VLDL) and low-density lipoprotein cholesterol
(LDL-C), HDL-C was measured, as well. Serum LDL-C were then obtained based on Friedewald
equation, in which, LDL-C = Total Cholesterol − (Triglyceride/5 + HDL-C) [18]. Blood glucose level
was determined by glucose oxidase method. Insulin level was determined with a commercialized
radioimmunoassay kit. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was
calculated based on the relationship between fasting plasma glucose and insulin: HOMA-IR = fasting
plasma glucose (mmol/L) × insulin (mIU/L)/22.5 [19].
2.3. Semiquantitative Reverse Transcriptase Polymerase Chain Reaction
Total RNA of the epididymal adipose tissue was extracted using Trizol reagent (Promega, Madison,
WI, USA). The concentration of RNA was determined using nucleic acid analyser (Eppendorf,
Germany). RNA (3 μg) was reverse transcribed in a 25 μL reaction system into complementary
DNA which was then amplified using polymerase chain reaction (PCR). The following primers were
used for PCR: 5′-TCCCTCCACCCAAGGAAACT-3′ (sense) and 5′-TTGCCAGTGCTGCCGTGATA-3′
(antisense) for adiponectin; 5′-CATCACTATCGGCAATGAGC-3′ (sense) and 5′-GACAGCACTG
TGTTGGCATA-3′ (antisense) for β-actin; 5′-TCCGTGATGGAAGACCACTC-3′ (sense) and
5′-CCCTTGCATCCTTCACAAGC-3′ for PPARγ. β-actin served as a loading control.
All PCR reactions contained 0.2 mmol/L dNTP (deoxyribonucleotide triphosphate), 1.5 μL
complementary DNA, 0.25 μmol/L of each primer, 1 × PCR buffer, and 0.8 μL Taq polymerase. The
following cycling profile was used for PCR reactions: 5 min of denaturation at 95 ◦C followed by
30 cycles with 1 min at 94 ◦C, 45 s at 58 ◦C and 1 min at 72 ◦C for adiponectin or 35 cycles with 1 min
at 94 ◦C, 40 s at 56 ◦C and 1 min at 72 ◦C for PPARγ or 35 cycles with 1 min at 94 ◦C, 45 s at 59 ◦C
and 1 min at 72 ◦C for β-actin and the final extension step of 10 min at 72 ◦C in a PCR Thermocycler
(Biometra, Göttingen, Germany).
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PCR products were subjected to electrophoresis in 1.5% agarose gels and the results were
analyszed by gel imaging and analysis system (Biometra, Göttingen, Germany). The expression
levels of adiponectin mRNA and PPARγ mRNA were shown using the absorbance ratio of target
mRNA and β-actin mRNA.
2.4. Statistical Analysis
All the data were analysed using one-way ANOVA followed by Least Significant Difference
(LSD)-test with SPSS version 12 software (SPSS Inc., Chicago, IL, USA). Transformation was applied
to correct for unequal variances. Pearson correlation coefficient was used to analyze the linear
relationship between adiponectin mRNA level and different parameters, i.e., body weight, blood
glucose, total cholesterol, triglyceride, HDL-C and insulin. Similar tests were applied to analyze the
linear relationship between PPARγ mRNA level and those parameters. In all tests, a value of p ≤ 0.05
was considered statistically significant.
3. Results
3.1. Calorie Intake and Body Weight
Average calorie intakes of all three groups demonstrated a similar decreasing trend over the
12-week feeding period due to decreased growth rates of rats with maturation (Figure 1). In good
agreement with the study design, the ratio of total calorie intake of AL, CR1 and CR2 groups during
the feeding period was calculated as 100:81:61.
Figure 1. Weekly average calorie intakes of three groups over the 12-week feeding period. Average
calorie intake of rats across all groups was shown to be higher at the beginning of the study when
rats were fast-growing and then slowly decreased to a plateau with decreasing growth rates of rats.
One-way ANOVA followed by LSD-test was used to detect significant differences of the means of the
body weights at the end of the study ** p < 0.001.
The effect of CR on body weights of rats was found to be significant (Figure 2). Compared to the
control group AL, growth rates of rats in CR1 and CR2 group were much slower. Our results indicated
that significant differences of body weights of rats among groups were detected in Week 4 (p < 0.05)
and the differences were greater towards the end of the study (p < 0.001).
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Figure 2. Change of body weights of rats from three groups over the 12-week feeding period. One-way
ANOVA followed by LSD-test was used to detect significant differences of the means of the body
weights at the end of the study ** p < 0.001.
3.2. Changes in Metabolic Parameters
Both 80% (CR1) and 60% (CR2) calorie-restricted diets led to a significant decrease in triglyceride
as compared to control diet (AL) (p < 0.05; Table 2). However, total cholesterol was found increased in
CR2 group (p < 0.05) whereas no change was observed in CR1 when compared to AL group (p > 0.05;
Table 2). Though HDL-C in CR1 and CR2 groups were higher than those in AL group (p < 0.05),
no significant differences were observed in the ratios of total cholesterol to HDL-C among all the
groups (p > 0.05). The effect of CR on LDL-C resembled that on total cholesterol which LDL-C increased
only in CR2 group (p < 0.05).














AL 1.55 ± 0.59 1.47 ± 0.40 0.69 ± 0.16 0.47±0.39 2.14 ± 0.53 5.54 ± 0.98 23.92 ± 8.76 5.59 ± 0.41
CR1 1.19 ± 0.32 a 1.58 ± 0.39 0.82 ± 0.19 a 0.52±0.47 1.95 ± 0.39 5.46 ± 0.67 16.02 ± 9.43 3.88 ± 0.63 a
CR2 0.92 ± 0.13 a 2.09 ± 0.71 a 0.92 ± 0.22 a 0.99±0.61 a 2.25 ± 0.36 5.97 ± 0.98 10.53 ± 7.59 a 2.79 ± 0.58 a,b
† Abbreviations: AL: ad libitum; CR: calorie restriction; HDL-C: high density lipoprotein cholesterol; LDL-C:
low density lipoprotein cholesterol; * Blood samples were collected at the end of the study; Data was presented
as arithmetic mean ± 1 SD (n = 12 for each group); # HOMA-IR (Homeostasis Model Assessment of Insulin
Resistance) = Fasting Blood Glucose (mmol/L) × Fasting Insulin (mIU/L)/22.5 [19]; a p < 0.05 versus AL group;
b p < 0.05 versus CR1 group.
No significant difference was detected in blood glucose among all groups (Table 2). Insulin
levels decreased by CR which was significant in CR2 compared to AL (p < 0.05). Insulin resistance,
as presented as HOMA-IR, significantly decreased with increased levels of CR (p < 0.05).
All groups demonstrated a similar level of serum adiponectin at the beginning of the study
(Figure 3). At the end of the study, serum adiponectin was only significantly increased in CR2 group
but not in AL and CR1 groups.
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Figure 3. The effect of calorie restriction on serum adiponectin. Serum adiponectin showed no
significant difference among all three groups at the beginning of the study. During the 12-week period,
only CR2 group demonstrated a significant increase in serum adiponectin level as compared to the
baseline. One-way ANOVA followed by LSD-test was used to detect significant differences of the
means, * p < 0.05.
CR also led to a decrease in mass of visceral adipose tissue (Table 3). At the end of the 12-week
study, wet weights of VAT and its percentage to the total body weight in CR groups were significantly
lower than those in AL group (p < 0.05). As compared to CR1 group, further calorie restriction in CR2
group resulted in a significantly lower visceral fat mass (p < 0.05).
Table 3. Effect of calorie restriction on visceral adipose tissue †.
Group Visceral Fat Mass [g] #,* Visceral Fat Mass [%] *,Δ
AL 16.47 ± 3.76 3.29 ± 0.48
CR1 12.08 ± 3.71 a 2.51 ± 0.68 a
CR2 6.72 ± 2.61 a,b 1.79 ± 0.69 a,b
† Abbreviations: AL: ad libitum; CR: calorie restriction; * Data was presented as arithmetic mean ± 1 S.D. n = 12
for each group; # Visceral Fat Mass [g] = total perirenal adipose tissue [g] + total peri-epididymal adipose tissue
[g] [20]; Δ Visceral fat mass [%] = Visceral fat mass/Body weight × 100; a p < 0.05 versus AL group; b p < 0.05
versus CR1 group.
3.3. Gene Expression
Results obtained from RT-PCR indicated that the expression levels of adiponectin mRNA and
PPARγ mRNA in CR groups were significantly higher than those in AL group (Figure 4). Within two
CR groups, adiponectin and PPARγ mRNA levels in CR2 group were significantly higher than those
in CR1 group (Figure 4(A2,B2)).
3.4. Correlation Analysis
Pearson correlation analysis was performed for mRNA levels of adiponectin, PPARγ with different
serum parameters (Table 4). Results showed that no correlation was detected between adiponectin,
PPARγ mRNA levels, total cholesterol (p > 0.05), and fasting glucose (p > 0.05). However, adiponectin,
and PPARγ mRNA levels were positively associated with HDL-C (p < 0.05) and inversely correlated
with body weight (p < 0.05), triglyceride (p < 0.05) and fasting insulin (p < 0.05).
8









































Figure 4. The effect of calorie restriction on the expressions of adiponectin and PPARγ in adipose
tissues. (A1, B1) demonstrate the expression levels of mRNA of β-actin, adiponectin and PPARγ,
respectively, quantified by RT-PCR. The expression levels (absorbance) of mRNA of adiponectin and
PPARγ were then normalized against those of β-actin (served as loading control) (A2, B2). One-way
ANOVA followed by LSD-test was used to detect significant differences of the means, * p < 0.05.
Table 4. Correlation analysis of adiponectin mRNA, PPARγ † mRNA with different serum parameters.
Independent Variables
Adiponectin PPARγ
r p r p
Body weight −0.389 0.001 −0.425 0.005
Triglyceride −0.345 0.042 −0.532 0.032
Total Cholesterol 0.47 0.624 0.673 0.431
HDL-C † 0.376 0.026 0.354 0.032
Glucose 0.530 0.231 0.492 0.485
Insulin −0.411 0.003 −0.537 0.013
† Abbreviations: PPAR-γ: peroxisome proliferator activator receptor γ; HDL-C: High density
lipoprotein cholesterol.
4. Discussion and Conclusions
MetS represents a cluster of conditions including glucose intolerance, hypertension, dyslipidemia,
and insulin resistance. CR via carbohydrate reduction has elicited a great deal of interest among
nutritionists because studies have shown that carbohydrate restriction can improve biological markers
that define MetS. In the present study, we conducted a 12-week CR with different levels of carbohydrate
reduction in healthy Wistar rats to investigate the changes in MetS-associated biomarkers as well as
the expressions of insulin-sensitive adiponectin and its regulator PPARγ.
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Body weight and peripheral adipose tissues (Table 3) in CR groups were significantly lower
than the AL group and the change of these parameters were inversely associated with the degree of
CR. VAT is associated with the development of insulin resistance, glucose intolerance, dyslipidemia
and hypertension, whereas subcutaneous adipose tissue is not [21–24]. The study conducted by
Gerbaix et al. has validated that removing perirenal and peri-epididymal adipose tissue in rats appears
to be more representative of visceral fat mass as dissection of mesenteric and subcutaneous fat is
challenging [20]. Hence, in the present study, visceral fat mass was evaluated as the total weight of
perirenal and peri-epididymal adipose tissue (Table 3). Our result indicated that CR via carbohydrate
reduction lowered visceral fat mass markedly, even when presented as visceral fat mass %, suggesting
the potential beneficial effect of CR via carbohydrate reduction on fat distribution and insulin sensitivity
in Wistar rats.
Consistent with the results obtained by previous studies involving carbohydrate restriction [25,26],
a 68% carbohydrate reduction in CR2 group led to a significant decrease in serum triglyceride and
significant increases in LDL-C, HDL-C and total cholesterol as compared to AL group. Our result
suggested that in contrast to traditional carbohydrate restriction diets with a low percentage of
carbohydrate or even ketogenic diets, our CR diet with 34% carbohydrate reduction was better at
improving lipid profiles, as it not only resulted in an increase in HDL-C and a reduction in triglyceride,
but also maintained LDL-C at the same level as those fed with control diets, thereby maintaining
the total cholesterol at the same level. Decreases in plasma triglyceride by carbohydrate-restricted
diet might be the result of downregulation of hepatic de novo lipogenesis [16,26,27]. In addition,
carbohydrate restriction might increase muscle lipoprotein Lipase (LPL), thus enhance triglyceride
clearance. Increased tissue expression and activity of LPL may partially explain increases in HDL-C in
our experimental groups. Increased LPL-mediated catabolism of triglyceride-rich lipoproteins resulted
in transfer of unesterified cholesterol, apoprotein and phospholipid to form mature HDL-C [16,26,27].
It is reported that long-term CR leads to an alteration of glucose homeostasis in humans [16]
and rats [15,28,29], resulting in decreased glycemia and insulinemia. Nevertheless, our results
demonstrated unchanged plasma glucose in CR groups as compared to the AL group. This finding
may be owing to the relatively short experimental period (12-week) and the moderate CR in the
present study. When the ingested carbohydrates fail to meet the energy needs of the body, the body
starts to mobilize glucose from glycogen storage pools for energy supply, and continues to maintain
blood glucose level via gluconeogenesis. The low glycogen storage stimulates insulin action in the
body. In good agreement with previous studies [15,28,29], fasting insulin level in the present study
demonstrated a decreasing trend with CR but only showed marked reduction in CR2 group. HOMA-IR
also manifested a decreasing trend and significant reduction in HOMA-IR was observed in both CR1
and CR2 groups. Maintaining relatively low levels of fasting insulin and HOMA-IR is shown to be
beneficial for the prevention and treatment of diabetes.
Adiponectin is considered to have antiatherogenic and antidiabetic effects [30]. In accordance
with the findings obtained by Zhu et al. [31] and Sung et al. [14], our results suggest that though serum
adiponectin level was only significantly elevated by 60% calorie-restricted diet, gene expression levels
of adiponectin and PPARγ in adipose tissues were proportionally elevated with increased degree of
energy restriction (Figures 3 and 4)-lower energy intakes led to higher expression levels. A high level
of adiponectin predicts good insulin sensitivity and improves lipid and glucose metabolism [32,33].
Activation of PPARγ can induce the synthesis and secretion of adiponectin as a response element
of PPARγ was discovered on the promoter of adiponectin gene [10]. CR might activate PPARγ and
thus up-regulate the gene expression of adiponectin. Our result indicated that decreased insulin
and HOMA-IR achieved by CR might be a result of increased adiponectin. Consistent with previous
findings [7,34], our results demonstrated a significant inverse relationship of VAT adiponectin mRNA
level and triglyceride and a significant positive relationship of adiponectin mRNA and HDL-C (Table 4).
The present study additionally showed a significant association of PPARγ mRNA with triglyceride
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and HDL-C. Our correlation analysis suggested that elevated gene expression of adiponectin and
PPARγ might lead to elevated level of HDL-C and reduced level of serum triglyceride.
Both low-carbohydrate CR diet [16,35] and low-fat, high-carbohydrate diet [36] have been
proposed for the prevention of MetS. Despite the fact that a low-fat, high-carbohydrate diet has
been advocated for controlling weight [37], a low-carbohydrate CR diet has gained in popularity.
Although the low-fat, high carbohydrate diet was better at reducing total cholesterol and LDL-C [26],
it is controversial [38], because it raises plasma triglycerides [39] and may adversely affect LDL
composition [40,41]. The greater the amount of carbohydrates that are substituted for fat, the greater
the increase in triglycerides [42]. Increasing evidence has pointed to the role of triglycerides in
atherogenic risk [43]. Consumption of a low-carbohydrate CR diet, however, as shown in our
present study and numerous previous studies, resulted in a reduction in triglycerides due to lack of
substrates for triglyceride synthesis in liver. In addition, elevated levels of HDL-C were observed
in subjects on low-carbohydrate CR diets [16,44], whereas HDL-C declined in subjects on low fat,
high-carbohydrate diets [45]. The elevated HDL-C and reduced triglycerides in plasma are the
advantages of a carbohydrate restricted diet over a high carbohydrate diet [24].
The long-term low-carbohydrate CR diet, however, is difficult for patients to comply with. Studies
have shown the efficacy of a moderate-carbohydrate CR diet in weight management and improvement
of serum lipid profiles [46]. In addition, a moderate-carbohydrate CR diet is more acceptable to
people for the prevention and treatment of type 2 diabetes, as a strict carbohydrate restricted diet is not
required [47,48]. In the present study, for the first time ever, we identified that a moderate-carbohydrate
diet (34% carbohydrate reduction) is not only effective in raising gene expressions of adiponectin and
PPARγ that potentially lead to better metabolic conditions but is also better in improving lipid profiles
than a low-carbohydrate diet in rats. Our results suggest that a moderate-carbohydrate CR diet can be
a new dietary intervention strategy for prevention and treatment of MetS.
There are certainly some limitations in this study. First, the investigation period (12 weeks)
may be too short to predict long-term effects of CR on expression of adiponectin, PPARγ and serum
parameters. Second, RT-PCR is a semiquantitative technique. Although our conclusions were based
on the results of the adiponectin, PPARγ expression and other serum parameters, more quantitative
techniques such as real-time PCR for mRNA or Western blotting for protein expression of adiponectin
should be used in a future study. Finally, whether the conclusion drawn from rats in the present study
can be extrapolated to other organisms, such as humans, remains to be determined.
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Abstract: Pregnant rats were fed a high fat diet (HFD) for the first (HF1), second (HF2), third (HF3)
or all three weeks (HFG) of gestation. Maintenance on a HFD during specific periods of gestation
was hypothesized to alter fetal glycemia, insulinemia, induce insulin resistance; and alter fetal
plasma and hepatic fatty acid (FA) profiles. At day 20 of gestation, fetal plasma and hepatic FA
profiles were determined by gas chromatography; body weight, fasting glycemia, insulinemia and
the Homeostasis Model Assessment (HOMA-insulin resistance) were also determined. HF3 fetuses
were heaviest concomitant with elevated glycemia and insulin resistance (p < 0.05). HFG fetuses had
elevated plasma linoleic (18:2 n-6) and arachidonic (20:4 n-6) acid proportions (p < 0.05). In the liver,
HF3 fetuses displayed elevated linoleic, eicosatrienoic (20:3 n-6) and arachidonic acid proportions
(p < 0.05). HFG fetuses had reduced hepatic docosatrienoic acid (22:5 n-3) proportions (p < 0.05).
High fat maintenance during the final week of fetal life enhances hepatic omega-6 FA profiles in
fetuses concomitant with hyperglycemia and insulin resistance thereby presenting a metabolically
compromised phenotype.
Keywords: fatty acid analysis; fetal programming; metabolic disease
1. Introduction
Fetal metabolism, and consequently fetal growth, directly depends on the nutrients crossing the
placenta, and therefore the mother adapts her metabolism to support this continuous draining of
substrates [1].
Fatty acids (FAs) are important for fetal growth and development. Specifically, linoleic acid
(18:2 n-6) and α-linolenic acid (ALA, 18:3 n-3) are the essential fatty acids (EFAs), which together
with their long-chain polyunsaturated FA (LCPUFA) derivatives are essential for fetal and postnatal
development. The fetus obtains both EFAs and LCPUFAs from maternal circulation by transfer across
the placenta [2,3].
High intakes of n-3 FAs solely during early pregnancy in rats have beneficial long-term
consequences in their offspring, reducing the age-related decline in insulin sensitivity in male
offspring [4].
A high fat diet (HFD) was shown to contribute to the development of obesity, insulin resistance,
type 2 diabetes and the impairment of the glucose signaling system in the beta cells [5–8]; in neonates,
these effects were dependent on the period of fetal life when the HFD was administered [5]. In the
present study, we investigated, in fetal rats, how exposure to a HFD during specific weeks of fetal life
influences plasma and hepatic FA profiles, glycemia, insulinemia and insulin resistance.
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2. Experimental Section
Institutional ethical approval was obtained before the experiments commenced. Wistar rats were
maintained as previously described [5]. Briefly, pregnant mothers were fed a HFD during specific
periods of gestation. The experimental groups are displayed in Figure 1. Although the HFD was
administered to the mothers, their fetal offspring were subsequently maintained on the respective
gestational diets. In the present study, 20-day-old fetuses maintained on a HFD for the first (HF1),
second (HF2), third (HF3) or all three (HFG) weeks of fetal life were studied. Specifically, HF1 fetuses
were maintained on a HFD from embryonic day (e) 0–7, HF2 fetuses from e8–14, HF3 fetuses from
e15–20 and HFG fetuses from e0–20. When HF1, HF2 and HF3 fetuses were not maintained on a HFD,
they were instead maintained on a standard laboratory diet for the remainder of fetal life, e.g., HF1
fetuses were maintained on a HFD for the first week of fetal life and a control diet for weeks 2 and
3 of fetal life (Figure 1). Fetuses maintained on a standard laboratory diet throughout represented
the control group. The standard laboratory diet (control) (Epol, South Africa) comprised 10% fat,
15% protein and 75% carbohydrate (2.6 kcal/g). The HFD contained 40% fat, 14% protein and 46%
carbohydrate (2.06 kcal/g). The HFD predominantly comprised saturated FAs (myristic, palmitic and
stearic acid) and the mono-unsaturated FA, oleic acid, derived from animal fat with carbohydrates
mainly derived from starch to mimic a westernized diet. The control diet was a standard commercial
rodent laboratory diet.
Figure 1. Experimental groups. The fetuses were maintained (through their mothers’ nutrition) on a
high fat diet (HFD) for either the first week (HF1), second week (HF2), third week (HF3) or all 3 weeks
(HFG) of fetal life.
Mothers were maintained on a HFD for specific periods of gestation and their 20-day-old fetal
offspring were studied. Therefore fetuses were maintained (through their mothers’ nutrition) on HFD
for either the first (HF1), second (HF2), third (HF3) or all 3 weeks (HFG) of fetal life. Control fetuses
were maintained on a standard commercial rodent laboratory diet.
At day 20 of pregnancy, mothers were euthanized after a 3 h fast. After removal from the uterus,
fetuses were weighed and decapitated and the trunk blood was used for FA analysis. Whole liver
was collected, weighed and stored at −80 ◦C until analysis. Blood was collected on ice-chilled tubes
containing 1 g/L of Na2-EDTA and pooled per litter from each mother. The pooled fetal blood was
centrifuged and plasma aliquots were stored at −20 ◦C until analysis.
Blood glucose (glucometer, Precision QID, MediSense, Oxfordshire, UK) and serum insulin (rat
insulin radio-immunoassay (RIA) kit, Linco Research, St. Charles, MO, USA) concentrations were
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measured. The Homeostasis Model Assessment (HOMA-insulin resistance) was calculated (fasting
plasma glucose (mmol/L) × fasting serum insulin (mU/L)/22.5)).
For FA analysis, nonadecenoic acid (19:1; Sigma-Aldrich, Madrid, Spain) was added as the
internal standard to fresh aliquots of frozen plasma and liver which were used for lipid extraction and
purification [9]. The final lipid extract was evaporated under vacuum and the residue suspended in
methanol/toluene followed by methanolysis in the presence of acetyl chloride at −80◦C for 2.5 h as
previously described [10]. FA methyl esters were separated and quantified on a gas chromatograph
(Autosystem, Perkin-Elmer, Madrid, Spain) with a flame ionization detector and a 20 m Omegawax
capillary column (internal diameter 0.25 mm). Nitrogen was used as carrier gas and the FA methyl
esters were compared to purified standards (Sigma-Aldrich). Quantification of the FAs in the samples
was performed as a function of the corresponding peak areas and compared to the internal standard.
One-way analysis of variance (ANOVA) and Bonferroni’s post-test were applied with data
reported as means ± standard error of the means (SEM) and significance established at p < 0.05.
3. Results
3.1. Anthropometry
As shown in Table 1, the HF3 fetuses had higher body weights relative to the other fetuses. HF2
fetuses had lower liver weights compared to the control, HF3 and HFG fetuses; after adjustment for
body weight, lower HF2 fetal liver weights persisted relative to all the groups (Table 1).
Table 1. Fetal anthropometry and metabolic parameters of 20-day-old rat fetuses.
Control HF1 HF2 HF3 HFG
Weight (g) 3.19 ± 0.06 3.23 ± 0.07 3.22 ± 0.05 3.79 ± 0.11 *,†,‡,Λ 3.20 ± 0.07
Liver weight (mg) 246.7 ± 12.69 196.0 ± 11.47 144.0 ± 16.85 *,§,Λ 253.7 ± 20.03 218.7 ± 10.81
Adjusted liver weight
(mg/100 g) 7.26 ± 0.24 6.23 ± 0.38 4.31 ± 0.50 *
,†,§,Λ 6.67 ± 0.43 6.95 ± 0.25
Blood glucose
(mmol/L) 2.54 ± 0.12 3.16 ± 0.16 2.97 ± 0.23 4.99 ± 0.56 *
,†,‡,Λ 3.06 ± 0.20
Serum insulin (pM) 48.24 ± 13.57 66.59 ± 11.50 62.68 ± 13.33 86.10 ± 22.96 75.72 ± 16.54
HOMA-insulin
resistance 1.09 ± 0.26 1.84 ± 0.30 1.68 ± 0.42 3.59 ± 0.13* 2.42 ± 0.92
The fetuses were maintained (through their mothers’ nutrition) on a high fat diet (HFD) for either the first week
(HF1), second week (HF2), third week (HF3) or all 3 weeks (HFG) of fetal life. Values are means ± standard error
of the means (SEM). n = 31–59 per group, but n = 3–6 for serum insulin and Homeostasis Model Assessment
(HOMA)-insulin resistance (due to pooling). Bonferroni’s test was used to determine differences between
groups after ANOVA. HF = high fat. Numerals refer to the week of maintenance on a high fat diet. * p < 0.05 vs.
control, † p < 0.05 vs. HF1, ‡ p < 0.05 vs. HF2, § p < 0.05 vs. HF3, Λ p < 0.05 vs. HFG.
3.2. Metabolic Parameters
The HF3 fetuses had higher glucose concentrations relative to the other fetuses (Table 1). However,
insulin concentrations did not differ amongst the groups (Table 1). Further, the HF3 fetuses were also
insulin resistant evident by their higher HOMA-insulin resistance values compared to the control
fetuses (Table 1).
3.3. Plasma and Hepatic FA Profiles
Changes in the FA profile in the maternal diet may affect the availability of certain FAs in
fetal plasma. HFG fetuses had enhanced plasma omega-6 FA profiles. Specifically, plasma linoleic
acid was higher in HFG fetuses relative to control, HF1 and HF2 fetuses (Table 2). Further, plasma
dihomo-gamma-linolenic acid (DGLA; 20:3 n-6) was higher in HFG fetuses compared to HF1 fetuses.
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In addition, plasma arachidonic acid (20:4 n-6) was higher in HFG fetuses compared to control and
HF1 fetuses (Table 2).
Table 2. Plasma fatty acid profiles (%) of 20-day-old rat fetuses maintained on a high fat diet.
Fatty Acid Control HF1 HF2 HFG
Saturated
14:0 1.59 ± 0.17 2.47 ± 0.40 1.86 ± 0.17 2.20 ± 0.17
16:0 27.47 ± 0.57 32.34 ± 3.59 31.77 ± 0.99 25.90 ± 0.54
18:0 11.43 ± 0.60 12.49 ± 0.58 11.83 ± 0.49 11.20 ± 0.60
22:0 0.84 ± 0.09 0.81 ± 0.19 0.82 ± 0.05 0.75 ± 0.11
24:0 0.84 ± 0.14 0.72 ± 0.01 0.65 ± 0.09 0.71 ± 0.18
Monounsaturated
14:1 0.62 ± 0.28 0.71 ± 0.08 1.29 ± 0.30 0.96 ± 0.22
16:1 (n-7) 5.42 ± 0.52 5.00 ± 0.52 5.61 ± 0.41 5.27 ± 0.42
18:1 (n-9) 25.55 ± 1.23 25.23 ± 0.39 23.65 ± 0.49 26.15 ± 0.90
Omega-3
20:5 (n-3) 1.34 ± 0.45 2.03 ± 1.39 1.08 ± 0.37 1.05 ± 0.63
22:5 (n-3) 0.58 ± 0.27 - 0.13 ± 0.05 0.69 ± 0.35
22:6 (n-3) 8.99 ± 0.68 5.44 ± 1.15 7.19 ± 1.10 5.57 ± 0.98
Omega-6
18:2 (n-6) 8.10 ± 0.35 6.54 ± 0.47 7.23 ± 0.42 9.87 ± 0.29 *,†,‡
18:3 (n-6) 0.38 ± 0.03 0.32 ± 0.04 0.41 ± 0.03 0.48 ± 0.04
20:3 (n-6) 0.45 ± 0.10 0.38 ± 0.12 0.50 ± 0.04 0.76 ± 0.03 †
20:4 (n-6) 5.84 ± 0.39 5.05 ± 0.94 5.97 ± 0.62 8.41 ± 0.32 *,†
The fetuses were maintained (through their mothers’ nutrition) on a high fat diet (HFD) for either the first
(HF1), second (HF2), third (HF3) or all 3 weeks (HFG) of fetal life. Values are means ± standard error of the
means (SEM). n = 3–4 per group. n = 2 for HF3 which was excluded from analyses. Bonferroni’s test was used
to determine differences between groups after one-way analysis of variance (ANOVA). HF = high fat; Numerals
refer to the week of maintenance on a high fat diet. * p < 0.05 vs. control, † p < 0.05 vs. HF1, ‡ p < 0.05 vs. HF2 −
n = 2 for HF1.
As shown in Table 3, the proportion of different FAs in fetal liver remained relatively constant.
However, specific omega-6 FAs were elevated in HF3 fetuses: linoleic (compared to control and HF2
fetuses), eicosatrienoic (compared to HF1 fetuses) and arachidonic acid (compared to control fetuses;
Table 3). Further, hepatic docosapentaenoic acid (DPA; 22:5 n-3) was lower in HFG fetuses compared
to control and HF3 fetuses (Table 3).
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Table 3. Hepatic fatty acid profiles (%) of 20-day-old rat fetuses exposed to a maternal high fat diet.
Fatty Acid Control HF1 HF2 HF3 HFG
Saturated
14:0 1.03 ± 0.20 0.93 ± 0.09 1.00 ± 0.07 1.39 ± 0.16 1.22 ± 0.15
16:0 24.46 ± 0.92 23.15 ± 0.43 23.62 ± 0.59 24.20 ± 0.90 23.75 ± 0.50
18:0 15.40 ± 0.40 15.57 ± 0.37 14.85 ± 0.17 15.20 ± 0.43 14.55 ± 0.21
20:0 0.31 ± 0.05 0.30 ± 0.04 0.26 ± 0.01 0.28 ± 0.02 0.32 ± 0.04
Monounsaturated
15:1 0.49 ± 0.05 0.33 ± 0.09 0.34 ± 0.07 0.36 ± 0.06 0.36 ± 0.06
16:1 (n-7) 4.20 ± 0.37 3.82 ± 0.31 3.93 ± 0.13 3.43 ± 0.23 4.03 ± 0.11
18:1 (n-9) 21.01 ± 0.70 20.09 ± 0.77 21.35 ± 0.79 19.03 ± 1.31 22.44 ± 0.67
20:1 (n-9) 0.21 ± 0.07 0.24 ± 0.03 0.24 ± 0.01 0.23 ± 0.03 0.23 ± 0.03
Omega-3
20:5 (n-3) 0.83 ± 0.10 0.70 ± 0.08 0.57 ± 0.03 0.65 ± 0.09 0.69 ± 0.10
22:5 (n-3) 0.40 ± 0.03 0.37 ± 0.06 0.34 ± 0.03 0.41 ± 0.04 0.24 ± 0.01 *,§
22:6 (n-3) 12.64 ± 0.91 13.00 ± 0.96 12.01 ± 0.56 9.99 ± 1.21 8.81 ± 0.51
Omega-6
18:2 (n-6) 7.24 ± 0.30 7.86 ± 0.53 8.06 ± 0.25 10.16 ± 0.79 *,‡ 8.79 ± 0.30
20:2 (n-6) 0.22 ± 0.03 0.25 ± 0.05 0.24 ± 0.02 0.25 ± 0.01 0.23 ± 0.02
20:3 (n-6) 0.83 ± 0.03 0.79 ± 0.03 0.87 ± 0.06 1.03 ± 0.03 † 0.99 ± 0.05
20:4 (n-6) 8.68 ± 0.33 10.53 ± 0.46 10.21 ± 0.26 10.95 ± 0.52* 10.65 ± 0.72
22:4 (n-6) 0.40 ± 0.01 0.43 ± 0.01 0.47 ± 0.02 0.50 ± 0.05 0.48 ± 0.04
The fetuses were maintained (through their mothers’ nutrition) on a high fat diet (HFD) for either the first week
(HF1), second week (HF2), third week (HF3) or all 3 weeks (HFG) of fetal life. Values are means ± standard
error of the means (SEM). n = 3–5 per group. Bonferroni’s test was used to determine differences between
groups after one-way analysis of variance (ANOVA). HF = high fat. Numerals refer to the week of maintenance
on a high fat diet. * p < 0.05 vs. control, † p < 0.05 vs. HF1, ‡ p < 0.05 vs. HF2, § p < 0.05 vs. HF3.
4. Discussion
The hyperglycemia and insulin resistance in fetuses maintained on a HFD for the final week of
fetal life concomitant with increased hepatic omega-6 FA proportions were the main findings. During
the final week of fetal life the endocrine pancreas differentiates into functional islet cells specialized for
the maintenance of glucose homeostasis. Fetal programming refers to intrauterine stimuli or insults
(such as the insult of maintenance on a HFD) that have immediate, transient or durable effects. With the
fetal high fat programming insult during this critical developmental window, viz., late fetal life, islet
cell, and specifically beta cell, development coincides with the HFD insult. We have previously shown
that neonates maintained on a HFD throughout fetal life had compromised beta cell development and
function [5,11]. Fetal high fat programming may therefore contribute to the hyperglycemia and insulin
resistance in fetuses maintained on a HFD for the final week of fetal life.
In Westernized society, diets contain omega-6 to omega-3 ratios that far exceed the recommended
ratio of 1:1; this increased ratio is believed to contribute to the global increase in metabolic disease.
In rodents, from e15 up to birth and into postnatal life, the maturation and growth of the
liver occurs [12,13] with liver expansion of 84-fold, from e13.5–20.5, evident by the hepatoblasts
undergoing 8-doublings [14–16]. Hence this critical hepatic developmental period of rapid and
significant expansion overlaps with the administration of the HFD to HF3 neonates (exposed to a HFD
from e15–20). With an increase of the precursor, linoleic acid, in the HF3 fetal livers, more substrate was
available for conversion into arachidonic acid to help meet the fetal growth demands. FA elongation
and desaturation are two key metabolic routes for the synthesis of saturated, monounsaturated and
polyunsaturated FAs [17]. The elevated hepatic eicosatrienoic acid provided further evidence of
lipogenesis along the omega-6 pathway. This also suggested activation of delta-6 desaturase, elongase
and delta-5 desaturase to facilitate fetal hepatic lipogenesis. However, this requires the application of
assays to assess enzymatic activities followed by Western blot analyses. However, enzyme activity
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and expression should be studied in older progeny due to low elongase and desaturase expression in
the fetal liver [18]. The increase in hepatic omega-6 FA in fetuses maintained on a HFD for the final
week of fetal life appears to contribute to their compromised metabolic phenotype. The exact role of
the elevated hepatic omega-6 FAs in inducing these metabolically compromised fetuses remains to
be elucidated.
DPA (22:5 n-3) is an elongation metabolite of eicosapentaenoic acid (EPA; 20:5 n-3) and an
underexplored omega-3 FA. Supplementation of liver cells with DPA down-regulated the expression
levels of key genes and proteins involved in FA synthesis [19]. The reduced DPA n-3 proportions in the
livers of fetuses maintained on a HFD throughout fetal life may therefore result in higher expression
profiles of FA synthesis factors.
The elevated omega-6 plasma FAs in HFG fetuses to some extent mimicked the hepatic FA
profiles of HF3 fetuses. The EFAs, linoleic and alpha-linoleic acid are supplied by the diet, and
their LCPUFA derivatives, play a critical role in fetal development [1]. Linoleic acid’s metabolite,
arachidonic acid, is essential for neonatal growth and development [20] which suggests that postnatal
growth in these HF3 fetuses may be accelerated. Both fetuses and neonates are dependent upon the
supply of preformed LCPUFAs from their mothers, which is obtained from maternal circulation [21].
An enhancement in arachidonic acid and docosahexaenoic acid (DHA; 22:6 n-3) in fetal circulation is
called magnification and infers their effective transfer throughout the placenta [22]. The ratio of the
proportions of arachidonic acid to linoleic acid is higher in fetal serum than in maternal serum [23],
which suggests the preferential transfer of arachidonic acid through the placenta [24]. In all of the
groups, the ratios of arachidonic acid to linoleic acid were elevated in the fetal plasma relative to the
maternal plasma (data not shown) reflecting the preferential transfer of arachidonic acid through the
placenta [24]. Despite the pooling of fetal litter plasma samples to yield sufficient volumes for analyses,
the plasma sample number was too low for HF3 fetuses. Hence no HF3 fetal plasma FA profiles were
determined which was a constraint. In summary, fetuses maintained on a HFD throughout fetal life
had elevated plasma linoleic and arachidonic acid proportions concomitant with elevated plasma
arachidonic acid to linoleic acid ratios in fetuses relative to mothers which suggested preferential
placental transfer of arachidonic acid to sustain fetal and postnatal growth.
DGLA (20:3 n-6) is metabolized to the anti-inflammatory eicosanoid, prostaglandin (PG) E1,
via the cyclooxygenase (COX) pathway [25] and was recently reported to be positively correlated to
increased type 2 diabetes risk [26]. Although plasma DGLA proportions were increased in HFG fetuses
relative to HF1 fetuses, the increase in this rare FA may not have any biological relevance [26].
Liver mass and its later function are essentially set during fetal development which is regulated
by the intrauterine environment [27]. Disease risk is amplified by a greater mismatch between the
prenatally predicted and actual adult environments [28]. Epidemiological data imply that hepatic
organogenesis is susceptible to nutritional reprogramming and that impaired liver development in
utero can result in durable functional consequences on disease risk later in life [27]. From e8–14
hepatic fate is specified, followed by gut tube formation, the liver domain relocating to the mid-gut
followed by the liver diverticulum expanding into a liver bud [12,13]. These major liver development
processes coincide with the HF2 neonates who had low liver weights. Hence the HFD administration
during mid fetal life, i.e., e8–14, appeared to stunt liver development. The reduced liver weights
in fetuses maintained on a HFD for the second week of fetal life may render them susceptible to
metabolic disease.
Although we found altered fetal plasma and hepatic FA profiles in some offspring, our study has
several limitations. Varying FA abundance can affect processes such as inflammation, angiogenesis and
insulin sensitivity [29]. Early life hepatic fat accumulation is an early manifestation of non-alcoholic
fatty liver disease (NAFLD) and an independent pathophysiological event that potentiates postnatal
metabolic liver disease [30]. Therefore hepatic inflammation, steatosis and disrupted insulin signaling
potentially contribute to the metabolically compromised phenotype that presented in the HF3 fetuses.
Unfortunately FA analyses were conducted on all the frozen fetal liver samples, with no additional
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samples available for further investigation to reinforce our findings. Moreover, stratifying the study
according to gender would likely have revealed gender-specific differences. The role of the elevated
plasma and hepatic omega-6 FAs also remains to be fully elucidated.
5. Conclusions
Fetuses maintained on a HFD solely for the final week of fetal life were hyperglycemic and insulin
resistant concomitant with enhanced hepatic omega-6 FA proportions, viz., linoleic, eicosatrienoic
and arachidonic acid. These events may reflect enhanced omega-6 lipogenesis in response to the
compromised metabolic phenotype.
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Abstract: Excessive fat intake is a global health concern as women of childbearing age increasingly
ingest high fat diets (HFDs). We therefore determined the maternal fatty acid (FA) profiles in
metabolic organs after HFD administration during specific periods of gestation. Rats were fed a
HFD for the first (HF1), second (HF2), or third (HF3) week, or for all three weeks (HFG) of gestation.
Total maternal plasma non-esterified fatty acid (NEFA) concentrations were monitored throughout
pregnancy. At day 20 of gestation, maternal plasma, liver, adipose tissue, and placenta FA profiles
were determined. In HF3 mothers, plasma myristic and stearic acid concentrations were elevated,
whereas docosahexaenoic acid (DHA) was reduced in both HF3 and HFG mothers. In HF3 and HFG
mothers, hepatic stearic and oleic acid proportions were elevated; conversely, DHA and linoleic
acid (LA) proportions were reduced. In adipose tissue, myristic acid was elevated, whereas DHA
and LA proportions were reduced in all mothers. Further, adipose tissue stearic acid proportions
were elevated in HF2, HF3, and HFG mothers; with oleic acid increased in HF1 and HFG mothers.
In HF3 and HFG mothers, placental neutral myristic acid proportions were elevated, whereas DHA
was reduced. Further, placental phospholipid DHA proportions were reduced in HF3 and HFG
mothers. Maintenance on a diet, high in saturated fat, but low in DHA and LA proportions, during
late or throughout gestation, perpetuated reduced DHA across metabolic organs that adapt during
pregnancy. Therefore a diet, with normal DHA proportions during gestation, may be important for
balancing maternal FA status.
Keywords: docosahexaenoic acid; feto-placental; lipids; ω-3 fatty acids; ω-6 fatty acids; triglycerides
1. Introduction
Fatty acids (FAs) are structural components of organs, energy sources, precursors of bioactive
compounds such as eicosanoids, including prostacyclins, prostaglandins, thromboxanes, and
leukotrienes. FAs also regulate the expression of transcription factors. All FAs provide energy,
whereas polyunsaturated fatty acids (PUFAs) are required for structural and metabolic functions.
The ω-3 and ω-6 PUFA families are synthesized from their essential fatty acids (EFAs), namely
α-linolenic acid (αLA, 18:3 ω-3) and linoleic acid (LA, 18:2 ω-6), respectively. αLA and LA cannot
be synthesized de novo [1] and are, therefore, supplied in the diet [2]. During pregnancy, the EFAs
and PUFAs cross the placenta to maintain their supply to the fetus [3]. LA is abundant in the Western
dietary pattern and is the precursor of arachidonic acid (AA, 20:4 ω-6) [2]. αLA is abundant in seed
oils and is the precursor of eicosapentanoic acid (EPA, 20:5 ω-3) and docosahexaenoic acid (DHA,
22:6 ω-3) [1]. Metabolically important PUFAs during development are AA, EPA, and DHA which
are not required from the maternal diet during pregnancy to meet fetal demands since they can be
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synthesized endogenously from the EFAs. However, the conversion of EFAs to PUFAs by the fetus
is very limited and, therefore, the plasma and tissue concentrations of these FAs depend mainly on
exogenous supply. Thus, during periods of rapid intrauterine growth, the production of the EPAs,
DHA, and AA may be inadequate and considered as EFAs for the fetuses [4]. A sufficient supply of
these FAs during pregnancy and the neonatal period is critical for normal fetal growth and proper
neurological development and function [5,6].
Maternal dietary FAs, particularly PUFAs, may influence epigenetic gene regulation by inducing
or repressing transcription of specific genes during critical ontogenic periods [7,8] with long-term
consequences for offspring health. During pregnancy, the mother transitions through different metabolic
conditions, shifting from anabolism during the first two thirds of gestation, by accumulating fat depots,
to a catabolic state during the last third, when fat depot breakdown is enhanced [9–11]. These metabolic
transitions contribute to the development of maternal hyperlipidemia with major implications for fetal
growth [12]. Moreover, these adaptations are altered when the maternal diet is unbalanced by a high fat
(HF) content with consequences in placental nutrient transport and fetal growth [13]. Specific placental
nutrient transporters, namely glucose transporter (GLUT) 1 and sodium-coupled neutral amino acid
transporter (SNAT) 2, are up-regulated in response to a high fat diet (HFD) [13].
The ingestion of a HFD during pregnancy influences both maternal and offspring health outcomes
as gestational HF feeding are associated with derangements in both their metabolism and physiology
that may be immediate, transient or permanent. Whereas most studies focus on developmental
programming effects, the present study will investigate the differential FA profiles in maternal
metabolic organs near term. With the increasing proportion of women of childbearing age that
are overweight or obese and consume unhealthy diets during pregnancy, there is a great need to study
dietary patterns as they influence both maternal and offspring health outcomes. Since altered dietary
composition during specific periods of pregnancy could differentially affect maternal FA profiles with
consequences in their availability to the fetus, this study investigates the effect of a HFD administered
to pregnant rats at different stages of pregnancy on lipid profiles in near-term mothers. Maternal
plasma, hepatic, adipose tissue, and placenta FA profiles were determined.
2. Experimental Section
2.1. Experimental Design
Ethical approval was obtained by the Animal Ethics Committee of the South African Medical
Research Council prior to experimentation. Adult female Wistar rats from our animal facility were
maintained at 22 ˘ 2 ˝C, 55% ˘ 10% relative humidity and 12 h light/dark cycles and fed the control
diet. The female rats fed a control diet were mated with age-matched male rats. After mating
was confirmed by the presence of vaginal plug(s), pregnant rats were randomly assigned to the
experimental groups, housed singly, and subjected to the experimental design summarized in Table 1.
Briefly, pregnant mothers (n = 4–6 per group) were fed a control or HF diet ad libitum during specific
periods of gestation. The HFD was formulated by in-house dieticians and was constituted by 40%
fat, 14% protein, and 46% carbohydrate, whereas the control diet was acquired commercially (Epol,
Pietermaritzburg, South Africa) and contained 10% fat, 15% protein, and 75% carbohydrate (Table S1).
As summarized in Table 1, the groups were mothers maintained on a HFD during the first (HF1),
second (HF2), or third (HF3) week of gestation, or for all three (HFG) weeks of gestation; for the
remainder of gestation, mothers were fed the control diet.
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Table 1. Experimental design.
Groups Gestational Diet
Week 1 Week 2 Week 3
Control Control Control Control
HF1 HFD Control Control
HF2 Control HFD Control
HF3 Control Control HFD
HFG HFD HFD HFD
Control mothers (n = 4) were maintained on a standard laboratory (control) diet throughout. Experimental mothers
(n = 4 per group, but n = 6 for HF2) were maintained on a high fat diet (HFD) for specific weeks of gestation.
HF1, mothers maintained on a HFD for week one; HF2, mothers maintained on a HFD for week two; HF3, mothers
maintained on a HFD for week three; HFG, mothers maintained on a HFD for all three weeks of gestation.
2.2. Sample Collection
At days zero (e0, just prior to mating), seven (e7, early pregnancy), 14 (e14, mid pregnancy) and
20 (e20, near-term), blood was collected from the tail after 3 h of fasting. Mothers were anesthetized via
an anesthetic machine (Motivus Resuscitator Type AV, Crest Healthcare Technology Ltd., Johannesburg,
South Africa) with fluothane (Halothane, AstraZeneca Pharmaceuticals, Johannesburg, South Africa)
and 2% oxygen. After the mothers were anesthetized, the tip of the tail was heated with a ultraviolet
(UV) lamp to facilitate blood flow then snipped with a surgical blade. Blood was collected in ice-cooled
tubes containing 1 mg/ml of Na2-EDTA. After centrifugation, plasma samples were stored at ´20 ˝C
until analysis. After the last blood collection (e20), mothers were maintained under anesthesia and
whole liver, lumbar adipose tissue, and placenta were collected and stored at ´80 ˝C until analysis.
2.3. Determination of Blood Glucose and Serum Insulin Concentrations and Lipid Profiles
Blood glucose (glucometer, Precision QID, MediSense, Cambridge, UK) and serum insulin (rat
insulin RIA kit, Linco Research, St. Charles, MO, USA) concentrations were measured. Homeostasis
model assessment (HOMA)-insulin resistance ((fasting plasma glucose (mmol/L) X fasting serum
insulin (mU/L))/22.5)) was calculated. Plasma triglycerides (TAG), cholesterol (Spinreact Reactives,
Girona, Spain), and non-esterified fatty acid (NEFA) (Wako Chemicals, Neuss, Germany) were
determined enzymatically using commercial kits. For FA profile analyses, nonadecenoic acid (19:1)
(Sigma-Aldrich, Madrid, Spain) was added as the internal standard to fresh aliquots of diets and
frozen plasma and tissue which were used for lipid extraction and purification [14]. For the placenta,
lipid extracts were evaporated to dryness and resuspended in chloroform in the presence of activated
silicic acid to extract the neutral lipids whereas the dried chloroform-washed silicic acid fraction was
treated with methanol to extract the phospholipids. The final lipid extracts were evaporated under
vacuum and the residue suspended in methanol/toluene followed by methanolysis in the presence of
acetyl chloride at ´80 ˝C for 2.5 h as previously described [15]. FA methyl esters were separated and
quantified on a Perkin-Elmer gas chromatograph (Autosystem, Madrid, Spain) with a flame ionization
detector and a 20 m Omegawax capillary column (internal diameter 0.25 mm). Nitrogen was used
as the carrier gas and the FA methyl esters were compared to purified standards (Sigma-Aldrich).
Quantification of the FAs in the samples was performed as a function of the corresponding peak areas
and compared to the internal standard.
2.4. Statistical Analysis
One-way analysis of variance (ANOVA) and Bonferroni’s post-test were applied with data
reported as means ˘ standard error of the mean (SEM) and significance established at p < 0.05.
However, for dietary FA and fetal-maternal FA analyses, the Student’s t-test was applied.
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3. Results
3.1. Anthropometry
Although HFG mothers consumed more food compared to the other mothers, there were no
differences in body weights (Table S2). Despite no differences in placental weight, when adjusted for
body weight, placental weights were reduced in HF3 mothers relative to control mothers (Table S2).
There were no differences in conceptus weight, litter sizes, or any of the maternal organs that were
studied (Table S2).
3.2. Glycemia, Insulinemia and HOMA-Insulin Resistance
There were no differences in glycemia, insulinemia, and HOMA-insulin resistance amongst the
groups (Table S3).
3.3. Fatty Acid Profile in the Diets
As shown in Figure 1, the proportion of saturated FAs (namely myristic, palmitic, and stearic
acids) and oleic acid were higher in the HFD than in the control diet with lower proportions of αLA,
DHA, and LA in the HFD. In the HFD, palmitic and oleic acid were the predominant FAs (57% of total
diet), whereas in the control diet LA was most abundant.
Figure 1. Dietary fatty acids (g/100 g fatty acids). Values are means ˘ standard error of the mean
(SEM). HFD, high fat diet. * p < 0.0001.
3.4. Plasma Total Non-Esterified Fatty Acid, Triglyceride, and Cholesterol Concentrations and Individual Fatty
Acid Profiles
Near-term (e20) plasma total NEFA concentrations were elevated in control, HF1, HF2, and
HF3 mothers compared to pre-gravidity (e0), early (e7), and mid-term (e14); and in HFG mothers at
near-term (e20), compared to pre-gravidity (e0) and early term (e7) (Figure 2A).
With reference to the individual FA profiles at e20 in HF3 mothers, myristic (14:0) and stearic acid
(18:0) concentrations were elevated compared to control, HF1, HF2, and HFG mothers (Figure 2B).
However, DHA concentrations were reduced in HF3 and HFG mothers compared to the control
mothers (Figure 2B). Plasma αLA values in all the groups were negligible (data not shown).
26
Nutrients 2016, 8, 25
Plasma TAG concentrations at mid-term (e14) were elevated in HFG mothers compared to HF1
mothers (Figure 2C). Further, mid-term (e14) TAG concentrations were elevated in HF2 mothers
compared to pre-gravidity (e0) and early term (e7) (Figure 2C). Near-term (e20) TAG concentrations
were elevated in control and HFG mothers compared to pre-gravidity (e0) and early term (e7); further,
near-term (e20) TAG concentrations were elevated in HF1, HF2, and HF3 mothers compared to
pre-gravidity (e0), early (e7), and mid-term (e14) (Figure 2C).
Early term (e7) plasma cholesterol concentrations were reduced in HF2 mothers compared to
HF1 mothers (Figure 2D). In HF1 mothers, mid-term (e14) cholesterol concentrations were reduced
compared to early (e7) and near-term (e20) (Figure 2D). Near-term (e20) cholesterol concentrations
were elevated in HF3 mothers compared to HF2 mothers (Figure 2D). In HF1 mothers, near-term (e20)
cholesterol concentrations were elevated compared to pre-gravidity (e0) and mid-term (e14); and in
HF2 mothers only relative to mid-term (e14) (Figure 2D). In both HF3 and HFG mothers, near-term










Figure 2. Lipid profiles during gestation. (A) Plasma non-esterified fatty acid concentrations (μM);
(B) individual plasma fatty acid concentrations (mg/dL); (C) plasma triglyceride concentrations
(mg/dL); and (D) plasma cholesterol concentrations (mg/dL). Numerals refer to the specific week of
gestational high fat (HF) maintenance. G, gestation refers to HF maintenance throughout gestation.
Values are means ˘ standard error of the mean (SEM). Capital letters refer to inter-groups. Lower case
letters refer to intra-groups. Different letters reflect significant changes.
3.5. Placental Neutral Lipids and Phospholipid Fatty Acids Near Term (e20)
In HF3 mothers, placental neutral lipid myristic acid was increased compared to the control, HF1
and HF2 mothers (Figure 3A). In both HF3 and HFG mothers, DHA was reduced compared to control
and HF2 mothers (Figure 3A).
Similarly in HF3 and HFG mothers, placental phospholipid DHA was reduced compared to
control, HF1 and HF2 mothers (Figure 3B). Placental phospholipid myristic acid was elevated in HF3
mothers compared to HF2 mothers (Figure 3B).
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(A) 
(B) 
Figure 3. Placental fatty acids. (A) Placental neutral fatty acids (g/100 g fatty acids); and (B) placental
phospholipid fatty acids (g/100 g fatty acids). Numerals refer to the specific week of gestational
high fat (HF) maintenance. G, gestation refers to HF maintenance throughout gestation. Values are
means ˘ standard error of the mean (SEM). Different letters reflect significant changes.
29
Nutrients 2016, 8, 25
3.6. Plasma Fetal: Maternal Fatty Acids and Fetal and Maternal AA:LA Ratios
Although we recently reported the FA profiles in fetal plasma [16], we subsequently determined
the plasma fetal:maternal ratios of individual FAs. As shown in Figure 4, the fetal:maternal plasma
ratio of stearic acid was reduced in HF2, HF3, and HFG mothers compared to control mothers. The
fetal:maternal plasma oleic acid ratio in HF3 and HFG mothers was reduced, whereas the LA ratio
was elevated relative to control mothers (Figure 4). Fetal:maternal plasma LA ratio was also elevated
in HF3 mothers relative to HF1 mothers (Figure 4). Fetal:maternal plasma palmitic acid ratio was
reduced in HFG mothers compared to HF1 and HF2 mothers (Figure 4).
Figure 4. Fetal: maternal ratio of plasma fatty acids (g/100 g fatty acids). Numerals refer to the
specific week of gestational high fat (HF) maintenance. G, gestation refers to HF maintenance
throughout gestation. Values are means ˘ standard error of the mean (SEM). Different letters reflect
significant changes.
Although the fetal:maternal ratio of most FAs did not exceed 1, the DHA ratios in the HF3 and
HFG groups were increased ~two-fold, albeit non-significant. The plasma AA:LA ratio in either the
fetuses or the mothers did not differ between the different groups, but values were consistently higher
in fetuses than in mothers in all groups (Table S4).
3.7. Hepatic Fatty Acids
Hepatic stearic and oleic acid were elevated in HF3 and HFG mothers whereas LA and DHA
were reduced relative to control mothers (Figure 5). Hepatic LA proportions were also reduced in HF2
mothers compared to control mothers (Figure 5).
3.8. Adipose Tissue Fatty Acids
The proportion of adipose tissue myristic acid was elevated whereas LA and DHA were reduced
in HF1, HF2, HF3, and HFG mothers compared to controls (Figure 6). Further, adipose tissue LA was
reduced in HFG mothers compared to HF1, HF2, and HF3 mothers (Figure 6). In addition, adipose
tissue stearic acid was elevated in HF2, HF3, and HFG mothers relative to control mothers, and in
HFG mothers compared to HF1 mothers (Figure 6). Adipose tissue oleic acid was elevated in HF1
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and HFG mothers compared to control mothers (Figure 6). Further, adipose tissue palmitic acid was
elevated in HF3 relative to HF1 mothers (Figure 6).
Figure 5. Hepatic fatty acids (g/100 g fatty acids). Numerals refer to the specific week of gestational
high fat (HF) maintenance. G, gestation refers to HF maintenance throughout gestation. Values are
means ˘ standard error of the mean (SEM). Different letters reflect significant changes.
Figure 6. Adipose tissue fatty acids (g/100 g fatty acids). Numerals refer to the specific week of
gestational high fat (HF) maintenance. G, gestation refers to HF maintenance throughout gestation.
Values are means ˘ standard error of the mean (SEM). Different letters reflect significant changes.
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4. Discussion
The present rodent study sought to determine the effects of HFD administration during specific
periods of gestation on maternal lipid profiles, since we recently described its consequences on
the availability of FAs to the fetus [16]. The HFD administered was rich in saturated and oleic
acids but depleted in LA and DHA relative to the control diet with negligible amounts of αLA.
One of the key findings was that the intake of the HFD during the first, second, or third week of
gestation or throughout gestation did not modify the intense increase in plasma NEFA that occurs
physiologically near-term (in control rats). This observation may reflect an index of adipose tissue
lipolysis and, therefore, our data suggest that this pathway is highly augmented during late pregnancy
as expected [10]. The main fate of plasma NEFA is the liver [17,18] for partial re-esterification in the
synthesis of TAG which are released back into the circulation, and this pathway is also known to be
enhanced in late pregnancy in the rat [19,20]. Bearing this in mind, we found that plasma TAG was
also greatly increased in all pregnant rats close to term, although the increase seemed to be gradual as
it was also evident at the end of mid pregnancy (day 14 of gestation) in those rats maintained on the
HFD solely for the second week of pregnancy (HF2) or throughout pregnancy (HFG). This occurred
despite unaltered plasma NEFA until near-term in all the groups suggesting that the HFD may increase
TAG release from the liver already from mid pregnancy.
The profile of individual FAs in plasma and in the various organs provides insight into the
metabolic changes taking place due to the HFD administration during gestation. In agreement with
the known direct relationship between FA composition in the diet and maternal adipose tissue in
pregnant rats fed different diets [21], the profile of FAs in the adipose tissue of the mothers maintained
on the HFD for the different weeks of gestation closely reflected those of the diet. Moreover, there were
higher proportions of saturated FAs and oleic acid but lower LA and DHA proportions. However, only
the plasma had a decline in DHA in rats fed the HFD for the third week of gestation or throughout
gestation suggesting that other organs may compensate for the altered dietary FA profile. This seems
to be the case in the liver where an increase in stearic and oleic acid was only evident in those rats
fed the HFD for the third week of gestation or throughout gestation. This resonates as the rats were
studied at a time when they were maintained on the diet containing high proportions of saturated FAs
and oleic acid.
As reported in mice, HF feeding is likely to induce hepatic FA synthesis by chain elongation and
subsequent desaturation rather than de novo synthesis [22] which may justify the unaltered palmitic
acid but enhanced stearic and oleic acid in the livers of the mothers maintained on a HFD during the
third week of gestation or throughout gestation, and studied near-term. A different scenario presents
with the proportion of LA in the liver which was decreased near-term virtually in all the rats (apart
from HF1 mothers) maintained on the HFD for any of the three weeks of gestation. However, the
main PUFA derived from LA, AA, did not differ amongst the groups in either plasma or liver. Since
the proportion of AA in the diets was very low, this suggested that the conversion of LA to AA was
enhanced in those rats fed the HFD. An increase in the proportion of AA was previously reported
in the liver of rat mothers, newborn pups and suckling pups that were fed a HFD 10 days prior to
mating, throughout pregnancy, and during lactation [23]. These changes could be attributed to the
known effects that HFDs have on the expression of genes involved in lipid metabolism that would
facilitate LA elongation and desaturation in the synthesis of AA [24]. However, this situation cannot be
sustained for DHA since levels of its EFA precursor, αLA, were very low in the diet and therefore the
DHA levels mainly depend on its dietary availability which was greatly reduced in the HFD (~10-fold
lower) compared to the control diet. The consequence was the consistent decline of DHA availability as
demonstrated in the plasma, liver, and adipose tissue of rats fed the HFD for the last week of gestation
or throughout gestation.
A similar rationale could be applied to understand the FA profile of placental neutral lipids
(involved in lipid storage) and phospholipids (form cell membranes), where the most consistent
changes were the decline in the proportions of DHA. The placenta plays a key role in the mother-fetus
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relationship, maintaining fetal homeostasis through the regulation of nutrient transfer [25] and is
involved in materno-fetal exchanges, metabolism, endocrinology, and immune pathways, and is an
active component for fetal growth [26]. Although lipogenesis occurs in the rat placenta [27], its rate
seems to be slow [28,29] and, therefore, most placental FAs are a result of the balance between those
taken up from maternal plasma and those released to the fetus. In the present study, DHA was the
only FA that was consistently reduced in both placental neutral lipids and phospholipids in rats fed
the HFD for the third week of gestation and throughout gestation. This change reflected the decrease
of this PUFA in plasma and therefore may be a consequence of its limited uptake by the placenta
from maternal circulation. The placenta is known to preferentially transfer PUFA, such as DHA, due
to their absolute requirement for brain and retina development [30]. Further, the reduced placental
phospholipid DHA profiles in rats maintained on the HFD for the third week of gestation or throughout
gestation may also result in reduced transfer of this PUFA to their fetuses which may potentially stunt
fetal brain and retina development. Interestingly, the fetal:maternal DHA ratio increased ~two-fold
in rats maintained on the HFD for the third week of gestation or throughout gestation although the
change versus the one value was not statistically significant. This finding resonates with the known
magnification of this specific FA in the fetus in relation to the mother indicating a higher proportional
placental transfer of DHA relative to other FAs [31], although absolute concentrations are lower in the
fetus than in the mother under different dietary regimens [32] as also shown in humans [3].
The metabolic state and nutrition of mothers during pregnancy has developmental programming
consequences for their progeny. PUFA dietary content, particularly a more balanced ω-6 to ω-3 ratio,
may be a key dietary variable in the developmental programming of cardiometabolic function in
adult offspring [33]. In rodent studies, the ω-6 to ω-3 FA ratio in the maternal diet may impact bone
parameters and therefore indirectly also the body weight [34]. Modulation of dietary ω-6 to ω-3
ratio and/or early leptin levels may also have long-term effects on later metabolic parameters [35].
Increased maternal intake of ω-3 FAs led to a decreased growth rate, reduced adipose tissue mass,
lower serum leptin concentrations [36], reduced fat accretion, and reduced the age-related decline
in insulin sensitivity in progeny [37]. The reduced DHA in mothers maintained on a HFD for the
third week of gestation or throughout gestation in the plasma, liver, adipose tissue, and placenta may
predispose their offspring to metabolic disease.
In humans, DHA supplementation during normal pregnancy was associated with lower infant
ponderal index at birth and decreased umbilical cord insulin concentrations compared to infants from
mothers consuming placebos [38]. Higher cord plasma DHA concentrations and ω-3 to ω-6 PUFA
ratios were associated with improved fetal insulin sensitivity, whereas cord plasma saturated FAs
(namely stearic acid and arachidic acid (C20:0)) were negatively correlated with fetal insulin sensitivity,
suggesting a positive impact of certain ω-3 FAs and a negative impact of saturated FAs on fetal insulin
sensitivity [39]. This may be explained by PUFAs constituting important structural elements of cell
membranes and, concomitant with their eicosanoid products, they also modulate gene expression [35].
In our study, in rats maintained on a HFD for the third week of gestation, plasma myristic and stearic
acid proportions were elevated, whereas DHA proportions were reduced in both mothers maintained
on a HFD during the third week of gestation or throughout gestation, which likely contributes to
insulin insensitivity in their fetal offspring. Indeed, fetuses exposed to a HFD for the third week
of fetal life were heaviest concomitant with elevated glycemia and insulin resistance [16] reflecting
,insulin insensitivity.
Unfortunately, the mechanisms involved cannot be derived from our data, although other studies
provide some insight. Studies in pregnant mice reported that a HFD causes marked up-regulation of
placental transport of specific nutrients, such as glucose and neutral amino acid transport [13]. Thus,
since DHA is essential for normal fetal and neonatal growth and development [5,40], its deficiency
in the HFD may enhance its placental transfer. The impact of dietary ω-3 on placental function is
well recognized [41]. Another consideration is that an ω-3 deficient condition, as induced by the HF
administration during gestation, could up-regulate the fetal synthesis of DHA from its EFA precursor,
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αLA. The near-term rat fetus has the capacity to synthesize DHA from αLA [42,43] via different
desaturases and elongases [44–47]. Moreover in the adult rat, it was shown that an ω-3 deficient diet
up-regulates the hepatic expression and activity of delta-6-desaturase [48] and the synthesis of DHA
from αLA is enhanced by diets low in PUFA [49]. Additional studies are required to determine which
of these mechanisms are in effect to justify the trend of the increase in the proportion of DHA in fetal
plasma relative to their mothers under conditions of HF feeding during late pregnancy.
5. Conclusions
Mothers maintained on a HFD for the final week of gestation or throughout gestation had
reduced DHA in plasma, liver, adipose tissue, and placenta. Altered circulating and hepatic FA
profiles, particularly saturated FA elevation, and reduced key ω-3 and ω-6 PUFA, coinciding with
the compromised maternal metabolic state of pregnancy, reflects altered lipid metabolism that may
have adverse health outcomes. Low DHA maternal availability in rats fed the HFD may up-regulate
its placental transfer or stimulate its fetal synthesis from its EFA precursor thereby allowing the
maintenance of a higher proportion in fetal plasma relative to maternal plasma. Therefore, maternal
intake of a HFD during the critical stage of peak fetal development should be avoided for stabilizing
lipid profiles to promote healthy outcomes in mothers and their fetuses.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/2072-6643/
8/ 1/25/s1.
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Abstract: Excess free fatty acid accumulation from abnormal lipid metabolism results in the
insulin resistance in peripheral cells, subsequently causing hyperinsulinemia, hyperglycemia and/or
hyperlipidemia in diabetes mellitus (DM) patients. Herein, we investigated the effect of phenolic
acids on glucose uptake in an insulin-resistant cell-culture model and on hepatic insulin resistance
and inflammation in rats fed a high-fat diet (HFD). The results show that vanillic acid (VA)
demonstrated the highest glucose uptake ability among all tested phenolic acids in insulin-resistant
FL83B mouse hepatocytes. Furthermore, rats fed HFD for 16 weeks were orally administered
with VA daily (30 mg/kg body weight) at weeks 13–16. The results show that levels of serum
insulin, glucose, triglyceride, and free fatty acid were significantly decreased in VA-treated HFD
rats (p < 0.05), indicating the protective effects of VA against hyperinsulinemia, hyperglycemia and
hyperlipidemia in HFD rats. Moreover, VA significantly reduced values of area under the curve
for glucose (AUCglucose) in oral glucose tolerance test and homeostasis model assessment-insulin
resistance (HOMA-IR) index, suggesting the improving effect on glucose tolerance and insulin
resistance in HFD rats. The Western blot analysis revealed that VA significantly up-regulated
expression of hepatic insulin-signaling and lipid metabolism-related protein, including insulin
receptor, phosphatidylinositol-3 kinase, glucose transporter 2, and phosphorylated acetyl CoA
carboxylase in HFD rats. VA also significantly down-regulated hepatic inflammation-related proteins,
including cyclooxygenase-2 and monocyte chemoattractant protein-1 expressions in HFD rats. These
results indicate that VA might ameliorate insulin resistance via improving hepatic insulin signaling
and alleviating inflammation pathways in HFD rats. These findings also suggest the potential of VA
in preventing the progression of DM.
Keywords: vanillic acid; insulin resistance; hyperinsulinemia; hyperglycemia; hyperlipidemia
1. Introduction
As advanced medical technology and improved living standards extend the expectancy of human
life, chronic diseases have become a major threat to the health of people. Diabetes mellitus (DM) is
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one of the fastest-growing chronic diseases. The World Health Organization (WHO) reported that
there were more than 347 million people suffering from DM worldwide, and predicted the patient
number would double (694 million) by 2030 [1]. The process of DM development involves an initial
prediabetes state, and develops into DM if the condition is not appropriately controlled. Therefore,
effectively maintaining blood glucose homeostasis has become a crucial issue in DM prevention.
After consuming high-calorie foods, the body is in a hyperglycemic state with an increased
insulin secretion, reducing serum glucose to maintain a steady level of serum glucose. Long-term
excess intake of high-calorie or high-fat diet (HFD) resulted in increasing blood glucose level and
free fatty acid content and induced metabolic related diseases, such as obesity, dyslipidemia, type 2
diabetes mellitus (T2DM), and fatty liver disease [2–4]. The increased blood glucose level caused islet
cells to continuously secrete insulin, while the increased free fatty acid content caused an increased
lipid synthesis, leading to the accumulation of diacylglycerol in the liver and activation of protein
kinase Cε (PKCε). Activated PKCε inhibits the insulin signaling, consequently resulting in hepatic
insulin resistance [4]. HFD also tends to be obesity associated. Previous studies indicated that insulin
resistance that occurred via obesity is correlated with internal chronic inflammation, which is among
the major causes of insulin resistance [5–7]. Increased release of free fatty acids from adipocytes into
blood was reported to activate protein kinases, e.g., protein kinase C, which subsequently affected the
expression of inhibitor of kappa β kinase, c-Jun N-terminal kinases (JNK), and p38 mitogen-activated
protein kinases, stimulating the release of inflammatory factors such as tumor necrosis factor-alpha
(TNF-α) and interleukin-6 (IL-6), and causing internal inflammatory responses [8].
Phenolic acids are phytochemicals abundant in various vegetables and fruits. Hydroxybenzoic
acid derivatives and hydroxycinnamic acid derivatives are two major categories of phenolic
acid [9]. Hydroxycinnamic acid derivative p-methoxycinnamic acid promoted glycolysis, reduced
gluconeogenesis in the liver of diabetic rats, and increased the secretion of insulin to reduce
hyperglycemia in streptozotocin (STZ)-induced diabetic rats [10]. Ferulic acid improved the
serum glucose levels and counteracted lipid peroxidation in STZ-induced diabetic mice and KK-Ay
spontaneous diabetic mice [11]. Caffeic acid was reported to increase the utilization of glucose by the
liver and adipocytes to reduce serum glucose levels in type 2 diabetic mice [12]. Various phenolic acids
were found to alleviate the DM and its associated syndromes [9–12]. However, the study of phenolic
acids against HFD-induced hyperinsulinemia, hyperglycemia and hyperlipidemia is limited. The
aim of the present study is to assess the glucose uptake-enhancing effect in vitro and investigate the
hypoinsulinemic, hypoglycemic and hypolipidemic effect in vivo of phenolic acids. The mechanism of
the selected phenolic acid on attenuating insulin resistance in HFD rats is also elucidated.
2. Materials and Methods
2.1. Chemicals
Bovine serum albumin (BSA), caffeic acid, chlorogenic acid, cinnamic acid, D-(+)-glucose, dimethyl
sulfoxide (DMSO), disodium hydrogen phosphate (Na2HPO4), ferulic acid, 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), insulin, pioglitazone hydrochloride (Pio), potassium
chloride (KCl), potassium dihydrogen phosphate (KH2PO4), protocatechuic acid, sinapic acid,
sodium chloride (NaCl), sodium phosphate dibasic (Na2HPO4), syringic acid, vanillic acid (VA),
recombinant mouse tumor necrosis factor (TNF)-α, sulfuric acid (H2SO4), Triton X-100, TEMED
(N,N,N,N1-Tetramethyl-eyhylenediamine), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT reagent), and F12 Ham Kaighn’s modification (F12K) medium were purchased
from Sigma-Aldrich Co. (St. Louis, MO, USA). Fetal bovine serum (FBS) was obtained from
Gemini Bio-Products (Woodland, CA, USA). The fluorescent dye 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino)-2-deoxyglucose (2-NBDG) was purchased from Invitrogen (Camarillo, CA, USA). Bio-Rad
protein assay dye reagent was obtained from Bio-Rad Laoboratories (Richmond, VA, USA). All of the
chemicals used in this study were of analytical grade.
38
Nutrients 2015, 7, 9946–9959
2.2. Cell Culture
Experiments were performed on a hepatocyte cell line (FL83B) deriving from a fetal mouse
(15–17 days). The FL83B cells were incubated in F12K medium containing 10% fetal bovine serum
and 1% penicillin and streptomycin (Invitrogen Corporation, Camarillo, CA, USA) in 10 cm Petri dishes
at 37 ˝C and 5% carbon dioxide. Experiments were performed when cells were 80%–90% confluent.
2.3. Tumor Necrosis Factor-Alpha (TNF-α) Induction of Insulin Resistance
The induction of insulin resistance in hepatocytes referred to the method reported by Chang
and Shen with minor modifications [13]. FL83B cells were seeded in 10 cm dishes and incubated
at 37 ˝C for 48 h to 80% confluence. Serum-free F12K medium containing 20 ng/mL recombinant
mouse TNF-α was then added and incubated for 5 h to induce insulin resistance.
2.4. Uptake of Fluorescent 2-(N-(7-Nitrobenz-2-oxa-1,3-Diazol-4-yl)Amino)-2-Deoxyglucose in FL83B
Mouse Hepatocytes
The FL83B cells were detached with trypsin and suspended in 1200 μL of Krebs-Ringer bicarbonate
buffer containing 1 μM insulin. Aliquots of the cell suspension (172 μL) were transferred to Eppendorf
tubes and co-incubated with 20 μL of 6.25 ng/mL VA and 8 μL of the fluorescent dye 2-NBDG (to a
final concentration of 200 μM) in a water bath at 37 ˝C for 1 h in the dark. The reaction was stopped
on ice. The cell suspension was centrifuged at 3000ˆ g (4 ˝C) for 5 min to remove the supernatant.
The pellet was washed with phosphate-buffered saline (PBS) and centrifuged 3 times before being
suspended in 1 mL of PBS. The fluorescence intensity of the cell suspension was evaluated using flow
cytometry (FACScan, Becton Dickinson, Bellport, NY, USA) at an excitation wavelength of 488 nm and
an emission wavelength of 542 nm. Fluorescence intensity reflected the cellular uptake of 2-NBDG.
Amelioration rate p%q “ ppfluorescence intensity of phenolic acid ´ treated groupq ´
pfluorescence intensity of TNF ´ α ´ treated groupqq{
pfluorescence intensity of TNF ´ α ´ treated groupq ˆ 100 p%q.
(1)
2.5. Animals and Diets
Male Sprague-Dawley (SD) rats (5 weeks old) were obtained from the National Laboratory Animal
Center, Taipei, Taiwan. The rats were maintained in standard laboratory conditions (22 ˘ 1 ˝C and a
12 h light/12 h dark cycle) with free access to food and water. Rats were fed a normal diet for 1 week
and had a body weight of approximately 250 g. The rats were divided into 4 groups, with each group
containing 6 rats. One group was fed a normal diet for 16 weeks (Control group). A second group
was fed an HFD (60% calories from fat) throughout the experimental period (HFD group). A third
group was provided an HFD for 16 weeks and daily administered Pio (30 mg/kg body weight) on a
daily basis during weeks 13–16 (HFD + Pio group). A final group was provided an HFD for 16 weeks,
and orally administered VA (30 mg/kg body weight) on a daily basis during weeks 13–16 (HFD + VA
group). The rats were sacrificed at the end of the experiment before the blood samples were collected
and the biochemical analysis conducted. The organs such as liver, kidney, perirenal and epididymal
adipose tissues were isolated from animals and weighed. The liver was stored at ´80 ˝C for the free
fatty acid assay and Western blot analysis.
2.6. Blood Sample Preparation
Blood samples were collected and allowed to clot for 30 min at room temperature and then
centrifuged at 3000ˆ g for 20 min to obtain the serum, which was stored at ´80 ˝C before use.
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2.7. Biochemical Measurements
Enzyme-linked immunosorbent assay kits for rat insulin, total bilirubin, blood urea nitrogen,
creatinine, total cholesterol, triglyceride, free fatty acid, and leptin were purchased from Randox
Laboratories (Crumlin Co., Antrim, UK). Biochemical analyses were performed according to the
manufacturer’s protocols.
2.8. Oral Glucose Tolerance Test (OGTT)
The OGTT was performed on rats in all groups after an overnight fast at week 16. All animals
were orally administered 1.5 g of glucose/kg body weight. Blood was sampled from the tail vessels of
conscious animals before (t = 0) and 30, 60, 90, and 120 min after glucose administration. The samples
were allowed to clot for 30 min and then centrifuged (4 ˝C, 3000ˆ g, 20 min) to obtain the serum.
Glucose concentration was determined using a glucose enzymatic kit (Crumlin Co.). The obtained
glucose concentration values were plotted against time to provide a curve showing the changes in
glucose levels with time, expressed as an integrated area under the curve for glucose (AUCglucose).
2.9. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Index [14]
The HOMA-IR index was calculated using the following equation:
HOMA ´ IR index “ fasting serum insulin pmU{Lq ˆ fasting glucose pmmol{Lq{22.5 (2)
2.10. Western Blot Analysis
Aliquots of supernatants, each containing 50 μg protein, were used to evaluate the expression
of insulin receptor (IR), phosphatidylinositol-3 kinase (PI3K), glucose transporter 2 (GLUT-2),
cyclooxygenase-2 (COX-2), monocyte chemoattractant protein-1 (MCP-1), and acetyl CoA carboxylase
(ACC), phospho-acetyl CoA carboxylase (pACC). The samples were subjected to 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis, and the proteins were electrotransferred to a polyvinylidene
difluoride membrane. The membrane was incubated with block buffer (PBS containing 0.05% Tween-20
and 5% w/v nonfat dry milk) for 1 h, washed with PBS containing 0.05% Tween-20 (PBST) 3 times, and
then probed with 1:2000 diluted solutions of anti-IR, anti-PI3K, anti-GLUT-2, anti-COX-2, anti-MCP-1,
and anti-ACC, anti-pACC, antibodies (Gene Tex, Irvine, CA, USA) overnight at 4 ˝C. The intensity of
the blot probed with a 1:4000 diluted solution of mouse monoclonal antibody to bind actin (Gene Tex)
was used as a control to ensure that a constant amount of protein was loaded into each lane of the gel.
The membrane was washed 3 times (5 min each time) in PBST, shaken in a solution of horseradish
peroxidase-linked anti-mouse IgG or anti-rabbit IgG secondary antibody, washed 3 more times (5 min
each time) in PBST, and then exposed to enhanced chemiluminescence reagent (Millipore) according
to the manufacturer’s instructions. The films were scanned and analyzed using a UVP Biospectrum
image system (Level, Cambridge, UK).
2.11. Statistical Analysis
Results presented as mean ˘ standard deviation (SD) were analyzed using one-way ANOVA and
Duncan’s new multiple range tests. All comparisons were made relative to controls, and p < 0.05 was
considered significant.
3. Results and Discussion
3.1. Effect of Phenolic Acids on Cell Viability and Glucose Uptake Ability in Insulin-Resistant FL83B
Mouse Hepatocytes
The in vitro MTT assay is typically used to evaluate the cellular growth inhibition and assess
toxicity of drugs or chemicals [15]. Phenolic acids are known to possess antiviral, antioxidative,
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anticancer, and antihyperglycemic bioactivities [16–18]. However, the effect of phenolic acid on
bioactivity and the cytotoxicity in FL83B mouse hepatocytes have not been systematically investigated.
Table 1 shows the growth inhibitory of concentration effect of eight naturally occurred phenolic acids
on FL83B cells. The results from the cell viability test reveal that the all tested phenolic acids at
the concentration of 12.5 μM show above 80%, indicating non-toxicity to FL83B mouse hepatocytes.
Therefore, this concentration (12.5 μM) was used to evaluate the glucose uptake-enhancing effect of
phenolic acids in insulin resistance cell model.
Table 1. Effects of various concentrations of phenolic acids on cell viability and amelioration rate of
glucose uptake in insulin-resistant FL83B cells.
Phenolic Acids
Concentrations Cell Viability (%) a Amelioration Rate (%) b
(12.5 μM Phenolic Acid)12.5 μM 25 μM 50 μM 100 μM
Caffeic acid 102.8 ˘ 15.8 99.4 ˘ 16.8 82.0 ˘ 14.3 74.3 ˘ 8.6 ´6.60
Cinnamic acid 86.2 ˘ 2.1 88.7 ˘ 2.5 88.6 ˘ 6.7 89.6 ˘ 0.1 ´11.30
Ferulic acid 92.7 ˘ 7.3 88.9 ˘ 9.1 86.7 ˘ 6.7 77.4 ˘ 28.2 ´22.01
Protocatechuic acid 91.7 ˘ 10.4 91.8 ˘ 9.0 75.4 ˘ 8.1 71.8 ˘ 9.0 ´12.90
Rosmarinic acid 104.3 ˘ 17.6 97.2 ˘ 13.1 102.5 ˘ 16.5 90.7 ˘ 22.4 ´10.28
Sinapic acid 97.2 ˘ 2.9 102.1 ˘ 10.1 102.0 ˘ 10.5 80.0 ˘ 9.2 ´15.37
Syringic acid 90.9 ˘ 2.2 79.8 ˘ 17.4 70.2 ˘ 13.1 64.6 ˘ 14.5 8.36
Vanillic acid 114.2 ˘ 26.3 114.8 ˘ 18.5 109.8 ˘ 25.5 116.7 ˘ 17.6 13.66
a Cell viability (%) = (A570 of sample group)/(A570 of control group) ˆ 100 (%); b Amelioration rate
(%) = ((fluorescence intensity of phenolic acid-treated group) ´ (fluorescence intensity of TNF-α-treated
group))/(fluorescence intensity of TNF-α-treated group) ˆ 100 (%). Data are expressed as percentage relative to
control value (100%) or mean ˘ SD (n = 3).
TNF-α is a cytokine found to interfere with the transmission of insulin signaling and the abilities
of liver cells, myofibroblasts, and adipocytes to absorb and metabolize glucose [19–21]. Previously,
the 2-NBDG, a modified D-glucose fluorescent derivative, was used to assess the viability of yeast
and Escherichia coli, and the ability of glucose uptake in FL83B cells treated with TNF-α to induce
insulin resistance [13,22,23]. In the present study, fluorescent 2-NBDG was used to evaluate the
effect of phenolic acids on glucose uptake ability in insulin-resistant FL83B mouse hepatocytes. As
shown in Table 1, VA at concentration of 12.5 μM showed the highest potential for reducing insulin
resistance (amelioration rate, 13.66%) among tested phenolic acids. VA was thus used in the subsequent
animal experiments.
3.2. Effect of Vanillic Acid on Glucose Tolerance, Serum Insulin and Insulin Resistance Index in High-Fat
Diet (HFD)-Fed Rats
HFD is associated with insulin resistance and reduced insulin secretion by β-cells in the pancreas,
leading to abnormal glucose tolerance in animal [24–27]. Figure 1a shows the results of OGTT in
rats fed HFD for 16 weeks and orally administered with VA daily during the last 4 weeks. The serum
glucose levels of rats in the HFD group increased significantly after 30 min, and then decreased slowly.
HFD rats treated with Pio or VA exhibited similar changes in serum glucose levels. The AUCglucose
for the OGTT, indicating the degree of glucose tolerance in the rats, remained at high levels, thereby
indicating low glucose tolerance in the present study. The HFD rats exhibited significantly (p < 0.05)
lower glucose tolerance than the control rats and VA-treated HFD rats (Figure 1b). In other words, VA
can ameliorate the HFD-induced glucose intolerance.
Hyperinsulinemia is likely a marker of insulin resistance, rather than a major, direct contributor to
the process [28]. Under hyperglycemic conditions, the pancreas compensates for the decreased insulin
response by increasing the insulin secretion; however, the result is hyperinsulinemia to maintain
the stable plasma glucose. This process will continue until the reserve capacity is surpassed by
metabolic demands and insulin secretion is no longer sufficient; then, blood glucose concentration
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rises and glucose intolerance and T2DM develop [29–31]. HFD is also reported to be associated
with the hyperinsulinemia of rats [32]. In this study, the fasting serum insulin concentration of
rats in the HFD group (4.30 ˘ 1.14 μg/L) was 347.9% higher than that in the control (normal diet)
group (0.96 ˘ 0.33 μg/L) (Figure 1c), indicating the hyperinsulinemia in the HFD rats. However,
the serum insulin level of VA-treated HFD rats (2.13 ˘ 0.64 μg/L) was significantly lower than
that in HFD-fed rats, indicating the hypoinsulinemic ability of VA. The rats fed HFD over the long
term will develop diabetic symptoms such as insulin resistance [33]. Matthews et al. proposed
methods using the fasting serum insulin and glucose levels during leisure time to calculate the
HOMA-IR index, which is considered a sensitive indicator to assess the degree of insulin resistance [14].
A high HOMA-IR value represents high insulin resistance [14,34]. The advantages of the HOMA-IR
are ease of calculation of fasting serum insulin and glucose levels, and potential for extensive use
in epidemiological research. As shown in Figure 1d, the HOMA-IR index of VA-treated HFD rats
was significantly lower than that of HFD rats, indicating VA may ameliorate the insulin resistance in
HFD rats. VA derivative was previously reported to inhibit protein-tyrosine phosphatase 1B (PTP1B)
activity, reduce the interference on insulin-signaling proteins, and lead to the alleviation of insulin
resistance in T2DM patients [35].
Figure 1. (a) Oral glucose tolerance test (OGTT); (b) area under the curve for glucose (AUCglucose) of
OGTT; (c) fasting serum insulin, and (d) homeostasis model assessment of insulin resistance (HOMA-IR)
in rats fed high-fat diet for 16 weeks and orally administered with vanillic acid during the last 4 weeks.
Control: normal diet; HFD: high-fat diet (60 kcal % fat); HFD + Pio: HFD (60 kcal % fat) + pioglitazone
(30 mg/kg body weight); HFD + VA: HFD (60 kcal % fat) + vanillic acid (30 mg/kg body weight);
(A–C) indicate statistically significant differences p < 0.05. Data are presented as mean ˘ SD (6 rats in
each group).
3.3. Effect of Vanillic Acid on Energy Intake, Body Weight, and Selected Organ Weight in HFD-Fed Rats
No significant difference (p > 0.05) in the energy intakes among tested groups was observed,
indicating that orally administered VA exerts no significant effect on energy intake in HFD rats
(Table 2). There was no significant difference in the kidney weights of each group (Table 2). However,
after 4 weeks of treatment, the average body, liver and adipose tissue weights of HFD rats were
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significantly higher than those of Pio and VA-treated HFD rats (p < 0.05). HFD was reported to increase
serum triglyceride and non-esterified free fatty acid (NEFA) content, thereby resulting in increased
lipogenesis in rats [36]. Pio was reported to restrict the increase of adipose tissue and body weight
in obese women [37]. Thus, VA was postulated to possess the similar effect as Pio on suppressing
accumulation of body fat in HFD-fed rats via the inhibition of lipid synthesis or lipogenesis.
Table 2. The body weight, selected tissue weight, and energy intake in rats fed a high-fat diet
for 16 weeks and orally administered with vanillic acid during the last 4 weeks.
Items/Groups Control HFD HFD + Pio HFD + VA
Body weight (g) 627.1 ˘ 28.7 C 760.7 ˘ 63.1 A 686.0 ˘ 30.4 B 676.9 ˘ 70.2 B
Diet intake (kcal/rat/day) 104.45 ˘ 4.43 A 110.04 ˘ 11.33 A 101.63 ˘ 5.77 A 104.97 ˘ 9.91 A
Liver weight (g) 14.6 ˘ 0.7 B 18.5 ˘ 2.2 A 13.9 ˘ 1.4 B 13.9 ˘ 1.6 B
Kidney weight (g) 1.1 ˘ 0.4 A 1.4 ˘ 0.5 A 1.7 ˘ 0.2 A 0.9 ˘ 0.6 A
Adipose weight (g) 17.7 ˘ 4.6 C 56.1 ˘ 12.7 A 36.7 ˘ 6.4 B 35.3 ˘ 12.7 B
Control: normal diet; HFD: high-fat diet (60 kcal % fat); HFD+Pio: HFD (60 kcal % fat) + pioglitazone
(30 mg/kg body weight); HFD + VA: HFD (60 kcal % fat) + vanillic acid (30 mg/kg body weight). Adipose
weight: total weight of perirenal and epididymal adipose tissues. (A´C) indicate statistically significant
differences p < 0.05. Data are presented as mean ˘ SD (n = 6/group). Adipose weight includes epididymal fat
pad and abdominal adipose tissue weight.
3.4. Effect of Vanillic Acid on Serum Biochemical Parameters in HFD-Fed Rats
Long term consumption HFD resulting in the increment of adipose tissues. The fatty acids from
adipocytes are subsequently released into the blood then transported to periphery tissues such as liver
and muscle. The process inhibits the utilization of glycogen and glucose and induces insulin resistance
in peripheral tissues. HFD was reported to induce dyslipidemia, resulting in elevated serum glucose,
triglyceride, NEFA levels and reduced high-density lipoprotein levels in rats [33,38]. After feeding
rats for 16 weeks, the fasting serum glucose of the HFD group was 18.1% higher than that of control
group (Table 3). The significant difference (p < 0.05) between these two groups was consistent to the
previous study and revealed that hyperglycemia was induced in HFD-fed rats in the present study [38].
Furthermore, the fasting serum glucose level in VA-treated rats (94.5 ˘ 1.9 mg/L) was significantly
lower than that in the HFD rats (p < 0.05) (Table 3), indicating the hypoglycemic ability of VA.
Moreover, the fasting serum triglyceride and free fatty acid concentration of rats in the HFD
group are higher than those in the control group by 20.8% and 27.2%, respectively (Table 3), indicating
the hyperlipidemia in the HFD rats. However, the fasting serum triglyceride and free fatty acid were
significantly reduced in HFD rats supplemented with VA (71.63 ˘ 13.42 μg/L, 0.76 ˘ 0.14 mmol/L)
compared to the HFD rats (p < 0.05), suggesting the hypolipidemic ability of VA.
Leptin is a hormone secreted by adipose tissues and regulates utilization of lipid in human body.
The serum leptin concentration of in the HFD rats was significantly (p < 0.05) higher than that in
control group (Table 3). Comparatively, the serum leptin level was significantly reduced (p < 0.05)
in HFD rats after 4-weeks VA treatment (Table 3). Previous studies reported a positive correlation
between serum leptin concentration and body fat content, and suggested that people with obesity or
T2DM have higher serum leptin levels than healthy people do [39,40]. Studies have also indicated that
leptin reduces body weight, body fat, energy intake, serum glucose levels, and insulin concentration in
mice [41,42]. However, the mechanism underlying such effects was still unidentified. We speculate
that HFD promotes leptin production and is involved in the accumulation of hepatic NEFA and the
induction of hepatic insulin resistance in rats subsequently.
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Table 3. The fasting serum parameters in rats fed high-fat diet for 16 weeks and orally administered
with vanillic acid during the last 4 weeks.
Items/Groups Control HFD HFD + Pio HFD + VA
Glucose (mg/dL) 90.8 ˘ 1.7 B 107.2 ˘ 5.5 A 97.0 ˘ 3.7 B 94.5 ˘ 1.9 B
Triglyceride (mg/dL) 74.13 ˘ 18.20 B 89.50 ˘ 11.70 A 61.50 ˘ 9.80 B 71.63 ˘ 13.42 B
Free fatty acid (mmol/L) 0.92 ˘ 0.09 B 1.17 ˘ 0.26 A 0.69 ˘ 0.16 C 0.76 ˘ 0.14 B,C
Total cholesterol (mg/dL) 62.38 ˘ 9.71 A 51.63 ˘ 14.35 A 58.13 ˘ 9.95 A 40.00 ˘ 6.41 B
Leptin (ng/mL) 162.3 ˘ 32.6 B 986.3 ˘ 413.8 A 429 ˘ 69.7 B 303.2 ˘ 84.2 B
Bili-total (mg/dL) 0.08 ˘ 0.01 A 0.07 ˘ 0.01 A 0.05 ˘ 0.01 B 0.07 ˘ 0.02 A
BUN (mg/dL) 15.33 ˘ 1.25 A 9.55 ˘ 0.91 C 12.80 ˘ 1.05 B 10.96 ˘ 2.11 C
Creatinine (mg/dL) 0.35 ˘ 0.05 AB 0.38 ˘ 0.05 A 0.31 ˘ 0.04 B 0.38 ˘ 0.05 A
Bili-total: total bilirubin; BUN: blood urea nitrogen. Control: normal diet; HFD: high-fat diet (60 kcal % fat);
HFD + Pio: HFD (60 kcal % fat) + pioglitazone (30 mg/kg body weight); HFD + VA: HFD (60 kcal % fat) +
vanillic acid (30 mg/kg body weight); (A´´C) indicate statistically significant differences p < 0.05. Data are
presented as mean ˘ SD (6 rats in each group).
3.5. Effect of Vanillic Acid on Hepatic Insulin Signaling, Inflammation and NEFA Formation in HFD-Fed Rats
Insulin is a hormone with multiple effects. Binding of insulin to the α-subunit of the insulin
receptor molecule induces rapid auto-phosphorylation of the β-subunit, which leads to an increase
of its tyrosine kinase activity [43]. Tyrosine phosphorylation of insulin receptor proteins induces the
cytoplasmic binding activity of insulin receptor substrate-1 (IRS-1) to insulin receptor. IRS-1 plays a
pivotal role in transmitting signals from insulin receptors to intracellular PI3K/Akt pathway, which
eventually results in the second intracellular step of insulin action, targeting tyrosine-phosphorylated
insulin receptor β and IRS-1 [29,43–45]. IR is a condition in which defects in the action of insulin are
such that normal levels of insulin do not operate as the signal for glucose uptake [43]. After a 4-week
administration of VA, a down-regulation of hepatic insulin signaling-related proteins, such as IR, PI3K,
and GLUT-2, was found in HFD group rats as compared with the control group (Figure 2). These
results suggested that VA normalizes hepatic insulin signaling and alleviates hepatic insulin resistance
in the liver of HFD-fed rats.
The chronic inflammation increases the development of obesity-related insulin resistance [5].
COX-2, an enzyme involved in inflammatory responses, is barely detectable in normal conditions
and rapidly up-regulated in the inflammation conditions [28]. MCP-1, an inflammatory cytokine,
is up-regulated in the conditions of hyperlipidemia and inflammation [46]. As shown in Figure 3,
HFD up-regulated the hepatic COX-2 and MCP-1 protein expressions as compared with the control
group. In contrast, the expressions of COX-2 and MCP-1 protein were down-regulated (p < 0.05) after
a 4-week VA treatment in HFD-fed rats. Diet-induced obesity is a type of inflammatory response,
with up-regulated COX-2 and MCP-1 protein expressions observed in the internal tissues of obese
rats [47,48].
HFD increases the lipid synthesis in liver and adipose tissues, induces chronic inflammatory
responses thus leading to insulin resistance in mice [28,37]. Acetyl CoA carboxylase (ACC), an
essential enzyme in fatty acid synthesis, is activated by dephosphorylation and transforms acetyl
CoA into malonyl CoA through carboxylation. Enhancing phosphorylation of ACC protein may thus
reduce adipose tissue formation and NEFA accumulation in peripheral tissue, including liver [49].
Excess NEFA from adiposity was reported to cause insulin resistance by inhibiting insulin signaling in
T2DM [49]. In the present study, the phosphorylated ACC/ACC protein expression of liver significantly
decreased, indicating the increment of hepatic lipogenesis in the HFD rats (Figure 4a). The expression
of hepatic phosphorylated ACC/ACC protein expression was increased, and the hepatic NEFA level
reduced in HFD rats treated with VA for 4 weeks (Figure 4b). The current study suggests that VA may
reduce hepatic NEFA accumulation via promoting the phosphorylation of ACC protein expression in
liver of HFD rats.
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Figure 2. Hepatic (a) insulin receptor (IR); (b) phosphoinositide 3-kinase (PI3K); and (c) glucose
transporter 2 (GLUT-2) proteins expression in rat fed high-fat diet for 16 weeks and orally administered
vanillic acid during the last 4 weeks. Control: normal diet; HFD: high-fat diet (60 kcal % fat); HFD + Pio:
HFD (60 kcal % fat) + pioglitazone (30 mg/kg body weight); HFD + VA: HFD (60 kcal % fat) + vanillic
acid (30 mg/kg body weight); (A–C) indicate statistically significant differences p < 0.05. Data are
presented as mean ˘ SD (3 rats in each group).
Figure 3. Hepatic (a) cyclooxygenase 2 (COX-2) and (b) monocyte chemoattractant protein-1 (MCP-1)
protein expression in rats fed high-fat diet for 16 weeks and orally administered with vanillic acid
during the last 4 weeks. Control: normal diet; HFD: high-fat diet (60 kcal % fat); HFD + Pio: HFD
(60 kcal % fat) + pioglitazone (30 mg/kg body weight); HFD + VA: HFD (60 kcal % fat) + vanillic acid
(30 mg/kg body weight); (A–C) indicate statistically significant differences p < 0.05. Data are presented
as mean ˘ SD (3 rats in each group).
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Figure 4. (a) Hepatic phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase (pACC/ACC)
protein expression; and (b) non-esterified free fatty acid (NEFA) in rats fed high-fat diet for 16 weeks
and orally administered with vanillic acid during the last 4 weeks. Control: normal diet; HFD: high-fat
diet (60 kcal % fat); HFD + Pio: HFD (60 kcal % fat) + pioglitazone (30 mg/kg body weight); HFD + VA:
HFD (60 kcal % fat) + vanillic acid (30 mg/kg body weight); NEFA: non-esterified free fatty acid in
supernatant of liver homogenate. The liver tissue was homogenized with PBS (1/4; w/v and centrifuged
at 4 ˝C for 60 min to obtain the supernatant; (A–C) indicate statistically significant differences p < 0.05.
Data are presented as mean ˘ SD (6 rats in each group).
Previous studies indicated that high concentration of NEFA was associated with increased
expression of MCP-1 or COX-2 [50,51]. Recent reports also suggest that chronic MCP-1 or
COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance [52,53]. Phenolic
acids were previously reported to exert counteractive effect on inflammation, and prevent the
processing of chronic diseases [18]. The results from this study elucidate that VA may reduce hepatic
NEFA level, decrease hepatic inflammatory responses and subsequently alleviate insulin resistance in
HFD rats.
4. Conclusions
VA is a naturally occurring phenolic acid widely existing in various plant foods. The present
study demonstrates that the protective effect of VA against hyperinsulinemia, hyperglycemia and
hyperlipidemia is through decreasing hepatic NEFA accumulation, alleviating hepatic inflammation
as well as hepatic insulin resistance in HFD-fed rats (Figure 5). Our findings support that VA exerts
therapeutic effects and has the potential to be used in clinical medicine or as a dietary supplement for
preventing the progression of DM.
Figure 5. The postulated mechanisms underlying the effect of vanillic acid on hepatic insulin resistance
by regulating insulin signaling and inflammation pathways in rats fed an HFD.
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Abstract: Niacin is a popular nutritional supplement known to reduce the risk of cardiovascular
diseases by enhancing high-density lipoprotein levels. Despite such health benefits, niacin impairs
fasting blood glucose. In type 2 diabetes (T2DM), an increase in jejunal glucose transport has been well
documented; however, this is intriguingly decreased during niacin deficient state. In this regard, the
role of the niacin receptor GPR109a in T2DM jejunal glucose transport remains unknown. Therefore,
the effects of diabetes and high-glucose conditions on GPR109a expression were studied using jejunal
enterocytes of 10-week-old m+/db and db/db mice, as well as Caco-2 cells cultured in 5.6 or 25.2 mM
glucose concentrations. Expression of the target genes and proteins were quantified using real-time
polymerase chain reaction (RT-PCR) and Western blotting. Glucose uptake in Caco-2 cells and
everted mouse jejunum was measured using liquid scintillation counting. 10-week T2DM increased
mRNA and protein expression levels of GPR109a in jejunum by 195.0% and 75.9%, respectively,
as compared with the respective m+/db control; high-glucose concentrations increased mRNA and
protein expression of GPR109a in Caco-2 cells by 130.2% and 69.0%, respectively, which was also
confirmed by immunohistochemistry. In conclusion, the enhanced GPR109a expression in jejunal
enterocytes of T2DM mice and high-glucose treated Caco-2 cells suggests that GPR109a is involved
in elevating intestinal glucose transport observed in diabetes.
Keywords: enterocytes; jejunum; glucose transport; SGLT1; GLUT2; Caco-2; hyperglycemia;
hyperlipidemia
1. Introduction
Diabetes mellitus is classically one of the most common chronic metabolic disorders, which is
characterized by a plethora of clinical complications; they include, but are not limited to, cardiovascular
disease, end-stage renal diseases, diabetic foot disorders, and blindness. One of the most notable clinical
manifestations of diabetic patients is dyslipidemia, which is the major risk factor for cardiovascular
disease in type 2 diabetes mellitus (T2DM). It has been reported that diabetics have significantly higher
coronary-event-associated deaths than the non-diabetics [1]. Furthermore, diabetic individuals without
known clinical coronary heart disease (CHD) are exposed to comparable risk of mortality compared to
those non-diabetics who have experienced a myocardial infarction [2], thus leading to the recognition
of diabetes as a CHD-risk-equivalent condition [3].
In order to address this issue, scientists have taken strides to develop novel therapeutic agents that
ameliorate cardiovascular disease by specifically targeting dyslipidemia in diabetic patients. In recent
years, niacin, also known as nicotinic acid or Vitamin B3, has been a popular nutritional supplement;
in fact, it is widely used to treat cardiovascular disease which is associated with dyslipidemia by
lowering the level of low-density lipoprotein and triglycerides, while raising the level of high-density
lipoprotein simultaneously [4]. Notwithstanding the existence of these health benefits, niacin has been
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shown to induce glucose intolerance in patients, as evidenced by significant increases in blood glucose
levels (5.83 mg/dL) after three years of niacin treatment in euglycemic patients (9.88 mg/dL for niacin
vs. 4.05 mg/dL for without niacin) [5]. Meanwhile, the incidence rate of impaired fasting blood glucose
was increased by 29%. In patients suffering from hyperglycemia, high doses of niacin also increased
their level of Hemoglobin A1c by about 0.3% [6]. It is recognized that oral niacin elevated blood
glucose levels and thereby deteriorated diabetes in some patients; however, the precise mechanism
still remains unknown [7]. In contrast, a lower Vmax for jejunal glucose uptake vs. control group
was observed in rats fed with niacin deficient diet [8]. Niacin deficiency also significantly lowers the
active electrogenic absorption of glucose across jejunal mucosa [9]. Collectively, these findings have
shown that niacin, to a certain extent, might not be beneficial in terms of its adverse effects on glucose
homeostasis observed in diabetic patients.
Of interest in this context is our recent data showing that such a niacin-induced hyperglycemia
is probably mediated via the activation of niacin receptor GPR109A-mediated ROS-PPARγ-UCP2
(reactive oxygen species-peroxisome proliferator-activated receptor-γ-uncoupling protein 2) signaling
pathway in the pancreatic islet β-cells [10]. In addition, previous studies have shown that niacin exerts
its effects by binding to its specific G protein-coupled receptors HM74 (GPR109B) and its homologues
HM74A (GPR109A) [11–13]. In terms of its potency, niacin activates GPR109A and GPR109B with
half maximal effective concentration (EC50) values of 0.1 mM and 100 mM, respectively [14]. Both
GPR109A and GPR109B have been expressed in the human colon and localized to the apical membrane
of colonocytes [15]. In mice, GPR109A is expressed in both small and large intestines [12,16]. Despite
these findings, the role of GPR109A in jejunal glucose uptake is still elusive. Interestingly, jejunal
glucose transport via both sodium-dependent glucose transporter (SGLT1) and glucose transporter 2
(GLUT2) is greatly increased in early diabetes [17]. In this respect, SGLT1 is a high-affinity, low-capacity
transporter localized at the brush border membrane (BBM) of jejunal enterocytes, which is responsible
for active uptake of glucose from the intestinal lumen; however, GLUT2 is a glucose transporter
normally situated on the basolateral membrane of the jejunal enterocytes but it is translocated and
inserted into the BBM during enhanced SGLT1-mediated glucose uptake [18–20]. In this way, glucose
transport capability of GLUT2 can be up to three times greater than that of SGLT1 [21].
Given the fact that dietary glucose is a critical component in determining our blood glucose
homeostasis and in light of the above-mentioned findings, the present study was designed to unravel
the undiscovered role of niacin in the regulation of intestinal glucose uptake, with particular emphasis
on T2DM, and its potential interaction with the intestinal glucose transporters, SGLT1 and GLUT2,
thus its consequence on glucose homeostasis.
2. Experimental Section
2.1. Animals
4- to 12-week-old male m+/db and db/db mice in this study were used and supplied by the
Laboratory Animal Services Centre at The Chinese University of Hong Kong. Animals were maintained
on a standard chow (Prolab RMH 2500, 5P14; Lab Diet, St. Louis, MO, United States) and water ad
libitum up to the time of experiment. Only those diabetic mice with blood glucose levels above
10 mM were included in the diabetic group. Anesthesia before experimentation was achieved with
pentobarbitone sodium (50 mg/kg) intraperitoneally. All procedures have been approved by the
Animal Experimentation Ethics Committee of the Chinese University of Hong Kong (No. 10/064/MIS).
2.2. Isolation of Enterocytes
Enterocytes were prepared from 4 cm long jejunal segments, beginning 4 cm distal to the ligament
of Treitz. Intestinal epithelia cells were isolated and harvested by a Ca2+-chelation technique [22].
Briefly, isolated intestinal segments were flushed through with ice-cold saline followed by air. The
segment was tied off at one end and filled with Ca2+-free hypertonic isolation buffer (7 mM K2SO4,
52
Nutrients 2015, 7, 7543–7561
44 mM K2HPO4, 9 mM NaHCO3, 10 mM HEPES, 2 mM L-glutamine, 0.5 mM dithiothreitol, 1 mM
Na2EDTA, and 180 mM glucose, pH 7.4), equilibrated with 95% O2 and 5% CO2, where over-distention
was avoided. The segment was then tied off to form a closed sac and incubated in 0.9% saline at 37 ◦C
with gentle shaking for 16 min. Cells were dislodged manually, and the resulting suspension was
collected and centrifuged for 30 s at 500 g; the pellet was re-suspended in freshly prepared cold buffer
and this procedure was repeated twice, as we reported previously [23,24].
2.3. Western Blot Analysis
The procedures of Western blot have been described previously [25]. Proteins from the enterocyte
and Caco-2 cells were extracted using the CytoBuster protein extraction reagent (Novagen, Darmstadt,
Germany) and quantified using Bio-Rad Bradford assay kit (Bio-Rad, Munich, Germany). Proteins
(10 μg/lane) were subjected to electrophoresis on a 10% (weight (wt)/volume (vol)) polyacrylamide
gel. Proteins from the polyacrylamide gel were transferred to the polyvinylidene difluoride membrane
using a semi-dry transblot unit (Bio-Rad, Munich, Germany). The protein-blotted membrane
was saturated by submersion in 5% (wt/vol) nonfat skimmed milk in phosphate buffered saline
(PBS) (pH 7.4) with 0.1% (vol/vol) Tween-20 for one hour at room temperature. The membranes
were incubated with anti-HM74(M-65) receptor rabbit polyclonal antibodies (SC-134583; Santa
Cruz Biotechnology, Dallas, TX, United States)(1:100), anti-NIACR1 (Niacin receptor 1) rabbit
polyclonal antibodies (NBP1-92180, Novus Biologicals, Littleton, CO, United States) (1:100), and
anti-β-actin mouse polyclonal antibodies (EMD Millipore, Danvers, Massachusetts, United States)
(1:5000) overnight at 4 ◦C. After washing with 0.1% Tween-20 in Phosphate-buffered saline (PBS),
membranes were incubated with the following corresponding peroxidase-labeled secondary antibodies
for one hour at room temperature: anti-rabbit Immunoglobulin G (IgG) antibody (GE Healthcare
Bio-Sciences, Pittsburgh, PA, United States) (1:1300) and anti-mouse IgG antibody (GE Healthcare
Bio-Sciences, Pittsburgh, PA, United States) (1:2500). The positive signal was revealed using Enhanced
Chemiluminescence-plus (ECL-plus); GE Healthcare Bio-Sciences, Pittsburgh, PA, United States)
western blotting detection reagent and Fuji Medical Super RX-N autoradiography film (FUJIFILM,
Valhalla, NY, United States). The intensity of the bands was quantified using FluorChem software
(ProteinSimple, San Jose, CA, United States). The corresponding expression of β-actin of each sample
was used to normalize its expression of the target protein.
2.4. Real-Time PCR Analysis
Quantitative RT-PCR was performed using StepOne™ Real-Time PCR Systems (ThermoFisher
Scientific, Grand Island, NY, United States). The procedure has been described previously [26]. Briefly,
total RNA was extracted from freshly prepared enterocytes or Caco-2 cells grown in 5.6, 11.2, or
25.2 mM glucose using Trizol reagent (ThermoFisher Scientific, Grand Island, NY, United States)
according to the manufacturer’s instructions. RNase Out (ThermoFisher Scientific, Grand Island,
NY, United States) was added to the RNA solutions to prevent degradation by RNase. Total RNA
served as the template for cDNA preparation using iScript™ Select cDNA Synthesis Kit (Bio-Rad
Laboratories, Munich, Germany). Primers were designed from mice and human cDNA sequences
using Primer Express Software provided by ThermoFisher Scientific. Mice β-actin and Human β-actin
were used as reference genes to normalize the relative expression of each target gene. The sequences of
primers used are shown in Table 1. Sybergreen reactions were set up in a volume of 25 μL with ABI
two-step sybergreen PCR reagents (ThermoFisher Scientific, Grand Island, NY, United States). Each
reaction consisted of 12.5 μL PCR master mix, 0.05 to 0.30 μM of each amplification primer, and 1 μL
cDNA. Each sample was run in duplicate with an initial 10-min period at 95 ◦C to enable the reaction,
followed by 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min. The samples were heated to 60 ◦C for
1 min, then to 95 ◦C over the next minute, and finally cooled slowly from 95 ◦C to 60 ◦C over 20 min to
collect data for the analysis of dissociation curve. Amplification data were collected by the detector
of the StepOne™ Real-Time PCR Systems and analyzed with Sequence Detection System software
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(ThermoFisher Scientific, Grand Island, NY, United States). The threshold cycle (CT) of each sample
was determined from the time point where fluorescence was first detected, with the cycle number
being inversely related to cDNA concentration. The fold changes in mRNA expression were calculated
using the 2−ΔΔCT method [27].
Table 1. Sequences of specific primers used for real-time quantitative RT-PCR.
Gene Forward Primer Reverse Primer
Mouse β-actin (NM_007393.4) TCCTCCTGAGCGCAAGTACTC GTGGACAGTAGTGAGGCCAGGT
Mouse GPR109a (NM_030701.3) GGCGTGGTGCAGTGAGCAGT GGCCCACGGACAGGCTAGGT
Human β-actin (NC_000007.14) GGCACCCAGCACAATGAAGATC ATGCTTCTAGGCGGACTATGACTT
Human GPR109a (NM_177551.3) TGCCGCCCTTCCTGATGGACA TGTTCAGGGCGTGGTGGGGA
2.5. Immunohistochemistry
Immunofluorescence was carried out as described previously with some modifications to
determine the mucosal localization of niacin receptors [23]. Isolated jejunal segments were rinsed
with cold saline and then quickly transferred to ice-cold 4% paraformaldehyde (PFA) in 0.1 M PBS
(pH 7.4) and incubated at 4 ◦C overnight. Tissue segments were rinsed with PBS and incubated
with 20% sucrose in PBS at 4 ◦C overnight and later embedded in optimum cutting temperature
medium (Tissue-Tek, Sakura Finetek Europe B.V., Zoeterwoude, The Netherlands). Sections (6 μm)
were collected on Superforst slides (Gerhard Menzel GmbH, Braunschweig, Germany), and these were
boiled in 10 mM citrate buffer for 10 min to retrieve the antigens. Sections were incubated with 1%
(wt/vol) bovine serum albumin (BSA) and 6% (wt/vol) normal donkey serum (NDS) (Jackson Immuno
Research, West Grove, PA, United States) for one hour at room temperature to block nonspecific
antibody binding. The slides were incubated overnight at 4 ◦C with primary antibody (SC-134583;
Santa Cruz Biotechnology, Dallas, TX, United States) (1:100), diluted in PBS with 2% NDS and 0.1%
Triton X-100. After three washes with PBS, bound primary antibodies were detected by incubation
with their corresponding secondary antibodies labeled with Cyc-3 (Jackson Immuno Research, West
Grove, PA, United States) (1:100, diluted with 0.1 M PBS containing 2% NDS) at room temperature
for 1 h. Immunoreactivity was captured with a fluorescent microscope equipped with a DC480 digital
camera (Leica Microsystems, Buffalo Grove, IL, United States). Human Caco-2 cells were grown on
silane-coated cover slips, incubated with ice-cold 4% PFA in 0.1 M PBS (pH 7.4) for 8 min, and washed
three times with 0.1 M PBS, followed by the same steps as the immunostaining procedures mentioned
above starting from the incubation with 1% BSA and 6% NDS (wt/vol), except that anti-NIACR1
rabbit polyclonal antibodies (NBP1-92180) (1:100) was used as the primary antibody.
2.6. Glucose Uptake by Everted Jejunal Sleeves
Prior to measurements of glucose uptake, long jejunal segments (3 to 4 cm long) were taken 3 cm
distal to the ligament of Treitz. Glucose uptake was measured using everted jejunal sleeves [28,29].
In brief, isolated jejunal segments were rinsed with cold saline and everted over a glass rod. The tissue
was tied securely to the rod and pre-incubated in gassed carbogen (95% O2, 5% CO2) bicarbonate
buffer (128 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 20 mM
NaHCO3) without glucose for 4 min at 37 ◦C followed by 15 min using the same buffer, with 0.1 μM
to 2 mM of niacin (Sigma-Aldrich, St Louis, MO, United States). Then, concentrated D-glucose
was added to the buffer to make up to a final glucose concentration of 50 mM with 0.2 μCi/mL
D-[14C]glucose (GE Healthcare Bio-Sciences, Pittsburgh, PA, United States) with trace amounts of
0.1 μCi/mL L-[3H]glucose (Sigma-Aldrich, St Louis, MO, United States) to correct for non-specific
uptake. After a 2 min incubation, the segments were washed rapidly with ice-cold saline containing
0.3 mM phlorizin with stirring for 1 min. The tissue was removed from the rod, oven-dried, and
weighed. The dried residue was incubated with Soluene-350 (Perkin-Elmer, Waltham, MA, United
States) at 60 ◦C for 4 h. Scintillation fluid (Ultima Gold; Perkin-Elmer, Waltham, MA, United States)
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was added, and counting of radioactivity was carried out. The rate of glucose uptake was calculated
as picomole per milligram dry weight intestine per second.
2.7. Glucose Uptake by Caco-2 Cells
Caco-2 cells were purchased from ATCC (catalog no. HTB-37). Cells were grown at 37 ◦C in
minimum essential medium (M2279; Sigma-Aldrich, St Louis, MO, United States) with 20% fetal
bovine serum (FBS), 1% nonessential amino acids (#11140; ThermoFisher Scientific, Grand Island,
NY, United States), and 1% penicillin-streptomycin and gassed with 95% air–5% CO2. Cells were
subcultured at ~80% confluence, at a cell density of between 8 × 104 and 1 × 105 cells/cm2. The
medium was changed every two days, and cells were used 14 days after confluence, when they
expressed characteristics of enterocyte differentiation [30,31]. Caco-2 cells grown in media containing
5.6 and 25.2 mM glucose for 14 days after confluence were harvested by Trizol reagent (Thermo Fisher
Scientific, NY, United States) for RNA isolation and real-time PCR reaction, and Cytobuster (EMD
Millipore, Danvers, MA, United States) for Western blotting.
Caco-2 cells grown in 5.6 mM glucose were rinsed with 25 ◦C oxygenated bicarbonate buffer
(128 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 20 mM NaHCO3)
with 10% FBS, 1% penicillin-streptomycin, and 1% nonessential amino acids. Cells were preincubated
in gassed (95% O2–5% CO2) bicarbonate buffer containing 50 mM mannitol for 1 h at 37 ◦C. The
buffer was then replaced with fresh bicarbonate buffer containing 50 mM glucose and 0.2 μCi/mL
D-[14C]glucose (GE Healthcare Bio-Sciences, Pittsburgh, PA, United States), with or without 0.1 μM to
2 mM niacin. In some experiments, 0.3 mM phlorizin or 0.1 mM phloretin was also present. Cells were
washed quickly three times by stirring in ice-cold saline containing 0.3 mM phlorizin. The cells were
digested with 0.3 M NaOH, and aliquots were added to scintillation fluid (Ultima Gold; Perkin-Elmer,
Waltham, MA, United States). Glucose uptake was measured as disintegrations per min per well of a
six-well plate containing a monolayer of Caco-2 cells.
2.8. siRNA Knockdown of GPR109a in Caco-2 Cells
Caco-2 cells grown on six wells plates reached 70% confluence at the time of transfection. One
day before the transfection, the medium was changed to one containing no antibiotics. Stock Stealth™
RNA (ThermoFisher Scientific, Grand Island, NY, United States) was diluted to 40 nM with 50 μL
Opti-MEM® I Reduced Serum Medium without serum. Lipofectamine®2000 (ThermoFisher Scientific,
Grand Island, NY, United States) was diluted 50 times with Opti-MEM®I Reduced Serum Medium
(ThermoFisher Scientific, Grand Island, NY, United States) and incubated 5 min at room temperature.
The diluted Stealth™ RNA and Lipofectamine®2000 was mixed and incubated at room temperature for
10 min. The oligomer-Lipofectamine®2000 complexes were added to each well, followed by incubation
of the cells at 37 ◦C in CO2 incubator for 72 h. The transfected cells were harvested for either protein
detection or glucose uptake.
2.9. Statistical Analysis
All results were analyzed using Prism 3.0 software. The data were expressed as means ± standard
error of the mean (SEM). Student’s unpaired two-tailed t-test and One-Way Analysis of variance
(ANOVA) (Tukey’s post-hoc test) were employed to detect significant differences between two groups
and among three or more groups, respectively. For all comparisons, p < 0.05 was considered statistically
significant. For RT-PCR, the CT value of the target gene of a sample was first corrected for the CT value
of β-actin, before being statistically analyzed [27].
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3. Results
3.1. Enterocyte Expression of GPR109a
The real-time PCR analysis of mRNA expression of GPR109a normalized to β-actin revealed
the presence of GPR109a mRNA in both m+/db and db/db mouse jejunal brush border (Figure 1A).
Expression of GPR109a mRNA in enterocytes from 10-week-old db/db mice was higher than that seen
in four-week-old db/db mice. At the age of 10 weeks, expression of GPR109a in db/db mouse jejunum
was 2.96 folds greater than that of the control 10-week-old m+/db mouse jejunum. Consistently, Western
blotting of enterocyte protein also revealed the presence of GPR109a protein in both m+/db and db/db
mice (Figure 1B). Expression levels of GPR109a protein in enterocytes from 10-week-old diabetic db/db
mice were 1.76 folds greater than their corresponding control 10-week-old m+/db mice.
Figure 1. (A) Effects of age and Type 2 Diabetes Mellitus (T2DM) on the mRNA expression of GPR109a
in jejunal mucosa. Mouse mRNA abundance was determined by real-time PCR using jejunal mucosa
and data were calculated as the percentage of their corresponding m+ non-diabetic controls. All results
are expressed relative to enterocytes of non-diabetic rats, and are given as mean ± standard error of
the mean (SEM), n = 3–4; 10 db vs. 10 m+, ** p < 0.01; (B) Effects of age and T2DM on the protein
expression of GPR109a in jejunal enterocytes. Western blot analysis showing the relative expression
of GPR109a in homogenates of enterocytes prepared from jejuna of m+/db and db/db mice of 4, 10 or
12 weeks of age. Data were calculated as the percentage change compared to their corresponding m+
non-diabetic control. Results are expressed as means ± SEM, n = 3–5, 10m+ vs. 10 db, * p < 0.05. 4m+,
8m+, 10m+ and 12m+ represent 4-, 8-, 10- and 12-week-old m+/db mice respectively; whereas 4 db, 8 db,
10 db and 12 db represent 4-, 8-, 10- and 12-week-old db/db mice, respectively.
56
Nutrients 2015, 7, 7543–7561
3.2. Localization of GPR109a in Jejunal Mucosa of m+/db and db/db Mice, and Caco-2 Cells
Immunohistochemical results showed the localization of GPR109a at the level of the BBM along
the entire jejunal villus length in both normal (m+/db) (Figure 2A–C) and diabetic (db/db) (Figure 2D–F)
animals. However, expression of GPR109a was consistently higher in diabetic jejunum and this was
particularly apparent at higher magnification (Figure 2H diabetic vs. Figure 2G normal). On the other
hand, immunocytochemistry also revealed the presence of niacin receptors at the cell membrane of
Caco-2 cells from the 14 days after confluence (Figure 2J–O). In examination, expression of niacin
receptor was higher in cells grown in 25.2 mM glucose (Figure 2M) compared to those cultured in
5.6 mM glucose (Figure 2J).
Figure 2. Immunodetection of GPR109a in jejunum of 10-week-old m+/db mice (A) and 10-week-old
db/db mice (D). (B,E) are the nuclear DAPI staining of (A,D) respectively; (C,F) are their corresponding
merged images. Higher magnification of niacin receptor staining of m+/db (G) and db/db (H); (I) shows
jejunal sections prepared in the absence of primary antibodies (negative control). Immunodetection
of niacin receptor in Caco-2 cells grown in 5.6 mM (J) and 25.2 mM glucose (M); (K,N) show nuclear
4′,6-diamidino-2-phenylindole (DAPI) staining of (J) and (M) respectively; (L,O) are the corresponding
merged images.
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3.3. Effects of Niacin on Jejunal Glucose Uptake
Next, we attempted to study the role of GPR109a in modulating jejunal glucose uptake. By
using the intestine from non-diabetic (m+/db) mice, mucosal exposure to niacin for 10 min increased
glucose uptake in a dose-dependent fashion (Figure 3). At 1 mM niacin, glucose uptake was increased
by 26.8%.
Figure 3. The dose-dependent effect of niacin on jejunal glucose uptake using 10-week-old m+/db mice.
Data are expressed as relative percentage of glucose uptake relative to the control (con). n = 6 for each
concentration of niacin. Data are given as means ± standard error of the mean (SEM), * p < 0.05 vs.
control; ** p < 0.01 vs. control.
3.4. Effects of Glucose Concentrations on the Expression of GPR109a in Caco-2 Cells
Caco-2 cells were used to study the effects of glucose concentrations of the growth medium on
the gene expression of GPR109a. GPR109a mRNA was expressed in Caco-2 cells grown in both low
glucose and high glucose media. In comparison with the low glucose concentration (5.6 mM), it was
observed that high glucose concentration (25.2 mM) increased both of the gene and protein levels of
niacin receptor expression by 130.2% and 69%, respectively (Figure 4A, B).
3.5. Effects of Niacin and Glucose Transporter Inhibitors on Glucose Uptake in Caco-2 Cells
We also sought to study the role of the niacin receptor GPR109a in the modulation of glucose
uptake in Caco-2 cells. Caco-2 cells grown on normal glucose (5.6 mM) and exposed to niacin for
10 min increased glucose uptake in a dose-dependent fashion (Figure 5A); at 1 mM niacin, glucose
uptake was increased by 20.1%. On the other hand, the effects of the two glucose transporter inhibitors,
the SGLT1 blocker phlorizin (0.3 mM) and GLUT2 blocker phloretin (0.1 mM), in the presence or
absence, on the glucose uptake of Caco-2 cells grown in normal 5.6 mM glucose were also examined.
As shown, 0.3 mM phlorizin and 0.1 mM phloretin inhibited glucose uptake by 23.3% and 62.5%,
respectively.In addition, 1 mM niacin further increased glucose uptake when present with 0.3 mM
phlorizin and 0.1 mM phloretin (Figure 5B). These data indicate that both SGLT1 and GLUT2 may be
involved in the upregulation of niacin-induced glucose uptake.
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Figure 4. (A) Effects of high glucose concentration (25.2 mM) on the mRNA expression of GPR109a in
Caco-2 cells vs. low glucose concentration (5.6 mM). Results are expressed as means ± standard error
of the mean (SEM), n = 3, control = 5.6 mM glucose, control vs. 25.2 mM glucose, * p < 0.05; (B) Effects
of high glucose (25.2 mM) on GPR109a protein expression in Caco-2 cells vs. control 5.6 mM glucose
concentrations. Results are expressed as means ± SEM, n = 6, control = 5.6 mM vs. 25.2 mM, * p < 0.05.
Figure 5. Cont.
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Figure 5. (A) Dose dependent effect of niacin on glucose uptake by Caco-2 cells grown in glucose
(5.6 mM) (expressed as percentage of glucose uptake relative to their control). n = 6 for each
concentration of niacin. Data are given as means ± standard error of the mean (SEM), 0 nM vs.
treatment groups, * p < 0.05; (B) Glucose uptake by Caco-2 cells grown in 5.6 mM glucose showing
effect of 1 mM niacin, with or without phlorizin (PHZ, 0.3 mM) and phloretin (PHR, 0.1 mM). Results
are expressed relative to the respective control value (con). All data are given as means ± SEM, n = 6.
0.3 mM PHZ vs. 0.3 mM PHZ + 1 mM niacin and 0.1 mM PHR vs. 0.1 mM PHR + 1 mM niacin,
* p < 0.05.
3.6. Effects of Knockdown of GPR109a on Glucose Uptake in Caco-2 Cells
Three different siRNA sequences (HSS155268, HSS155269 and HSS155270) were tried in the
study of knockdown of niacin receptor in Caco-2 cells grown in 5.6 mM glucose. Western blot
analysis showed that the knockdown experiments with siRNA HSS155269, HSS155270 and HSS155268
decreased protein expression of niacin receptors by 45.0%, 53.7%, and 32.5%, respectively as compared
with the negative siRNA control group (Figure 6A). Therefore, we selected the siRNA HSS155270, the
most effective knockdown sequence, which decreased the rate of glucose uptake of Caco-2 cells grown
in 5.6 mM glucose by 30.2% (Figure 6B).
Figure 6. Cont.
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Figure 6. (A) Effects of siRNA knockdown of GPR109a on the expression of GPR109a protein in Caco-2
cells grown in 5.6 mM glucose. Western blot analysis showing the relative expression of niacin receptor
in homogenates of cells prepared from the -ve negative (negative control siRNA, Silencer® Select
Negative Control siRNA, non-targeting SiRNA with limited sequence similarity to known genes), and
three different sequences of siRNA (HSS155269, HSS155270 and HSS155268). “Lipofetamine” contains
only the lipofetamine transfection buffer, without any siRNA. “No treatment” contains neither the
transfection buffer nor any siRNA. Results are expressed as means ± standard error of the mean (SEM),
n = 6. HSS155269 vs. negative control, 45% decrease in expression, * p < 0.05; HSS155270 vs. negative
control, 53.8% decrease in expression, * p < 0.05; (B) Effects of siRNA (HSS155270) knockdown of
GPR109a on the glucose uptake of Caco-2 cells grown in 5.6 mM glucose. Knockdown of GPR109a
decreased the rate of glucose uptake by 30.2%, n = 5, * p < 0.05.
4. Discussion
Niacin is a commonly employed anti-hyperlipidemia drug but it is also widely known to induce
hyperglycemia during chronic and high-dose therapy [5,6]. Despite this, the mechanistic action of
niacin and its receptor GPR109a in the regulation of glucose homeostasis, in particular with intestinal
glucose uptake, remains ambiguous. The present study has shown, for the first time, that enterocyte
GPR109a is expressed and functional in the local control of intestinal glucose absorption, and that
type 2 diabetic and high glucose conditions upregulate the GPR109a expression, thus enhancing
niacin-induced intestinal glucose uptake in the mice. Our laboratory has recently reported the novel
role of niacin, via its activation of GPR109A, in pancreatic islets [10]. In that study, niacin was found to
increase fasting glucose concentrations, reduce glucose-stimulated insulin secretion (GSIS) and insulin
secretion, and impair glucose tolerance, thereby inducing pancreatic islet dysfunctions in high-fat diet
(HFD) induced obese mice [10]. In this regard, the present study establishes a previously undiscovered
role of niacin in local regulation of glucose homeostasis at the level of the small intestine in normal
and diabetic states.
In the present study, we have first demonstrated that the mRNA and protein expression levels of
the niacin receptor GPR109a were elevated in the diabetic db/db mice, as evidenced by real-time qPCR
and Western blot, as well as further supported by the immunohistochemical results. Interestingly,
an upregulated expression GPR109a was also observed in diabetic mouse and human retina, where
GPR109a could serve as an anti-inflammatory receptor in retinal pigement epithelial cells and is
closely associated with diabetic retinopathy [32]. It is well recognized that inflammatory process is
a key causative factor in the pathogenesis of diabetes and GPR109a has been shown to be a potent
anti-inflammatory receptor in various physiologically important organs, including but not limiting to,
the colon [33], blood vessels [34], and pancreas [10]. In light of these findings, it prompts us to speculate
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that such an elevated GPR109a expression may be responsible for acting as a strategic counteractive
mechanism against the inflammatory insults, as induced by hyperglycemia in diabetic states.
To address this issue, we sought to examine whether niacin could locally regulate glucose uptake
across the small intestinal BBM. In fact, our laboratory has previously shown the functional existence
of a local renin-angiotensin system (RAS) in the regulation of intestinal glucose uptake, where binding
of the two physiologically active components of this system, angiotensin II, to its angiotensin type 1
receptor and the binding of angiotensin (1–7) to the Mas receptor at the jejunal BBM in enterocytes
inhibit SGLT1-mediated glucose transport across this membrane in a dose-dependent fashion [23,35].
Therefore, we explore to investigate whether niacin is also able to regulate glucose uptake locally in the
intestine. First of all, it is necessary to address if niacin arriving at the small intestine would be adequate
to elicit its physiological function. Studies have shown that niacin is indeed equally absorbed by the
stomach and the upper small intestine in human [36]. In fact, up to about four grams of niacin could be
almost completely absorbed by adults. Intestinal luminal concentration of niacin under physiological
conditions has been reported to lie in the micromolar but not in the millimolar range [37]. As a
result, there should be sufficient amount of niacin reaching the jejunum for its physiological actions.
Our results showed that niacin increased intestinal glucose uptake in m+/db mice significantly and
dose-dependently; these data were further substantiated by the observed decrease in glucose uptake
after GPR109a knockdown in Caco-2 cells. Our findings are in line with the observation that niacin
treatment increases glucose uptake in adipocytes where such an effect of niacin on glucose uptake
was antagonized by theophylline and isoprenaline, which are that agents that increase intracellular
concentrations of 3′,5′-cyclic adenosine monophosphate (cAMP); in addition, niacin could further
increase the maximum rate of glucose transport stimulated by insulin in adipocytes [38]. In adipocytes,
niacin treatment significantly lowered the intracellular concentrations of cAMP in adipocytes, and
a decrease in cAMP level upregulated glucose uptake [38,39]. However, cAMP has been shown to
stimulate SGLT1 and thus mediated intestinal glucose uptake in enterocytes [40], thereby contradicting
the findings in adipocytes. Not withstanding these findings, it might be plausible to postulate that
cAMP is a downstream signaling molecule of GPR109a for its subsequent mediation of glucose uptake.
Despite this, further investigations are warranted in order to confirm the precise role of cAMP in
jejunal enterocytes.
Apart from the in vivo data, we further investigated the effects of high glucose treatment on
the expression profiles of mRNA and protein of GPR109a in human Caco-2 cells. Our data revealed
that 25.2 mM glucose concentration raised remarkably the mRNA and protein levels of GPR109a,
when compared to those of the Caco-2 cells grown in 5.6 mM glucose. To address which glucose
transporters are involved in GPR109a-mediated intestinal glucose uptake, we sought to add phlorizin
(SGLT1 blocker) and phloretin (GLUT2 blocker) to examine whether the stimulatory effect of niacin on
glucose uptake was mediated via SGLT1 and/or GLUT2. In this regard, we found both SGLT1 and
GLUT2 were responsible for this regulatory process. In terms of SGLT1, cAMP has been shown to
stimulate SGLT1 function in enterocytes as mentioned above [40] and involved in post-transcriptional
stabilization of SGLT1 message [41]. Therefore, it is plausible to propose that cAMP may act as a
downstream mediator for the action of niacin on SGLT1-mediated glucose uptake. In term of GLUT2,
however, cAMP has been previously reported to prevent glucose-mediated stimulation of GLUT2
in hepatocytes [42], and thus a decrease in cAMP level in hepatocytes is supposed to upregulate
GLUT2-mediated glucose uptake; however, this postulate is apparently contradictory with that of
SGLT1. In view of this, the signaling molecules rather than GLUT2 might be involved in the regulation
of niacin-stimulated GLUT2 activity, which merits intensive investigations in the future.
Besides, we also questioned whether there a crosstalk among GPR109A, SGLT1, and GLUT2 might
exist. In this context, niacin binding to GPR109A has been shown to increase the Protein Kinase C (PKC)
activity in CHO-K1 cells [43]. Furthermore, GLUT2 can be PKC-dependently translocated apically
upon high glucose exposure [44]. In the pancreatic islet, activation of Protein Kinase A (PKA) by
adenylyl cyclase inhibited the GLUT2 mediated initial rate of 3-O-methyl glucose uptake by 48% [45].
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Also, activation of PKC has been shown to activate human SGLT1 [46]. In the apical GLUT2 model,
SGLT1-mediated glucose transport promotes insertion of GLUT2 into the apical membrane within
minutes, where the capacity of GLUT2 mediated glucose transport can be increased up to more than
three fold [21]. On the grounds of the evidence, it might be possible that niacin binding to GPR109a
inhibits the PKA activity, and activates PKC activity at the same time. The niacin binding might
increase the translocation of GLUT2 to the apical membrane, thus GLUT2-mediated glucose uptake.
Another possibility is that GPR109a activation by niacin effects the production of SGLT1. In the uptake
experiment, the time of the niacin treatment lasted only few minutes. The time may not be long enough
to induce the upregulation of SGLT1 expression. Since an increased SGLT1 activity would upregulate
GLUT2 activity [21], the increase in GLUT2 activity by niacin binding to GPR109a might upregulate
SGLT1 mediated glucose uptake.
5. Conclusions
In conclusion, the present study is the first to report that niacin is able to bind to the niacin
receptor GPR109a to stimulate SGLT1- and GLUT2-mediated jejunal glucose uptake in hyperglycemia
observed in diabetes. Given niacin is a crucial nutritional supplement that garners attention over the
recent years, our results should provide a clinical implication that the niacin receptor GPR109a may
serve as a potential therapeutic target for novel dietary or pharmacological approaches to controlling
intestinal sugar delivery, thereby improving glycemic control for diabetes.
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Abstract: Decreased mitochondrial number and dysfunction in skeletal muscle are associated with
obesity and the progression of obesity-associated metabolic disorders. The specific aim of the
current study was to investigate the effects of rutin on mitochondrial biogenesis in skeletal muscle
of high-fat diet-induced obese rats. Supplementation with rutin reduced body weight and adipose
tissue mass, despite equivalent energy intake (p < 0.05). Rutin significantly increased mitochondrial
size and mitochondrial DNA (mtDNA) content as well as gene expression related to mitochondrial
biogenesis, such as peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear
respiratory factor-1 (NRF-1), transcription factor A (Tfam), and nicotinamide adenine dinucleotide
(NAD)-dependent deacetylase, sirtulin1 (SIRT1) in skeletal muscle (p < 0.05). Moreover, rutin
consumption increased muscle adenosine monophosphate-activated protein kinase (AMPK) activity
by 40% (p < 0.05). Taken together, these results suggested at least partial involvement of muscle
mitochondria and AMPK activation in the rutin-mediated beneficial effect on obesity.
Keywords: rutin; obesity; skeletal muscle; mitochondria; AMPK activity
1. Introduction
The rapidly increased prevalence of obesity has become a worldwide health epidemic due to its
strong association with metabolic disorders, including type 2 diabetes, dyslipidemia, hypertension,
and heart disease [1,2]. Skeletal muscle from obese humans shows increased intramuscular triglyceride
content and decreased lipid oxidation [3,4]. In addition, decreased activities of enzymes indicative of
muscle mitochondrial content and mitochondrial number in obese human skeletal muscle have also
been reported [4–6]. Given the close association between obesity and skeletal muscle, the regulation of
obesity-induced mitochondrial changes in skeletal muscle may be possible targets for the prevention
and/or treatment of obesity and its associated comorbidities.
Mitochondrial dysfunction, including mitochondrial loss and decreased functional capacity
of mitochondria, is associated with several transcriptional regulators and enzyme activities in
obese skeletal muscle. Adenosine monophosphate-activated protein kinase (AMPK) stimulates
mitochondrial biogenesis and β-oxidation by regulating a transcriptional regulation factor, peroxisome
proliferator-activated receptor γ coactivator-1α (PGC-1α) [7–9]. PGC-1α directly increases the
synthesis of nuclear respiratory factors (NRF1 and NRF2) and mitochondrial transcription factor
A (Tfam), all of which increase mitochondrial DNA (mtDNA), an indicator of mitochondrial
biogenesis and mitochondrial function [10,11]. In studies that investigated the association between
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mitochondrial biogenesis and obesity, genetic variation in the mtDNA demonstrates a close association
with the severity of obesity [12,13]. A nicotinamide adenine dinucleotide (NAD)-dependent
deacetylase, sirtulin1 (SIRT1) also interacts with PGC-1α, which plays a critical role in apoptosis,
energy homeostasis, longevity, and mitochondrial function [14]. Another transcriptional candidate
for mitochondrial function is carnitine palmitoyltransferase 1 (CPT1). CPT1 is a mitochondrial
transmembrane enzyme that regulates the entry of long-chain fatty acids into mitochondria for fatty
acid oxidation [15]. In obese human skeletal muscle, CPT1 activity and mitochondrial content are
decreased, which in turn contribute to reduced fatty acid oxidation [4].
Rutin (rutoside, quercetin-3-O-rutinoside and sophorin) is a flavonol glycoside composed of
quercetin and disaccharide rutinose and is present in many plants, including buckwheat [16]. In vivo
and in vitro studies showed the anti-oxidant, anti-inflammatory, anti-hypertensive, and anti-platelet
properties of rutin [17,18] by modulating oxidative stress, inflammation, lipogenesis, and glucose
and lipid metabolism in liver and adipose tissue [19–22]. However, the favorable effect of rutin on
obesity in relation to muscle mitochondrial changes has never been investigated. Thus, the purpose of
our study was to determine the effect of rutin on obesity-induced mitochondrial loss and decreased
functional capacity in skeletal muscle from high-fat diet-induced obese rats.
2. Experimental Section
2.1. Reagents
Trizol reagent and Moloney murine leukemia virus (M-MLV) reverse transcriptase were obtained
from Invitrogen (Carlsbad, CA, USA). A universal SYBR Green polymerase chain reaction (PCR)
Master Mix and Puregene DNA isolation kit were obtained from Qiagen (Valencia, CA, USA). Kits for
the analysis of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol
(TC), triglyceride (TG), and high density lipoprotein (HDL)-cholesterol were purchased from Asan
Pharmaceutical Co. (Seoul, Korea). The AMPK Kinase Assay kit was obtained from MBL International
Co. (Woburn, MA, USA). The BCA protein assay kit was purchased from Thermo Scientific (Waltham,
MA, USA). Zoletil was provided by Virbac Laboratories (Carros, France). Rompun was supplied by
Bayer Korea (Ansan, Korea). All other reagents including rutin were obtained from Sigma-Aldrich Inc.
(St. Louis, MO, USA).
2.2. Animals and Experimental Design
Experimental protocols were approved by the Animal Experimentation Ethics Committee of Ewha
Womans University in Seoul, Korea for the care and use of laboratory animals (permission number:
2012-02-080). A total of 24 male Sprague-Dawley rats (3 weeks old) were obtained from Daehan
Experimental Animals (Eumseong, Korea), individually housed in stainless steel wire-mesh cages in
a room maintained at 22 ± 2 ◦C with a 12-h light/dark cycle (light period: 6 am to 6 pm), and fed
laboratory chow and water ad libitum for 1 week to stabilize their metabolic condition. After 1 week
of acclimation, rats were randomly divided into groups (n = 8/group) and fed a normal diet (NOR),
a high-fat diet (HFD) or a 0.1% (wt:wt) rutin-supplemented high-fat diet (HFD + Rutin) for 12 weeks.
NOR was a commercial diet (Harlan 2018s; Harlan, Indianapolis, IN, USA) containing 18% crude
protein, 6% fat, 44% carbohydrate, 18% fiber, and 5% ash. HFD (45% of energy) consisted of 23% fat,
17% casein, 12% sucrose, 20% starch, 15% dextrose, 6% cellulose, 4.3% minerals, and 1.2% vitamins
(wt:wt), based on a modification of the AIN-93 diet [23]. Rutin was added to HFD. Body weight and
food intake were monitored twice a week.
2.3. Sample Collection
At the end of 12 weeks, rats fasted overnight and were anesthetized with Zoletil:Rompun (4:1) at
a dose of 0.1 mL/80 g body weight. Blood was collected by cardiac puncture, centrifuged at 1500× g
for 20 min at 4 ◦C to obtain serum, and stored at −20 ◦C until analysis. Liver, white adipose tissue
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(epididymal and retroperitoneal), and skeletal muscle were dissected, immediately frozen in liquid
nitrogen, and stored at −70◦C until further analysis.
2.4. Blood Biochemical Measurements
Serum concentrations of AST, ALT, TC, TG and HDL-cholesterol were determined by enzymatic
colorimetric methods using commercial kits (Asan Pharmaceutical Co., Ltd., Seoul, Korea).
Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedewald equation [24], and the
atherogenic index (AI) was calculated using the Rosenfeld formula [25].
LDL-cholesterol = TC − HDL-cholesterol − (TG/5) (1)
AI = (TC − HDL-cholesterol)/HDL-cholesterol (2)
2.5. Hepatic and Fecal Lipids Analyses
Hepatic and fecal lipids were extracted using the method described by Bligh and Dyer [26]. Briefly,
500 mg of tissues or feces was homogenized in 1.5 mL of 0.9% saline and 7.5 mL of methanol:chloroform
(2:1, v:v). After the addition of 2.5 mL of chloroform, the mixture was shaken horizontally for 10 min
and centrifuged at 2000× g for 10 min. The lower chloroform phase was collected into a fresh tube
and subsequently dried and weighed. TC and TG concentrations were determined by enzymatic
colorimetric methods using commercial kits as described above.
2.6. Histological Analysis
Dissected epididymal adipose tissue samples were fixed in 10% (v/v) formalin for 24 h. Tissues
were then embedded in paraffin, sliced into 5-μm-thick sections, and stained with hematoxylin-eosin
(H&E). H&E-stained sections were observed under a microscope (Olympus, Tokyo, Japan) and digital
images were captured at 200× magnification.
2.7. Electron Microscopic Analysis
Skeletal muscle was prefixed with 2% glutaraldehyde plus 2% paraformaldehyde in 0.1 M
phosphate buffer. Glutaraldehyde-fixed samples were treated with 2% osmium tetroxide, dehydrated,
and embedded in epoxy resin. Selected 1-μm-thick sections were stained with toluidine blue and then
cut into approximately 60- to 70-μm ultra-thin sections using an Ultramicrotome (Richert-Jung, Buffalo,
NY, USA) using a diamond knife. Thin sections were stained with 1%–2% aqueous uranyl acetate,
followed by 1% lead citrate. Stained sections were examined using an H-7650 transmission electron
microscope (Hitachi, Japan) at the accelerating voltage of 80 kV.
2.8. Real-time Quantitative Reverse-transcription Polymerase Chain Reaction (qRT-PCR)
The isolation of RNA from epididymal adipose tissue and skeletal muscle was performed using
Trizol reagent. Complementary DNA (cDNA) was synthesized from 4 μg of total RNA using a
M-MLV Reverse Transcriptase Kit. Primers used are shown in Table 1. Real-time quantitative
reverse-transcription polymerase chain reaction (qRT-PCR) was carried out using Universal SYBR
Green PCR Master Mix on a fluorometric thermal cycler (Rotor-GeneTM 2000; Corbett Research,
Mortlake, NSW, Australia). Data were analyzed using the ΔΔCt method for relative quantification [27].
The expression of each target was normalized to the average of β-actin as a control and expressed as
the fold change related to the HFD group.
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Table 1. Primers used for quantitative real-time polymerase chain reaction (PCR).





























aP2, fatty acid-binding protein 2; CPT-1, carnitine palmitoyltransferase 1; NRF1, nuclear respiratory factor
1; PGC-1α, peroxisome proliferative activated receptor gamma coactivator 1 alpha; PPAR-γ, peroxisome
proliferator-activated receptor-γ; SIRT1, sirtuin 1; SREBP-1c, sterol regulatory element-binding protein-1c; Tfam,
mitochondrial transcription factor A.
2.9. Mitochondrial DNA (mtDNA) Content Analysis
Total DNA was extracted from muscle using a Puregene DNA isolation kit. The mtDNA content
was calculated using real-time quantitative PCR by measuring the mitochondrial gene (Cox1, subunit
1 of cytochrome oxidase) vs. nuclear gene (GAPDH, glyceraldehyde 3-phosphate dehydrogenase).
2.10. AMPK Activity Assay
AMPK activity was evaluated using an AMPK Kinase Assay kit as described previously [28].
Using a semi-quantitative method, AMPK activity was detected by measuring the phosphorylation of
Ser789 on IRS-1 with anti-mouse phospho-Ser789 IRS-1 monoclonal antibody and peroxidase-coupled
anti-mouse IgG, which catalyzes the conversion of the chromogenic substrate tetramethylbenzidine.
Protein was determined using a BCA protein assay kit. AMPK activity was normalized to protein
concentration and expressed as the fold change compared to the HFD group.
2.11. Statistical Analysis
Data are expressed as the mean ± standard error of the mean (SEM). Differences among groups
were determined by Student’s t-test for the comparison of two groups or one-way analysis of variance
(ANOVA) following Tukey’s multiple comparison using SPSS software (version 17; IBM Corporation,
Armonk, NY, USA). Statistical significance was defined as p < 0.05.
3. Results
3.1. Effect of Rutin Supplementation on Body Weight, Energy Intake, and Fat Accumulation
At the beginning of the experiment, the initial body weight was not significantly different among
groups. After 12 weeks of rutin consumption, final body weight was significantly decreased by 8.5%
compared to the HFD group (p < 0.05) (Figure 1A and Table 2). The HFD + Rutin group showed a
significantly lower total weight of epididymal and retroperitoneal adipose tissues by 24% than total
adipose tissue weight of HFD group (p < 0.05) (Table 2). As shown in Figure 1C, the size of epididymal
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adipocytes was smaller in the HFD + Rutin group than in the HFD group. The food intake and energy
efficiency ratio were not significantly different between HFD and HFD + Rutin, which indicate that the
beneficial effects of rutin on body weight and the mass of white adipose tissue were not caused by
reduced energy consumption (Figure 1B and Table 2).
Figure 1. Effect of rutin on diet-induced obesity. Changes in body weight (A) and food intake (B).
Representative histological sections (C) of epididymal adipose tissue (hematoxylin and eosin stain,
scale bar = 50 μm). The data are expressed as the mean ± standard error of the mean (SEM) (n = 8 per
group). * p < 0.05; ** p < 0.01 compared to the high-fat diet (HFD; 45% of energy) group. NOR, normal
diet; HFD, high-fat diet; HFD + Rutin, rutin-supplemented high-fat diet.
73
Nutrients 2015, 7, 8152–8169
Table 2. Effect of rutin on body weight, food intake, and tissue weight.
Variables NOR HFD HFD + Rutin
Initial body weight (g) 92.36 ± 1.41 91.10 ± 1.76 92.12 ± 1.68
Final body weight (g) 487.40 ± 12.59 c 573.64 ± 7.22 a 528.54 ± 9.05 b
Food intake (g/day) 24.97 ± 0.57 a 21.96 ± 0.30 b 21.63 ± 0.38 b
Total food intake (kg/12 weeks) 2.02 ± 0.05 a 1.78 ± 0.02 b 1.75 ± 0.03 b
Food efficiency (g gain/g consumed) 0.19 ± 0.002 c 0.27 ± 0.003 a 0.25 ± 0.006 b
Energy intake (kcal/day) 77.42 ± 1.77 b 101.99 ± 1.40 a 100.45 ± 1.79 a
Total energy intake (kcal/12 weeks) 6271 ± 144 b 8261 ± 113 a 8137 ± 145 a
Energy efficiency (g gain/kcal consumed) 0.06 ± 0.001 a 0.06 ± 0.001 a 0.05 ± 0.001 b
Liver weight (g/100 g body weight) 2.65 ± 0.06 2.44 ± 0.03 2.54 ± 0.09
Adipose tissue weight (g/100 g body weight)
Epididymal 2.30 ± 0.18 b 3.84 ± 0.16 a 3.28 ± 0.18 a
Retroperitoneal 2.28 ± 0.16 b 4.29 ± 0.19 a 2.94 ± 0.26 b
Total 4.58 ± 0.33 b 8.14 ± 0.29 a 6.22 ± 0.33 b
The data are expressed as the mean ± standard error of the mean (SEM) (n = 8). a, b, c Different letters indicate a
significant difference among groups according to Tukey’s multiple comparison test (p < 0.05). NOR, normal
diet; HFD, high-fat diet.
3.2. Effect of Rutin on Serum Lipid Profiles
HFD-increased serum concentrations in TG and LDL-cholesterol showed 43% and 55% reduction
in the rutin-supplemented group, respectively (p < 0.05). Rutin consumption significantly increased
the serum HDL-cholesterol level by 62% compared to HFD group (p < 0.05), resulting in a significant
decrease of the atherogenic index (AI) (Table 3).
Table 3. Effect of rutin on serum lipid profiles.
Serum Lipid Profiles NOR HFD HFD + Rutin
Serum lipids (mmol/L)
Triglyceride 1.03 ± 0.12 a,b 1.25 ± 0.09 a 0.71 ± 0.04 b
Total cholesterol 2.32 ± 0.14 a,b 2.65 ± 0.12 a 2.16 ± 0.15 a,b
HDL cholesterol 1.45 ± 0.21 b 1.3 ± 0.13 b 2.1 ± 0.32 a
LDL cholesterol 0.7 ± 0.17 a,b 1.09 ± 0.12 a 0.49 ± 0.22 b
Atherogenic index (AI) 0.91 ± 0.27 a,b 1.7 ± 0.36 a 0.51 ± 0.24 b
AST (IU/L) 65.8 ± 4.0 69.7 ± 4.1 66.0 ± 2.5
ALT (IU/L) 8.8 ± 3.1 6.2 ± 2.4 7.2 ± 2.9
Values are shown as the mean ± standard error of the mean (SEM) (n = 8). a, b Different letters indicate
a significant difference among groups according to Tukey’s multiple comparison test (p < 0.05). NOR,
normal diet; HFD, high-fat diet; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; IU, international unit.
3.3. Alterations in Hepatic and Fecal Lipid Profiles by Rutin Supplementation
Twelve weeks of rutin supplementation significantly reduced the hepatic total lipid, TG, and TC
by 27%, 37%, and 35%, respectively, compared to the HFD group (p < 0.05) (Table 4). The amount of
fecal lipid in the HFD + Rutin group was significantly increased by 33% compared to the HFD group
(p < 0.05). There was an increasing trend of fecal TG levels in the HFD + Rutin group, but there was
no significance.
3.4. Influence of Rutin on Liver Weight and Serum AST and ALT Activities
Liver weight was not altered by rutin supplementation (Table 2). In addition, serum levels of AST
and ALT were not significantly different among groups (Table 3). The data indicated that rutin did not
induce hepatic toxicity.
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Table 4. Effect of rutin on hepatic and fecal lipid profiles.
Hepatic and Fecal Lipid Profiles NOR HFD HFD + Rutin
Hepatic lipids (μmol/g)
Total lipid 26.7 ± 1.3 b 42.2 ± 1.3 a 30.9 ± 1.9 b
Triglyceride 3.79 ± 0.69 c 11.70 ± 1.76 a 7.33 ± 1.36 b
Total cholesterol 1.26 ± 0.10 b 2.70 ± 0.21 a 1.75 ± 0.13 b
Fecal lipids (μmol/g)
Total lipid 23.9 ± 1.6 b 28.5 ± 1.0 a,b 38.0 ± 3.8 a,*
Triglyceride 0.36 ± 0.04 b 0.47 ± 0.04 a,b 0.66 ± 0.09 a
Values are expressed as the mean ± standard error of the mean (SEM) (n = 8). a, b, c Different letters indicate
a significant difference among groups according to Tukey’s multiple comparison test (p < 0.05). Asterisks (*)
indicate a significant difference from HF diet, p < 0.05. NOR, normal diet; HFD, high-fat diet.
3.5. Effect of Rutin on Expression of Adipogenic Genes and AMPK Activity in Adipose Tissue
The mRNA levels of adipogenic genes such as peroxisome proliferator activated receptor-γ
(PPAR-γ), sterol regulatory element binding protein-1c (SREBP-1c), and adipocyte protein 2 (aP2)
were significantly decreased by rutin in epididymal white adipose tissue (p < 0.05) (Figure 2A).
AMPK activation, which regulates body fat accumulation by modulating adipogenic or fatty acid
oxidation-related genes, was measured by a semi-quantitative analysis. As shown in Figure 2B, the
HFD + Rutin group exhibited significantly increased AMPK activity by 50% in adipose tissue compared
to the HFD group (p < 0.05). Therefore, the favorable effects of rutin on body weight and adipose tissue
mass may be associated with a decrease of adipogenesis in adipose tissue.
Figure 2. Effect of rutin on adipogenic gene expression and adenosine monophosphate-activated
protein kinase (AMPK) activity in adipose tissue. The messenger RNA (mRNA) levels of peroxisome
proliferator activated receptor-γ (PPAR-γ), sterol regulatory element binding protein-1c (SREBP-1c)
and adipocyte protein 2 (aP2) were determined by real-time polymerase chain reaction (RT-PCR) and
normalized for all samples to β-actin (A). AMPK activity was measured using an AMPK kinase kit and
normalized to protein levels (B). The results are expressed as the fold change compared to the HFD
group (mean ± standard errof of the mean (SEM), n = 8 per group). Bars with different letters (a, b) are
significantly different according to Tukey’s multiple comparison test at p < 0.05.
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3.6. Effect of Rutin on Mitochondrial Morphology and Content (mtDNA) in Skeletal Muscle
To investigate the effect of rutin on changes in muscle mitochondria, transmission electron
microscopy (TEM) was used. The HFD group showed a smaller size and number of skeletal muscle
mitochondria, which was reversed by rutin administration (Figure 3A). In addition, Figure 3B showed
that mtDNA content was significantly increased by rutin supplementation, which served as evidence
of enlargement and increased mitochondria number (p < 0.05).
Figure 3. Effect of rutin on muscle mitochondrial morphology and mitochondrial DNA (mtDNA)
content. Electron microscopy of muscle (magnification of 20,000; scale bars = 2 μm) (A). Arrows indicate
the position of mitochondria (M). The mtDNA content was quantified by real-time PCR (B). Values
are expressed as the mean ± standard error of the mean (SEM) (n = 8 per group). Bars with different
letters (a, b) indicate significant differences compared to the HFD group according to Tukey’s multiple
comparison test (p < 0.05).
3.7. Effect of Rutin on Mitochondrial Gene Expression and AMPK Activity in Skeletal Muscle
Rutin administration significantly increased mRNA expression of NRF1, Tfam, PGC-1α, SIRT1,
and CPT1 involved in muscle mitochondrial biogenesis and function (p < 0.05) (Figure 4A). Next, we
determined AMPK activity, which affects muscle mitochondrial biogenesis and oxidative capacity
for β-oxidation. Rutin-supplemented HFD significantly increased AMPK activity by 40% in muscle
compared to the HFD group (Figure 4B). The data indicated that the beneficial effect of rutin on obesity
may be due to an increase in mitochondrial biogenesis and capacity in skeletal muscle.
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Figure 4. Effect of rutin on mitochondrial gene expression of genes related to mitochondrial biogenesis
and function in skeletal muscle. The levels of nuclear respiratory factor 1 (NRF1), transcription factor
A (Tfam), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), sirtulin1 (SIRT1) and
arnitine palmitoyltransferase 1 (CPT1) mRNA were analyzed by real-time PCR and normalized to
β-actin (A). adenosine monophosphate-activated protein kinase (AMPK) activity was measured using
an AMPK kinase kit and normalized to protein levels (B). The results are expressed as the fold change
compared to the HFD group (mean ± standard error of the mean (SEM), n = 8 per group). Bars
with different letters (a, b) indicate a statistically significant difference according to Tukey’s multiple
comparison test (p < 0.05).
4. Discussion
Mitochondrial changes and dysfunction, including decreased mtDNA content, mitochondrial
size, and functional capacity of mitochondria, manifest in the skeletal muscle of obese human
subjects and rodents [4–6,29–31]. Beneficial effects of rutin supplementation on obesity have been
reported [19,20,22,32]. The favorable role of rutin in glucose and lipid metabolism and its associated
metabolic disorders led us to investigate the effects of rutin on obesity-induced mitochondrial changes
in skeletal muscle.
In the present study, we evaluated the influence of rutin on the HFD-decreased mitochondrial
content, mitochondrial gene expression, and AMPK activity, which is involved in mitochondrial
biogenesis and function. Using three groups of rats fed a NOR, HFD and HFD + Rutin, we found
that rutin supplementation led to significant increases in the HFD-decreased size and number of
mitochondria, mtDNA and gene expression and enzyme activity related to mitochondrial biogenesis
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and function in skeletal muscle, together with reductions in HFD-induced weight gain and the
enlargement of adipose tissue.
In the present study, rutin-fed rats showed a significant decrease in body weight without changing
food intake, consistent with other previous results [21,32]. Moreover, rutin consumption decreased
adipose size, adipogenic gene expression of PPAR-γ, SREBP-1c, and aP2, and AMPK activity in
epididymal adipose tissue, indicating the anti-obesity property of rutin. PPAR-γ and SREBP-1c are
critical transcription factors that regulate adipocyte differentiation and lipogenesis [33,34]. In addition,
aP2 is highly expressed in adipose tissue and regarded as a marker of obesity, reflecting the magnitude
of fat accumulation [35]. In adipocyte energy homeostasis, AMPK regulates body fat deposition by
decreasing adipogenic genes such as SREBP-1c and PPAR-γ [36]. Adipogenic gene expression and
adipose tissue hypertrophy were inhibited in vitro in 3T3-L1 cells treated with rutin and animals
fed with rutin supplemented with a high-fat diet [19,20]. Therefore, our findings demonstrated
that the beneficial effect of rutin on obesity was at least partially due to anti-adipogenic activity in
adipose tissue.
The currently used rutin dosage was determined as described in previous studies [21,37].
A concentration of 0.1% rutin in the diet was well tolerated by rats in the present study, as demonstrated
by the results showing that liver weight and serum ALT and AST levels were unaffected by rutin
supplementation. In rodent animal models, HFD generally does not induce liver damage. When
fed with 60% HFD, 16 weeks period of HFD significantly increases hepatic expression involved in
inflammation [38]. In addition, high-fat liquid diet including 71% of energy derived from fat induces
hepatic inflammation after 4 weeks [39] or 6 weeks [40]. However, 42% HFD for 12 weeks dose not
induce any liver changes in Sprague-Dawely rats which were similar as our current study design [41].
Similar to published data showing the beneficial effects of rutin on diet-induced dyslipidemia [21],
12 weeks of rutin supplementation in the present study significantly attenuated HFD-increased serum
and hepatic lipid parameters and decreased the atherogenic index. Moreover, total fecal lipids were
increased in the HFD + Rutin group, implying that increased total fecal lipid excretion may contribute
to a reduction in body weight and serum lipids in the HFD + Rutin group.
Concerning the association between rutin and muscle, studies have shown that rutin improves
glucose transport in isolated soleus muscles from rats [42,43]. However, the effect of rutin on
mitochondrial changes in skeletal muscle during the progression of obesity has never been elucidated.
Obesity is closely associated with mitochondrial dysfunction (i.e., decreased oxidation capacity and
fatty acid oxidation), reduced expression in a cluster of nuclear genes responsible for oxidative
metabolism (PGC-1α), and decreased mitochondrial biogenesis (i.e., the generation of new mtDNA
and proteins) in skeletal muscle [5,6]. Indeed, HFD-induced obesity reduced the number and size of
muscle mitochondria observed by TEM, mtDNA content, and AMPK activation, all of which were
improved by rutin supplementation in the present study. Therefore, we suggest that rutin plays a
preventive role in obesity-induced mitochondrial changes in skeletal muscle.
Mitochondrial dysfunction, including decreased mitochondrial biogenesis and functional capacity,
is associated with several transcriptional regulators and enzyme activities in obese skeletal muscle.
As a regulator of mitochondrial biogenesis and function, AMPK promotes mitochondrial biogenesis
by direct phosphorylation and interaction with PGC-1α, which up-regulates the synthesis of NRF1
and Tfam. PGC-1α activity is increased by SIRT1-induced deacetylation. AMPK also regulates energy
metabolism by increasing the gene expression of PGC-1α and SIRT1, which are involved in fatty
acid oxidation [7–10,44]. All key regulators of muscle mitochondrial biogenesis and function, such as
NRF1, Tfam, PGC-1α, and SIRT1, were significantly decreased by HFD and then were fully recovered
by rutin supplementation in our current study. NRF1 stimulates the expressions of Tfam, a key
nuclear-encoded transcription factor of mtDNA transcription [45,46]. Another mitochondrial enzyme
involved in fatty acid oxidation [15], CPT-1, was also significantly increased with rutin. Increased
transcription of mtDNA initiates mitochondrial biosynthesis, ultimately leading to mitochondrial
abundance in size and number [11,47]. However, rutin-modified mitochondrial size and number
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were not directly measured in the present study. Using more precise and direct methods such as
digital imaging software and stereological principles of point sampling in a blind fashion needs to
be taken into consideration to evaluate the role of rutin on muscle mitochondrial size and volume
density in the future study [5,48,49]. In addition, molecular mechanisms by which rutin improves
mitochondrial function in muscle of obese rats have not been fully determined. Abnormalities in both
mitochondrial biogenesis and mitochondrial function including ATP synthesis, oxidative respiration,
and intracellular calcium and nitric oxide production are involved in increased reactive oxygen species
(ROS) production and endoplasmic reticulum (ER) stress in aging, heart failure, insulin resistance,
and obesity [50–53]. Therefore, further investigation is needed to determine whether rutin affects
mitochondrial contents of ATP, calcium, ROS, and ER stress. Given association between SIRT1 and
muscle mitochondrial biogenesis and function, actions of rutin-induced quercetin cannot be ruled
out. Indeed, rutin supplemented diet significantly increases plasma quercetin concentration [54–56],
which is involved in the activation of SIRT1, a NAD-dependent deacetlyase [57]. In human fecal
microbiota, rutin is involved in bacterial metabolism and action in the gut in relation to fat uptake [58].
In this regard, there is a possibility that rutin-decreased body weight gain in HF-diet fed rats may
be associated with direct effect of gut fat uptake and/or indirect influence of rutin-increased blood
quercetin on SIRT1 activation. A following study might be necessary to investigate direct and indirect
effects of rutin on obesity.
Taken together, the prevention of obesity-induced muscle mitochondrial loss and the improvement
of high diet-reduced mitochondrial gene expression in skeletal muscle may demonstrate the favorable
effect of rutin on obesity.
5. Conclusions
Our study demonstrated that rutin supplementation decreases high-fat diet-induced weight
gain and adipose tissue mass, accompanied by increased mtDNA and mitochondrial gene expression
involved in mitochondrial biogenesis and function and AMPK activation in skeletal muscle. These
results suggested anti-obesity property of rutin may possibly be associated with rutin-mediated muscle
mitochondrial changes. Further studies are warranted to delineate more precise mechanisms by
which rutin affects muscle fibers, mitochondrial biogenesis, oxidative capacity and function, and its
associated health outcomes. To the best our knowledge, this is the first study to suggest that rutin may
be partially associated with increased mitochondrial biogenesis and function in muscle of obese rats.
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Abstract: Long-term high-fat diet increases muscle mitochondrial enzyme activity and endurance
performance. However, excessive calorie intake causes intra-abdominal fat accumulation and
metabolic syndrome. The purpose of this study was to investigate the effect of an alternating
day high-fat diet on muscle mitochondrial enzyme activities, protein content, and intra-abdominal
fat mass in rats. Male Wistar rats were given a standard chow diet (CON), high-fat diet (HFD),
or alternate-day high-fat diet (ALT) for 4 weeks. Rats in the ALT group were fed a high-fat diet and
standard chow every other day for 4 weeks. After the dietary intervention, mitochondrial enzyme
activities and protein content in skeletal muscle were measured. Although body weight did not differ
among groups, the epididymal fat mass in the HFD group was higher than those of the CON and
ALT groups. Citrate synthase and beta-hydroxyacyl CoA dehydrogenase activities in the plantaris
muscle of rats in HFD and ALT were significantly higher than that in CON rats, whereas there was no
difference between HFD and ALT groups. No significant difference was observed in muscle glycogen
concentration or glucose transporter-4 protein content among the three groups. These results suggest
that an alternate-day high-fat diet induces increases in mitochondrial enzyme activities and protein
content in rat skeletal muscle without intra-abdominal fat accumulation.
Keywords: high-fat diet; alternate-day; mitochondria; skeletal muscle; rat
1. Introduction
Endurance exercise training induces an increase in mitochondrial content in skeletal muscle [1],
resulting in increased capacity of muscles to regenerate ATP. The increase in muscle mitochondrial
content also results in a change in substrate utilization—with increased fat oxidation and decreased
utilization of muscle glycogen [2,3]. Since the performance of endurance exercise is directly related to
the muscle glycogen concentration prior to exercise, these biochemical adaptations of skeletal muscle
lead to enhanced exercise performance after exercise training.
Aforementioned muscle adaptation is also caused by a high-fat diet feeding. Miller et al. [4]
demonstrated that a 5-week high-fat diet in rats elevated mitochondrial enzyme activities in skeletal
muscle. This biochemical adaptation in skeletal muscle has been reported by other groups in rodents
and human subjects [5–8], although other groups reported opposite results, which high-fat diet feeding
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results in down-regulation of mitochondrial genes [9] or skeletal muscle from over-feeding-induced
obese subject has impaired mitochondrial oxidative capacity [10,11]. Interestingly, in contrast to
exercise training [12], the biochemical adaptation to high-fat diet in skeletal muscle occurs slowly,
over at least 3–4 weeks [13]. Recent studies have shown the possible mechanisms by which a high-fat
diet induces an increase in mitochondrial biogenesis in skeletal muscle [13–16], e.g., peroxisome
proliferator activated receptor (PPAR) δ activation by raising plasma free fatty acids (FFA) and
induction of PPAR γ coactivator-1α (PGC-1α).
It is well known that a long-term high-fat diet causes intra-abdominal fat accumulation, insulin
resistance, and obesity. Miller et al. [4] reported that high-fat diet-fed rats gained more body weight
than did the control diet-fed rats, despite a significant increase in mitochondrial enzyme activities.
This observation might be the reason why a high-fat diet is not adopted by the endurance athlete,
although it has some merit in that there is an increase in mitochondrial enzyme activities and
a concomitant decrease in utilization of glycogen during endurance exercise. Thus, the dietary
regimen that induces increases in mitochondrial oxidative capacities in skeletal muscle without
intra-abdominal fat accumulation and body weight gain will offer many advantages. In this context,
the present study aimed to determine whether the repeated increase in FFA caused by an alternate-day
high-fat diet results in an increase in the mitochondrial oxidative capacity without accumulation
of intra-abdominal fat mass. Here, we report that an alternate-day high-fat diet, comprising a
high-fat diet and standard diet every other day, has a significant effect on muscle mitochondrial
enzymes—it increases mitochondrial enzyme activities and protein content without causing excess
body weight gain and intra-abdominal fat accumulation.
2. Methods
2.1. Materials
Reagents for SDS-PAGE were obtained from Bio-Rad (Hercules, CA, USA). Monoclonal long-chain
acyl CoA dehydrogenase antibody and horseradish peroxidase (HRP)-conjugated secondary antibodies
were obtained from Sigma (St. Louis, MO, USA) and Cell Signaling Technologies (Danvers, MA, USA),
respectively. Anti-PGC-1α antibody was obtained from Calbiochem (San Diego, CA, USA). Polyclonal
antiserum specific for GLUT-4 was a generous gift from Mike Mueckler (Washington University,
St. Louis, MO, USA). Enhanced chemiluminescence (ECL) reagent was purchased from Millipore
(Temecula, CA, USA). All other chemicals were obtained from Sigma.
2.2. Treatment of Animals
Four-week-old male Wistar rats (70–90 g body weight) were obtained from CLEA Japan
(Tokyo, Japan). All rats were housed in rooms lighted from 9:00 a.m. to 9:00 p.m. The room temperature
was maintained at 22–24 ˝C. Rats were separated into those receiving a control diet (CON: n = 6),
high-fat diet (HFD: n = 6), and an alternate-day high-fat diet (ALT: n = 6). The high-fat diet was prepared
using lard, corn oil, sucrose, and casein (32%, 18%, 27%, and 23%, respectively, of total calories),
supplemented with minerals (51 g/kg, AIN93G mineral mix: CLEA Japan), vitamins (22 g/kg, AIN93
vitamin mix: CLEA Japan), and methionine (4.4 g/kg: Wako Pure Chemical). The standard diet, CE-2
was obtained from CLEA Japan; it contained as percentage of calories, 59% carbohydrate, 12% fat,
and 29% protein. The energy content of the high-fat diet was 5.1 kcal/g, whereas that of the standard
diet was 3.4 kcal/g. The rats were provided with food and water ad libitum. Rats in the CON and
HFD groups were fed the control diet and the high-fat diet for 4 weeks, respectively. Rats in the ALT
group were fed the control diet alternated with the high-fat diet every other day. The ALT animals
were fed the high-fat diet on the day before sacrifice. Food was removed at 9:00 p.m. the day before
muscle dissection. Between 9:00 and 12:00 a.m. on the next day, rats were anesthetized with an
intraperitoneal injection of pentobarbital sodium (50 mg/kg) and blood samples were drawn from the
abdominal aorta. After the blood sampling, plantaris muscle and epididymal fat pads were removed.
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This experimental protocol was approved by the Committee for Animal Experimentation in the School
of Sport Sciences at Waseda University (No. 2014-A096).
2.3. Measurement of Mitochondrial Enzyme Activities
For enzyme activity measurements, a portion of plantaris muscles were homogenized in ice-cold
buffer containing 175 mM KCl, 10 mM GSH, and 2 mM EDTA, pH 7.4. The homogenates were frozen
and thawed three times and mixed thoroughly before enzyme activities were measured. For the
β-hydroxyacyl-CoA dehydrogenase (β-HAD) assay, an aliquot of the homogenate was centrifuged at
700ˆ g for 10 min at 4 ˝C. Citrate synthase (CS), a marker of oxidative enzymes, and β-HAD activities
were measured using Srere’s [17] and Bass’s [18] methods, respectively.
2.4. Western Blot Analysis
A portion of frozen plantaris muscles were homogenized in ice-cold RIPA buffer containing 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, and a protease
inhibitor cocktail (Cell Signaling Technologies, Danvers, CA, USA). Protein concentrations were
measured using a BCA protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer’s
instruction. Samples were diluted in 4ˆ sample buffer (Invitrogen, Camarillo, CA, USA). Equal
amounts of sample protein were subjected to SDS-PAGE (10% resolving gels) and then transferred to
PVDF membranes at 200 mA for 90 min. After transfer, the membranes were washed in Tris-buffered
saline with 0.1% Tween 20 (TBST; 20 mM Tris base, 137 mM NaCl, pH 7.6), and then membranes were
blocked with TBST supplemented with 5% skimmed powdered milk for 1 h at room temperature. After
blocking, the membranes were incubated overnight at 4 ˝C with antibodies specific for long chain
acyl CoA dehydrogenase (LCAD), glucose transporter-4 (GLUT-4) and PGC-1α at concentrations
of 1:2000–5000. The HRP-conjugated secondary antibody (goat anti-rabbit IgG) was used at a
concentration of 1:10,000. Bands were visualized by ECL and scanned using a chemiluminescence
detector (LAS 3000, FUJIFILM). The membranes were stained with Coomassie Brilliant Blue (CBB) to
verify and normalize the protein loading [19]. Band intensities were quantified using ImageJ (NIH).
2.5. Analytical Procedure
Concentrations of plasma glucose, FFA, and triglyceride were determined using kits (Glucose C2
Test Wako, NEFA-C Test Wako, Triglyceride E Test Wako, respectively) according to the manufacturer’s
instructions. Plasma insulin concentration was measured using an enzyme-linked immunospecific
assay kit according to the manufacturer’s instruction (Mercodia AB, Uppsala, Sweden).
2.6. Succinate Dehydrogenase (SDH) Staining
For histological analysis, plantaris muscles were frozen in isopentane, which had been cooled
in liquid nitrogen. Serial cross-sections (5 μm thick) were cut in a cryostat at ´20 ˝C. Sections were
stained for succinate dehydrogenase (SDH) activity, complex II of the mitochondrial respiratory chain,
as follows. Sections were first allowed to reach room temperature before they were then incubated in a
solution containing nitro blue tetrazolium (0.5 mg/mL), sodium succinate (50 mM), and phosphate
buffer (0.12 M potassium dihydrogenphosphate, 0.88 M disodium hydrogen phosphate) for 25 min
at 37 ˝C. Cross-sections were then washed three times in distilled water, dehydrated in 70% (1 min),
80% (1 min), 90% (1 min), and 100% (1 min) ethanol, and then cover-slipped using an aqueous
mounting medium.
2.7. Muscle Glycogen Concentration
Glycogen concentration in plantaris muscles was determined by using the method of Lowry and
Passonneau [20] after acid hydrolysis.
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2.8. Statistical Analysis
The data are presented as the mean ˘ standard error of the mean (SEM). Statistical analysis was
performed using analysis of variance (ANOVA). The Tukey’s test was used for post hoc analysis when
the ANOVA test indicated significant differences. When the normality (Shapiro–Wilk test) was not
met, variables were analyzed using the Kruskal–Wallis test and the Steel–Dwass post hoc test was used
as needed. Statistical significance accepted at p < 0.05.
3. Results
3.1. Body Weight, Epididymal Fat Weight, and Plasma Parameters
Table 1 shows the body weight and epididymal fat weight. The 4-week high-fat diet resulted in
an increase in epididymal fat weight in the HFD group (CON vs. HFD, p < 0.05). However, at 4 weeks,
epididymal fat weight in the ALT group was not significantly different from that in CON group.
Table 1. Effects of alternate-day high-fat diet feeding on body weight, epididymal fat mass, plasma
glucose, free fatty acids, and insulin concentrations in rats.
CON HFD ALT
Initial body weight (g) 87 ˘ 1 86 ˘ 5 87 ˘ 1
Final body weight (g) 298 ˘ 5 297 ˘ 9 298 ˘ 3
Epididymal fat mass (g) 3.1 ˘ 0.2 5.1 ˘ 0.3 * 3.8 ˘ 0.1
Plasma glucose (mg/mL) 96.9 ˘ 2.6 96.8 ˘ 6.3 81.1 ˘ 2.6 #
Plasma FFA (mEq/L) 0.28 ˘ 0.02 0.44 ˘ 0.05 * 0.44 ˘ 0.06 *
Plasma insulin (μg/L) 0.39 ˘ 0.3 0.42 ˘ 0.4 0.39 ˘ 0.3
CON, control group; HFD, high-fat diet group; ALT, alternate-day high-fat diet group. Values are mean ˘ SEM
of 6 animals per group. * indicates significant difference at a level of p < 0.05 vs. CON. # indicates significant
difference at a level of p < 0.05 vs. CON and HFD.
Plasma FFA concentration in the HFD and ALT groups was significantly higher than that in
the CON group (CON vs. HFD and ALT, p < 0.05). Although the precise mechanism is not clear,
plasma glucose concentration in the ALT group was significantly lower than those of CON and HFD
(ALT vs. CON and HFD, p < 0.05). There was no significant difference in plasma insulin concentration
among the three groups (Table 1).
3.2. Mitochondrial Enzymes Activities and PGC-1α Protein Content
Citrate synthase activities in the plantaris muscle of the HFD and ALT rats were significantly
higher than in the same muscle of the CON rats (Figure 1A) (CON vs. HFD, p < 0.01; CON vs. ALT,
p < 0.05). After the 4-week dietary intervention, the β-HAD activity in the HFD and ALT groups
was significantly higher than that in the CON group (Figure 1B) (CON vs. HFD and ALT, p < 0.05).
Protein content of PGC-1α in HFD group was significantly higher than that of the CON group (p < 0.05,
Figure 2A). Furthermore, PGC-1α protein content was increased by 4-week alternate-day high-fat
diet feeding (p < 0.05. Figure 2A). Both HFD and ALT induced a significant increase in LCAD protein
content in plantaris muscle (Figure 2B) (CON vs. HFD and ALT, p < 0.05).
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Figure 1. Effects of alternate-day high-fat diet feeding on citrate synthase (A) and β-HAD (B) enzyme
activities in rat skeletal muscle. Values are mean ˘ SEM of 6 animals per group. * and ** indicate
significant differences at levels of p < 0.05 and p < 0.01 vs. CON, respectively.
Figure 2. Effects of alternate-day high-fat diet feeding on PGC-1α (A) and LCAD (B) protein content in
rat skeletal muscle. Values are mean ˘ SEM of 6 animals per group. * indicates significant difference at
a level of p < 0.05 vs. CON.
3.3. SDH Activity
Next, we assessed the effect of an alternate-day high-fat diet on the oxidative capacity in skeletal
muscles using histochemistry. Figure 3 shows representative images of SDH staining of the plantaris
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muscle from CON, HFD, and ALT groups. Succinate dehydrogenase activity staining was increased in
HFD and ALT groups compared to the CON group.
Figure 3. Effect of alternate-day high-fat diet feeding on succinate dehydrogenase (SDH) staining in
plantaris muscle. Representative SDH-stained images are presented. SDH staining of superficial region
of plantaris muscle from CON (a), HFD (b) and ALT (c) and deep region from CON (d), HFD (e) and
ALT (f). Plantaris muscle of both HFD and ALT showed relatively dark staining for SDH compare to
that of CON. Scale bar, 100 μm.
3.4. Muscle Glycogen Concentration and Glucose Transporter-4 Protein Content
Previous studies reported that long term high-fat diet feeding reduces muscle glycogen
concentration [4,6,8]. Since GLUT-4-mediated glucose transport across the plasma membrane is
one of the rate-limiting step of glycogen synthesis in skeletal muscle [21], we measured muscle
glycogen concentration and GLUT-4 protein content. As shown in Figure 4, we observed no significant
difference in glycogen concentration (Figure 4A) or GLUT-4 content (Figure 4B) in plantaris muscles
among the three groups.
Figure 4. Effects of alternate-day high-fat diet feeding on glycogen concentration (A) and GLUT-4
protein content (B) in rat skeletal muscle. Values are mean ˘ SEM of 6 animals per group.
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4. Discussion
The main findings of the present study were that an alternate-day high-fat diet induces increases
in mitochondrial enzyme activities and protein content in rat skeletal muscle, without causing
intra-abdominal fat accumulation.
It was first reported by Holloszy [1] that endurance exercise training increases mitochondrial
enzyme activities in rat skeletal muscle, and this finding was confirmed by other research groups
assessing human skeletal muscle [22]. The most important physiological effect of an increase in
mitochondrial content in skeletal muscle is the sparing of muscle glycogen during submaximal
exercise. The glycogen-sparing effect mediated by a smaller decrease in creatine phosphate and
ATP, and a smaller increase in inorganic phosphate, stimulates glycogenolysis [2,23]. Miller et al. [4]
reported that rats, which were fed a high-fat diet for 5 weeks ran for a longer duration than those
fed a high-carbohydrate diet. The improvement in endurance performance is concomitant with
an increase in skeletal muscle citrate synthase (a key enzyme of the tricarboxylic acid cycle) and
β-HAD enzyme activity (a major index of the β-oxidation) and lower utilization of muscle glycogen
concentration. This result suggests that a high-fat diet induces an increase in mitochondrial biogenesis,
muscle glycogen sparing during exercise, which thereby prolongs submaximal endurance exercise
performance. In agreement with this finding, our results also showed that a 4-week high-fat diet
induces an increase in key mitochondrial enzyme activities in rat skeletal muscle, and that an
alternate-day high-fat diet induces an increase in mitochondrial enzymes in rat skeletal muscle to a
level comparable to that observed after a daily high-fat diet (Figure 1A,B). This result suggests that an
alternate-day high-fat diet is sufficient to increase mitochondrial enzyme activities and protein content
in skeletal muscle.
The main disadvantage of a long-term high-fat diet is the huge accumulation of intra-abdominal
fat and increasing body weight. In the present study, intra-abdominal fat mass in HFD rats was about
60% higher than that of CON rats (Table 1). Since there is a strong correlation between intra-abdominal
fat mass and insulin resistance [24,25], it is difficult to adopt the long term high-fat diet for endurance
athletes. Not only is it particularly unhealthy, but also will it result in an increase in body weight,
which negatively affects endurance exercise performance. However, an alternate-day high-fat diet
induced muscle adaptation, but did not cause excessive intra-abdominal fat accumulation. Results
from the present investigation suggest that it is possible that dietary intervention with a high-fat diet
can induce increases in mitochondrial oxidative capacities in skeletal muscle, while reducing health
risk. However, in the present study, the diet intervention period was only 4 weeks to determine the
effect of alternate-day high-fat diet feeding on intra-abdominal fat accumulation. If a longer period of
dietary intervention is performed, an increase in body fat might be observed. It should be investigated
whether time course changes of accumulation of intra-abdominal fat by an alternate-day high-fat diet.
Recently, the possible mechanisms involved in this high-fat diet-induced increase in mitochondrial
protein content in skeletal muscle have been studied. It has been reported that raising plasma FFA
results in an increase in PPAR δ activation and mitochondrial biogenesis [13]. In this study, plasma
concentration of FFA is higher in both HFD and ALT groups than in the CON group. Therefore, it is
likely that there is a similar activation of PPARδ by raising plasma FFA in both the HFD and ALT groups
resulting in an increase in mitochondrial enzyme activities in skeletal muscle. The transcriptional
coactivator PGC-1α is known to induce mitochondrial biogenesis by activation of transcription factors
and coordinated expression of a large number of proteins [26]. In this study, PGC-1α protein content
in HFD was significantly higher than that of CON. Furthermore, the ALT group had an elevated
protein content of PGC-1α (Figure 2A). It was reported that PGC-1α proteins significantly increase
after 4 weeks of HFD, without an increase in the rate of transcription [13]. The finding that PGC-1α
mRNA expression does not increase in skeletal muscle of rat fed a high-fat diet [13], suggested a
hypothesis that high-fat diet results in an increase in PGC-1α protein content through post-translational
mechanisms, such as decrease in degradation of PGC-1α protein. Although the precise mechanisms by
which high-fat diet increases PGC-1α protein content through post-translational mechanisms are not
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clear, our findings suggested that repeated stimulation of HFD by ALT is sufficient to elevate PGC-1α
protein content and mitochondrial proteins.
Several studies reported that rats fed a high-fat diet are capable of intense exercise despite a
limited muscle glycogen stores [4,6,8]. In the present study, we did not find differences in muscle
glycogen concentration among the different groups. Furthermore, the protein content of GLUT-4,
a predominant form of glucose transporter in skeletal muscle, was not different among the three
groups (Figure 4A,B). The difference in glycogen concentration in response to a high-fat diet between
our study and previous studies might be due to the fat content of the diet. The diet used in this study
comprised 50% of calories from fat, whereas rats in the previous studies were fed diets comprising
78% fat [4,8]. This extremely low carbohydrate diet may result in lower glycogen concentrations in
skeletal muscle.
In contrast to animal studies, human studies have failed to demonstrate a beneficial effect of
a high-fat diet on endurance exercise performance [5,27]. The difference in results between animal
and human studies may be because of fat composition in diet. The control diet used in most of the
animal studies comprised approximately 10% of calories from fat, whereas a typical Japanese and
American diet consists of about 25% [28] and 34% fat [29], respectively. It might be difficult to detect
a high-fat diet-induced increase in endurance performance in humans, because the fat content in
the diet of humans is higher than that used in experimental animals. However, because a high-fat
diet, containing 62% calories from fat, induces increases in mitochondrial enzymes in human skeletal
muscle [7], human skeletal muscle is capable of adaptation responses to a high-fat diet. Therefore,
it will be interesting in future studies to determine whether manipulation of dietary fat, not using
a high-fat diet, induces an increase in mitochondrial oxidative enzyme capacity in human skeletal
muscle and enhance endurance exercise performance.
Recent works by Shortreed et al. demonstrated that high-fat diet feeding for 8 weeks impaired
oxidative capacity in mice skeletal muscle [30]. In contrast, Sadler et al. reported that 2-week
high-fat diet feeding in mice down-regulated citrate synthase activity, but it gradually increased
at 16 weeks [31]. While it is difficult to be certain why the adaptations to high-fat diet differ from
the studies, the time course of development of mitochondrial impairment by over-feeding or high-fat
diet, and the differences of animal model (mouse or rat), should be investigated carefully in future
studies. Furthermore, although the increase in mitochondrial volume, enzyme activity, and changes in
organelle composition is referred to as mitochondrial biogenesis, we assessed the limited numbers
of mitochondrial proteins, including β-oxidation enzymes (β-HAD and LCAD) and citrate cycle
enzyme (citrate synthase) in this study. In addition, recent studies showed the functional role of
mitochondrial reactive oxygen species, which affecting calcium handling proteins involved in muscle
contractility [32,33]. Future extensive investigations are expected to directly measure the mtDNA
copy number, mitochondrial volume, and calcium handling capacity of mitochondria to examine
whether the alternate-day high-fat diet feeding induces an increase in functional mitochondria in
skeletal muscle.
5. Conclusions
In conclusion, we found that provision of an alternate-day high-fat diet for 4 weeks induces
increases in mitochondrial enzyme activities and protein content in rat skeletal muscle without
intra-abdominal fat accumulation.
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Abstract: Diabetic dyslipidemia contributes to an increased risk of cardiovascular disease. Hence,
its treatment is necessary to reduce cardiovascular events. Honey reduces hyperglycemia and
dyslipidemia. The reproducibility of these beneficial effects and their generalization to honey samples
of other geographical parts of the world remain controversial. Currently, data are limited and findings
are inconclusive especially with evidence showing honey increased glycosylated hemoglobin in
diabetic patients. It was hypothesized that this deteriorating effect might be due to administered high
doses. This study investigated if Nigerian honey could ameliorate hyperglycemia and hyperlipidemia.
It also evaluated if high doses of honey could worsen glucose and lipid abnormalities. Honey (1.0, 2.0
or 3.0 g/kg) was administered to diabetic rats for three weeks. Honey (1.0 or 2.0 g/kg) significantly
(p < 0.05) increased high density lipoprotein (HDL) cholesterol while it significantly (p < 0.05) reduced
hyperglycemia, triglycerides (TGs), very low density lipoprotein (VLDL) cholesterol, non-HDL
cholesterol, coronary risk index (CRI) and cardiovascular risk index (CVRI). In contrast, honey
(3.0 g/kg) significantly (p < 0.05) reduced TGs and VLDL cholesterol. This study confirms the
reproducibility of glucose lowering and hypolipidemic effects of honey using Nigerian honey.
However, none of the doses deteriorated hyperglycemia and dyslipidemia.
Keywords: honey; diabetes mellitus; hyperglycemia; hyperlipidemia; dyslipidemia; lipid profile;
alloxan; rats
1. Introduction
Diabetes mellitus is a metabolic disorder associated with an increased risk of cardiovascular
disease (CVD), a main cause of mortality in diabetes [1]. Although several factors account for increased
CVD risk in diabetes, abnormalities of lipid metabolism are important contributors [2]. Hence, in
addition to controlling hyperglycemia, treatment of dyslipidemia is inevitable to reduce cardiovascular
events in diabetes [3]. While the current agents employed for the treatment of dyslipidemia are
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effective, these drugs are not easily affordable to many patients [4]. Besides, the use of some of these
agents is associated with undesirable side effects. Some of these factors compel patients to seek
alternative and complementary medicines. Even though complementary and alternative medicines are
easily accessible and more affordable, their use is not without drawback. These agents are of unproven
efficacy, and there are great concerns for safety and risk of untoward adverse effects [5].
One such complementary medicine that has gained wide attention in the past decade is honey.
The anecdotal use of honey dates back to 2100–2000 BC [6]. Research in the past few years has provided
convincing evidence in support of antioxidant, antibacterial and the wound healing properties of
honey [7–9]. With regard to other reported beneficial effects, especially metabolic and cardiovascular
effects such as antihypertensive, hypolipidemic, hypoglycemic and antidiabetic effects of honey, data
are limited and the findings remain inconclusive particularly in clinical studies. At the moment, due
to paucity of data, it remains unclear if these reported beneficial metabolic effects of honey can be
reproduced using any honey sample or is restricted to a specific honey or certain honeys. Evidence has
revealed that there is variation in the composition of honey. This variation depends on certain factors
including geographical origin and botanical sources of the nectar [10]. Other factors such as climate,
environment and processing techniques also contribute to variation in honey composition [10,11].
The variation in honey composition may influence the pharmacological effects derived from the honey
samples. This leads to another uncertainty as to whether findings obtained with a honey sample
from a particular geographical origin or floral source can be generalized to honey samples from other
geographical parts or botanical sources of the world [12].
More worrisome is the evidence from a study which showed that honey increased glycosylated
hemoglobin in diabetic patients [13]. This finding appears to suggest a potential deteriorating effect of
honey on glycemic control. However, it was later explained that this particular finding should not
be generalized to all honey samples as a result of two factors. These factors are: the administered
high doses and the high glucose content of the administered honey [14]. In that particular study,
graded doses of honey were administered orally to diabetic patients for eight weeks. The initial dose
(1.0 g/kg/day) was increased by 0.5 g/kg/day every two weeks till the end of the study. Besides,
the honey in question had a considerably higher glucose content than that found in most honey
samples [15]. It was suggested that these two factors would invariably enhance glycosylation and
contribute to increased glycosylated hemoglobin in diabetic patients [14]. This potential deterioration
of glycemic control resulting from honey administration may also aggravate dyslipidemia in diabetes.
Therefore, this study was carried out to investigate if Nigerian honey could reduce hyperglycemia and
ameliorate lipid abnormalities in alloxan-induced diabetic rats. It also aimed to evaluate if high doses
of honey could deteriorate glucose and lipid derangements in alloxan-induced diabetic rats.
2. Materials and Methods
2.1. Chemicals
Alloxan and glucose were purchased from Sigma-Aldrich, MO, USA. All other reagents used
were of analytical grade.
2.2. Animals
The Wistar rats were purchased from animal house unit, Nsukka, Nigeria. The animals
were acclimatized for at least 2 weeks. Two rats were housed per cage and maintained in a well
ventilated animal room with temperature of 25–27 ˝C and 12-h light/dark cycle. The rats had free
access to rat chow and portable water ad libitum. The animals were handled with humane care
and in accordance with institutional guidelines of Ethics Committee of Ebonyi State University
(EBSU/UREC/15/FCM/004) and international guidelines on the Use and Handling of Experimental
Animals [16].
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2.3. Honey
Honey was purchased from a bee farm in Ebonyi State, Nigeria. The honey had a NAFDAC
(National Agency for Food and Drug Administration Control) registered number. The honey was
dissolved in drinking water and prepared freshly each time it was administered.
2.4. Induction of Diabetes Mellitus
Diabetes mellitus was induced in overnight fasted male Wistar rats (180–220 g) via intraperitoneal
administration of 150 mg/kg body weight (BW) of alloxan dissolved in normal saline. Another
group of fasted rats was administered normal saline without alloxan. The rats were given 20% (w/v)
glucose solution to prevent fatal post-alloxan hypoglycemia. Forty-eight hours (48 h) post-alloxan
administration, rats with elevated fasting blood glucose (BG) concentrations ě250 mg/dL were
considered diabetic and included in the study.
2.5. Treatment
The animals were randomly divided into five groups. All the groups (except group 5) consisted
of 6 rats. Group 5 comprised 5 rats because a rat died few days to the end of the treatment period.
Using oral canula, the rats were administered drinking water or honey once daily between 8:00 and
9:00 a.m. for 3 weeks as follows:
‚ Group 1: Non-diabetic rats administered 1 mL/kg BW of drinking water
‚ Group 2: Diabetic rats administered 1 mL/kg BW of drinking water
‚ Group 3: Diabetic rats treated with 1.0 g/kg BW of honey
‚ Group 4: Diabetic rats treated with 2.0 g/kg BW of honey
‚ Group 5: Diabetic rats treated with 3.0 g/kg BW of honey
Before the commencement of treatment, body weight and fasting blood glucose concentrations
were measured using weighing scale and Accu-Chek Active glucometer (Roche, Germany), respectively.
After treatment for 3 weeks, the rats were fasted overnight for at least 16 h (4 p.m.–8 a.m.). The body
weight and blood glucose concentrations were measured. The animals were then sacrificed under
light diethyl ether anesthesia. Blood samples were collected in plain tubes and allowed to clot at room
temperature. The blood samples were centrifuged at 1500 rpm for 10 min. The supernatants (sera)
were collected and stored at ´20 ˝C till further analysis.
2.6. Biochemical Analysis
The serum concentrations of total cholesterol (TC), triglycerides (TGs) and high density lipoprotein
(HDL) cholesterol were determined using Agappe kits (Agappe Diagnostics, Knonauerstrasse, Cham,
Switzerland) on EMP-168 Biochemical Analyzer according to the manufacturer’s instructions. Serum
low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol were estimated
using the Friedewald equations [17].
LDL cholesterol “ TC ´ rHDL cholesterol ` pTG{5qs (1)
VLDL cholesterol “ TG{5 (2)
Non-HDL cholesterol was calculated by the formula:
Non-HDL cholesterol “ TC ´ HDL cholesterol (3)
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2.7. Determination of Atherogenic Index (AI), Coronary Risk Index (CRI) and Cardiovascular
Risk Index (CVRI)
The AI, CRI and CVRI were calculated using the formulae ([18,19]):
AI “ LDL cholesterol{HDL cholesterol (4)
CRI “ TC{HDL cholesterol (5)
CVRI “ TGs{HDL cholesterol (6)
2.8. Statistical Analysis
The results were analyzed using SPSS version 14. Data are expressed as mean ˘ SEM. Each
group consisted of 6 rats (except the diabetic + 3.0 g/kg BW honey group which comprised 5 rats).
Differences among treated groups were assessed by one way analysis of variance (ANOVA) followed
by Tukey’s post hoc test. The results of initial and final blood glucose concentrations were analyzed
using paired t test. p ď 0.05 was considered statistical significant.
3. Results
3.1. Effect of Honey on Percentage (%) Change in Body Weight (BW) of Diabetic Rats
The % change in BW was significantly reduced (p < 0.01 or p < 0.001) in diabetic rats including
those treated with honey (Figure 1). Honey treatment did not improve % change in BW in diabetic rats.
Figure 1. Effect of honey on % change in BW of diabetic rats. Data are expressed as mean ˘ SEM.
** & *** A significant decrease (p < 0.01 & p < 0.001) when compared with non-diabetic control.
3.2. Effects of Honey on Blood Glucose (BG) Concentrations and Percentage (%) Change in BG of Diabetic Rats
Figure 2 shows the effect of honey on BG concentrations of diabetic rats. The initial and final BG
concentrations in non-diabetic and diabetic control groups did not differ. Compared with the initial
BG concentrations, final BG levels were significantly (p < 0.05) lower in diabetic rats administered
1.0 or 2.0 g/kg BW of honey. Compared with diabetic control rats, only 1.0 or 2.0 g/kg BW of honey
significantly (p < 0.05) reduced % change in BG in diabetic rats (Figure 3). The 3.0 g/kg BW of honey
did decrease % change in BG but was not statistically significant.
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Figure 2. Effect of honey on BG concentrations of diabetic rats. Data are expressed as mean ˘ SEM.
* A significant decrease (p < 0.05) when compared with initial BG concentrations within the same group.
Figure 3. Effect of honey on % change in BG of diabetic rats. Data are expressed as mean ˘ SEM.
* A significant decrease (p < 0.05) when compared with non-diabetic control; † A significant decrease
(p < 0.05) when compared with diabetic control.
3.3. Effects of Honey on Triglycerides (TG), High Density Lipoprotein (HDL), Non-HDL and Very Low Density
Lipoprotein (VLDL) Cholesterol of Diabetic Rats
The data on the effects of honey on TG, HDL, non-HDL and VLDL cholesterol in diabetic rats are
presented in Figures 4–7 respectively. The diabetic control group had significantly (p < 0.05) elevated
levels of TG compared with non-diabetic rats. All the three doses of honey significantly (p < 0.05)
reduced TG levels in diabetic rats (Figure 4). Though not statistically significant (p > 0.05), HDL
cholesterol was reduced in diabetic control group (Figure 5). The 2.0 g/kg BW of honey significantly
(p < 0.05) increased HDL cholesterol in diabetic rats. The diabetic control rats had significantly (p < 0.05)
elevated levels of non-HDL cholesterol (Figure 6). Compared with diabetic control, the non-HDL
cholesterol level was significantly (p < 0.05) reduced in diabetic rats administered 1.0 or 2.0 g/kg BW of
honey. The reduction of non-HDL cholesterol produced by 3.0 g/kg BW of honey was not statistically
significant. The diabetic control group had significantly (p < 0.05) elevated levels of VLDL cholesterol
compared with non-diabetic rats (Figure 7). All the three doses of honey significantly (p < 0.05) reduced
VLDL cholesterol levels in diabetic rats.
99
Nutrients 2016, 8, 95
Figure 4. Effect of honey on triglycerides of diabetic rats. Data are expressed as mean ˘ SEM.
* A significant increase (p < 0.05) when compared with non-diabetic control; † A significant decrease
(p < 0.05) when compared with diabetic control.
Figure 5. Effect of honey on HDL cholesterol of diabetic rats. Data are expressed as mean ˘ SEM.
† A significant increase (p < 0.05) when compared with diabetic control.
Figure 6. Effect of honey on non-HDL cholesterol of diabetic rats. Data are expressed as mean ˘ SEM.
* A significant increase (p < 0.05) when compared with non-diabetic control; † A significant decrease
(p < 0.05) when compared with diabetic control.
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Figure 7. Effect of honey on VLDL cholesterol of diabetic rats. Data are expressed as mean ˘ SEM.
* A significant increase (p < 0.05) when compared with non-diabetic control; † A significant decrease
(p < 0.05) when compared with diabetic control.
3.4. Effects of Honey on Coronary and Cardiovascular Risk Indices of Diabetic Rats
Figure 8 shows the effect of honey on coronary risk index (CRI) in diabetic rats. The diabetic
control rats had significantly (p < 0.05) higher levels of CRI compared with non-diabetic control.
Administration of 1.0 or 2.0 g/kg BW of honey significantly (p < 0.05) reduced CRI in diabetic rats.
The 3.0 g/kg BW of honey did reduce coronary risk index but not statistically significant. The effect of
honey on cardiovascular risk index (CVRI) in diabetic rats is presented in Figure 9. The diabetic control
rats had significantly (p < 0.05) higher CVRI compared with non-diabetic control. With the exception
of 3.0 g/kg BW of honey, honey treatment significantly (p < 0.05) reduced CVRI in diabetic rats.
Figure 8. Effect of honey on coronary risk index of diabetic rats. Data are expressed as mean ˘ SEM.
* A significant increase (p < 0.05) when compared with non-diabetic control; † A significant decrease
(p < 0.05) when compared with diabetic control.
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Figure 9. Effect of honey on cardiovascular risk index of diabetic rats. Data are expressed
as mean ˘ SEM. * A significant increase (p < 0.05) when compared with non-diabetic control;
† A significant decrease (p < 0.05) when compared with diabetic control.
3.5. Effects of Honey on Total Cholesterol (TC), LDL Cholesterol and Atherogenic Index of Diabetic Rats
Table 1 shows the data on the effects of honey on TC, LDL cholesterol and atherogenic index.
Though not statistically significant, the diabetic control rats had elevated levels of TC, LDL cholesterol
and atherogenic index compared with non-diabetic rats. Although honey treatment (especially 1.0 or
2.0 g/kg BW of honey) reduced these parameters towards those of the non-diabetic rats, the reductions
were not statistically significant (p > 0.05).
Table 1. Effects of honey on total cholesterol (TC), low density lipoprotein (LDL) cholesterol and
atherogenic index.
Group TC (mg/dL) LDL Cholesterol (mg/dL) Atherogenic Index
Non-diabetic control 54.3 ˘ 2.4 8.0 ˘ 3.7 0.2 ˘ 0.1
Diabetic control 86.7 ˘ 18.1 23.2 ˘ 13.0 1.1 ˘ 0.7
Diabetic + Honey (1.0 g/kg BW) 52.6 ˘ 5.4 7.9 ˘ 2.9 0.2 ˘ 0.1
Diabetic + Honey (2.0 g/kg BW) 61.6 ˘ 5.6 4.4 ˘ 2.8 0.1 ˘ 0.1
Diabetic + Honey (3.0 g/kg BW) 49.4 ˘ 3.0 21.6 ˘ 7.5 1.0 ˘ 0.6
Data are expressed as mean ˘ SEM.
4. Discussion
In this study, a model of alloxan-induced diabetes was utilized to investigate the potential glucose
lowering and hypolipidemic effect of Nigerian honey and also to evaluate if high doses of honey
would deteriorate hyperglycemia and dyslipidemia. The three doses used in this study were selected
based on previous findings as reported for Malaysian honey [7,20]. The lowest dose (1.0 g/kg BW) was
shown to improve glycemic control and hyperlipidemia in streptozotocin-induced diabetic rats [21].
Two additional higher doses of honey (2.0 and 3.0 g/kg BW) were chosen as a follow-up to a study that
reported exacerbating effect of honey on glycemic control in diabetic patients [13]. It was suggested
that the administered high doses of honey might contribute to such deteriorating effect of honey [14].
The study found that alloxan-induced diabetic rats exhibited significant % reduction in body
weight. Decreased body weight is commonly observed in alloxan-induced diabetic rodents [22]. This is
attributed to break down of adipose tissue lipids and skeletal muscle protein [23]. Honey treatment
did not improve % change in body weight in diabetic rats. This is in contrast with previous reports
which found improved body weight following honey supplementation in streptozotocin-induced
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diabetic rats [7,20]. In the present study, honey treatment (1.0 or 2.0 g/kg BW) significantly reduced
blood glucose levels in diabetic rats. These findings concur with previous results which demonstrated
glucose lowering effect of honey in diabetic rats [7,20,22] and diabetic patients [24]. The potential
mechanisms by which honey mediates its glucose lowering effect have been elaborated [25]. Fructose,
oligosaccharides, antioxidants and mineral elements are some of the numerous honey constituents
that may contribute to its glucose lowering effect [25–27]. Besides these individual constituents with
glucose-lowering properties, their synergistic interactions will contribute considerably to glucose
lowering effect of honey.
The results showed that, unlike 1.0 or 2.0 g/kg BW dose, 3.0 g/kg BW dose did not produce
significant reduction in blood glucose concentrations. In a previous study, 0.2 g/kg BW of honey did
not produce significant reduction in blood glucose level but 1.2 or 2.4 g/kg BW significantly decreased
hyperglycemia [20]. As reported in that study, there was no additional benefit of doubling the dose
of honey from 1.2 to 2.4 g/kg BW on hyperglycemia. Likewise in this study, there was no significant
difference in the glucose lowering effect of 1.0 or 2.0 g/kg BW of honey. However, there is a clear
disparity in the findings of these two studies. While the previous study revealed a dose-dependent
glucose lowering response [20], this new study did not show that. In order to harmonize these
inconsistencies, it is imperative to consider all the doses in these two studies in a context. The doses
are 0.2, 1.0, 1.2, 2.0, 2.4 and 3.0 g/kg BW. While the 0.2 g/kg BW dose did not elicit glucose lowering
effect most probably as a result of insufficient dose, the reason for the lack of significant glucose
lowering response of 3.0 g/kg BW dose remains unknown. An analysis of these doses and their
glycemic responses reveals a trend whereby honey at a particular dose (sub-therapeutic dose) did
not exert glucose lowering effect. However, as the dose was increased, it produced glucose lowering
effect. Additional dose increments also resulted in glucose lowering responses but with no additional
glucose-lowering benefit. It then reached a dose at which further dose increment resulted in a loss of
glucose lowering effect. Further studies are necessary to reveal if additional doses beyond 3.0 g/kg
BW of honey will eventually deteriorate hyperglycemia.
Considering that 0.2 g/kg BW and 3.0 g/kg BW of honey did not elicit significant glucose lowering
effect, based on existing studies, it can be inferred that the therapeutic doses of honey range between
1.0 and 2.4 g/kg BW. In view of the fact that any dose of honey selected between 1.0 and 2.4 g/kg
BW will exert glucose lowering effect without further glucose-lowering benefit, it would be plausible
to propose 1.0 g/kg BW as the optimal dose of honey. This dose (1.0 g/kg BW) of honey has been
investigated in several other studies involving various diseases and therapeutic effects have been
reported [28–33]. It is worth mentioning that even if 3.0 g/kg BW of honey had elicited considerable
glucose lowering response, considering the lack of additional glucose-lowering response compared
with 1.0 g/kg BW dose, it would still not be pharmacologically acceptable to utilize this dose or
other higher doses for therapeutic purposes in diabetes studies especially clinical research. In view
of the fact that 3.0 g/kg BW of honey neither reduced considerably nor increased blood glucose
concentrations, it is uncertain if administration of this dose to diabetic rats over a longer period of
time will alter hyperglycemic level. This could not be observed in this study, which was terminated
at three weeks because of increased mortality in the diabetic control group. Another limitation is the
fact that glycosylated hemoglobin (which was found to be increased in honey-supplemented diabetic
patients [13]) was not measured in this study though it will not be valid.
Diabetic dyslipidemia constitutes an important modifiable risk factor for cardiovascular disorders.
Consequently, the treatment of dyslipidemia is an important strategy in diabetes management [34].
The diabetic control rats had significantly elevated serum levels of TGs, non-HDL and VLDL cholesterol
similar to what was reported previously [35]. The serum concentrations of TC and LDL cholesterol
in diabetic rats were also increased but not statistically significant. In contrast, HDL cholesterol level
was non-significantly lower in the diabetic control group than in the non-diabetic group. The findings
on TC, LDL and HDL cholesterol in alloxan-induced diabetic control rats are comparable to those
reported in a previous study [36]. Alloxan-induced diabetes is associated with reduced insulin level
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resulting from destruction of β-cells following alloxan administration [37]. This low level of insulin
promotes hypertriglyceridemia and secretion of VLDL cholesterol [38,39]. Elevated levels of TGs in turn
displace protein content of VLDL and LDL. This disproportionate imbalance of protein and triglyceride
content of lipoproteins leads to decreased uptake of these lipoproteins by lipoprotein receptors [40].
The accumulation of these lipoproteins and TGs is implicated in many vascular disorders. LDL
cholesterol is an independent risk factor for the development of coronary heart disease (CHD) [41].
The TGs, unlike LDL cholesterol, are not directly atherogenic, but it is an important risk factor for the
development of cardiovascular disease (CVD) [25]. Administration of honey to diabetic rats markedly
reduced TGs, non-HDL and VLDL cholesterol. However, honey (3.0 g/kg BW) did not significantly
reduce non-HDL cholesterol. While the lowest dose of honey (1.0 g/kg BW) increased the HDL
level towards that of the non-diabetic rats, the highest dose (3.0 g/kg BW) produced no such effect.
In contrast, 2.0 g/kg BW of honey significantly increased HDL cholesterol. In previous studies, honey
at a dose of 1.0 g/kg BW was found to significantly reduce TGs and VLDL cholesterol while it increased
HDL cholesterol in diabetic rats [21,32]. Similar beneficial effects of honey on lipid abnormalities were
also reported in both type 1 and type 2 diabetic patients [13,24,42]. The ameliorative effects of honey
as observed in this study as well as those of the previous studies clearly demonstrate the benefits of
honey in the treatment of dyslipidemia.
Even though honey supplementation of diabetic rats was associated with non-significant reduction
of LDL cholesterol, it is noteworthy that honey administration significantly reduced elevated levels
of both TGs and non-HDL cholesterol (which consists of the LDL, intermediate density lipoprotein
(IDL) and VLDL cholesterol fractions). This is important because increased non-HDL cholesterol level
together with hypertriglyceridemia in the presence of abnormal glucose metabolism increases risk
of CVD [43]. Therefore, the marked ameliorative effects of honey on TGs and non-HDL cholesterol
indicate honey can reduce risk of CVD. In this study, the effect of honey on lipid ratios (such as
LDL/HDL cholesterol, TC/HDL cholesterol and TG/HDL cholesterol) in diabetic rats was evaluated.
Assessment of lipid ratios is better than individual lipid parameters in predicting risk of atherogenicity,
CHD and CVD [44]. Non-significant increase in LDL/HDL cholesterol was observed in diabetic
control group. LDL/HDL cholesterol reflects atherogenic index (AI) [44]. Increased AI has also been
reported in alloxan-induced diabetic rats [35]. Honey administration (especially 1.0 or 2.0 g/kg BW)
tended to reduce atherogenic index. The data indicated TC/HDL cholesterol was markedly increased
in diabetic control rats. The TC/HDL cholesterol is an index of CHD and is designated as coronary risk
index (CRI) [45]. Honey supplementation (except the 3.0 g/kg BW dose) considerably reduced CRI
which indicates honey can decrease the risk of CHD in diabetic rats. On the other hand, the TG/HDL
cholesterol predicts the development of CVD and serves as cardiovascular risk index (CVRI) [46].
Recent evidence has also shown that TG/HDL cholesterol is an important predictor of cardiac disease
mortality [47]. The results showed that the diabetic control rats had significantly elevated CVRI.
However, some researchers reported non-significant elevation of this lipid ratio in alloxan-induced
diabetic control mice [48]. Honey therapy (except the 3.0 g/kg BW dose) significantly reduced CVRI in
diabetic rats. This finding therefore suggests that honey is capable of reducing risk of CVD in diabetic
rats. Increased TG/HDL-C ratio is also a reflection of elevated levels of small and dense subclass of
LDL cholesterol (sdLDL), which contribute to increased cardiovascular risk [49]. Hence, the decreased
TG/HDL cholesterol in honey-treated diabetic rats suggests that honey supplementation reduced
sdLDL in diabetic rats.
In view of the role of insulin in lipid metabolism and prevention of hypertriglyceridemia [50],
it is plausible to propose a role of insulin in the hypolipidemic effect of honey. Based on the current
literature, honey may ameliorate dyslipidemia in part via enhanced release of insulin from the remnant
pancreatic β-cells. This proposition is supported by compelling evidence from previous studies. Some
beneficial effects of honey on insulin have been reported in human subjects [42,51]. Similarly, honey has
been shown to increase serum insulin level in streptozotocin-induced diabetic rats [21] and C-peptide
(a peptide released from the β-cells during cleavage of insulin from proinsulin) in diabetic patients [24].
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Histological examination of pancreata from honey-treated diabetic rats has also revealed less severe
injury, incomplete restoration of cellular population as well as bigger size of the islets of Langerhans
compared with pancreata from untreated diabetic rats [52]. Besides, honey has been shown to protect
the pancreas against oxidative stress [53]. This may, in turn, contribute to protection of β-cells against
hyperglycemia-induced oxidative damage [52–54]. All these pancreatic protective effects of honey
will help to preserve the β-cells which invariably will contribute to increased serum insulin levels as
reported [21]. Increased secretion of insulin will enhance lipogenesis and inhibit lipolysis leading to
amelioration of hyperlipidemia [55].
It is worthy of note that, compared to the other two doses, the 3.0 g/kg BW of honey ameliorated
dyslipidemia to a less extent or partially. This is evident by the lack of significant effect of this
dose on serum levels of HDL, non-HDL cholesterol, TC/HDL cholesterol and TG/HDL cholesterol.
Furthermore, an analysis of the data presented in Table 1 reveals the values of LDL cholesterol
and atherogenic risk index in the diabetic rats treated with 3.0 g/kg BW of honey were elevated
towards those of the diabetic control rats. These data on the lipid parameters and lipid ratios seem to
suggest that honey at 3.0 g/kg BW lost its hypolipidemic effect. Interestingly, this reduced or loss of
hypolipidemic effect of 3.0 g/kg BW of honey is in agreement with its loss of glucose lowering effect.
Additional studies involving higher doses or the same dose but for a longer duration of treatment may
help to reveal if honey can worsen dyslipidemia.
5. Conclusions
This study shows that, using comparable doses as reported for Malaysian honey, Nigerian honey
ameliorates hyperglycemia and dyslipidemia in alloxan-induced diabetic rats. Thus, this study adds
to the limited available evidence that the glucose lowering and hypolipidemic effects of honey are not
restricted to honey samples of a particular geographical origin. In addition, the study extends previous
findings by reporting that the beneficial effects of honey on glucose and lipid metabolism as well as
lipid ratios may be lost at high doses of honey. The study, however, did not find any deteriorating
effect of the highest dose of honey (3.0 g/kg BW) on hyperglycemia and dyslipidemia. Considering
that the therapeutic benefits of honey on metabolic derangements tended to be lost or reduced at the
highest dose, it remains unclear if 3.0 g/kg BW of honey or higher doses administered over a longer
duration of time would worsen hyperglycemia and dyslipidemia in diabetes.
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Abstract: Leucine has been shown to acutely inhibit hepatic glucose production in rodents by a
mechanism requiring its metabolism to acetyl-CoA in the mediobasal hypothalamus (MBH). In the
early stages, all branched-chain amino acids (BCAA) are metabolized by a shared set of enzymes to
produce a ketoacid, which is later metabolized to acetyl-CoA. Consequently, isoleucine and valine
may also modulate glucose metabolism. To examine this possibility we performed intrahypothalamic
infusions of isoleucine or valine in rats and assessed whole body glucose kinetics under basal
conditions and during euglycemic pancreatic clamps. Furthermore, because high fat diet (HFD)
consumption is known to interfere with central glucoregulation, we also asked whether the action
of BCAAs was affected by HFD. We fed rats a lard-rich diet for a short interval and examined their
response to central leucine. The results showed that both isoleucine and valine individually lowered
blood glucose by decreasing liver glucose production. Furthermore, the action of the BCAA leucine
was markedly attenuated by HFD feeding. We conclude that all three BCAAs centrally modulate
glucose metabolism in the liver and that their action is disrupted by HFD-induced insulin resistance.
Keywords: branched-chain amino acids; leucine; isoleucine; valine; glucose metabolism; nutrient
sensing; hypothalamus; liver
1. Introduction
Excessive calorie intake resulting from the consumption of fat-rich diets is the most important
environmental factor contributing to the emergence and worsening of the current world pandemic of
diabetes and obesity [1,2]. Mammals have developed complex mechanisms for detecting changes in the
availability of nutrients and responding to them with metabolic adaptations to maintain homeostasis.
Multiple organs and tissues are involved in these physiological adaptive mechanisms of nutrient
sensing, but the mediobasal hypothalamus (MBH) of the central nervous system (CNS) has been
identified as a key integration center for these nutritional cues [3–6]. Dietary protein and amino
acids (AA) exert a powerful influence on insulin action and glucose metabolism. The mechanisms
underlying this effect are generally attributed to the metabolic actions of AAs in the liver and
skeletal muscle [7–13]. Recently however, a number of metabolic actions of AAs have been localized
to the MBH of rodents [14–17]. In particular, we have shown that the metabolism of leucine to
acetyl-CoA in the MBH is coupled to the inhibition of endogenous glucose production (EGP) and a
consequent decrease of circulating glucose levels [16]. In the brain, leucine is initially metabolized
through the consecutive action of five enzymes [18,19]. First, leucine is transaminated to α-KIC by the
branched-chain amino transferase (BCAT). Next, α-KIC is oxidatively decarboxylated by the action of
Nutrients 2016, 8, 79 109 www.mdpi.com/journal/nutrients
Nutrients 2016, 8, 79
the branched-chain α-ketoacid dehyrogenase (BCKDH) to form isovaleryl-CoA, which, after three more
reactions, is converted to acetyl-CoA. In our studies [16], interventions that antagonized the activity
of the enzyme BCKDH or otherwise prevented the formation of acetyl-CoA in the MBH markedly
attenuated the glucoregulatory action of leucine. Thus, the conversion of leucine to acetyl-CoA was
required to bring about the glucoregulatory effect. Further experiments also revealed that acetyl-CoA
had to be converted to malonyl-CoA. More importantly, we showed that the incapacitation of leucine
sensing in the MBH contributes to the development of hyperglycemia [16]. Interestingly, the first
two enzymes, BCAT and BCKDH, also catalyze the metabolism of the other two members of the
branched-chain amino acids (BCAA) family, isoleucine and valine, to form their respective ketoacid
products. Successive enzymatic reactions give rise to various metabolites, including acetyl-CoA, a key
intermediate for glucoregulation.
Several studies have shown that acute diet-induced insulin resistance partially obliterates the
hypothalamic glucoregulatory response to fatty acids [20–22]. This acquired defect is induced by the
consumption of a diet enriched in saturated fat. Furthermore, previous studies indicated that the
hypothalamic sensing of glucose and lactate, both of which need to be converted to pyruvate, are
attenuated by high-fat diet (HFD) feeding [23]. Importantly, studies in rats revealed that HFD feeding
caused a marked decrease in the levels of hypothalamic long-chain fatty acyl CoAs (LCFA-CoA) and
that their restoration normalized nutrient-dependent glucoregulation [22]. Based on these findings, we
hypothesized that HFD feeding may also perturb the glucoregulatory response to BCAA.
Currently it is not known whether or not isoleucine and valine modulate glucose metabolism;
furthermore, the effect of HFD on the central metabolic actions of BCAA has not yet been examined.
Here we investigated the possibility that the central metabolism of isoleucine and valine may also be
coupled to the regulation of glucose metabolism in the liver. Additionally, to determine whether HFD
feeding has an impact on the glucoregulatory action of BCAAs, we infused leucine in the MBH of rats
previously fed with a lard-enriched diet. In both cases we assessed glucose metabolism in vivo through
a combination of pancreatic insulin clamps and measurements of whole body glucose kinetics.
2. Experimental Section
2.1. Animal Studies
The animal studies were approved by the Institutional Animal Care and Use Committee (IACUC)
of the Albert Einstein College of Medicine. Ten-week-old Sprague-Dawley male rats (Charles River
Laboratories, Wilmington, MA, USA) were used for the studies. The animals were individually housed
and subjected to a light–dark cycle (0600–1800/1800–0600) with free access to water and food.
2.1.1. Animal Surgeries
Rats were subjected to stereotaxic surgery for implantation of a stainless steel bilateral cannula
in the MBH as previously described [16]. The stereotaxic coordinates for cannula placement were
(from bregma): −3.3 mm anterior–posterior axis; 0.4 mm lateral axis; and 9.6 mm vertical axis
(depth) [24]. On recovery, the animals underwent a second surgery for the placement of indwelling
vascular catheters that were used for infusions and blood sampling during the pancreatic clamp
studies [16]. Postoperative recovery was monitored by measuring daily food intake and body weight.
Only fully recovered animals were used for the experiments. Proper placement of the cannulas was
confirmed histologically in brain slices prepared postmortem.
2.1.2. Diets
In the experiments where we compared leucine, isoleucine, and valine, the rats were fed with a
regular chow diet (Cat#5001, Lab Diet, Richmond, IN, USA). In separate experiments designed to test
the effect of saturated fat on leucine sensing, the animals were subjected to a 3-day regime of a HFD
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consisting of regular chow enriched with 10% of lard (Cat#01P5704C-K, Test Diet, Richmond, IN, USA)
prior to the clamps.
2.1.3. Intrahypothalamic Infusions
Rats were randomized into three groups and received 6 hr intrahypothalamic (MBH) infusions of
the following solutions: (1) Vehicle (artificial cerebrospinal fluid); (2) isoleucine; and (3) valine. For the
glucose kinetics experiments, an additional group of animals received leucine at an equimolar dose for
comparative purposes. Each AA was dissolved in vehicle and delivered at a total dose of 12 nmoles
over the course of 6 h (0.33 μL/h per side). The protocol and dose was based on our previous in vivo
studies with leucine [16]. A separate group of rats were subjected to HFD feeding and then similarly
infused with leucine during pancreatic clamps.
2.1.4. Pancreatic Clamp Studies and Glucose Kinetics Measurements
All rats on regular chow consumed 60 kcal of food the night prior to the study to ensure
comparable nutritional status. Plasma levels of circulating glucose were monitored from the start
(t = 0 min) of the central infusion (Figure 1A,B). A primed, continuous infusion of [3-3H] glucose
(Perkin Elmer, San Jose, CA, USA; 40 μCi bolus; 0.4 μCi/min) was initiated at t = 120 min and
maintained throughout the study to assess glucose kinetics by tracer dilution methodology [25], then a
pancreatic clamp with insulin replaced at basal levels was performed (t = 240–360 min). At the end of
the study, the animals were euthanized and tissue samples were freeze-clamped in situ and stored for
subsequent analysis.
0 120 240 360






Bilateral Cannula time (min)
A B
Figure 1. Experimental procedures. (A) Schematic of rat brain (sagittal view) with bilateral cannula
implanted stereotactically for infusions into the mediobasal hypothalamus (MBH); (B) Time-line for
in vivo central infusions of branched-chain amino acids (BCAAs) during euglycemic pancreatic clamp
protocol with isotopic glucose tracer.
2.2. Analytical Procedures and Calculations
Plasma glucose was measured using an Analox instrument (Analox Instruments USA Inc.,
Lunenburg, MA, USA). The radioactivity of [3-3H] glucose in plasma was measured from supernatants
of Ba(OH)2 and from ZnSO4 precipitates (Somogyi procedure) of plasma samples after each was
evaporated to dryness to remove tritiated water. The rate of glucose uptake and endogenous glucose
production were calculated as previously described [26].
2.3. Statistical Analysis
All data values are expressed as mean ± S.E.M. of the indicated number of experiments. Statistical
comparisons were assessed by unpaired Student’s t test or analysis of variance (ANOVA) followed by
the Tukey HSD test. We used the customary threshold of p < 0.05 to declare statistical significance.
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3. Results
We first asked if increasing the local levels of isoleucine or valine in the MBH of rats modifies
circulating glucose levels. To answer this question we performed intrahypothalamic infusions
of these BCAAs under basal conditions and measured blood glucose during the course of the
infusion. As predicted, both isoleucine and valine individually decreased the plasma levels of glucose
compared to vehicle-infused control animals (Figure 2). Thus isoleucine and valine replicated the
glucose-lowering action of leucine.
a*; b**
Figure 2. Effect of central isoleucine and valine on circulating glucose levels. Symbols (circles): white,
vehicle; black, isoleucine; gray, valine. Each point represents the mean ± s.e.m for 6–8 individual
experiments. * a, p < 0.05 Isoleucine vs. control; ** b, p < 0.05 Valine vs. control.
To determine if central isoleucine or valine modulates hepatic glucose metabolism, we performed
pancreatic insulin clamps and glucose kinetics analysis in the same animals. During the clamps, when
glucose and insulin levels in circulation are kept constant, both isoleucine and valine individually
produced a marked increase in the glucose infusion rate (GIR) required to maintain euglycemia
compared to vehicle (Figure 3A). Kinetic analysis revealed that the increase of GIR was the result
of a marked inhibition of EGP (Figure 3B,C), since peripheral glucose utilization (GU) did not
change (Figure 3D). The individual effect of isoleucine and valine on all these kinetic parameters
was comparable in magnitude to that reported for leucine [16] at the equimolar dose (12 pmoles) used
here. Taken together these results indicate that isoleucine and valine fully replicated the effect of
leucine on liver glucose metabolism. On close examination, the individual potency of isoleucine to
inhibit EGP was approximately the same as for leucine but somewhat lower than for valine.
Short-term (3-day) feeding of rodents with a diet enriched in saturated fat (HFD) induces insulin
resistance in the absence of changes in body weight compared to regular chow (RC) fed animals [27,28].
To examine the consequences of acutely-induced insulin resistance on the ability of BCAAs to inhibit
EGP, we subjected rats to three days of HFD feeding and repeated our measurements during central
infusions of leucine. We used leucine because its effects on glucose metabolism have been previously
characterized in detail by our group [16]. During pancreatic clamps, acute insulin resistance was
manifested by decreased GIR (RC = 2.3 ± 0.6 vs. HFD = 0.7 ± 0.2 mg/kg·min; p < 0.05) due to an
increase of EGP (RC = 9.9 ± 0.4 vs. HFD = 11.6 ± 0.6 mg/kg·min; p < 0.05) without change in GU
(RC = 12.3 ± 0.7 vs. HFD = 11.9 ± 0.5 mg/kg·min). Next, as shown in Figure 4A, animals treated
with HFD required remarkably less glucose infusion to maintain appropriate plasma glucose levels
than animals treated with regular chow (not insulin resistant) when infused centrally with leucine.
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Analysis of the clamp tracer data revealed that the ability of leucine to reduce EGP was markedly
attenuated in these HFD treated animals (Figure 4B,C). Importantly, there was no change in GU
(Figure 4D), indicating that all the effect was essentially hepatic. In summary, these results indicate









Figure 3. In vivo comparison of the central action of isoleucine, valine, and leucine on glucose
kinetics during pancreatic insulin clamps. (A) Glucose infusion rate (GIR) to maintain euglycemia;
(B) Endogenous glucose production (EGP); (C) Inhibition of EGP by insulin (I-EGP); (D) Peripheral
glucose utilization (GU). White bars, vehicle; black bars, leucine; check-filled bars, isoleucine; striped






Figure 4. Impact of high-fat diet (HFD) feeding on the central glucoregulatory action of leucine.
(A) Glucose infusion rate (GIR) to maintain euglycemia; (B) Endogenous glucose production (EGP);
(C) Inhibition of EGP by insulin (I-EGP); (D) Peripheral glucose utilization (GU). White bars, regular
chow-fed (control) animals; black bars, HFD-fed animals. Each bar represents the mean ± s.e.m for
6 individual experiments. * p < 0.05 vs. control.
4. Discussion
In the current studies, our measurements of whole body glucose kinetics during pancreatic clamps
showed that isoleucine and valine each individually modified the main parameters in a very similar
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way: increased GIR, decreased EGP, and no change in peripheral GU. At an equimolar dose, the
magnitude of their effects were comparable to those of leucine. These findings strongly support
our hypothesis that all BCAAs are capable of signalling in the MBH through a common upstream
metabolic mechanism. Although the goal of our work was to determine whether or not isoleucine
and valine had central glucoregulatory activity rather than studying the mechanisms, it would be
appropriate to discuss the possibilities. We think that it is the metabolic fate of these BCAAs that
allows them to signal in the MBH. In the case of isoleucine, the explanation seems straightforward
because this amino acid is directly converted to acetyl-CoA, which can then be used to generate
malonyl-CoA. More intriguing, though, is the effect of valine, since this amino acid is not directly
metabolized to acetyl-CoA but rather to propionyl-CoA. This metabolite is converted to succinyl-CoA,
which then enters the tricarboxylic acid (TCA) cycle, a feature that makes it a glucogenic amino acid.
As a glucogenic AA, valine is the second example of its kind, after proline [17], found to modulate
glucose metabolism by acting in the hypothalamus. Interestingly, the glucogenic AA histidine was
recently shown to inhibit liver glucose production when delivered in the third ventricle of rats,
suggesting that it acts in the hypothalamus [29]. However, in contrast with proline, histidine requires
binding to histamine receptors rather than its metabolism in the brain to modify liver glucose fluxes.
More importantly, we have shown that physiologically relevant elevations of the circulating levels of
leucine or proline modulate hepatic glucose metabolism in vivo [16,17]. Similarly, it is possible that
physiological elevations of isoleucine and valine also regulate circulating glucose levels, but further
studies are required to confirm (or rule out) this idea. Several studies in rodents appear to support a
role for BCAAs in the improvement of glucose metabolism reported here. For example, dietary leucine
supplementation improves glucose metabolism and prevents obesity in various mouse models [30,31].
Furthermore, mice lacking BCAT in the brain display high circulating levels of leucine in association
with a lean phenotype and enhanced insulin sensitivity [32]. Interestingly, recent reports of studies in
humans have identified a link between elevated levels of circulating BCAAs and the development of
insulin resistance or diabetes [33,34]. However, the details of such an association are not clear, and
therefore it is currently unknown how the elevated levels of BCAAs are connected to the development
of these disorders of glucose metabolism. Interestingly, in one of these studies [33], the administration
of BCAA to HFD-fed rodents induced insulin resistance while the administration of BCAA alone
did not. These results not only indicate that BCAAs are not directly involved in the development of
insulin resistance, but they also coincide with our report in that HFD feeding modifies the metabolic
actions of BCAAs in a detrimental fashion. Thus, our current studies showing a blunting of central
glucoregulation by leucine after short-term HFD feeding allows us to add amino acids, or leucine at
least, to the list of nutrients whose hypothalamic sensing is nutritionally regulated. In this regard, our
previous studies showing that molecular disruption of leucine sensing in the MBH precipitates the
development of hyperglycemia in rats fed with a high-protein diet [16] further supports the idea that
the faltering of central leucine sensing may contribute to disease development.
5. Conclusions
The MBH responded to a local increase of isoleucine or valine with an inhibition of EGP, which
mainly reflects glucose production by the liver. At an equimolar dose, the magnitude of the individual
glucoregulatory effect of either isoleucine or valine was similar to that of leucine. Importantly, insulin
resistance induced by short-term high fat feeding markedly attenuated the central glucoregulatory
effect of leucine. In summary, we conclude that not only leucine but also circulating isoleucine and
valine may participate in the acute postprandial regulation of glycemia. Furthermore, consumption of
diets rich in saturated fat incapacitates this centrally-mediated glucoregulation.
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Abstract: Metabolic syndrome including obesity, dyslipidemia and hypertension is a cluster of risk
factors of cardiovascular disease. Fermentation of medicinal herbs improves their pharmacological
efficacy. Red ginseng (RG), a widely used traditional herbal medicine, was reported with
anti-inflammatory and anti-oxidant activity. Aim in the present study was to investigate that the
effects of fermented red ginseng (FRG) on a high-fructose (HF) diet induced metabolic disorders, and
those effects were compared to RG and losartan. Animals were divided into four groups: a control
group fed a regular diet and tap water, and fructose groups that were fed a 60% high-fructose
(HF) diet with/without RG 250 mg/kg/day or FRG 250 mg/kg/day for eight weeks, respectively.
Treatment with FRG significantly suppressed the increments of body weight, liver weight, epididymal
fat weight and adipocyte size. Moreover, FRG significantly prevented the development of metabolic
disturbances such as hyperlipidemia and hypertension. Staining with Oil-red-o demonstrated
a marked increase of hepatic accumulation of triglycerides, and this increase was prevented by
FRG. FRG ameliorated endothelial dysfunction by downregulation of endothelin-1 (ET-1) and
adhesion molecules in the aorta. In addition, FRG induced markedly upregulation of Insulin receptor
substrate 1 (IRS-1) and glucose transporter type 4 (Glut4) in the muscle. These results indicate that
FRG ameliorates obesity, dyslipidemia, hypertension and fatty liver in HF diet rats. More favorable
pharmacological effects on HF diet induced metabolic disorders were observed with FRG, compared
to an equal dose of RG. These results showed that the pharmacological activity of RG was enhanced
by fermentation. Taken together, fermentated red ginseng might be a beneficial therapeutic approach
for metabolic syndrome.
Keywords: fermented red ginseng; metabolic syndrome; obesity; hyperlipidemia; hypertension
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1. Introduction
Obesity, hyperinsulinemia, hyperlipidemia, and hypertension, etc., such as variable coexistence
diseases are characterized by metabolic syndrome [1]. Patients with various diseases have increased.
There are several reasons for that is obesity population by western food, cardiovascular disease by
hypertension, atherosclerosis, diabetes from insulin resistance, and so on. Patients with metabolic
syndrome, as defined by the NCEP-ATP III (National Cholesterol Education Program Adult Treatment
Panel III), simultaneously exhibit three or more of the following characteristics: increased blood
pressure, increased waist circumference, decreased high-density lipoprotein (HDL) level, increased
triglyceride level and hyperglycemia [2]. In metabolic syndrome, the liver is highly affected by excess
dietary nutrients from the intestines and inflammatory adipocytokines from enlarged visceral adipose
tissues. Thus, fatty liver is considered as a representative of metabolic syndrome [3–5].
Fructose is an isomer of glucose with a hydroxyl group on carbon-4 reversed in position.
It is promptly absorbed and rapidly metabolized by the liver. Increased consumption of fructose
commonly leads to rapid stimulation of lipogenesis and Triglyceride (TG) accumulation, which, in
turn, leads to reduced insulin sensitivity and hepatic insulin resistance/glucose intolerance [6,7].
Thus, a high-fructose diet induces a well-characterized metabolic syndrome, generally resulting in
hypertension, dyslipidaemia and low levels of HDL-cholesterol [8]. In addition, many recent studies
suggest that consumption high fructose may be an important risk factor for the development of fatty
liver [9]. Rodents, especially rats, are commonly used as a model to mimic human disease, including
metabolic syndrome [10]. Similarly, lots of data suggests that experiments of fructose-diet rats tend to
produce some of the changes associated with metabolic syndrome, such as altered lipid metabolism,
fatty liver, hypertension, obesity and dyslipidemia [11].
Currently, available pharmacological agents for metabolic disorder have a number of limitations,
such as various side effects and high rates of secondary failure. Therefore, the demand has increased
from those interested in complementary and alternative approaches, including the use of natural
herbs. Especially, natural substances and materials based on traditional medicines are of interest for
the prevention or obstruction of diseases related to fatty liver, hypertension, high cholesterol and
diabetes [12–14].
Red ginseng (RG), which is a famous herb of Korean origin,is produced by steaming and drying
fresh and raw ginseng. During the steaming process, red ginseng formation allows for numerous
chemical changes such as saponin deformation, amino acid changes, and browning reactions, in
order to concentrate the activity principles [15,16]. The pharmacological components of red ginseng
include various saponins (such as ginsenoside), non-saponins and amino acids. These components are
known to have beneficial anti-inflammatory, anti-oxidant, anti-diabetic and anti-aging effects [17–19].
Recently, according to lots of literature, fermentation using microorganisms for the production of more
effective compounds has been extensively studied. In particular, the pharmacological effects of new
saponin generated by red ginseng fermentation have been reported, and this saponin can be mass
produced. Fermented red ginseng (FRG) has displayed 30 types of metabolic factors, including Rb1,
Rb2, Rc and Rd. Moreover, several studies have already reported that compound K exhibits anti-cancer,
anti-diabetic and elevating immune system effects [20]. In addition, many studies have already
reported that fermentation can also increase the effectiveness of pharmacological factors in red ginseng
through easier and more effective endogenous absorption via degradation into small molecules, as
well as disintegration of their toxicity [21]. In addition, several studies have recently reported that FRG
elevates hyperlipidemia and protects pancreatic β-cells from streptozotocin toxicity [22,23]. However,
the effect of fermented red ginseng on high fructose (HF) diet animal models has not been yet reported.
Therefore, the aim of this study was to investigate and compare the effects of dietary supplied FRG
and RG on high fructose diet-induced metabolic syndrome.
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2. Materials and Methods
2.1. Preparation of Fermented Red Ginseng, Red Ginseng and Losartan
The fermented Red ginseng and Red ginseng extracts were provided from the Institute of JinAn Red
Ginseng, Jinan, Jeonbuk Province, Korea. The losartan was purchased from Sigma-Aldrich (Yongin,
Korea). For the fermentation of RG (FRG), a microbial strain, Lactobacillus plantarum A KFCC11611P,
provided from the Korean Culture Center of Microorganisms (KCCM, Seodaemun-gun, Seoul, South
Korea) was used for RG and Rubuscoreanus Miq. (RC) fermentation. The microbes were precultured in
De Man–Rogosa–Sharpe (MRS) (BD biosciences, Sparks, MD, USA) broth medium for Lactobacillus
at 30 ˝C for 24 h before being used for fermentation. For fermentation, 1 L of 0.05 g/m red ginseng
(RG) and 1 L of 0.025 g/mL RG with RC mixture in distilled water was prepared and sterilized.
After inoculation with 100 mL of precultured L. plantarum A, the RG and mixture solution containing
the fermentation microbes was incubated at 35 ˝C for 10 and 5 days, respectively.
2.2. Animal Experiments and Diet
All experimental procedures and animal care were conducted in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory Animals and were published by the
Institutional Animal Care and Utilization Committee for Medical Science of Wonkwang University
(approve code WKU14-105). Seven-week-old male Sprague–Dawley (SD) rats were obtained from
Samtako (Osan, Korea). All rats were housed in a room automatically maintained under a controlled
12 h light/dark cycle at 23 ˘ 2 ˝C with 45%–55% relative humidity. After acclimatization, animals were
divided into 5 groups: a control group fed a regular diet, and fructose groups fed the 60% high-fructose
(HF) diet with/without RG 250 mg/kg/day or FRG 250 mg/kg/day or losartan 30 mg/kg/day for
8 weeks, respectively. Both diets were purchased from Research Diet, Inc. (New Brunswick, NJ, USA).
All groups received a regular diet and the HF diet, respectively, for 8 weeks. The composition of both
diets is listed in Table S1.
2.3. Estimation of Blood Pressure
Systolic blood pressure (SBP) of rats in all groups were measured at 1, 2, 5 and 8 weeks of
period, respectively. SBP was determined by using non-invasive tail-cuff plethysmogrphy method and
recorded with an automatic sphygmotonography (MK2000, Muromachi Kikai, Tokyo, Japan).
2.4. Estimation of Oral Glucose Tolerance Tests
The oral glucose tolerance tests (OGTT) were performed 2 days apart at 7 weeks. For the OGTT,
rats were deprived of food for 12 h. After the food deprivation period, the basalblood samples were
obtained from the tail veins of fully conscious rats and were analyzed using a glucometer (Onetouch®
Ultra™, Boston, MA, USA) and Test Strip (Life Scan, Chesterbrook, CA, USA), respectively. Rats were
then given 2 g/kg body weight as glucose solution by oral gavage. The tail blood samples were taken
at 30, 60, 90 and 120 min after glucose administration.
2.5. Estimation of Biochemical Analysis of Plasma
The levels of triglyceride (TG), blood urea nitrogen (BUN), total billiubin (T-bill), glutamic-
oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) in plasma were
enzymatically measured using commercially available kits (ARKRAY, Inc., Minami-ku, Kyoto, Japan).
Plasma total cholesterol, low density lipoprotein (LDL)-cholesterol and HDL-cholesterol were
determined using HDL and LDL/very low density lipoprotein (VLDL) Assay kit (E2HL-100, BioAssay
Systems, Hayward, CA, USA). The plasma concentration ofleptin and insulin were measured based
on the ELISA method using commercial rat leptin and insulin ELISA kit (Leptin Rat ELISA ab100773,
Abcam, Cambridge, MA, USA; Insulin, 80-INSRT-E01, ALPCO, Cambridge, MA, USA).
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2.6. Protein Preparation and Immunoblotting in the Rat Aorta and Muscle
Thoracic aorta and muscle were homogenized in a buffer consisting of 250 mM sucrose, 1 mM
EDTA, 0.1 mM phenyl methylsulfonyl fluoride, and 20 mM potassium phosphate buffer (pH 7.6). Large
tissue debris and nuclear fragments were removed by two successive low-speed spins (3500 rpm, 5 min;
8000 rpm, 10 min, 4 ˝C). Quantity of protein was measured by the Bradford method. An equal amount
(35 μg) of protein was separated by 10% Sodium Dodecyl Sulfate (SDS)-PAGE. After electrophosis,
protein was transferred electrophoretically to nitrocellulose membranes using a Mini-Protean II
apparatus (Bio-Rad, Hercules, CA, USA). The membranes were then blocked by 5% bovine serum
albumin (BSA) powder in 0.05% Tween 20-Tris-bufferd saline (TBS-T) for 1 h, and subsequently
washed and incubated with primary antibodies to VCAM-1, ICAM-1, E-selectin and ET-1 (in aorta)
and Insulin receptor substrate-1 (IRS-1) and glucose transporter type 4 (Glut4) (in muscle) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at a final dilution of 1:1000 overnight at 4 ˝C. After washing
with TBS-T, membranes were incubated with the appropriate horseradish peroxidase-conjugated
secondary antibody for 1 h. Signals were detected by a chemiluminescence (ECL) using detection
system (Amersham, Buchinghamshire, UK). The bands were analyzed densitometrically by using a
Chemi-doc image analyzer (Bio-Rad, Hercules, CA, USA).
2.7. Histopathological and Oil Red OStaining of Aortic Tissues, Epididymal Fat and Liver Tissues
For histopathological staining, aortic tissues were fixed in 10% (v/v) formalin in 0.01 M phosphate
buffered saline (PBS) for 2 days with a change of formalin solution every day to remove traces of
blood from tissue. The tissue samples were embedded in paraffin, and then thin sections (6 μm) of
the aortic arch in each group were cut and stained with hematoxylin and eosin (H & E) stain for
histopathological comparisons.
Epididymal fat and liver tissues were fixed by immersion in 4% paraformaldehyde for 2 days
at 4 ˝C, and incubated with 30% sucrose for 2 days. Each fat and liver was embedded in an
optimum cutting temperature (OCT) compound (Tissue-Tek, Sakura Finetek, Torrance, CA, USA),
frozen in liquid nitrogen, and stored at ´80 ˝C. Frozen sections were cut with a Shandon Cryotome
Special Motorized Electronic (SME) (Thermo Electron Corporation, Pittsburg, PA, USA) and placed
on poly-L-lysine-coated slide. Epididymal fat sections were stained with H & E. For quantitative
histopathological comparisons, each section was determined by Axiovision 4 Imaging/Archiving
software (Axiovision 4, Carl Zeiss, Oberkochen, Germany). Liver sections were assessed by using
Oil red o staining. Each section was stained with Oil red O for 20 min at room temperature after
rinsing with 60% isopropyl alcohol and distilled water. Images of Oil red O stained liver were taken
with Axiovision 4 Imaging/Archiving software. For quantitative analysis, the average scores of
10–20 randomly selected areas were calculated by using National institutes of health (NIH) Image
analysis software, Image J (NIH, Bethesda, MD, USA).
2.8. Immunihistochemical Staining of Aortic Tissues
Parraffin sections for immunohistochemical staining were placed on poly-L-lysine-coated
slides (Fisher Scientific, Pittsburgh, PA, USA). Slides were immunostained by Invitrogen’s
HISOTO-STAIN®-SP kits (Carlsbad, CA, USA) using the Labeled-[strept] Avidin-Biotin (LAB-SA)
method. After antigen retrieval, slides were immersed in 3% hydrogen peroxide for 10 min to
block endogenous peroxidase activity. After being rinsed with PBS, slides were incubated with 10%
non-immune goat serum for 10 min and incubated with primary antibodies of ICAM-1, VCAM-1
and ET-1 (1:200; Santa Cruz, CA, USA) in humidified chambers overnight at 4 ˝C. All slides
were then incubated with biotinylated secondary antibody for 20 min, and then incubated with
horseradish peroxidase-conjugated streptavidin for 20 min. Peroxidase activity was visualized by
3,31-Diaminobenzidine (DAB; Novex®, Los Angeles, CA, USA) substrate-chromogen system, and
counterstaining with hematoxylin (Zymed, Carlsbad, CA, USA). For quantitative analysis, the average
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scores of 10–20 randomly selected areas were calculated by using NIH Image analysis software, Image J
(NIH, Bethesda, MD, USA).
2.9. Statistical Analysis
All the experiments were repeated at least three times. The results were expressed as a mean ˘ S.E.,
and the data were analyzed using one-way ANOVA followed by a Dunnett’s test or Student’s t-test to
determine any significant differences. p < 0.05 was considered as statistically significant.
3. Results
3.1. Effects of FRG on Changes in Body Weight, Liver Weight and Epididymal Fat Pad Weight
Rats from all five groups showed significant increases in body weight gain during the experimental
period. There was no significant change in body weight after eight weeks of high-fructose feeding
in HF diet groups compared with the control group. However, treatment of FRG and losartan (Los.)
groups showed significant decreases in body weight (Table 1). There was no significant change in food
intake in all groups. Although there were no significant changes in body weight between HF groups
and RG groups, there were decrease those levels. Moreover, HF diet resulted in a significant increase
in liver weight and epididymal fat pad weight. Liver weight and epididymal fat pad weight were
34.81% and 40.92% higher than that of the HF diet group compared with the control group, respectively.
However, treatment of the FRG group significantly reduced the liver weight and epididymal fat pad
weight (23.44%, 38.26%) compared with HF diet groups, respectively. Similarly, treatment of losartan
showed similar results to the FRG group. Although there was no significant change in liver weight
between HF groups and RG groups, they decrease at those levels (Table 1).




Initial BW (g) 270.5 ˘ 3.3 270.0 ˘ 3.1 275.8 ˘ 3.6 272.6 ˘ 1.8 275.5 ˘ 4.3
Terminal BW (g) 399.6 ˘ 7.4 421.2 ˘ 6.0 384.1 ˘ 9.8 # 405.8 ˘ 10.5 393.9 ˘ 6.4 #
Food intake (g/day) 18.5 ˘ 0.3 18.4 ˘ 0.4 18.2 ˘ 0.5 18.8 ˘ 0.4 18.4 ˘ 0.5
Liver weight (g) 9.0 ˘ 1.3 12.3 ˘ 0.4 * 9.2 ˘ 0.4 ## 10.5 ˘ 0.7 9.9 ˘ 0.3 #
Epididymal fat pads weight (g) 6.4 ˘ 0.9 9.0 ˘ 0.4 * 5.5 ˘ 0.4 ## 7.6 ˘ 0.7 # 6.6 ˘ 0.7 #
Values were expressed as mean ˘ S.E. (n = 10). * p < 0.05 versus Cont.; # p < 0.05, ## p < 0.01 versus HF.
Abbreviations: HF, high fructose; HF + Los., high fructose diet with losartan; HF + RG, high fructose diet with
red ginseng; HF + FRG, high fructose diet with fermented red ginseng; BW, body weight.
3.2. Effect of FRG on the Morphology of Epididymal Fat Pads
Because FRG effectively reduced the epididymal fat pad weight, we prepared frozen sections
of epididymal fat pads and stained them with H & E. Histological findings, as shown in Figure 1,
revealed hypertrophy of adipocytes in HF diet groups compared with the control group (+34.86%,
p < 0.01). However, treatment of FRG, Los. and RG groups showed significantly decreases in the
hypertrophy of adipocytes (´23.81%, ´29.62% and ´21.44% respectively, p < 0.01) (Figure 1).
3.3. Effect of FRG on Plasma Lipid Levels
After eight weeks of fructose feeding, rats of HF diet groups showed a significant increase in
plasma triglycerides, total cholesterol, and LDL-cholesterol levels compared with the control group.
However, biochemical analysis of blood samples of the FRG groups showed significant decreases of
T-Cho (104.2 ˘ 11.5 versus 70.3 ˘ 7.1 mg/dL, p < 0.05) and LDL-c (30.0 ˘ 2.6 versus 22.2 ˘ 1.7 mg/dL,
p < 0.05) when compared with HF diet groups (Table 2), respectively.Although there was no significant
change in triglyceride levels between HF group and FRG groups, there tended to decrease at those
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levels. Similarly, Los. group, TG, T-Cho and LDL-c were significantly lower than those levels of
the HF diet group. Moreover, FRG was found to be more effective in reducing the elevated plasma
triglycerides, total cholesterol, and LDL-cholesterol levels compared with RG groups. Besides the
plasma levels of HDL-c levels in administration of Los., RG and FRG groups increased compared with
HF diet groups (45.2 ˘ 4.1 versus 56.4 ˘ 1.6, 56.0 ˘ 3.1 and 60.5 ˘ 4.4 mg/dL, respectively, p < 0.05)
(Table 2).
Figure 1. Effects of fermented red ginseng (FRG) on adipocytes on high fructose (HF) diet rats.
Representative microscopic photographs of hematoxylin and eosin (H & E) stained sections of
epididymal fat pads in HF diet rats. The lower panels indicated the size of adipose cells (magnification
ˆ400). Scale bar shows 50 μm. (a) control; (b) HF; (c) HF + Losartan (Los.); (d) HF + RG (red ginseng);
(e) HF + FRG (fermented red ginseng). Values were expressed as mean ˘ S.E. (n = 3). ** p < 0.01 versus
Cont.; ## p < 0.01 versus HF.




T-Cho (mg/dL) 69.1 ˘ 7.2 104.2 ˘ 11.5 * 72.5 ˘ 5.5 # 80.0 ˘ 4.1 # 70.3 ˘ 7.1 #
TG (mg/dL) 155.0 ˘ 12.8 243.6 ˘ 27.5 * 117.8 ˘ 17.1 ## 180.3 ˘ 32.6 169.0 ˘ 25.1
HDL-c (mg/dL) 57.7 ˘ 5.5 45.2 ˘ 4.1 56.4 ˘ 1.6 # 56.0 ˘ 3.1 # 60.5 ˘ 4.4 #
LDL-c (mg/dL) 22.2 ˘ 2.1 30.0 ˘ 2.6* 20.2 ˘ 1.8 # 26.0 ˘ 1.6 22.2 ˘ 1.7 #
Values were expressed as mean ˘ S.E. (n = 10). * p < 0.05 versus Cont.; # p < 0.05 versus HF. Abbreviations:
HF, high fructose; HF + Los., high fructose diet with losartan; HF + RG, high fructose diet with red ginseng;
HF + FRG, high fructose diet with fermented red ginseng; T-Cho, total cholesterol; TG, triglyceride; HDL-c,
high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
3.4. Effect of FRG on Plasma Parameters
Although there was no significant change of glutamic oxaloacetic transaminase (GOT), glutamic
pyruvic transaminase (GPT), T-bills and non-fasting blood glucose levels in HF groups and
administration drug groups, they decrease at those levels (Table 3). Similar to the plasma lipid
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levels, the plasma levels of leptin and insulin were significantly increased in HF diet groups compared
with the control group. However, treatment of drug groups, especially FRG and Los. Groups, showed
a significantly decreased in those levels compared with HF diet groups (Table 2). Moreover, FRG was
found to be more effective in reducing the elevated plasma insulin level compared with RG groups.




GOT (IU/L) 137.9 ˘ 10.5 164.3 ˘ 15.0 155.1 ˘ 9.8 161.8 ˘ 28.6 137.00 ˘ 16.4
GPT (IU/L) 22.2 ˘ 3.8 29.3 ˘ 6.7 30.3 ˘ 4.5 26.8 ˘ 1.8 28.1 ˘ 6.5
T-bill (mg/mL) 0.49 ˘ 0.04 0.48 ˘ 0.04 0.48 ˘ 0.03 0.49 ˘ 0.02 0.38 ˘ 0.03
Leptin (ng/mL) 5.76 ˘ 1.0 10.93 ˘ 2.0 * 3.80 ˘ 0.7 ## 6.32 ˘ 1.1 5.41 ˘ 1.3 #
Insulin (ng/mL) 2.1 ˘ 0.5 4.1 ˘ 0.6 * 2.0 ˘ 0.5 # 2.4 ˘ 0.6 2.2 ˘ 0.3 #
Blood glucose (mg/dL) 129.4 ˘ 5.6 136.9 ˘ 3.2 128.1 ˘ 4.6 129.4 ˘ 7.1 130.3 ˘ 2.9
Values were expressed as mean ˘ S.E. (n = 10). * p < 0.05 versus Cont.; # p < 0.05 versus HF. Abbreviations:
HF, high fructose; HF + Los., high fructose diet with losartan; HF + RG, high fructose diet with red ginseng;
HF + FRG, high fructose diet with fermented red ginseng; GOT, glutamic-oxaloacetic transaminase; GPT,
glutamic-pyruvic transaminase; T-bill, total billiubin.
3.5. Effect of FRG on Oral Glucose Tolerance Tests
Oral glucose tolerance tests were carried out to check insulin resistance in high-fructose diet rats
after eight weeks. The results showed that HF diet groups maintained a significant increase in blood
glucose levels at 30 (p < 0.01), 60 and 90 min (p < 0.05), respectively. However, the plasma glucose
levels in treatment of FRG and RG groups were significantly decreased at 30 min as compared with
HF diet groups (p < 0.05) (Figure 2A). Similarly, treatment of Los. groups was significantly decreased
at 30 and 60 min as compared with HF diet groups. Moreover, area analysis (AUC) showed that HF
diet groups significantly increased compared with the control group. However, FRG and Los. groups
was significantly decreased compared to that of the HF groups (Figure 2B). Moreover, FRG was found
to be more effective in reducing the elevated plasma glucose level compared with RG group.
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Figure 2. Effect of an FRG on oral glucose tolerance tests (A) and the blood glucose area under curve
(AUC) (B). Values were expressed as mean ˘ S.E. (n = 10). * p < 0.05, ** p < 0.01 versus Cont.; # p < 0.05
versus HF. Abbreviations: HF, high fructose; HF + Los., high fructose diet with losartan; HF + RG, high
fructose diet with red ginseng; HF + FRG, high fructose diet with fermented red ginseng.
3.6. Effect of FRG on Blood Pressure
At the beginning of the experimental feeding period, the levels of systolic blood pressure in all
groups were approximately 106–108 mmHg as investigated by the tail-cuff technique. After eight
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weeks, systolic blood pressure of HF groups were significantly increased compared to that of the
control groups (p < 0.01). However, treatment of FRG and RG groups was significantly decreased
compared to that of the HF groups during all experimental period (135.7 ˘ 1.3 versus 120.7 ˘ 1.1 and
122.0 ˘ 1.1, respectively, p < 0.01) (Figure 3A). Similarly, treatment of losartan showed similar results
to FRG and RG groups. In addition, the protein expression of ET-1 level was increased in the HF diet
group compared with the control group. However, administration drug groups showed significantly
decreased expression levels of protein compared with HF diet groups (Figures 3B and 4).
Figure 3. Effects of FRG on systolic blood pressure (A) and expression of ET-1 immunoreactivity (B) in
aortic tissues of HF diet rats. Representative immunohistochemistry and quantifications are shown.
Values were expressed as mean ˘ S.E. n = 10 (A) and n = 3 (B). ** p < 0.01 versus Cont.; # p < 0.05,
## p < 0.01 versus HF.
3.7. Effect of FRG on the Morphology of Aortas
FRG effectively decreased blood pressure. Thus, we examined staining with hematoxilin-eosin
in thoracic aortas. Figure 5 showed that thoracic aortas of HF diet groups revealed roughened
endothelial layers and increased tunica intima-media of layers compared with the control group.
However, treatment of FRG and RG groups significantly maintained the smooth character of the intima
endothelial layers and decreased tunica intima-media thickness in aortic sections. Similarly, treatment
of losartan showed similar results to FRG and RG groups. Moreover, FRG was found to be more
effective in maintaining the smooth character of the intima endothelial layers and decreased tunica
intima-media thickness compared with RG groups.
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Figure 4. Representative microscopic photographs of H & E stained section of the thoracic aorta in HF
diet rats. Lower panel indicated length of intima-media. Lower panel indicated the size of adipose
cells (magnification ˆ400). (a) control; (b) HF; (c) HF + Los.; (d) HF + RG; (e) HF + FRG. Values were
expressed as mean ˘ S.E. (n = 3). ** p < 0.01 versus Cont.; ## p < 0.01 versus HF.
Figure 5. Effects of FRG on ICAM-1 (A) and VCAM-1 (B) immunoreactivity in aortic tissues of HF
diet rats. Representative immunohistochemistry and quantifications are shown (magnification ˆ400.
Values were expressed as mean ˘ S.E. (n = 3). ** p < 0.01 versus Cont.; # p < 0.05, ## p < 0.01 versus HF.
Abbreviations: HF, high fructose; HF + Los., high fructose diet with losartan; HF + RG, high fructose
diet with Red ginseng; HF + FRG, high fructose diet with fermented Red ginseng.
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3.8. Effect of FRG on the Expressions Levels of Adhesion Molecules and ET-1 in Aortas
The protein expression of VCAM-1, ICAM-1, E-selectin and ET-1 in the descending aortas of all
groups of rats was examined by Western blot analysis. Expression of adhesion molecules (VCAM-1,
ICAM-1 and E-selectin) and ET-1 levels were increased in the HF diet groups compared with the
control group. However, treatment of FRG and RG groups showed significantly decreased expression
levels of protein compared with HF diet groups (Figure 6). Similarly, treatment of losartan groups
showed similar results to FRG and RG groups.
Immunohistochemistry was performed to determine the direct expression of adhesion molecules
in the aortic wall. Adhesion molecule expressions such as ICAM-1 and VCAM-1 were increased in
the HF diet groups (p < 0.01). However, treatment of FRG and RG groups was significantly decreased
expression levels of protein (ICAM-1 and VCAM-1, p < 0.05) (Figure 4). Similarly, treatment of losartan
groups showed similar results to FRG and RG groups. Moreover, FRG was found to be more effective
in decreased expression levels of protein levels compared with RG groups.
Figure 6. Effects of FRG on VCAM-1, ICAM-1, E-selectinm and ET-1 immunoreactivity in aortic
tissues. Representative western blots of VCAM-1, ICAM-1, E-selectinm and ET-1 protein levels are
quantifications are shown. Values were expressed as mean ˘ S.E. (n = 3). ** p < 0.01 versus Cont.;
# p < 0.05, ## p < 0.01 versus HF.
3.9. Effect of FRG on Hepatic Lipids
To investigate the existence of fat accumulation in the livers in all experimental groups, we
prepared frozen sections of livers and stained them with Oil red O. Lipid droplets were detected in HF
diet groups. However, treatment of FRG groups showed that the number of lipid droplets significantly
decreased compared with HF diet groups (Figure 7). Similarly, treatment of losartan group showed
similar results to the FRG groups. However, RG groups was no significant in RG groups compared
with HF group. These results also showed that FRG was found to be more effective in decreased lipid
droplets compared with RG groups.
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3.10. Effect of FRG on the Expressions Levels of IRS-1 and Glut4in Muscle Tissue
To investigate the signals in insulin signaling, we examined the expression of IRS-1 and Glut4
in muscle tissue. The expression of IRS-1 and Glut4 were significantly decreased in HF diet groups.
However, treatment of FRG groups increased expression levels of protein compared with HF diet
groups (Figure 8). Similarly, treatment of losartan groups showed similar results to FRG groups.
Figure 7. Representative microscopic photographs of Oil red O stained sections of the livers in HF diet
rats. Representative Oil red O staining and quantifications are shown (magnification ˆ100). Values
were expressed as mean ˘ S.E. (n = 3). ** p < 0.01 versus Cont.; # p < 0.05, ## p < 0.01 versus HF. (a) control;
(b) HF; (c) HF + Los.; (d) HF + RG (red ginseng); (e) HF + FRG (fermented red ginseng).
Figure 8. Effect of FRG on the expression of IRS-1 and Glut4 in the muscle of HF diet rats. Each
electrophoretogram is representative of the results from three individual experiments. Values were
expressed as mean ˘ S.E. (n = 3). ** p < 0.01 versus Cont.; ## p < 0.01 versus HF. Abbreviations: HF, high
fructose; HF + Los., high fructose diet with losartan; HF + RG, high fructose diet with red ginseng;
HF + FRG, high fructose diet with fermented red ginseng.
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4. Discussion
Past several years, many various plant extracts have been clinically evaluated for the treatment of
metabolic disorder disease, such as diabetes, hypertension, dyslipidemia and atherosclerosis [24]. RG
has been shown to possess beneficial clinical activity in vivo and in vitro studies [25,26]. Interestingly,
the pharmacological effects of RG were further increased by fermentation. It has been reported
that during the fermentation, the chemical composition of ginsenosides are transformed into their
readily absorbable and more potent deglycosylated forms. In addition, FRG contains a much
higher concentration of total ginsenosides and metabolites [27]. Therefore, future study will be
required to clarify the active compounds of FRG and their pharmacological relevance for treatment of
metabolic syndrome.
In the present study, we investigated anti-obesity, hypotension, hypolipidemia improved glucose
tolerance and ameliorated fatty liver effects of FRG in HF diet rats for eight weeks, and the efficacies
were compared to those of RG and losartan. The HF diet induced rodent model is a well-established
model of induced hypertension, hypertriglyceridemia, obesity, impaired glucose tolerance, fatty liver
and vascular remodeling [28,29]. As expected, the present study showed that the results marked
hypertension (increased systolic blood pressure and protein levels of ET-1), obese states (increased
body weight, fat weight, adipocyte size and plasma levels of leptin), hyperlipidemia (increased plasma
total cholesterol, triglycerides and LDL-cholesterol), impaired glucose tolerance (decreased protein
levels of IRS-1 and Glut4), fatty liver (increased liver weight and fat accumulation) and vascular
remodeling (increased endothelial dysfunction and adhesion molecules) through eight weeks of
an HF diet.
It is reported that a high fructose diet induced high blood pressure, intima-media thickness of the
aorta and progress of blood vessel inflammation, which is correlated with prognosis and extension
of the initial stage of atherosclerosis and initial stage of cardiovascular disease [30,31]. In addition,
endothelial dysfunction was also related with lipid metabolism disorders [32]. The present results
showed that an HF diet induced hypertension, dyslipidemia and endothelial dysfunction. However,
administering FRG improved endothelial dysfunction with the amelioration of hypertension and
dyslipidemia. In addition, interestingly, more favorable anti-hypertension, anti-vascular, inflammatory
and regulating lipid homeostasis effects were observed with FRG as compared with an equal
dose of RG.
The accumulation of fat deposition and increase in adipocyte size in the body is a major
characteristic of obesity, as well as an increase of leptin level processes of leptin resistance, which
classically has been characterized by expansion of intra-adipose tissue [33]. Although some studies
have reported that losartan has no anti-obesity effects [34], the present results shows losartan has
anti-obesity effects that decreased body weight, epididymal fat pad weight, adipocyte size and induced
development of leptin resistance [35,36]. Further study is required to clarify the regulatory mechanisms
of obesity and leptin levels in metabolic syndrome models. In addition, FRG effectively inhibited the
leptin resistance with the amelioration of downregulation of body weight, epididymal fat pad weight
and adipocyte size. These results suggest that FRG may be useful for inhibiting the development of
leptin resistance and obesity. In addition, FRG was observed to homeostasis about anti-obesity and
regulating leptin.
Recently, report has been found a low activation state of AMP-activated protein kinase
(AMPK) with metabolic disorder associated with impaired insulin sensitivity, fat accumulation and
dyslipidemia [37,38]. It is suggested that fructose-driven leptin resistance in the present study may
be associated with impaired leptin-mediated decrease in AMPK phosphorylation. Although we did
not examine specific research related to energy metabolism in the AMPK pathway, we speculate
that treatment of FRG could be related to the improvements of metabolic disorders by activation of
AMPK-related signal pathways.
It is reported that a high fructose diet induced impaired glucose tolerance via the elevation of
plasma triglyceride levels, which plays an important role in the development of such abnormalities
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as insulin resistance, type 2 diabetes, dyslipidemia and fatty liver [39,40]. In addition, there are two
signal transduction pathways for glucose/insulin transport in skeletal muscles. IRS-1 is an important
tool for stimulating glucose transport induced by insulin [41]. The magnitude of a dense membrane
compartment of Glut4 is related to the degree of insulin stimulated and thereby improves glucose
uptake in skeletal muscles [42]. Thus, these factors are important key elements in insulin-dependent
signal transduction pathways [43]. The present results showed that an HF diet impaired glucose
tolerance, which is downregulation of IRS-1 and Glut4 expression. Moreover, an HF diet produced
increased liver weight and accumulation of fat deposition in the liver, whereas, FRG improved impaired
glucose tolerance with upregulation of IRS-1 and Glut4 protein level expression and decreased liver
weight and accumulation of fat deposition in the liver. Hepatic steatosis is associated with metabolic
syndrome and is a risk factor for the development of chronic hepatitis. Hyperinsulinemia and
hyperglycemia associated with various metabolic disorders may act directly to promote hepatic
injury including inflammation and fatty liver. In addition to investigating damage of the liver with
aggravation of inflammation, the present study measured plasma levels of GPT, GOT and T-bill.
Although all groups did not observe significant changes in plasma levels of GPT, GOT and T-bill, FRG
tended to ameliorate those levels. Taken together, the present results showed direct/indirect evidence
that FRG has regulated insulin signals and hepatoprotective effects. Moreover, FRG was observed
to have more favorable regulating insulin signals and hepatoprotective effects compared with equal
doses of RG.
In the future, we plan for more studies that clarify specific mechanism research in relation to other
energy metabolic controls in an intestinal body and what ingredients or compounds are most effective
in fermented red ginseng in HF diet induced metabolic syndrome.
5. Conclusions
Oral treatment of fermented red ginseng (FRG) effectively ameliorated HF diet induced metabolic
disorders such as obesity, dyslipidemia, hypertension and fatty liver. Moreover, treatment of FRG had
more favorable pharmacological effects on HF diet induced metabolic disorders compared with an
equal dose of red ginseng. Taken together, fermented red ginseng might be a beneficial therapeutic
approach for metabolic syndrome.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/6/369/s1,
Table S1: Composition of diet obtained from Research diet.
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Abstract: Obesity and diabetes are associated with excessive inflammation and impaired wound
healing. Increasing evidence suggests that macrophage dysfunction is responsible for these
inflammatory defects. In the setting of excess nutrients, particularly dietary saturated fatty acids
(SFAs), activated macrophages develop lysosome dysfunction, which triggers activation of the
NLRP3 inflammasome and cell death. The molecular pathways that connect lipid stress to lysosome
pathology are not well understood, but may represent a viable target for therapy. Glutamine uptake
is increased in activated macrophages leading us to hypothesize that in the context of excess lipids
glutamine metabolism could overwhelm the mitochondria and promote the accumulation of toxic
metabolites. To investigate this question we assessed macrophage lipotoxicity in the absence of
glutamine using LPS-activated peritoneal macrophages exposed to the SFA palmitate. We found that
glutamine deficiency reduced lipid induced lysosome dysfunction, inflammasome activation, and
cell death. Under glutamine deficient conditions mTOR activation was decreased and autophagy
was enhanced; however, autophagy was dispensable for the rescue phenotype. Rather, glutamine
deficiency prevented the suppressive effect of the SFA palmitate on mitochondrial respiration
and this phenotype was associated with protection from macrophage cell death. Together, these
findings reveal that crosstalk between activation-induced metabolic reprogramming and the nutrient
microenvironment can dramatically alter macrophage responses to inflammatory stimuli.
Keywords: lysosome; cell death; metabolism; inflammasome
1. Introduction
Diabetes and obesity are common metabolic disorders that are associated with macrophage
dysfunction. Moreover, pathologic inflammation driven by macrophages is recognized as a
contributing factor to the impaired tissue repair responses observed in obese and diabetic patients [1–4].
Therefore, understanding the mechanisms by which the nutrient microenvironment alters macrophage
inflammatory responses is highly relevant to human disease. Individuals with obesity and diabetes
have excess circulating triglycerides and free fatty acids (FFAs) leading to ectopic lipid deposition
in non-adipose tissues including macrophages [5,6]. Toll-like receptor 4 (TLR4) is an inflammatory
receptor expressed at high levels on macrophages, which is activated in response to bacterial infection
and/or sterile tissue damage [7,8]. Recently, we demonstrated that activation of macrophage TLR4
in a lipid rich environment triggers lysosome damage, which contributes to NLRP3 inflammasome
activation and macrophage cell death [9–11]. However, the molecular pathways that precede lysosome
pathology are not well understood.
Macrophage activation leads to dramatic reprogramming of cellular metabolism to facilitate
ATP generation and the production of macromolecules such as proteins, nucleotides, and lipids [12].
Activation of TLR4 on macrophages triggers an increase in glycolysis with variable effects on fatty
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acid oxidation (FAO) [13,14]. Glutamine uptake and metabolism is also enhanced in response to
TLR4 activation [15]. Although metabolic reprogramming is important for macrophage activation,
it remains unclear how changes in the nutrient microenvironment interface with these changes in
cellular metabolism to influence cell phenotype. This is particularly relevant in situations of nutrient
excess where mitochondria can be presented with energetic substrates in excess of what is needed for
ATP generation. In this context, oversupply of substrates and reducing equivalents to the mitochondria
has the potential to lead to accumulation of metabolites and reactive oxygen species [16].
Glutamine is a non-essential amino acid that is consumed by growing or activated cells. Following
uptake, glutamine can be broken down to produce glutamate and α-ketoglutarate (α-KG), the latter of
which enters into the TCA cycle. In addition to feeding energetic pathways glutamine also facilitates
the uptake of other amino acids, such as leucine via SLC7A5, and promotes activation of growth
kinases such as mTOR [17,18]. In line with these observations, when glutamine concentrations are
low, mTOR activation is suppressed, and catabolic processes such as autophagy are enhanced [19].
Therefore, glutamine and its metabolites significantly alter cell stress responses, making this a relevant
nutrient to consider in the context of lipid-induced macrophage dysfunction. To date, the role of
glutamine in macrophage responses to excess FAs has not been explored.
In light of previous data that TLR4 activation in primary macrophages triggers enhanced glucose
and glutamine metabolism in macrophages we hypothesized that excess SFA could lead to metabolic
gridlock from nutrient overload. This scenario would be expected to result in the accumulation of
toxic metabolites that could mediate lysosome damage. Based on prior evidence that lipid-induced
cell death is independent of glucose concentration we focused our analysis on how glutamine
influences macrophage lipotoxicity [9]. In the absence of glutamine, macrophage cell death and
inflammasome activation in response to excess dietary SFAs was attenuated. We provide evidence




Bafilomycin A was from Enzo life sciences (Farmingdale, NY, USA). The α-tubulin antibody,
α-actin antibody, α-ketoglutarate, and BPTES were from Sigma Chemical (St. Louis, MO, USA).
C968 was from Millipore-EMD-Calbiochem (Bellerica, MA, USA). Phospho- and total S6Kinase and
AKT S473 antibodies were from Cell Signaling (Danvers, MA, USA). L-glutamine was from Corning
(Manassas, VA, USA). The α-LC3 antibody was from Novus Biologicals (NB100-2220; Littleton, CO,
USA). The α-p62 antibody was from Abcam (ab56416; Cambridge, MA USA). Lysotracker red was
from Life Technologies (Carlsbad, CA, USA). Ultrapure E. coli LPS was from Invivogen (San Diego, CA,
USA). Thioglycollate was from Difco-BD (Franklin Lakes, NJ, USA). Fatty acids were from Nu-Chek
Prep (Waterville, MN, USA). Ultrapure-bovine serum albumin (BSA) was from Lampire (Ottsville, PA,
USA) and was tested for TLR ligand contamination prior to use by treating primary macrophages and
assaying for TNFα release.
2.2. Cell Culture
Peritoneal macrophages were isolated from C57BL/6, or the indicated knockout mice 4 days after
intraperitoneal injection of 1 mL, 3.85% thioglycollate and plated at a density of 1 ˆ 106 cells/mL in
DMEM containing 10% inactivated fetal serum (IFS), 50 U/mL penicillin G sodium, and 50U/mL
streptomycin sulfate (pen-strep). For glutamine free experiments media was prepared with dialyzed
serum (Gibco-ThermoFisher, Waltham, MA, USA) to remove all sources of glutamine. Stimulations
were performed on the day after harvest. For flow cytometry experiments, peritoneal cells were
cultured on low adherence plates (Greiner Bio-One) to facilitate cell harvest. Cells were removed from
low adherence plates by washing with PBS followed by 10 min with Cell Stripper (Gibco) and then
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10 min with EDTA/trypsin (Sigma). Growth medium was supplemented with palmitate or stearate
complexed to BSA at a 2:1 molar ratio, as described previously [9], and BSA-supplemented media was
used as control. For cell stimulations, PBS or LPS (100 ng/mL) were added to BSA or free fatty acid
containing media.
2.3. Mice
Wild type (WT) C57BL/6 mice were bred in our mouse facility; ATG5flox X LysM-Cre, were from
Skip Virgin (Washington University). All lines were in the C57BL/6 background. Mice were maintained
in a pathogen free facility on a standard chow diet ad libitum (6% fat). All animal experiments were
conducted in strict accordance with NIH guidelines for humane treatment of animals and were
reviewed by the Animal Studies Committee of Washington University School of Medicine.
2.4. RNA Isolation and Quantitative RT-PCR
Total cellular RNA was isolated using Qiagen RNeasy columns and reverse transcribed using a
high capacity cDNA reverse transcription kit (Applied Biosystems, Thermo-Fisher Scientific, Waltham,
MA, USA). Real-time qRT-PCR was performed using SYBR green reagent (Applied Biosystems) on
an ABI 7500 fast thermocycler. Relative gene expression was determined using the delta-delta CT
method normalized to 36B4 expression. Mouse primers sequences were as follows (all 51-31): 36B4
(forward- ATC CCT GAC GCA CCG CCG TGA, reverse-TGC ATC TGC TTG GAG CCC ACG TT);
LC3 (forward-CGT CCT GGA CAA GAC CAA GT, reverse-ATT GCT GTC CCG AAT GTC TC); p62
(forward-GCT GCC CTA TAC CCA CAT CT, reverse-CGC CTT CAT CCG AGA AAC).
2.5. Western Blotting
Total cellular protein was isolated by lysing cells in 150 mM NaCl, 10 mM Tris (pH 8), triton X-100
1% and 1X Protease Complete and phosphatase inhibitors (Thermo-Fisher Scientific). Subsequently,
25 μg of protein from each sample was separated on a TGX gradient gel (4%–20%; Biorad) and
transferred to a nitrocellulose membrane. For blots of Phospho-S6, S6K, and AKT transfer was
for 1 h on ice. For LC3 blots, proteins were transferred overnight in the cold room at 140 mAmp
constant current.
2.6. Lysosome Imaging
After the indicated stimulations, cells were stained with 500 nM lysotracker red in tissue culture
media for 15 min at 37 ˝C. After staining, cells were washed three times with PBS, harvested as
described above, and analyzed by flow cytometry.
2.7. Metabolism Assays
Cells were plated into 96 well Seahorse plates at density of 75,000 cells/well and stimulated as
indicated in the text. After stimulation the cells were washed and placed in XF media (non-buffered
RPMI 1640 containing, 25 mM glucose, 2 mM L-glutamine and 1 mM sodium pyruvate) with 10%
FCS. Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured
under basal conditions and following the addition the following drugs: 1.5 μM flurorcarbonyl cynade
phenylhydrazon (FCCP), and 100 nM rotenone + 1 μM antimycin A (all Sigma). Measurements were
taken using a 96 well Extracellular Flux Analyzer (Seahorse Bioscience; North Bellerica, MA, USA).
2.8. Ammonia Quantification
After stimulation, supernatants were collected from 0.5 ˆ 106 pMACs macrophages grown in a
24 well plate. The ammonia concentration was determined using an ammonia assay kit (BioVision,
Milpitas, CA, USA) as per the manufacturer’s instructions.
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2.9. Intracellular Glutamine Quantification
Two million pMACs were grown in 6 well plates. After stimulation the cells were washed
3 times with PBS and then were snap frozen and scraped in liquid nitrogen. Intracellular metabolites
were quantified by LC-MS/MS at Sanford Burnham Metabolomics Core, Medical Discovery Institute
(Lake Nona, FL, USA).
3. Results
3.1. Glutamine Deficiency Attenuates Macrophage Lipotoxic Responses
We have previously shown that resting macrophages are largely resistant to the effects of SFA
excess; however, upon activation exposure to SFAs leads to lysosome damage, cell death, and
inflammasome activation [9,11]. An important consequence of macrophage activation is dramatic
reprogramming of cellular metabolism, raising the intriguing possibility that interplay between the
internal and external metabolic milieu might be relevant to the toxic effects of lipids. Glutamine
metabolism is modulated by TLR4-activation, but the influence of this nutrient pathway on lipid
stress responses has not been explored. Consistent with increased uptake of glutamine, we observed
that macrophages treated with LPS or LPS with palmitate had increased intracellular glutamine
levels (Figure 1A). To further investigate glutamine handling in activated macrophages we quantified
ammonia release, a byproduct of glutamine catabolism. Treatment with LPS increased release of
ammonia from macrophages under control and lipid stress conditions. In contrast, baseline and
LPS-induced ammonia release were significantly decreased when cells were activated in glutamine
free conditions (Figure 1B,C).
Figure 1. Glutamine metabolism is increased in activated macrophages. (A) Peritoneal macrophages
(pMACs) were treated with control (BSA-PBS), BSA-LPS (100 ng), or palm (250 μM)-LPS (100 ng)
for 16 h; and intracellular glutamine levels were quantified by mass spectroscopy; (B) After the
indicated stimulations for 16 h, NH4 release was quantified in the supernatant; (C) pMACs were
stimulated in glutamine sufficient (open bars) or glutamine deficient (filled bars) media and NH4
release into the media was quantified at 16 h. Bar graphs report the mean ˘ standard error (SE) for
a minimum of 3 experiments, each performed in triplicate. *, p < 0.05 for PBS vs. LPS; #, p < 0.05
glutamine vs. no glutamine.
To elucidate the impact of glutamine on lipid-induced macrophage lysosome damage we activated
pMACs with palmitate and LPS in control media or media deficient in glutamine. In the absence
of glutamine, macrophage cell death and lysosome damage in response to palmitate and LPS were
significantly decreased (Figure 2A,B). In addition, release of the inflammasome regulated cytokine
IL-1β was also diminished when glutamine was absent. TNFα secretion, which is not regulated by
the inflammasome or lysosome damage, was not reduced with glutamine deficiency indicating that
macrophage inflammatory function was not globally suppressed (Figure 2C,D). Thus, alterations in
TLR4 activation-induced glutamine metabolism are required for FAs in the nutrient microenvironment
to produce toxicity in macrophages.
135
Nutrients 2016, 8, 215
Figure 2. Glutamine deficiency protects against lipotoxicity in macrophages. (A,B) pMACs were
stimulated with BSA-PBS or palm-LPS in glutamine sufficient (open bars) or glutamine deficient (black
bars) media and cell death was assessed at 30 h by annexin-PI (A), or lysosome damage was determined
at 24 h by lysotracker red staining (B), both coupled with flow cytometry; (C,D) After the indicated
stimulations IL-1β (C) or TNFα (D) release was quantified in the supernatant using ELISA. Bar graphs
report the mean ˘ SE for a minimum of 3 experiments, each performed in triplicate. *, p < 0.05 for
PBS vs. LPS; #, p < 0.05 glutamine vs. no glutamine.
3.2. Oxidative Glutamine Metabolism Is Partially Responsible for the Protection from Lipid Toxicity
Upon entering the cell, glutamine can be broken down by glutaminase to glutamate, which
is then converted to α-ketoglutarate (α-KG) for oxidation in the TCA cycle. To determine whether
depletion of α-KG was the cause of reduced macrophage lipotoxicity we added a membrane permeable
form of α-KG to glutamine deficient or sufficient media and assessed the lipotoxic phenotypes.
Restoration of α-KG significantly increased cell death and lysosome damage in macrophages stimulated
in glutamine deficient media (Figure 3A,B). In contrast, the addition of α-KG to macrophages cultured
in glutamine sufficient media did not increase macrophage cell death. Similar findings were observed
for IL-1β release (Figure 3C,D). However, the lysosome damage and cell death observed with α-KG
supplementation was still less severe compared to glutamine sufficient media, arguing that some of the
effects of glutamine are independent of glutamine breakdown. To further address this issue we used
two chemically distinct inhibitors of glutaminase, Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl
sulfide (BPTES) or compound 968. With both agents cell death and IL-1β release were attenuated,
although the compounds were significantly less effective than glutamine deprivation (Figure 4A–C).
These findings are consistent with the α-KG add-back experiments, and suggest that glutamine
deprivation protects through pathways that are both dependent and independent of its catabolism.
Figure 3. α-ketoglutarate partially restores macrophage lipotoxic phenotypes under glutamine
deficient conditions. (A) Macrophages were treated as indicated in glutamine sufficient and deficient
media ˘ 440 nM α-ketoglutarate (α-KG) and cell death (A) or lysotracker low cells (B) were quantified
by flow cytometry; (C,D) pMACs were stimulated with palm-LPS in glutamine sufficient and deficient
media ˘ α-KG and IL-1β (C) or TNF α (D) release was quantified by ELISA. Bar graphs report the
mean ˘ SE for a minimum of 3 experiments, each performed in triplicate. *, p < 0.05 for veh vs. α-KG;
#, p < 0.05 glutamine vs. no glutamine.
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Figure 4. Inhibition of glutaminolysis partially mimics glutamine deficiency. (A,B) Primary
macrophages were stimulated with BSA-PBS in the presece of the glutaminolysis inhibitors BPTES
((A) 10 μM) or C698 ((B) 10 μM); (C) IL-1β release was quantified from pMACs treated with palm-LPS
in the presence of BTPES of C968. Bar graphs report the mean ˘ SE for a minimum of 3 experiments,
each performed in triplicate. *, p < 0.05 for veh vs. inhibitor.
3.3. Glutamine Deficiency Is Protective Independent of Leucine
Glutamine is required for the cellular import of branched chain amino acids such as leucine [20].
Thus, a possible catabolism-independent function of glutamine deprivation could be explained
by reduced leucine uptake. To investigate whether leucine deprivation could mimic the effects of
glutamine removal we used media deficient in glutamine or leucine and analyzed macrophage cell
death. Removal of leucine from glutamine containing media did not protect the macrophages from
cell death (Figure 5). Thus, the phenotype of glutamine deficiency cannot be explained by reduced
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Figure 5. Leucine deficiency does not protect macrophage from lipotoxicity. Macrophages were
incubated in complete RPMI media (open bars) or RPMI lacking leucine (gray filled bars) or glutamine
(black filled bars), and after the indicated stimulation cell death was determined by annexin-PI flow
cytometry. Bar graphs report the mean ˘ SE for a minimum of 3 experiments, each performed in
triplicate. #, p < 0.05 glutamine vs. no glutamine.
3.4. mTOR Signaling Is Reduced in the Absence of Glutamine
mTOR is a nutrient responsive kinase that is activated by growth factors and/or amino acids,
including glutamine. mTOR exists as two complexes known as mTORC1 and mTORC2 in which mTOR
pairs with the adaptor proteins raptor or rictor, respectively (Figure 6A) [21]. To assess activation
of these mTOR complexes in the presence and absence of glutamine we analyzed phosphorylation
of the mTORC1 substrate S6kinase (S6K) and the mTORC2 substrate AKT. Consistent with prior
reports, LPS led to increased phosphorylation of both S6K and AKT. In the absence of glutamine S6K
phosphorylation was impaired, but no effect was observed on AKT phosphorylation. In contrast, the
SFA palmitate reduced AKT phosphorylation, but did not significantly affect S6K phosphorylation
(Figure 6B). We next determined whether the addition of α-KG could restore activation of S6K. As can
be seen in Figure 6C, α-KG add-back did not increase S6K phosphorylation in the absence of glutamine,
suggesting this was a direct effect of glutamine on mTORC1 activation and less likely to be involved in
the protection from lipotoxicity.
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Figure 6. Glutamine deficiency impairs activation of mTORC1. (A) mTORC can assemble in two
distinct complexes known as mTORC1 and mTORC2 which lead to the phosphorylation of S6K and
AKT, respectively; (B) pMACs were stimulated with BSA-PBS, BSA-LPS, or palm-LPS for 16 h in the
presence or absence of glutamine and phosphorlyation of S6K and AKT were assessed by Western
blotting. Total S6K and total AKT are shown as control; (C) Macrophages were treated as indicated
for 16 h in glutamine sufficient or deficient media ˘ α-KG (440 nM) and S6K phosphorylation was
determined by Western blotting.
3.5. Glutamine Deficiency Modulates Macrophage Autophagy
One important function of mTORC1 is to regulate autophagy, a fundamental process involved
the starvation response and in cell quality control. Glutamine availability has also been implicated
as a regulator of autophagy. Thus, to monitor autophagic flux in our system we performed western
blots of the autophagy proteins LC3 and p62 with or without bafilomycin present for the last 2 h of the
stimulation to block lysosomal flux. Under control conditions with BSA-PBS there were no differences
in LC3II or p62 protein levels whether or not glutamine was present. Treatment with bafilomycin to
block lysosomal degradation of autophagosomes increased both LC3II and p62 consistent with active
autophagic flux in these macrophages. Again, glutamine deficiency did not alter autophagic flux under
control conditions. In contrast, the absence of glutamine in cell treated with palm-LPS led to decreased
protein levels of LC3II and p62 and this response was partially restored by α-KG. In bafilomycin
treated samples LC3II levels increased in all of the treatment groups, although the greatest increase
was observed for BSA-PBS treated samples (Figure 7A). These findings are consistent with reduced
flux through the lysosome under lipid stress conditions. Even in the presence of bafilomycin, LC3II
levels were still reduced in palm-LPS samples from glutamine free conditions. As LC3 and p62 are
also regulated at the transcriptional level we assessed whether the observed differences between
glutamine sufficient or deficient conditions were driven by transcriptional changes using qRT-PCR.
Treatment with palm-LPS decreased LC3 and increased p62 mRNA levels compared to control, but
glutamine status did not alter this profile (Figure 7B). Together this data reveals that under lipid stress
conditions the absence of glutamine results in reduced LC3II protein likely through a combination
of increased autophagic degradation together with another post-translational regulatory pathway,
perhaps autophagolysosomal exocytosis [22].
To determine whether augmentation of macrophage autophagy under glutamine free conditions
was required for the protection against lipid stress, we turned to a model of autophagy deficiency.
ATG5 is absolutely required for classical autophagy. Therefore, we utilized macrophages in which
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ATG5 had been knocked out using a myeloid specific Cre driver (lysM-Cre). In ATG5 knockout (KO)
macrophages we observed that LC3 was predominantly in the non-lipidated form known as LC3I
and p62 levels were increased at baseline (Figure 8A). These observations indicate a block at the
initiation step of autophagy. Wild type (WT) and ATG5KO macrophages were then activated in the
presence or absence of the FA palmitate ˘ glutamine. As we had shown previously, palm-LPS induced
macrophage cell death was not affected by ATG5 deficiency [9]. Importantly, the protection afforded
by glutamine deficiency occurred in both WT and ATG5KO macrophages, demonstrating that this
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Figure 7. Autophagy is modulated by glutamine deficiency. (A) pMACs were treated with BSA-PBS
or palm-LPS in glutamine sufficient or glutamine deficient media ˘ α-KG (440 nM). The cells were
incubated for 16 h followed by 2 h of veh or bafilomycin (BAF; 50 nM). Protein lysates were analyzed
for expression of LC3 or p62. Actin is shown as a loading control; (B) Cells were stimulated as indicated
for 16 h in media with or without glutamine followed by qRT-PCR assessment of LC3 and p62 mRNA
expression. Bar graphs report the mean ˘ SE for a minimum of 3 experiments, each performed in













































Figure 8. Autophagy is dispensable for protective effects of glutamine deficiency. (A) Primary
macrophages were isolated from WT (ATG5 flx/flx) or ATG5KO (ATG5 flx/flx-LysM-Cre) followed
by stimulation with BSA-PBS or palm-PLS in the presense or absence of glutamine. The levels of LC3
and p62 protein protein expression were assessed by western blotting. Actin is shown as a protein
loading control; (B) pMACs from WT and ATG5KO mice were stimulated as indicated and cell death
was determinded at 30 h using annexin-PI flow cytometry. The bar graph reports the mean ˘ SE for a
minimum of 3 experiments, each performed in triplicate. *, p < 0.05 for WT vs. ATG5KO.
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3.6. Glutamine Deficiency Prevents the Suppression of Mitochondrial Function by Palmitate
Glutamine is a critical substrate for mitochondrial metabolism and TCA function and can directly
or indirectly impact mitochondrial metabolism. To investigate the affects of glutamine deficiency
on cellular metabolism we employed a Seahorse flux analyzer to measure mitochondrial oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR), a marker of glycolytic flux.
In response to LPS, macrophage OCR at baseline dramatically increased and this response was
suppressed by the presence of palmitate. Maximal OCR, assessed after injection of the uncoupling agent
FCCP, was also increased with LPS (Figure 9A). In the absence of glutamine, macrophages had similar
baseline OCR under control conditions compared to glutamine sufficient conditions; however, upon
activation with LPS the increase in mitochondrial OCR was significantly less than that seen in glutamine
sufficient conditions. In addition, palmitate no longer suppressed LPS-induced mitochondrial
respiration as it did when glutamine was present. The addition of α-KG to glutamine deficient
media yielded only a small increase in LPS-induced OCR, but the suppression of mitochondrial
respiration in response to palmitate returned (Figure 9A–D). Glycolytic flux as estimated by ECAR was
also reduced in the absence of glutamine, but unlike OCR this response was unaffected by the presence
of palmitate. The addition of α-KG to glutamine deficient media led to a very small increase in ECAR
(Figure 9E). These results indicate that the toxicity of excess SFA appears to track with mitochondrial
respiration dynamics as opposed to changes in ECAR/glycolysis.
Figure 9. Glutamine deficiency alters mitochondrial metabolism. (A–C) pMACs were stimulated for
16 h with BSA-PBS (black), BSA-LPS (red), or palm-LPS (blue) in glutamine sufficient media (A) or
glutamine deficient media ˘ α-KG (B,C) and mitochondrial metabolism was assessed using a Seahorse
flux analyzer. Mitochondrial oxygen consumption rate (OCR) was assessed at baseline and after the
injection of oligomycin (O), FCCF (F) and rotenone/antamycin (R/A); (D,E) Baesline OCR (D) or
extracellular acidification rate (ECAR; (E)) are reported from cells stimulated as in (A–C). Bar graphs
report the mean ˘ SE for a minimum of 3 experiments, each performed in triplicate. *, p < 0.05 for
BSA-PBS vs. BSA-LPS; **, p < 0.05 BSA-LPS vs. palm-LPS; #, p < 0.05 glutamine vs. no glutamine.
4. Discussion
It is increasingly being recognized that the nutrient composition present in tissues can influence
the phenotypes and inflammatory functions of macrophages [23]. The central finding of this study is
that the removal of glutamine from the nutrient microenvironment renders activated macrophages
resistant to the toxic effects of dietary SFAs. Consistent with a role for glutaminolysis in this process,
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the sensitivity to lipid stress is partially restored by the addition of α-KG, an important metabolite
of glutamine breakdown. Although mTOR activation and autophagic flux are altered by glutamine
deficiency, the mechanism of protection appears to be independent of these pathways. Instead
alterations in mitochondrial oxidative metabolism that occur in the absence of glutamine are associated
with macrophage sensitivity to cell death. These findings add to a growing body of literature arguing
that the interplay between lipid and amino acid metabolism in the mitochondria is relevant to cell
dysfunction in metabolic disease [24,25].
Figure 10. Model of macrophage lipotoxicity under glutamine sufficient and deficient conditions. When
glutamine is available, TLR4 activation stimulates glutamine uptake, mTORC1 activation, enhanced
formation of TCA intermediates, such as α-KG, and increased mitochondrial respiration. The presence
of excess fatty acids like palmitate leads to suppression of mitochondrial respiration, which in the
setting of LPS activation likely promotes accumulation of toxic metabolites, lipids and/or redox stress.
Lysosome dysfunction ensues leading to macrophage cell death and inflammasome activation. In the
absence of glutamine, mTORC1 activation and mitochondrial respiration are diminished leading to
enhanced rates of autophagy. In this scenario palmitate no longer suppresses mitochondrial function,
which appears to protect against lysosome dysfunction, perhaps by decreasing the formation of
damaging metabolites and lipids.
Glutamine is the most abundant amino acid in the body and its uptake and utilization are
significantly increased in macrophages following activation signals, such as LPS [15]. Once inside
the cell glutamine has several potential fates; however, the best-described metabolic pathway is its
break down to glutamate and α-KG by the enzymes glutaminase and glutamate dehydrogenase,
respectively. The activity of both of these enzymes is enhanced in LPS-activated macrophages [26].
The α-KG generated by these reactions is critical for TCA cycle anapleurosis, particularly since
oxidation of citrate is reduced by LPS activation [27]. However, the majority of glutamine does not
undergo complete oxidation and instead is converted to ammonia, aspartate, or pyruvate/lactate [28].
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To determine the importance of glutaminolysis in cell death we used two approaches. First, we added
back the glutaminolysis product α-KG to cells lacking glutamine and discovered a partial restoration of
lipotoxicity. We also inhibited glutaminolysis using two chemically distinct inhibitors of glutaminase.
Both of these approaches suggested that glutamine catabolic pathways were partially responsible for
the observed effects on lipotoxicity. We also considered that an important non-catabolic function of
glutamine might be related to its role in the import of leucine via SLC7A5 [18]. However, cell death
was not affected under leucine free conditions arguing that impaired uptake of this branched chain
amino acid did not contribute to the protection afforded by glutamine deficiency.
Glutamine directly and indirectly modulates pathways related to the kinase mTOR and
autophagy [17,20]. In this study we showed that removal of glutamine from the nutrient
microenvironment during LPS activation modestly decreased the activity of mTORC1 as assessed by
the phosphorylation status of S6K. This phenotype was specific to mTORC1 as the mTORC2 substrate
AKT was unaffected under these conditions. However, the addition of α-KG to glutamine deficient
media did not restore mTOR activation, suggesting that suppression of mTORC1 was not the primary
mechanism accounting for reduced lipotoxicity. Autophagy is also regulated by glutamine, where
glutamine deficiency increases flux through this pathway [29]. Reduced mTORC1 activity is at part of
this response; however, decreased levels of other metabolites, such as cytosolic acetyl-CoA, may also
play a role in increasing autophagy [17,30]. In other systems autophagy has been shown to protect
against cell death related to accumulation of damaged organelles and proteins [31,32]. We show
that in macrophages the absence of glutamine did not change autophagic flux at baseline; however,
after LPS activation autophagy rates were increased in glutamine deficient macrophages. However,
genetic disruption of autophagy using ATG5KO macrophages did not reverse the protection afforded
by lack of glutamine. Thus, although mTORC1 activity is reduced and autophagy is enhanced in
a glutamine-free nutrient microenvironment, the protection from lipotoxicity occurs independent of
these events.
As discussed above, glutamine is an important contributor to mitochondrial metabolism in
part through the replenishment of TCA cycle intermediates. Using functional metabolism studies
we discovered an interesting mitochondrial phenotype in LPS activated cells lacking glutamine.
As expected, the increase in mitochondrial OCR induced by LPS activation was substantially attenuated
in the absence of glutamine. Interestingly, addition of α-KG to glutamine deficient media did not
reverse this OCR phenotype indicating that the mitochondrial reprograming is more than just a
loss of TCA cycle flux. The most striking difference was that the suppressive effect of palmitate on
LPS-induced OCR was reversed in glutamine free media and partially restored with addition of α-KG.
Although glycolytic flux, as estimated by ECAR, was also suppressed by ~50% in glutamine deficient
media neither palmitate nor α-KG significantly changed this phenotype.
It is now appreciated that obesity and diabetes impose a multifaceted nutrient stress on the
mitochondria. Specifically, the excess delivery of an uptake of FAs and amino acid metabolites to the
mitochondria can produce metabolic gridlock, especially when energy stores are replete [16]. In this
context, a “back pressure” develops on the mitochondrial electron transport chain due to lower activity
of ATP synthase. The consequence of this backlog can be the generation of reactive oxygen species
and/or accumulation of other metabolites, which have the potential to damage proteins and organelles.
Our data suggest that glutamine deficiency reduces the mitochondrial substrate burden, which may
be protective against cell damage in the setting of lipid overload. As we have previously shown
that scavenging of ROS does not reduce lysosome damage or cell death in our system, we expect
other pathways connecting mitochondrial metabolites (acetyl-CoA, acylcarnitines, etc.) with lysosome
damage exist [9] (Figure 10). This is an area of active exploration.
Our findings may be relevant to several physiologic situations in obese and diabetic hosts.
In the context of acute infection or tissue injury glutamine is released from skeletal muscle and its
uptake by macrophages is enhanced [33]. When excess lipids are present, as in diabetes, macrophage
inflammasome activation and cell death are anticipated to increase, contributing to the persistent
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inflammatory response seen in diabetics. The potential relevance of this pathway is supported by
recent data revealing that the inflammasome is a major contributor to diabetic inflammation in vivo,
including in humans [34–36]. In addition to acute inflammation, diabetes is associated with a chronic
inflammatory response [37]. Macrophages are recruited to adipose tissue during obesity and are
thought to contribute to the development of systemic insulin resistance [38,39]. It is well established
that macrophages accumulate lipid in obese adipose tissue suggesting that interaction between FAs
and glutamine metabolism would be of interest to explore in this situation [40]. Such studies could
be performed using macrophage specific knockout of glutamine transporters. Further investigation
into the role of glutamine in other inflammatory conditions that often co-exist with diabetes such as
vascular and rheumatologic disease could also be of interest.
There are several limitations of the current study that must be acknowledged. In order to
perturb the nutrient microenvironment, we used an in vitro system with thioglycollate-elicited
peritoneal cells as a model of monocyte-derived macrophages. Therefore, in vivo approaches will
be necessary to determine the relevance of these findings to diabetic inflammation. Moreover, the
studies were performed with murine macrophages and therefore additional studies with human
monocyte-derived macrophages are warranted. It is also important to acknowledge that glutamine
uptake by immune cells is important for full activation and therefore deprivation of this nutrient could
lead to increased risk of infection [26]. The relative balance of risk and benefit in diabetic patients will
require further investigation.
Macrophage dysfunction is a hallmark of lipid overload disorders such as obesity and diabetes.
In response to excess dietary saturated FAs activated macrophages develop lysosome damage,
inflammasome activation, and cell death and these events appear to be involved in clinical
complications of these metabolic conditions [3,36,41–43]. However, the mechanisms that lead to
these phenotypes are not well understood. Herein we describe an intriguing example whereby
TLR4-induced metabolic reprogramming of glutamine metabolism can be maladaptive in the setting of
lipid overload. These findings suggest that nutritional or pharmacologic interventions could potentially
be used to modulate macrophage function for therapeutic benefit in metabolic disease.
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Abstract: The aim of this work was to determine the effect of a fructose rich diet (FRD) consumed by
the pregnant mother on the endocrine-metabolic and in vivo and in vitro adipose tissue (AT) functions
of the male offspring in adulthood. At 60 days of age, rats born to FRD-fed mothers (F) showed
impaired glucose tolerance after glucose overload and high circulating levels of leptin (LEP). Despite
the diminished mass of retroperitoneal AT, this tissue was characterized by enhanced LEP gene
expression, and hypertrophic adipocytes secreting in vitro larger amounts of LEP. Analyses of stromal
vascular fraction composition by flow cytometry revealed a reduced number of adipocyte precursor
cells. Additionally, 60 day-old control (C) and F male rats were subjected to control diet (CC and
FC animals) or FRD (CF and FF rats) for three weeks. FF animals were heavier and consumed
more calories. Their metabolic-endocrine parameters were aggravated; they developed severe
hyperglycemia, hypertriglyceridemia, hyperleptinemia and augmented AT mass with hypertrophic
adipocytes. Our study highlights that manipulation of maternal diet induced an offspring phenotype
mainly imprinted with a severely unhealthy adipogenic process with undesirable endocrine-metabolic
consequences, putting them at high risk for developing a diabetic state.
Keywords: metabolic programming; adipocyte precursor cells; dysfunctional adipose tissue; altered
glucose tolerance; insulin resistance; pre-diabetes; metabolic syndrome
1. Introduction
Metabolic Syndrome (MS), obesity and type 2 diabetes have drastically increased to epidemic
levels worldwide in the last few decades. The World Health Organization has defined obesity as an
increment in adipose tissue (AT) mass which may or may not be detrimental to health [1]. These
illnesses have been attributed mainly to changes in lifestyle, including dietary habits. Fructose rich diet
(FRD) consumption has been shown to be associated with insulin resistance [2], hyperadiposity,
hypertriglyceridemia, hyperleptinemia [3], hyperglycemia, hyperinsulinemia, impaired glucose
tolerance [4] and hepatic steatosis [5], in both animal models and humans.
Diseases in adulthood may originate during an individual’s development, due to changes in the
environment in which the individual is subjected to [6]. Factors that may alter the environment can
include maternal nutrition, either during gestation and lactation [7,8]. Several studies highlighted the
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undesirable consequences of maternal unbalanced diet intake during gestation and/or lactation for the
offspring’s health in adult life [9,10]. Different works have focused on the effects of feeding mothers
a FRD during gestation and lactation, showing that their offspring displayed an increased risk of
developing obesity in adult life [11,12]. We previously reported deleterious metabolic-endocrine
function of pups born to FRD-fed lactating mothers [13]. These pups developed changes in
the hypothalamic circuitry controlling appetite, impaired peripheral insulin sensitivity, and both
hyperleptinemia and visceral adipocyte hypertrophy [13].
Carbohydrates are major metabolites involved in fetal growth and metabolism, and it is accepted
that fructose is present in fetal circulation [14]. The intake of refined sugar, particularly high-fructose
corn syrup, has increased in the United States from a yearly estimate of 8.1 kg/individual at the
beginning of the 19th century up to 65 kg/person in 2010 [15]. However, limited data exist on the
consequences of FRD intake through the mother for the offspring’s metabolic programming [16,17].
Indeed, most of the international literature showed studies wherein experimental designs were devoted
to mothers consuming FRD throughout gestation and lactation or only while lactating [11,18–20].
It was reported recently that adult male offspring born to FRD-fed dams throughout gestation
developed insulin resistance, dyslipidemia, a distorted pattern of peripheral adipokines and enhanced
oxidative stress [21]. Interestingly, later in life, the offspring normalized leptinemia, but became
hypoadiponectinemic [22]. Conversely, a recent study showed that FRD intake by gestating mothers
resulted in pronounced maternal dysfunctions but no major undesirable metabolic effects on offspring,
even after following their progress up to 6 months of age [23].
The current study was designed to test whether or not the feeding of mothers with a FRD
throughout gestation modifies endocrine-metabolic biomarkers and in vivo and in vitro AT functions
in adult male progeny. Moreover, we aimed to determine in utero fructose exposure impact on adult
rats challenged or not with a FRD during adult lifetime.
2. Materials and Methods
2.1. Animals and Experimental Designs
Sprague-Dawley (S-D) rats were kept in controlled conditions of temperature (21 ˘ 2 ˝C) and
lights (on between 07:00 a.m. and 7:00 p.m. with free access to standard commercial rat chow
(Ganave Lab., Argentina) and tap water. Virgin females (3 per cage) were mated with a male in
plastic cages until positive detection of sperm in their vaginal smears (daily examined at 08:00 a.m.).
Sperm positive dams were then individually housed and provided with standard chow ad libitum and
allocated into two groups: (a) drinking tap water only (control mothers, CM; n = 19); and (b) drinking
a FRD (fructose 10% w/v in tap water, fructose mothers, FM; n = 20) throughout pregnancy [24]. Fresh
fructose solution was provided every 2 days. Body weight (BW), food and fluid intakes were recorded
daily during pregnancy. Immediately after delivery, and as previously validated by our laboratory [13],
litter-size was adjusted to eight pups per dam (average male pups per litter ranged between 60% and
65%, approximately). Lactating mothers were provided with standard chow and water ad libitum.
Weaned (21 days old) male pups (born to CM and FM, assigned as C and F rats, respectively) were
individually housed and fed standard purina chow diet and tap water ad libitum until experimentation.
These groups of male rats (C and F) were made by including one male rat from each litter (see Figure 1).
Rats were euthanized following protocols in the National Institute of Health Guidelines for care and
use of experimental animals. All experiments also received approval from our Institutional Committee
on Animal Experimentation.
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Figure 1. Experimental design. Sperm positive dams fed standard chow ad libitum were allocated
in two groups: drinking water (control mothers, CM, n = 19) and drinking FRD (fructose mothers,
FM, n = 20). This diet was maintained until delivery. During lactation, both mothers groups were
fed standard chow ad libitum and drink tap water. The weaning day, male pups born to CM and FM,
assigned as C and F rats, respectively, were fed standard purina chow diet and tap water ad libitum.
At 60 days of age, 6 C and 7 F males were killed for basal determinations and AT studies. Others 6 C
and 7 F rats were subjected to an i.v. GTT at 60 day-old. The remaining 16 C rats were divided in two
sub-groups; 10 animals receive water (CC) and 6 receive FRD (CF). The remaining 12 F animals, they
also were subdivided into two sub-groups; 6 animals receive water (FC) and 6 receive FRD (FF) from
day 60 until 81 days of age. Groups were made by including one male rat from each litter, so as not to
include pups from the same litter in the same experiment.
2.1.1. Sixty-Day-Old Rats
Six C and seven F rats were killed (08:00–09:00 a.m.) by decapitation in non-fasting conditions
and trunk blood was collected into plastic tubes containing EDTA (10% w/v, in normal saline
solution). Plasma samples were then stored frozen (´20 ˝C) until determination of several metabolites.
Immediately after euthanization, retroperitoneal adipose tissue (RPAT) pads were dissected and
weighed. RPAT was used for histological, gene expression, stromal vascular fraction (SVF) cell
composition and adipocyte functional studies (see below). Additionally, six C and seven F rats were
subjected to an intravenous glucose tolerance test (i.v. GTT) (Figure 1).
2.1.2. Eighty-One Day-Old Rats
Sixteen C and 12 F 60-day-old male rats were allocated to four sub-groups according to the
drinking solution provided, either tap water only CC (n = 10) and FC (n = 6) groups; or FRD CF
(n = 6) and FF (n = 6) groups (Figure 1). All groups were fed standard purina chow ad libitum and
treatments lasted for three weeks. Rat BW and food and fluid intakes were recorded daily. Rats were
killed by decapitation (08:00 a.m.) in non-fasting conditions. Trunk blood was collected and plasma
samples kept frozen (´20 ˝C) until measurement of different metabolites. Additionally, RPAT pads
were dissected, weighed, and used for histological studies.
2.2. RPAT Adipocyte Isolation and Incubation
Isolated adipocytes from RPAT pads were obtained as previously described [25]. Cells were
diluted to a density of approximately 200,000 cells per 900 μL of DMEM-1% BSA medium and
distributed into 5 mL plastic tubes. Substances tested (diluted in 100 μL) were either medium alone
(basal) or contained insulin (INS) (final concentrations: 0.1, 1 or 10 nM; Novo Nordisk Pharma AG,
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Switzerland) [26]. Adipocytes were then incubated for 45 min at 37 ˝C in a 95% air-5% CO2 atmosphere.
At the end of incubation, media were carefully aspirated and kept frozen (´20 ˝C) until measurement
of LEP concentrations as described below.
2.3. RPAT Pad Histology
For histological studies, freshly dissected RPAT pads were fixed in 4% paraformaldehyde, then
washed with tap water, immersed in a series of graded ethanol (70%, 96% and 100%), and clarified in
xylene before being embedded in paraffin [13]. Four-micrometer sections were taken from different
levels of the blocks and stained with hematoxylin-eosin. Quantitative morphometric analysis was
performed using a RGB CCD Sony camera together with Image Pro-Plus 4.0 software (magnification,
ˆ400). For each tissue sample, seven sections and three levels were selected (n = 4 animals per group).
Systematic random sampling was used to select 15 fields for each section, and 2500 cells per group
were examined. Adipocyte diameter was measured [24] and cell volume was later calculated (4/3πr3).
2.4. RNA Isolation and Real-Time Quantitative PCR
Total RNA was isolated from RPAT pads by the single-step acid guanidinium isothiocyanate-
phenol-chloroform extraction method (TRIzol; Invitrogen, LifeTech.). One μg of total RNA was
reverse-transcribed using random primers (0.2 μg/μL) and RevertAid Reverse Transcriptase (200 U/μL
Thermo Scientific). Primers applied were β-actin (ACTB; sense, 51-GGTCCACACCCGCCACCAG-31
and anti-sense, 51-GGGCCTCGTCGCCCACGTA-31; 200 bp; Gene Code: NM_031144.3), ADIPOQ
(sense, 51-AATCCTGCCCAGTCATGAAG-31 and anti-sense, 51-TCTCCAGGAGTGCCATCTCT-31;
159 bp; Gene Code: NM_144744.3) and LEP (sense, 51-GAGACCTCCTCCATCTGCTG-31 and anti-sense,
51-CTCAGCATTCAGGGCTAAGG-31; 192 bp; Gene Code: NM_013076.3). One microliter of the RT
mix was amplified with Hot FIREPol EvaGreen qPCR Mix Plus (Solis BioDyne) containing 0.5 μM of
each specific primer and using the Light Cycler Detection System (MJMini Opticon, Bio-Rad). PCR
efficiency was near 1. Threshold cycles (Ct) were measured in separate tubes by duplicate. Identity
and purity of the amplified product were checked by electrophoresis on agarose mini-gels, and the
melting curve was analyzed at the end of amplification. Relative changes in the expression levels of
one specific gene were calculated by ΔCt analysis [13].
2.5. SVF Cell Composition Analysis by Flow Cytometry (FACS)
SVF cells from RPAT pads of C and F animals were isolated and at least 2 ˆ 105 cells (in 100 μL
PBS/0.5% BSA) incubated with fluorescent antibodies or respective isotype controls for 1 h at 4 ˝C. After
washing steps, flow cytometry was analyzed using a FACS Calibur flow cytometer (Becton Dickinson
Biosciences). A combination of surface cell markers were used to identify adipocyte precursor cells
(APCs) as: CD34+/CD45´/CD31´ [27]. Conjugated monoclonal antibodies used were: anti-rat
CD34:PE (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-rat CD45:FITC (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) and anti-rat CD31:FITC (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Samples were analyzed using CellQuest Pro (Becton-Dickinson, San Jose, CA,
USA) and FlowJo softwares (TreeStar, San Carlo, CA, USA) [27].
2.6. Intravenous Glucose Tolerance Test (i.v. GTT)
This test has been widely validated in our laboratory [13]. Briefly, 60 day-old C and F rats
(n = 6 C and n = 7 F rats) were subjected to an i.v. GTT. Rats were implanted (under light ketamine
anesthesia) with an i.v. cannula (in the right jugular vein 48 h before experimentation) kept patent by
administering heparin (10 U/mL in sterile saline solution: 100 μL). On the morning of the experimental
day (08:00–09:00 a.m.) a small volume of blood was taken in non-fasting condition before (time 0)
and 5, 15, 30, 60, and 90 min after i.v. glucose (GLU) (2 g/kg BW; dissolved in sterile saline solution)
administration [28]; the blood withdrawn was immediately replaced by a similar volume of sterile
artificial plasma. Plasma samples were kept frozen (´20 ˝C) until determination of GLU and INS
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concentrations. The area under the curve (AUC) was calculated with GraphPad Prism software using
basal (time 0) plasma GLU and INS as baseline.
2.7. Peripheral Metabolite Measurements
Circulating levels of GLU, triglycerides (TG) and total cholesterol (TC) were measured by
commercial kits (Wiener Lab., Rosario, Argentina). Plasma and medium LEP concentrations [25]
and circulating levels of INS [26] and corticosterone (CORT) [29] were determined by specific
radioimmunoassays (RIAs) previously validated. LEP (standard curve 0.05–25 ng/mL) coefficients
of variation (CV) intra- and inter-assay were 4%–7% and 9%–11%, respectively. INS (standard curve
0.08–10 ng/mL) CV intra- and inter-assay were 3%–7% and 8%–11%, respectively. CORT (standard
curve 0.05–50 μg/dL) CV intra- and inter-assay were 4%–6% and 8%–10%, respectively. Plasma
levels of adiponectin (ADIPOQ) were measured by commercial ELISA kit following manufacturer’s
instructions (Linco Research, Cat. #EZRADP-62 K, standard curve: 3–100 ng/mL CV intra- and
inter-assay were 0.43%–1.96% and 4.3%–8.44%, respectively).
2.8. Statistical Analysis
Results (expressed as means ˘ SEM) were analyzed by Student t-test when appropriate. One way
ANOVA followed by post hoc comparisons of mean values with the Newman Keuls test, was used
to compare different groups. ANOVA with repeated measures was used for analyses of i.v. GTT
values. Two-way ANOVA followed by Tukey’s multiple comparison test was used for analyses of the
effect of INS on LEP release by adipocytes; and for analyses of male caloric intake from weaning until
60 day-old. The non-parametric Mann-Whitney test was employed to analyze data on tissue mRNA
expression [13]. All data was analyzed using the software GraphPad Prism 6.0 on Windows (GraphPad
Software Inc., San Diego, CA, USA). P values lower than 0.05 were considered statistically significant.
3. Results
3.1. Pregnant Rats’ Body Weight and Food-Provided Energy Intake
The individual BW of pregnant rats were similar in both groups at the beginning (CM:
249.37 ˘ 9.83 g, and FM: 244.28 ˘ 6.16 g; n = 19 CM and n = 20 FM) and at the end (CM: 366.86 ˘ 19.04
g, and FM: 366.87 ˘ 10.11 g; n = 19 CM and n = 20 FM) of the gestational period. The 21-day average
of individual daily energy intake through diet was significantly higher in FM than in CM (84.71 ˘ 3.41
vs. 68.17 ˘ 5.07 kCal/day/100 g BW, respectively; p < 0.05, n = 19 CM and n = 20 FM).
3.2. Body Weight and Caloric Intake in Adult Male Offspring Born to CM and FM
The first male offspring born to CM and FM mothers (n = 12 and n = 14 rats in group C and F,
respectively) displayed similar BW between birth and 60 days of age (Figure 2A). No group-difference
was observed in 48 h-caloric intake corrected per 100g of BW (Figure 2B). Nevertheless, when a
two-way ANOVA analyses was performed, we observed that caloric intake is both influenced by time
and FRD intake during gestation was (p < 0.05). Even the interaction between these two factors was
statistically different (p < 0.05).
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Figure 2. Body weight and caloric intake. (A) Body weight and (B) mean 48 h cumulative caloric
intake corrected by 100 g of BW, between weaning and 60 days of age, in C and F rats. Values are
means ˘ SEM (n = 12 and n = 14 rats in group C and F, respectively). FRD during gestation, time, and
the interaction between them are considered significantly different between C and F rats, based on
two-way ANOVA.
3.3. Peripheral Levels of Several Metabolites and i.v. GTT in Adult Male Offspring
In non-fasting conditions, adult (60 day-old; n = 6 C rats and n = 7 F rats per group) F rats
displayed significantly (p < 0.05) higher circulating levels of LEP and lower levels of TG (Table 1).
Circulating concentrations of GLU, TC, CORT, INS and ADIPOQ remained the same (Table 1).
Table 1. Metabolic markers in 60 day-old rats.
C F
GLU (mmol/L) 6.58 ˘ 0.18 6.08 ˘ 0.24
TG (mmol/L) 1.44 ˘ 0.14 1.12 ˘ 0.06 *
TC (mmol/L) 1.56 ˘ 0.07 1.88 ˘ 0.13
CORT (nmol/L) 4.67 ˘ 1.08 3.43 ˘ 1.02
INS (nmol/L) 0.31 ˘ 0.02 0.26 ˘ 0.05
LEP (ng/mL) 2.41 ˘ 0.35 4.10 ˘ 0.31 *
ADIPOQ (μg/mL) 5.87 ˘ 0.72 5.60 ˘ 0.44
Circulating levels (in non-fasting conditions) of several metabolic markers in 60 day-old male rats born to either
normal diet (C)- or FRD (F)-fed mothers throughout pregnancy. Values are means ˘ SEM. n = 6 C rats and n = 7
F rats. * p < 0.05 vs. C values, based on Student’s t-test.
Circulating GLU levels (Figure 3A) and the AUC of these peripheral GLU levels (Figure 3B)
throughout the i.v. GTT were significantly (p < 0.05) higher in F than in C rats (n = 6 C and n = 7 F rats
per group). Moreover, while C rats did recover initial plasma GLU values 60 min after GLU load, F
rats failed to do so (Figure 3A). The altered tolerance to GLU overload observed in F rats was related
to changes in INS secretion in plasma throughout the test. The profile of circulating levels of INS and
the AUC of INS values in both groups are depicted in Figure 3 (C and D, respectively). As shown,
plasma INS peak values (time 15 min) were significantly (p < 0.05) higher in F than in C rats (Figure 3C).
Moreover, we found a significantly (p < 0.05) higher AUC for INS values in F than in C rats (Figure 3D).
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Figure 3. Glucose Tolerance Test. Circulating levels of GLU (A), INS (C) and the area under the
curve (AUC) of GLU (B) and INS (D) during an i.v. GTT in C and F rats. Values are means ˘ SEM
(n = 6 C rats, and n = 7 F rats; # p < 0.05 vs. time-zero values in the same group, * p < 0.05 vs. C values in
similar conditions). One way ANOVA with repeated measures was used to compare different groups.
Student’s t-test was used for AUC differences.
3.4. Retroperitoneal Adipose Tissue Characteristics and Functionality in Adult Male Offspring
Whereas no difference was found in RPAT mass in 30 day-old C and F rats (data not shown),
RPAT fat mass was significantly (p < 0.05 vs. C) lower in F rats at 60 days of age (Table 2). However,
RPAT adipocyte diameter, area and volume were significantly (p < 0.05 vs. C) higher in F pads (Table 2
and Figure 4A,B, respectively).
Table 2. RPAT pad characteristics in 60 day-old rats.
C F
Pad mass (g per 100g BW) 0.71 ˘ 0.07 0.54 ˘ 0.03 *
Adipocyte diameter (μm) 37.21 ˘ 0.09 48.45 ˘ 0.28 *
Adipocyte area (μm2) 1182.34 ˘ 10.64 2057.79 ˘ 23.57 *
Adipocyte volume (μm3 ˆ 103) 26.97 ˘ 1.84 59.97 ˘ 3.47 *
LEP mRNA (AU) 1.09 ˘ 0.19 2.99 ˘ 0.18 *
ADIPOQ mRNA (AU) 1.28 ˘ 0.40 1.94 ˘ 0.41
RPAT pad characteristics in 60 day-old male rats born to either control diet- (C) or FRD-fed (F) mothers
throughout pregnancy. Values are means ˘ SEM. n = 6 C rats and n = 7 F rats. * p < 0.05 vs. C values; based on
Student’s t-test. mRNA expression levels were analyze by the non-parametric Mann-Whitney test.
Figure 4C shows the results of in vitro LEP release by isolated RPAT adipocytes incubated in
the absence or presence of graded concentrations of INS. Spontaneous (INS 0 nM) LEP output was
significantly (p < 0.05) higher in the F than in the C cell-group. While INS 0.1 nM failed to enhance
LEP secretion over the baseline in both groups of cells, INS 1 and 10 nM were able to significantly
(p < 0.05) increase LEP release over the baseline, regardless of the group examined. Interestingly, the
amount of LEP released into the medium was significantly (p < 0.05) higher in F than in C cell-media,
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regardless of the condition examined (Figure 4C). These results tally with both circulating levels of LEP
(Table 1) and the RPAT LEP mRNA expression levels in these rats (Table 2), although no significant
group-difference was noticed in the RPAT mRNA levels of ADIPOQ (Table 2). The adipogenic cell
population (CD34+/CD31´/CD45´ cells) in the RPAT SVF from both groups was evaluated in order
to assess a possible effect of maternal FRD intake on their APC number (Figure 4D,E). Interestingly,
maternal high fructose exposure significantly (p < 0.05 vs. C) decreased APC number (Figure 4F).
This result strongly suggests that the low APC number could be related to the finding of both RPAT
adipocyte hypertrophy and decreased pad mass in the F male progeny.
Figure 4. RPAT Characteristics. (A and B) Histological characteristics, representative fields, in C (A)
and F (B) RPAT pads stained with hematoxylin eosin (scale bar: 50 μm; magnification: ˆ400); (C) Effects
of INS on LEP release by adipocytes. Values are means ˘ SEM (n = 4–5 different experiments; * p < 0.05
vs. C values in similar conditions, + p < 0.05 vs. 0 nM INS values in the same group, based on two way
ANOVA); (D and E) Representative dot plots showing the staining profile of RPAT SVF cells isolated
from C (D) and F (E) male adult rats; (F) Percentage of CD34+/CD45´/CD31´ cells, determined by
flow citometry. * p < 0.05 vs. C values, based on Student’s t-test.
3.5. Challenging Adult Male Offspring with a FRD
In these experiments, four groups of rats (CC, CF, FC and FF) were studied. The growth curves
of rats (studied over a 21 day-period: between 60 and 81 days of age) are shown in Figure 5A. Rat
BWs were similar in all groups on the initial day of diet administration. Throughout the indicated
period, energy intake (expressed as a 21 day-average) was similar in CC and CF rats. Conversely, this
parameter was significantly (p < 0.05) higher in FC than in CC rats. Notably, FF rats incorporated the
highest (p < 0.05 vs. remaining group-values) amount of energy (Figure 5B) and, as a result, FF rats
were heavier (p < 0.05 vs. CC rats) from day 68 until 81 days of age, although their final BWs were
similar to those from CF and FC rats (Figure 5A). Furthermore, no significant differences were found
in final BW values among CC, CF and FC rats (Figure 5A).
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Figure 5. Body weight and mean caloric intake. (A) Body weight of male rats, born to CM or FM, fed
with either control diet (CC and FC groups) or FRD (CF and FF groups), since postnatal day 60 until
day 81; (B) Mean caloric intake of animals from four different groups. Values are means ˘ SEM. n = 10
CC rats, n = 6 CF rats, n = 6 FC rats and n = 6 FF rats. * p < 0.05 vs. CC values, + p < 0.05 vs. CF values, #
p < 0.05 vs. FC values, based on one way ANOVA.
When evaluated in basal conditions, CF animals displayed (Table 3) significantly (p < 0.05 vs.
CC values) higher circulating levels of TG, LEP and ADIPOQ; conversely, no difference in plasma
GLU and INS levels were noticed. FC rats displayed a severely distorted peripheral profile in several
endocrine-metabolic parameters: hyperglycemia, hypertriglyceridemia and hyperleptinemia (p < 0.05
vs. CC values) although unchanged plasma for INS, TC and CORT (Table 3 data indicating a highly
compromised basal metabolic state. Notably, both FC and FF rats showed similar (even vs. CC values)
basal plasma adiponectinemia, and FF rats were unable (as CF rats did) to mount their adiponectinemia
for protection against the FRD challenge applied; moreover, they displayed the highest peripheral
levels of GLU, TG and LEP, although with normoinsulinemia (Table 3).
Table 3. Metabolic markers in 81 day-old rats.
CC CF FC FF
GLU (mmol/L) 4.96 ˘ 0.27 5.1 ˘ 0.33 5.88 ˘ 0.28 * 7.91˘ 0.56 *,+,#
TG (mmol/L) 1.19 ˘ 0.16 1.89 ˘ 0.17 * 1.7 ˘ 0.12 * 2.62 ˘ 0.11 *,+,#
TC (mmol/L) 0.26 ˘ 0.03 0.23 ˘ 0.01 0.23 ˘ 0.001 0.21 ˘ 0.02
CORT (nmol/L) 140.81 ˘ 37.41 87.45 ˘ 24.15 84.52 ˘ 12.99 190.98 ˘ 58.14
INS (nmol/L) 0.28 ˘ 0.04 0.31 ˘ 0.04 0.37 ˘ 0.06 0.34 ˘ 0.05
LEP (ng/mL) 2.87 ˘ 0.14 3.89 ˘ 0.38 * 3.89 ˘ 0.43 * 5.57 ˘ 1.4 *
ADIPOQ (μg/mL) 14.82 ˘ 0.94 20.08 ˘ 2.77 * 13.61 ˘ 1.95 14.89 ˘ 2.72
Circulating levels (in non-fasting conditions) of plasma metabolites in 81 day-old male rats from different
groups. Values are means ˘ SEM. n = 10 CC rats, n = 6 CF rats, n = 6 FC rats and n = 6 FF rats.* p < 0.05 vs.
CC values, + p < 0.05 vs. CF values, # p < 0.05 vs. FC values, based on one-way ANOVA.
Regarding RPAT characteristics, we found that at 81 days-old, pad mass (in g per 100 g BW) was
significantly (p < 0.05 vs. CC values) increased in CF rats and that, although no pad mass difference was
observed in FC rats, FF rats also displayed an increased RPAT mass (p < 0.05 vs. CC values) (Figure 6E).
Figure 6A–D displays the morphological characteristics of adipocytes isolated from RPAT pads of
different groups. As expected [30], three-week-FRD administration to normal animals (CF group)
resulted in enlarged (p < 0.05 vs. CC) RPAT adipocytes (Figure 6F). Moreover, RPAT pads from rats
either challenged (FF) or not (FC) with a FRD at adult age displayed hypertrophic adipocytes (p < 0.05
vs. CC values), the first being the largest (Figure 6F).
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Figure 6. RPAT characteristics. Representative fields of RPAT pads from CC (A), CF (B), FC (C) and FF
(D) rats stained with hematoxylin eosin (scale bar: 50 μm; magnification: ˆ400); Additionally, RPAT
mass (E) and, adipocyte diameter (F) from different groups is displayed. Values are means ˘ SEM.
n = 10 CC rats, n = 6 CF rats, n = 6 FC rats and n = 6 FF rats. * p < 0.05 vs. CC values, + p < 0.05 vs.
CF values; # p < 0.05 vs. FF values, based on one-way ANOVA.
4. Discussion
Our results clearly demonstrate a deleterious effect on male offspring’s endocrine-metabolic
and adiposity functions induced by feeding pregnant rats a FRD. The consequences of this diet
intake by the pregnant mother were evident when pups reached 60 days of age. At that time,
male offspring showed dyslipidemia, hyperleptinemia, impaired glucose tolerance and adipocyte
hypertrophy; several dysfunctions were further aggravated after offspring were re-challenged with
FRD for three weeks.
Epidemiological and experimental studies demonstrated a relationship between maternal
nutrition and long-term metabolic consequences in the offspring. Under-/malnourishment [31–33] or
over-nourishment [34,35] in pregnant mothers induces in their offspring severe endocrine, metabolic
and adiposity dysfunctions. In effect, FRD intake during both pre- and early post-natal periods impairs
INS and LEP cell signaling, thereby modifying carbohydrate metabolism in the progeny [11,16,19].
Previous studies have shown that mothers consuming a FRD during both gestation and lactation
resulted in offspring characterized by dyslipidemia [36] and insulin resistance [37]. Other studies
showed that offspring consumption of a rich carbohydrate-milk during lactation increased plasma
levels of INS and LEP, and also BW, resulting in pancreatic disorders [12,32,33]. Moreover, FRD-intake
by pregnant rats was reported to affect both mother and fetal metabolism by enhancing lipogenesis
and hepatic endoplasmic reticulum stress [38]. The deleterious consequences of FRD administration
to pregnant mothers have been previously addressed. This diet is able to induce altered glucose
tolerance, hyperinsulinemia and reduced placental vascular area, thus leading to high risk for the
mother of developing gestational diabetes and preeclampsia [24]; moreover, their fetuses (embryonic
day 20) displayed increased BW. Interestingly, these dysfunctions were fully prevented by metformin
co-treatment [24], thereby indicating that impaired overall insulin sensitivity in the mother seems to
be mainly responsible for these FRD effects.
A relevant observation made throughout the present study is that the detrimental consequences on
AT endocrine function seen in F animals (which never consume FRD) are similar to those developed by
CF animals. In both situations, a higher basal leptinemia and hypertrophic adipocytes from RPAT were
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found. However, while FRD administration to the adult offspring is able to enhance adiponectinemia
in CF animals, we found that in F animals there was no change in plasma adiponectin concentration.
These findings highlight that the AT seems to be the main target for this diet-noxa, and highlight the
importance of the perinatal environment for an individual’s development.
It is well known that AT endocrine dysfunction associated to obesity is closely related to
adipocyte size, rather than to pad mass [39], and hypertrophic adipocytes are characterized by
impaired insulin sensitivity [40] and changes in the adipokine secretory pattern, including higher
leptin production [39,41]. Therefore, enhanced adipocyte size could well explain the hyperleptinemia
found in F animals despite AT mass decrease. Changes in LEP concentration could contribute to
impaired peripheral insulin sensitivity [42]. In the present study, the male offspring born to FRD-fed
gestating mothers displayed an apparent paradoxical situation; although, they have a lower AT mass
it has large adipocytes. These results could indicate a lower number of adipocytes. It has been found
that, in both humans and animal models, AT development occurs mainly during late pregnancy and
early postnatal life [43–45]. In fact, the ability to generate new adipocytes in adult life is limited; as a
consequence, the number of adipocytes remains relatively stable. Therefore, it is possible to speculate
that lower adipocyte numbers is a consequence of the alterations in APC determination during the
AT development, leading to a decrease in adipocyte generation [43]. Then, considering this unusual
situation, we next examined the cellular composition of the RPAT SVF to determine whether cell
hypertrophy and low pad mass could be a result of a lower APC number. Interestingly, a low number
of APCs, CD34+/CD45´/CD31´ [46] was found in F RPAT pads. This diminished APC number could
be responsible for an impaired adipogenic potential [45], and therefore leading to the development of
hypertrophic adipocytes. To our knowledge, this is the first study that shows changes in APC numbers
induced by excessive prenatal fructose intake.
Indeed, malnutrition during perinatal life could trigger changes in DNA methylation and
in histone acetylation/methylation, causing transcriptional changes of key factors involved in
adipogenesis (C/EBPα, PPARγ) [47,48]. Examples of this emerge from several studies, such
as those findings indicating that, during differentiation of 3T3-L1 cells, there is a modification
in the DNA methylation degree (i.e., PPAR, C/EBP, LEP, GULT4) [49–52] and in histone
methylation/acetylation [53], thus demonstrating the relevance of epigenetic regulation during
the adipogenic process. It is reasonable to speculate that, at least partially, AT dysfunction found
in offspring born from FRD mothers could be a consequence of epigenetic changes. Further
research is needed to better clarify the role of epigenetic modifications in our model. Given the
endocrine-metabolic alterations that we found in 60 day-old animals from FRD-fed mothers, we
proposed studying the response of these rats to a direct challenge with FRD in adult life. For this
purpose, we treated C and F 60 day-old rats with a FRD or a normal diet for three weeks (achieving
81 days of life), which has been widely used as an animal model of the human MS [30,54]. When
older (81-day-old) pups were studied, surprisingly, we found a remarkably deteriorated AT function
and metabolic state in FC pups. These rats had higher basal plasma levels of TG and GLU than CC
rats, despite no changes in insulinemia, whereas offspring’s hyperleptinemia and RPAT hypertrophic
adipocytes remained. In this regard, it has been previously reported that FRD intake in rats induced
severe basal hyperglycemia, with concomitant normoinsulinemia, accompanied by a high risk of
cardiovascular events [55]. In our experiments with 81 day-old rats, we noticed that the FRD challenge
to control animals (CF), increased circulating levels of TG, LEP and ADIPOQ, as well as RPAT pad
mass and adipocyte size, confirming our previous data [30]. Nevertheless, the consequences of direct
FRD administration to male offspring born to FRD-fed mothers (FF rats) were even more serious: they
showed increased caloric intake, body weight, and plasma levels of GLU, TG and LEP, thus indicating
they could be developing diabetes type 2.
Unlike the FC group and similar to findings in the 60-day-old F male offspring, there was no
increase in peripheral levels of ADIPOQ. It is well known that ADIPOQ acts as an insulin-sensitizing
factor [56]. In fact, ADIPOQ regulates glucose metabolism by improving insulin signaling pathway [57],
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enhancing liver and muscle glucose uptake, decreasing hepatic glucose output [58,59] and enhancing
fatty acid oxidation [60]. Therefore, an increase in ADIPOQ plasma levels observed in 81 day-old
control animals challenged with FRD (CF rats in Table 3) might play a protective role in carbohydrate
metabolism. These results are in full agreement with those previously reported from our laboratory [30].
The lack of a physiological increase in adiponectin secretion in FF animals is highly indicative of the
loss of its protective effect on carbohydrate dys-metabolism, contributing to the worsening of overall
metabolic derangements.
5. Conclusions
Overall, the present study shows that maternal consumption of fructose during gestation alters
offspring’s development causing metabolic and AT dysfunctions. At 60 days of age, rats born to
FRD-fed mothers showed impaired insulin sensitivity and profound AT dysfunction, evidenced by
hypertrophic adipocytes that secrete in vitro larger amounts of LEP, although with decreased AT mass.
This paradoxical situation could be the result, at least partially, of the reduced APC number, present
in RPAT from F rats. At 81 days old, the results of FC rats corroborate that the impact of FRD on
pups worsened the metabolic profile throughout their lifetime, even when they were not directly
exposed to this diet. These changes are clearly aggravated when the offspring directly consume FRD
during adulthood.
Considering that hypertrophic expansion of AT mass is a key marker for AT dysfunction, we
further conclude that high fructose consumption by pregnant mothers primes the first male generation
with a high risk of developing MS, obesity and type 2 diabetes. To our knowledge, this study is the first
to report changes in adipose precursor cells numbers, induced by in utero diet manipulation. However,
the impact of high fructose in utero on overall developmental programming of individuals requires
deeper research.
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Abstract: We have previously addressed that fructose rich diet (FRD) intake for three weeks increases
the adipogenic potential of stromal vascular fraction cells from the retroperitoneal adipose tissue
(RPAT). We have now evaluated the effect of prolonged FRD intake (eight weeks) on metabolic
parameters, number of adipocyte precursor cells (APCs) and in vitro adipogenic potential from
control (CTR) and FRD adult male rats. Additionally, we have examined the direct fructose effects
on the adipogenic capacity of normal APCs. FRD fed rats had increased plasma levels of insulin,
triglyceride and leptin, and RPAT mass and adipocyte size. FACS studies showed higher APCs
number and adipogenic potential in FRD RPAT pads; data is supported by high mRNA levels
of competency markers: PPARγ2 and Zfp423. Complementary in vitro experiments indicate that
fructose-exposed normal APCs displayed an overall increased adipogenic capacity. We conclude that
the RPAT mass expansion observed in eight week-FRD fed rats depends on combined accelerated
adipogenesis and adipocyte hypertrophy, partially due to a direct effect of fructose on APCs.
Keywords: retroperitoneal adipose tissue; adipogenesis; SVF cells; precursor cell competency
1. Introduction
In the last few decades, obesity, metabolic syndrome and type 2 diabetes mellitus (DMT2) have
become serious problems for health systems, emerging as a worldwide epidemic. These metabolic
disorders are multifactorial depending on genetic background as well as environmental and behavioral
factors, such as eating habits. The quantity and quality of modern diets, in particular the increase of
sugar intake, have been associated with the high incidence of metabolic disorders [1,2]. In fact, high
fructose consumption, mainly through sweetened drinks, has been linked to deleterious metabolic
consequences, such as insulin resistance, dyslipidemias, increased abdominal adipose tissue (AAT)
mass and changes in the pattern of AT adipokine secretion [3,4].
The deleterious metabolic effects of high fructose intake have been related to the activating role
in the de novo lipogenesis pathway in the liver, and therefore stimulating AT fatty acid uptake. This
stimulation of de novo lipogenesis is not so markedly increased by other carbohydrates [5], mainly
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because fructose bypasses the main control point of glycolysis, the phosphofructokinase step, and
is converted into trioses [6], precursors of triglyceride synthesis. Although most of the absorbed
fructose is extracted and metabolized by the liver [7], a small amount remains in circulation and can be
absorbed through its specific cellular transporter GLUT-5 by tissues such as kidney and AT [8,9].
The increase in AAT mass has been considered one of the main disorders associated with
fructose overconsumption. AT expansion is the result of two independent processes: hyperplasia
and hypertrophy. Dysfunctional AT is correlated with adipocyte size rather than AT mass. In fact,
hypertrophic adipocytes are insulin resistant; secrete more leptin and pro-inflammatory cytokines
and less adiponectin [10–12]. AT hyperplasia is the consequence of activated adipogenesis; a process
involving two stages: the determination of the adipocyte precursor cells (APCs) and terminal cell
differentiation, wherein APCs change into adipocytes. The ability of APCs to turn into adipocytes after
specific stimulation is known as APCs competency and it is a characteristic of determined cells [13].
As we have previously shown, fructose rich diet (10% w/v, FRD) intake induces several metabolic
alterations related to AT mass expansion [14–16]; however the activation or inhibition of adipogenesis
in this phenomenon remains unclear. In the 3T3L1 preadipocyte cell line, the addition of fructose to
the culture medium stimulates the terminal stage of adipogenesis, a mechanism that is dependent on
the specific fructose transporter, GLUT-5 [17,18]. We earlier demonstrated that adult rats fed with FRD
for three weeks showed APCs from retroperitoneal AT (RPAT) displaying high levels of competency
markers, such as PPARγ2 and Zfp423 [15]. Nevertheless, the in vivo impact of FRD intake for a longer
period of time and the direct in vitro effect of fructose on APCs adipogenic potential and number have
not been studied up to now. Our study provides, for the first time, evidence that high fructose intake
for eight weeks increases, probably through a direct effect, the number and competency of APCs from
RPAT, therefore favoring adipocyte differentiation and contributing to its mass expansion.
2. Material and Methods
2.1. Animals and Treatment
Normal adult male Sprague-Dawley rats (60 days of age) were kept in a temperature-controlled
environment (20–22 ˝C and fixed 12 h light/12 h dark cycle, lights on at 07:00 a.m. and fed ad libitum
with Purina commercial rat chow. Rats were divided into two groups: one was provided with
tap water only (CTR) and, the other, a solution of 10% fructose (w/v, Sigma-Aldrich, St. Louis,
MO, USA) in tap water for eight weeks (conventionally called fructose rich diet, FRD). Rats were
euthanized under non-fasting conditions (between 08:00 a.m. and 09:00 a.m.) and trunk blood was
collected; plasma samples were then frozen (´20 ˝C) until metabolite measurements were taken. RPAT
was aseptically dissected (brown adipose tissue vessels surrounding the kidney were removed and
discarded), weighed and kept in sterile Dulbecco’s Modified Eagle’s Medium-Low Glucose (1 g/L)
(DMEM-LG) for further procedures. Animals were euthanized according to protocols for animal use,
in agreement with NIH guidelines for the care and use of experimental animals. All experiments were
approved by our Institutional Animal Care Committee.
2.2. Peripheral Metabolite Measurements
Plasma levels of leptin (LEP), insulin (INS) and corticosterone (CORT) were determined by
specific radioimmunoassays (RIAs) previously developed in our laboratory [19]. Circulating glucose
(Glu, Wiener Argentina Lab., Rosario, Argentina) and triacylglycerols (Tg, Wiener, Rosario, Argentina)
levels were measured using commercial kits.
2.3. RPAT Stromal Vascular Fraction (SVF) Cell and Adipocyte Isolation
Fresh RPAT pads were dissected, weighed and digested with collagenase as previously
reported [20]. Briefly, fat tissue was minced and digested using 1 mg/mL collagenase solution in
DMEM (at 37 ˝C, for 1 h). After centrifugation (1000 rpm, during 15 min), floating mature adipocytes
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were separated and reserved for later measurement. SVF pellets were filtered (in a 50 μm mesh nylon
cloth) and washed with DMEM-LG (ˆ3). SVF cells, containing APCs, were then resuspended in
DMEM-LG supplemented with 10% (v/v) fetal bovine serum (FBS), HEPES (20 nM), 100 IU/mL
penicillin and 100 μg/mL streptomycin (basal medium).
2.4. Adipocyte Size Analysis
The size of the isolated fat cells was measured as previously described [21], with minor changes.
Briefly, a 50–150 μL aliquot from the top layer (floating cells) was added to 450 μL DMEM. 5–10 μL
from the cell suspension were placed into a Neubauer chamber and cover-slipped. Five representative
pictures from each sample were taken using a Nikon Eclipse 50i microscope equipped with a camera
(Nikon Digital Sight D5-U3, Melville, NY, USA). Cell diameter was measured with image analysis
software (Image ProPlus6.0, Rockville, MD, USA). Values below 25 μm were discarded as they can be
considered lipid droplets. Values were recorded and assigned to groups differing by 10 μm diameter,
creating a histogram with 10 μm-bins. Histograms were used to determine whether the distribution
of adipocyte diameters was either normal or binomial, and to assess the presence of different sized,
adipocyte sub-populations. We measured an average of 500–600 cells per field to calculate average
adipocyte size.
2.5. RPAT SVF Cell Culture
RPAT SVF cells from CTR and FRD groups were seeded (2 ˆ 104 cells/cm2) in 24-well plates
(Greiner Bio-One, Kremsmünster, Austria) and cultured in the basal medium at 37 ˝C in a 5%
CO2-atmosphere [20]. Cells were induced to differentiate and processed for several determinations
as described in more detail below (Materials and Methods section: 2.8; 2.9; 2.10; 2.11). Additionally,
normal SVF cells from RPAT from control adult male rats were seeded and cultured for 7 days in
the basal medium alone (Basal) or supplemented with 1 g/L of fructose (FRU) or 1 g/L glucose
(GLU). After this period cells were immediately processed for RNA extraction or FACS analysis,
or differentiated to adipocytes for lipid content determination, as described below.
2.6. SVF Cell Composition Analysis by Flow Cytometry (FACS)
Freshly isolated or cultured SVF cells from RPAT pads (at least 2 ˆ 105 cells in 100 μL PBS/0.5%
BSA) were incubated with fluorescent antibodies or respective isotype controls for 1 h at 4 ˝C. After
washing steps, flow cytometry was performed using a FACSCalibur flow cytometer (Becton Dickinson
Biosciences, San Jose, CA, USA). A combination of cell surface markers were used to identify APCs as:
CD34+/CD45´/CD31´ for freshly isolated SVF cells and CD34+/CD31´ for cultured SVF cells [22].
Conjugated monoclonal antibodies used were: anti-rat CD34:PE, anti-rat CD45:FITC, and anti-rat
CD31:FITC (1 μg/1 ˆ 106 cells, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Samples were
analyzed using CellQuest Pro (Becton-Dickinson, San Jose, CA, USA) and FlowJo softwares (TreeStar,
San Carlo, CA, USA).
2.7. Cell Differentiation
Proliferating SVF cells (having reached 70%–80% confluence after 5–6 days of culture) were
induced to differentiate by the addition of a differentiation mix containing 5 μg/mL insulin,
0.25 μM DXM, 0.5 mM 3-isobutyl-L-methylxanthine (IBMX) in the basal medium [20]. After 48 h
media were removed and replaced with the fresh basal medium containing 5 μg/mL insulin. Cell
samples were harvested after 10 days of the induction of differentiation (Dd10) and processed for
several determinations, as described below. Medium samples were taken on Dd10 and kept frozen
at ´20 ˝C until measurement of leptin concentrations (see below).
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2.8. RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated from cells by the Trizol extraction method (Invitrogen, Life Tech., Carlsbad,
CA, USA). Total RNA was reverse-transcribed using random primers (250 ng) and RevertAid Reverse
Transcriptase (200 U/μL, Thermo Scientific, Vilnius, Lithuania). Two μL cDNA were amplified
with HOT FIRE Pol EvaGreenqPCR Mix Plus (Solis BioDyne, Tartu, Estonia) containing 0.5 μM of
each specific primer, using LightCycler Detection System (MJ Mini Opticon, Biorad, CA, USA). PCR
efficiency was near 1. Expression levels were analyzed for β-actin (ACTβ, reporter gene), Adiponectin
(ADIPOQ), CCAAT/enhancer binding protein alpha (C/EBPα), glucose transporter (GLUT-4), fructose
transporter (GLUT-5) glucocorticoid receptor (GR), insulin receptor 1 (IRS-1) and 2 (IRS-2), Leptin (Ob),
mineralocorticoid receptor (MR), Peroxisome Proliferator-Activated Receptor gamma 2 (PPAR-γ2),
Preadipocyte Factor 1 (Pref-1), wingless-type MMTV integration site family member 10b (WNT-10b)
and Zinc finger protein 423 (Zfp423). Designed primers are shown in alphabetical order in Table 1.
Relative changes in the expression level of one specific gene (ΔΔCt) were calculated by the ΔCt method.
Table 1. Rat specific primers for qRT-PCR.








































Zfp423 se, CCGCGATCGGTGAAAGTTG NM_053583.2 121as, CACGGCTGGATTTCCGATCA
Primers sequences are listed in alphabetical order (se: sense; as: anti-sense; GBAN: GenBank Accession Number;
bp: amplicon length in bp).
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2.9. Leptin Measurement
Medium leptin concentration was determined by specific RIA [23]. In this assay, the standard
curve ranged between 50 and 12,500 pg/mL, coefficients of variation intra- and inter-assay of 4%–7%
and 9%–11%, respectively.
2.10. Cellular Lipid Content
On Dd 10, cells were washed with PBS and fixed with 10% formalin (for 10–15 min) in PBS. Then
cells were quickly washed with PBS and stained for 1 h with Oil-Red O (ORO) solution (2:3 v/v
H2O:isopropanol, containing 0.5% ORO) [24]. After staining, cells were washed (ˆ3 with PBS) and
dye from lipid droplets was extracted by adding isopropanol (10 min). To quantify cell lipid content,
sample OD was obtained at 510 nm in a spectrophotometer. Remaining cells were digested with
0.25% Trypsin solution in PBS-EDTA, at 37 ˝C for 24 h and centrifuged at 8000ˆ g for 15 s. OD of
supernatants was read at 260 nm for DNA quantification and cell lipid content (measured by ORO and
expressed in OD units) was then expressed by the corresponding cell DNA content.
2.11. Percentages of Cell Differentiation and Maturation
On Dd 10, differentiated cells were fixed with 10% formalin solution for 1 h at room temperature,
and then stained using the Papanicolaou technique. The percentage of differentiated cells was
calculated by counting the total number of cells and that of cells containing lipid droplets, when
visualized in a light microscope (after counting 200–250 total cells per layer, at 40ˆ magnification).
Lipid-containing cells were assigned to one of the 3 graded stages of maturation according to the
nucleus position: stage I (central), stage II (between central and peripheral), and stage III (completely
peripheral) [25]. Percentages of cells corresponding to each maturation stage were expressed in relation
to the total number of differentiated cells. Image analysis was assessed using a light Nikon Microscope
and image analysis software (Image ProPlus6.0, Rockville, MD, USA).
2.12. Statistical Analysis
Results are expressed as mean values ˘ SEM. Data were analyzed by ANOVA (one-way) followed
by Fisher’s test. To determine the differential effect of the treatment according to age, ANOVA
(two-ways) was performed followed by Bonferroni’s test. The non-parametric Mann-Whitney test
was used to compare adipocyte size populations between groups. Normal or binomial distribution of
adipocyte size data was determined by Kruskall-Wallis test, followed by Mann-Whitney test. P values
lower than 0.05 were considered statistically significant. All statistical tests were performed using
GraphPad Prism 6.0.
3. Results
3.1. Effect of FRD Intake on Metabolic Parameters
FRD rats showed high average of total energy intake from three up to eight weeks of treatment
(Figure 1A), although they did not exhibit differences in body weight (Figure 1B). However, FRD
intake significantly increased INS, Tg and LEP plasma levels, and also induced a significant increase in
RPAT depot (Table 2). When we determined the size distribution of mature adipocytes contained in
the RPAT we found two adipocyte populations, one similar to and another larger than CTR adipocyte
population (Figure 2). The presence of small adipocytes in FRD rats may suggest that the generation of
new adipocytes took place (adipogenesis), whereas large adipocytes could be the result of enlargement
of preexisting fat cells, leading to adipocyte hypertrophy.
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Figure 1. Food-derived energy intake and body weight of CTR and FRD rats. (A) Caloric intake and
(B) body weight of CTR and FRD rats. Values are means ˘ SEM (n = 8 rats per group). * p < 0.05 vs.
CTR values on the same day.
Table 2. Metabolic parameters in CTR and FRD rats.
CTR FRD
Body Weight (g) 403.87 ˘ 10.54 408.69 ˘ 10.95
LEP (ng/mL) 5.34 ˘ 0.68 9.39 ˘ 1.66 *
CORT (nM) 345.21 ˘ 32.32 282.67 ˘ 23.36
INS (nM) 0.29 ˘ 0.04 0.46 ˘ 0.03 *
Glu (mM) 6.94 ˘ 0.11 7.05 ˘ 0.22
Tg (mM) 1.29 ˘ 0.09 2.51 ˘ 0.16 *
RPAT mass (g) 3.92 ˘ 0.29 5.30 ˘ 0.51 *
RPAT Adipocyte diameter (μm) 69.24 ˘ 0.67 77.36 ˘ 0.77 *
Body weight, plasma levels of several metabolites, AT mass and adipocyte size from RPAT in CTR and FRD rats.
Values are means ˘ SEM (n = 8 rats per group). * p < 0.05 vs. CTR values.
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Figure 2. RPAT adipocyte diameter distribution. Dotted and continuous lines represent FRD small
and large populations of adipocytes, respectively. Values are means ˘ SEM (n = 3 animals per group).
Representative images of CTR and FRD mature adipocytes in cell suspension are shown (right,
magnification 10ˆ). Scale bars at 200 μm.
3.2. FRD Modifies APCs Number and Adipogenic Potential
To test the effect of FRD intake on the adipogenic capacity of APCs, we measured the mRNA
levels of anti-adipogenic, pro-adipogenic and competency factors expressed by these cells contained in
the SVF. Freshly isolated SVF cells from FRD pads expressed significantly (p < 0.05 vs. CTR cells) higher
levels of Zfp423 and PPARγ2 (competency markers), and the pro-adipogenic factor MR (Figure 3A).
Conversely, no differences were found in Pref-1 and Wnt-10b mRNA levels (anti-adipogenic factors,
Figure 3A).
We also evaluated the expression levels of the specific fructose transporter GLUT-5 in APCs.
We found that this gene was expressed in APCs, although no differences were noticed in either group
of cells; the same phenomenon occurred when GLUT-4 mRNA expression was quantified. Importantly,
the APCs expression levels of GLUT-4 were markedly lower than those of GLUT-5, regardless of the
cell-group examined (Figure 3B).
Interestingly, the number of APCs contained in the SVF of RPAT pads, was significantly higher in
the FRD rats (Figure 3C). Collectively, these results strongly reveal that high fructose intake affects the
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Figure 3. Effect of FRD intake on the APCs adipogenic potential and number. (A) Gene expression levels
of cell competency (PPAR-γ2 and Zfp423), anti-adipogenic (Pref-1 and Wnt-10b) and pro-adipogenic
(GR and MR) markers. * p < 0.05 vs. CTR values; (B) Gene expression levels of the specific fructose
(GLUT-5) and glucose (GLUT-4) transporters in SVF cells in RPAT from CTR and FRD rats. Relative
values to GLUT-5 expression in CTR cells. (AU: arbitrary units). Values are means ˘ SEM (n = 4
different experiments). * p < 0.05 vs. GLUT-5 values from each group; (C) APCs number in SVF in
RPAT from CTR and FRD rats. APCs were identified by FACS analysis using CD34+CD45´CD31´
profile (indicated in red borders). Fluorescence profiles obtained for IgG isotype controls are shown in
Figure S1 (Supplementary materials) FITC: fluorescein isothiocyanate; PE: phycoerythrin. Values are
means ˘ SEM (n = 3/4 different experiments).
3.3. In vitro Adipocyte Differentiation
We measured two classical differentiation parameters, such as leptin release and intracellular
lipid content in order to determine whether the impact of FRD on APCs adipogenic potential affected,
in turn, terminal adipocyte differentiation. We found that while intracellular lipid content increased on
Dd 10 (Figure 4A) in FRD cells, leptin release was not modified (Figure 4B). Additionally, the mRNA
levels of fully differentiated adipocyte markers indicate that the expression levels of C/EBPα, IRS-1,
IRS-2, and Ob genes were higher in FRD than in CTR cells (Figure 4C).
Finally, we evaluated the percentage of differentiated cells and maturation degrees to determine
the extent of adipogenesis. Interestingly, we noticed a higher percentage of differentiated adipocytes
in RPAT from FRD, whereas the maturation degree in both groups remained the same (Figure 4E,F).
These results strongly support that higher APCs competency and number, described above, caused the
differentiation increase recorded in FRD adipocytes.
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Figure 4. Parameters of terminal adipocyte differentiation. (A) Quantification of intracellular lipid
accumulation and (B) leptin cell secretion (n = 5 different experiments with 12 wells per experiment);
(C) Gene expression of fully-differentiated adipocyte markers (PPAR-γ2, C/EBPα, Adipoq and
Ob, IRS-1 and IRS-2) on Dd 10 in cells isolated from CTR and FRD RPAT pads (n = 5/6 different
experiments; AU: arbitrary units); (D) Representative fields containing in vitro differentiated CTR and
FRD adipocytes (stained on Dd 10, magnification 40ˆ), displaying different degrees of maturation
depending on the nucleus position: GI, central (white arrows); GII, displaced from the center (gray
arrows); and GIII: fully peripheral (black arrows). Scale bars at 50 μm; (E) Percentage of differentiated
cells according to the presence of lipid droplets; (F) Percentages of cells according to the maturation
stage. (n = 4/5 different experiments; data from 200/250 cells were recorded 1 in each experiment).
Values are means ˘ SEM. * p < 0.05 vs. CTR values.
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3.4. Direct Effect of Fructose Exposure on the Adipogenic Potential of Normal APCs
To examine whether the effect of FRD on normal RPAT APCs was caused, at least in part, by a
direct cell exposure to fructose, cells were cultured with FRU and then the APCs adipogenic potential
was determined. Our results indicate that normal cells exposed to either FRU or GLU expressed
higher levels (vs. basal levels) of PPARγ2, without any change in those of Zfp423 (Figure 5A). We also
evaluated the mRNA expression level of GLUT-5, which was similarly expressed regardless of the
culture conditions, i.e., basal, FRU or GLU (Figure 5B). Similarly to that found in SVF cells (see above),
the mRNA expression of GLUT-4 was markedly lower than that of GLUT-5, regardless of FRU or
GLU condition. Again, APCs GLUT-4 mRNA levels were similar in all incubation conditions studied
(Figure 5B). Interestingly, MR expression level was higher only in FRU-exposed cells, whereas GR
expression levels were lower in both FRU- and GLU-exposed cells (Figure 5B).
Figure 5. Direct effects of fructose on cultured APCs. (A) APCs gene expression of competency
(PPAR-γ2 and Zfp423), anti-adipogenic (Pref-1 and Wnt-10b) and pro-adipogenic (GR and MR) markers.
* p < 0.05 vs. CTR values; (B) APCs gene expression of specific fructose (GLUT-5) and glucose
(GLUT-4) transporters, in Basal and FRU or GLU conditions, in cells from normal rats (AU: arbitrary
units). Values are means ˘ SEM (n = 4 different experiments). * p < 0.05 vs. GLUT-5 values in each
group; (C) Number of APCs in FRU- and GLU-exposed cells. APCs were identified by FACS analysis
using the CD34+CD31´ profile (boxes). Fluorescence profiles obtained for IgG isotype controls are
shown in Figure S2 (Supplementary materials). FITC: fluorescein isothiocyanate; PE: phycoerythrin;
(D) Intracellular lipid accumulation on Dd10 (n = 5 different experiments with 12 wells per experiment).
Values are means ˘ SEM (n = 4 different experiments). * p < 0.05 vs. Basal values.
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Additionally we quantified the number of APCs after either FRU or GLU condition. Interestingly,
we found that APCs number increased in FRU- but not in GLU-exposed cells (Figure 5C), similarly
to what we observed in APCs from FRD-fed rats. It is important to highlight that after seven days
of culture, the presence of immune cells was undetectable (Figure S2, Supplementary Materials),
and for that reason CD45 was not used in the FACS analysis. Finally, in order to assess whether
these APCs changes might increase adipocyte differentiation, we analyzed the in vitro intracellular
lipid accumulation on Dd 10. We found that FRU-exposed, but not GLU-exposed, cells showed a
significantly higher lipid accumulation than that found in cells cultured in basal condition (Figure 5D).
Taken together, these results strongly suggest that a direct effect of fructose on the adipogenic potential
of APCs might be responsible, at least in part, for the subsequent increase in adipocyte differentiation.
4. Discussion
High-fructose feeding has been widely used in animal models to induce similar dysfunctions to
those seen in human obesity and metabolic syndrome phenotypes. We previously used FRD intake in
rats (10% p/v fructose in drinking water for three weeks) and found numerous metabolic disorders,
including peripheral insulin resistance, AAT adipocyte hypertrophy and high oxidative stress, and
others [14,15,26]. In the present study the rats were fed a FRD for eight weeks, which was only
hyper-caloric during the last five weeks of the experiment. The switch from iso- to hyper-caloric intake
could be the result of modifications in the peripheral hormone levels (e.g., ghrelin, leptin and peptide
YY (PYY)) and hypothalamic factors (e.g., neuropeptide Y (NPY), pro-opiomelanocortin (POMC))
involved in appetite control, leading to an increase in the caloric intake. It has been suggested that the
time required for the establishment of these changes in appetite regulation depends on the amount of
fructose ingested [27,28]. Similarly to our previous studies [14,15,26], eight-week FRD intake induced
several alterations, including increased plasma levels of INS, LEP and Tg.
The impact of FRD on the development of abdominal obesity has been studied in rodents and
humans [15,29]. We have now observed that eight-week FRD intake contributes to abdominal obesity
by increasing the RPAT, one of the most representatives AT depots in the rat abdominal cavity. AT depot
remodeling after fructose feeding has been reported in a previous study describing larger abdominal
adipocytes in contrast to smaller subcutaneous ones [30]. Our results agree with those findings; indeed,
adipocyte size analyses from RPAT showed that FRD adipocytes were hypertrophic compared to CTR
adipocytes. Besides, adipocyte size distribution showed two adipocyte populations in RPAT from
FRD rats: one similar and other larger than CTR adipocyte population, respectively, thus suggesting
that RPAT mass expansion in FRD rats may occur from both the combination of newly generated
adipocytes through adipogenesis and the hypertrophy of existing adipocytes, respectively.
It is accepted that adipogenesis involves two sequential steps: commitment of mesenchymal stem
cells (MSCs) into APCs, acquiring the adipogenic potential and restricting them to the adipocyte linage,
followed by terminal adipocyte differentiation [13]. In the first step APCs begin to express CD34, a cell
surface antigen that distinguishes between adipogenic and non-adipogenic cell subpopulations [31].
This CD34+ cell subpopulation expresses almost exclusively the transcriptional factor Zfp423 [32],
which in turn activates the basal expression of PPAR-γ2, a key pro-adipogenic signal that assures APCs
conversion into adipocytes [33]. The differential expression of both transcriptional factors determines
the competency of APCs, in other words, a cell’s ability to differentiate into adipocytes upon the action
of adipogenic stimulus [13]. Finally, in response to the adipogenic stimulus, APCs differentiate into
mature adipocytes, cells mainly characterized by intracellular lipid storage and insulin responsiveness.
We were able to assess how the eight-week FRD intake affects competency of APCs from RPAT
pads. For this purpose we evaluated the mRNA expression levels of PPARγ2 and Zfp423 in freshly
isolated SVF cells. We found that APCs from FRD rats showed an increase in both competency markers,
which have also been found after shorter periods of high fructose intake [15], indicating that high APCs
competency is maintained between three and eight weeks of FRD intake. This phenomenon might be
responsible for the small new adipocyte population observed in FRD rats, as discussed above. FRD
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intake also induced an increase in APCs MR gene expression without any change in that of GR, both
receptors being natural mediators of the pro-adipogenic effects of glucocorticoids [34,35]. However,
FRD intake did not modify APCs expression of two anti-adipogenic factors Pref-1 and Wnt10b, thus
suggesting that the main FRD effect could be due to the change in APCs competency.
The cell expression pattern of both competency and pro-adipogenic factors in FRD-fed rats reveals
an increased APC ability to differentiate into mature adipocytes. Indeed, FRD differentiated adipocytes
also showed higher lipid intracellular content, differentiation percentage and expression levels of
C/EBPα, Ob and IRS-1/-2 than CTR adipocytes. Collectively, these results indicate that APCs from
FRD rats have a greater ability to become mature adipocytes. It is reasonable to speculate that some
of the alterations observed in FRD APCs could be due to, in some degree , a direct fructose effect
on these cells; in fact, after intestinal absorption a percentage of fructose enters into the systemic
circulation and is metabolized by extrahepatic tissues, such as the AT [36]. Both 3T3-L1 preadipocytes
and adipocytes express the specific fructose transporter GLUT-5 [17,37]. It has been described that
GLUT-5 gene expression is higher in undifferentiated than differentiated 3T3-L1 cells [17], in which
it is practically undetectable [17,38], thus indicating that adipocyte precursors are a better target for
fructose action than mature adipocytes. Our results showed that cell GLUT-5 expression was not
modified by either FRD intake (in vivo experiments) or direct fructose treatment (in vitro experiments).
These results correspond with other reports describing that GLUT-5 is not modulated by an increase in
substrate supply [39,40]. However, other authors have shown the opposite [18]. On the other hand, as
previously reported [17], we found that GLUT-5 gene expression in both fresh SVF cells and cultured
APCs, was greater than that of GLUT-4. Further studies are needed to evaluate any effect on other
glucose transporters, such as GLUT-10 and GLUT-12, which are also expressed in adipocytes and
SVF cells [41]. There are few available reports regarding direct fructose effects on adipogenesis that
have only focused on the terminal differentiation stage of 3T3-L1 preadipocytes [17]. The presence
of fructose (55–5500 μM) during adipocyte differentiation induced an increase in PPARγ2, C/EBPα
among other pro-adipogenic factors, and either GLUT-5 knockdown or overexpression reduced or
increased this effect, respectively [17]. GLUT-5´/´ mice have diminished EAT mass compared with
wild-type mice, and mouse embryonic fibroblasts derived from GLUT-5´/´ mice exhibited impaired
adipocyte differentiation [17]. Also, fructose in the culture medium increased lipolysis and the activity
of 11-β hydroxysteroid dehydrogenase-1 in differentiated 3T3-L1 cells [18]. To our knowledge, the
present work is the first that evaluates direct fructose effects on the early stages of adipogenesis;
i.e., before inducing cell differentiation. To this purpose, APCs were grown in presence of FRU for
seven days. In this condition APCs expressed higher mRNA levels of PPARγ2 without any change in
Zfp423, indicating a greater APCs competency. A similar result was found when cells were cultured
with a comparable concentration of GLU. As found in the APCs from FRD rats, FRU did not modify
the gene expression of Pref-1 and WNT10b. It has been proposed that the balance between MR/GR
plays a key role in the pro-adipogenic effects of glucocorticoids. We found that the APCs grown in the
presence of FRU had higher MR and lower GR mRNA levels. Interestingly, no GLU effect on cell MR
expression was found. In agreement with this data, it has been described that fructose decreases GR
gene expression in adipocytes [42]. Interestingly, when the FRU-exposed APCs were differentiated
they accumulated high lipid content. Taken together, these in vitro results are quite similar to those we
observed in freshly isolated SVF cells from FRD rats.
Another factor that can influence the adipogenic potential in each AT depot is its APCs number.
It is generally accepted that subcutaneous AT contains more APCs than AAT [43]. High fat diet intake
increases the number of APCs in different AT depots [43,44]. Interestingly, we have previously reported
that three-week FRD intake does not induce any change in the number of APCs in RPAT [15]. However,
in the present study we evaluated whether a longer period of FRD intake (eight weeks) might alter
RPAT APCs number, quantified by using the CD34+CD31´CD45´ FACS pattern [15]. Our results
showed an increase in the number of APCs present in RPAT SVF cells from FRD rats. This fact, together
with their higher APC competency, clearly indicates a greater differentiation capacity of the RPAT from
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FRD rats. Additionally, we evaluated the direct effect of fructose on APCs number. Our results showed
that FRU directly induced an increase in both CD34+CD31´ cell number and percentage. However,
these results were not observed by using GLU, thus indicating a fructose-specific effect.
5. Conclusions
The present study demonstrates that long-term FRD intake altered the RPAT APCs by enhancing
their adipogenic potential. Indeed, eight weeks of FRD intake were able to modulate APCs competency
and number. Although we previously reported that three weeks of FRD intake modified APCs
competency [15], the effect of FRD on APCs number is a novel observation. Moreover and importantly,
it has now been assessed that FRU directly modulates the adipogenic competency and number of APCs.
In addition, it is important to highlight that the fructose-induced changes in the number/competency
of the APCs were not observed with glucose, which agree with the highest GLUT-5 compared with
GLUT-4 expression levels in the APCs. It is more than likely that, after both direct and indirect fructose
effects, APCs are more capable of generating new adipocytes, which subsequently and as a result of the
positive energy balance, will become hypertrophic and contribute to an unhealthy AT mass expansion.
In conclusion, although we demonstrated that fructose intake can activate the adipogenic
process in the RPAT, overall the activation of the hyperplasia would not be enough to counteract the
hypertrophy. Therefore, predominant hypertrophic RPAT expansion could lead to the development
of adiposity dysfunctions, and consequently to the endocrine-metabolic alterations also seen in the
human metabolic syndrome/obese phenotype.
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Abstract: This study was aimed at determining potential effects of apple-derived pectin on weight
gain, gut microbiota, gut barrier and metabolic endotoxemia in rat models of diet-induced obesity.
The rats received a standard diet (control; Chow group; n = 8) or a high-fat diet (HFD; n = 32) for
eight weeks to induce obesity. The top 50th percentile of weight-gainers were selected as diet induced
obese rats. Thereafter, the Chow group continued on chow, and the diet induced obese rats were
randomly divided into two groups and received HFD (HF group; n = 8) or pectin-supplemented
HFD (HF-P group; n = 8) for six weeks. Compared to the HF group, the HF-P group showed
attenuated weight gain (207.38 ˘ 7.96 g vs. 283.63 ˘ 10.17 g, p < 0.01) and serum total cholesterol
level (1.46 ˘ 0.13 mmol/L vs. 2.06 ˘ 0.26 mmol/L, p < 0.01). Compared to the Chow group, the HF
group showed a decrease in Bacteroidetes phylum and an increase in Firmicutes phylum, as well as
subordinate categories (p < 0.01). These changes were restored to the normal levels in the HF-P group.
Furthermore, compared to the HF group, the HF-P group displayed improved intestinal alkaline
phosphatase (0.57 ˘ 0.20 vs. 0.30 ˘ 0.19, p < 0.05) and claudin 1 (0.76 ˘ 0.14 vs. 0.55 ˘ 0.18, p < 0.05)
expression, and decreased Toll-like receptor 4 expression in ileal tissue (0.76 ˘ 0.58 vs. 2.04 ˘ 0.89,
p < 0.01). The HF-P group also showed decreased inflammation (TNFα: 316.13 ˘ 7.62 EU/mL
vs. 355.59 ˘ 8.10 EU/mL, p < 0.01; IL-6: 51.78 ˘ 2.35 EU/mL vs. 58.98 ˘ 2.59 EU/mL, p < 0.01)
and metabolic endotoxemia (2.83 ˘ 0.42 EU/mL vs. 0.68 ˘ 0.14 EU/mL, p < 0.01). These results
suggest that apple-derived pectin could modulate gut microbiota, attenuate metabolic endotoxemia
and inflammation, and consequently suppress weight gain and fat accumulation in diet induced
obese rats.
Keywords: obesity; apple-derived pectin; gut microbiota; gut barrier function; metabolic endotoxemia
1. Introduction
In recent years, obesity and related metabolic disorders have emerged as major health concerns [1,2].
Obesity is associated with increased risks for developing type 2 diabetes mellitus (T2DM),
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hyperlipidemia, hypertension, coronary heart disease (CHD), stroke, and cancer. Development of
these diseases can also lead to psychological and psychiatric illnesses, adding to the societal burden
associated with these diseases [3–5].
Obesity and related metabolic disorders are attributable to a combination of genetics, unhealthy
diet and lifestyle. Recent studies have demonstrated that disturbance of gut microbiota, especially the
ratio of Bacteriodetes to Firmicutes phylum, is closely related to obesity and metabolic disorders [6–11].
In addition, obese subjects exhibit systemic chronic inflammation and a high level of serum endotoxins
(lipopolysaccharides (LPS), a key component of the cell wall of gram-negative bacteria), termed
“metabolic endotoxemia”, which associates with gut barrier dysfunction [12–16].
Gut microbiota in the lumen is normally isolated by the intestinal epithelium from lamina propria
and deeper layers [17,18], and LPS derived from gut microbiota is confined to the gut lumen and does
not penetrate healthy intestinal epithelium [19]. However, a damaged intestinal epithelium or other
gut barrier dysfunction can lead to disturbance of gut microbiota [16], allow for LPS permeation and
cause metabolic endotoxemia [20–22]. Recognition of LPS by Toll-like receptor 4 (TLR4) of host cells
triggers downstream inflammatory events [23,24] that contributes to the development of obesity and
metabolic disorders such as insulin resistance [10,25].
Tight junctions are key components for maintaining gut barrier integrity [17,26].
Another important protein for gut barrier function is intestinal alkaline phosphatase (IAP) that is
a type of glycoprotein anchored in the apical membrane of enterocytes. IAP has multiple roles in
maintenance of gut barrier, including detoxification of LPS via its dephosphorylation, remission of
systemic inflammation, protection of gut barrier function and modulation of gut microbiota [27,28].
Although various approaches are recommended for obesity management [29], such as dieting,
behavior therapy, exercise, pharmacotherapy, and bariatric surgery, they are often defective [29,30].
Here, we consider that modification of gut microbiota, protection of gut barrier, remission of metabolic
endotoxemia, and relief of systemic inflammation may provide a novel strategy for the treatment of
obesity and related metabolic disorders.
Dietary fiber consists of non-digestible carbohydrates that derived from plants. Recent animal
experiments and clinical trials have shown that dietary fiber, such as whole-grain cereal, grape skin
extract, yellow pea fiber and wheat-derived arabinoxylan oligosaccharides, has hypolipidemic and
hypoglycemic effects and may contribute to weight loss [31–35]. Apple-derived pectin is the main
soluble fiber in apples and can be fermented by gut microbiota in the colon to produce metabolites
with local intestinal and systemic effects. Apple-derived pectin may also help to maintain the balance
of gut microbiota [36].
The aim of the present study was to assess potential effects of apple-derived pectin on diet-induced
obesity in rats. We found that apple-derived pectin could modulate gut microbiota, preserve gut
barrier function, and alleviate metabolic endotoxemia and inflammation in diet-induced obese rats.
Our findings suggest that apple-derived pectin may be useful for the clinical management of obesity.
2. Materials and Methods
2.1. Animals
Male Sprague-Dawley rats were obtained from the Medical Experiment Animal Center of the
Jinling Hospital, Nanjing, China, at 4 weeks of age with an initial weight of 90 ˘ 10 g. Rats were
housed in individual cages in an optimum environment at 23 ˘ 2 ˝C and a relative air humidity of
55% ˘ 10% with a 12 h light/dark cycle. Animals had free access to a standard chow diet (10% kcal%
fat; D12450J, Research Diets, New Brunswick, NJ, USA) or a high fat diet (60% kcal% fat; D12492,
Research Diets) and water throughout the experiment. This study was approved by the Animal Care
and Use Committee of Nanjing University and Jinling Hospital and complied with the principles of
laboratory animal care (NIH publication No. 86–23, revised 1985).
180
Nutrients 2016, 8, 126
2.2. Diet and Study Design
Rats were randomized into two groups and received either a standard chow diet (Chow group,
n = 8) as a control or a HFD (n = 32) to induce obesity for 8 weeks. Body weight and food intake were
recorded every week.
After high fat feeding, diet induced obese rats were selected as previously described [37], wherein
the top 50th percentile of weight gainers were randomized for the following interventions. Sixteen were
randomized to receive either a HFD (HF group, n = 8) or a HFD supplemented with pectin (5% wt/wt)
(HF-P group, n = 8) for 6 weeks. The Chow group continued a standard chow diet for 6 weeks. Body
weight and food intake were recorded every week.
2.3. Sample Collection
All animals were anesthetized by intraperitoneal administration of ketamine (0.3 mL/100 g
body weight). Blood (about 3 mL) was immediately collected in a dry tube without heat source.
Blood samples were allowed to clot for 2 h at room temperature and were then centrifuged for 15 min
at 3000 rpm at 4 ˝C. Serum was removed, and the samples were stored at ´80 ˝C until further analysis.
After blood collection, a part of the liver, distal ileum, mesentery adipose, and the whole part
of epididymal fat pad were collected, weighed, wrapped, and immediately put into liquid nitrogen.
This process took no longer than 3 min after sacrifice of the animal. All samples were stored frozen
at ´80 ˝C until further analysis.
2.4. Body Weight and Adipose Tissue Wet Weight
Body weight and adipose tissue wet weight were measured using an electronic scale. Body weight
was measured once a week and adipose tissue wet weight was measured after the rats were sacrificed.
2.5. Blood Parameters
Serum glucose, triglycerides, and total cholesterol concentrations were measured by enzyme
linked immunosorbent assay (ELISA) kits in accordance with the manufacturer’s instructions
(Labassay™ Wako kit, Wako Pure Chemical Industries, Ltd., Osaka, Japan). Serum insulin concentrations
were measured using an ELISA kit (Millipore Corp., Billerica, MA, USA).
2.6. Measurement of Serum LPS
Serum LPS concentration was determined by Chromogenic End-point Tachypleus Amebocyte
Lysate (CE TAL) assay (Chinese Horseshoe Crab Reagent Manufactory, Co., Ltd., Xiamen, China).
In this assay, color intensity is directly proportional to endotoxin levels. Serum was diluted 1/10 with
pyrogen-free pipes to avoid interference in the reaction. Endotoxin in the serum activates a cascade
of enzymes in the assay, and the activated enzyme splits the synthetic substrate, producing a yellow
product with maximum absorbance at 405 nm. The yellow product can further react with diazo
reagents to form a purple product with maximum absorbance at 545 nm. Every sample was treated in
duplicate for determination. The limit of detection ranged from 0.1 to 1.0 EU/mL. An internal control
for LPS recovery was included in the calculation. Every reaction in the kit was done in duplicate.
2.7. Western Blot
Proteins of ileum or liver samples were separated by sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. After blocking
with skim milk (BioRad, Hercules, CA, USA), membranes were incubated at 4 ˝C overnight using the
antibodies indicated. Band density was detected by horseradish-peroxidase conjugated secondary
antibodies (Promega, Madison, WI, USA) and ECL (enhanced chemiluminescence reagent; GE
Healthcare, Chalfont St. Giles, UK). Bands located in a predicted molecular weight were used to
verify targeted proteins. β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
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as an internal control to adjust the density of bands on multiple membranes. For quantification of
signals, the images were quantified by an Image J software (Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA).
2.8. Quantitative RT-PCR Analysis
mRNA levels of TNF α, IL-6, IL-10, and TLR4 were measured by quantitative real-time polymerase
chain reaction (qPCR). The primers are listed in Table 1.














mRNA extraction and RT-PCR were performed according to the manufacturer’s instructions as
described in the PrimeScript RT reagent Kit (TaKaRa Bio, Tokyo, Japan). Q RT-PCR was performed
by SYBR Select Master Mix System (Applied Biosystems, Foster City, CA, USA). The levels of mRNA
expression were measured by StepOne Realtime PCR system with a ΔCt relative quantification
model. The mRNA expression of βactin and 36B4, two reference genes, were calculated and used for
normalization. In our study, mRNA expression of the tested genes displayed similar results with either
reference gene, thus we used βactin as the reference gene for normalization in this manuscript.
2.9. Hematoxylin and Eosin (H & E) Staining
The ileal tissues were processed (Tissue-Tek VIP; Sakura Finetek, Tokyo, Japan), embedded in
paraffin wax, and cut into 5-μm thick slices. Paraffin embedding, slicing, and H & E staining were
performed according to the standard procedure.
2.10. Immunohistochemistry (IHC) Staining
IHC staining was used to detect the location of IAP. After antigen retrieval with buffered citrate
and blocking with 5% bovine serum albumin (BSA), ileum tissues were incubated with primary
antibodies against IAP (Abcam, Cambridge, UK, 1:200) overnight at 4 ˝C. The sections were then
processed using the DAB Kit (ZSGB-Bio, Beijing, China) according to the manufacturer’s instructions.
Hematoxylin staining was performed at the end to counterstain nuclei. The cover slips were fixed with
50% glycerin.
2.11. 16S rRNA Pyrosequencing
2.11.1. Collection and Transportation of Samples
Cecum content was collected from every rat, stored in liquid nitrogen, transported to BGI
laboratory (Shenzhen, China), packed with dry ice, and then immediately stored in a ´80 ˝C
refrigerator before extraction of total DNA.
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2.11.2. Detection of Samples
Detection of samples included concentration and sample integrity. Concentration was detected by
a fluorometer or microplate Reader, while sample integrity was detected by agarose gel electrophoresis
(concentration of agarose gel: 1%; voltage: 150 V; electrophoresis Time: 40 min).
2.11.3. Library Construction
Total DNA was normalized to 30 ng per reaction, and then V4 Dual-index Fusion PCR Primer
Cocktail and PCR Master Mix were added to run PCR (melting temperature: 56 ˝C, PCR cycle: 30).
Subsequently, AmpureXP beads (AGENCOURT) were added to the PCR products to remove
unspecific products.
2.11.4. Library Validation
The final library was quantitated by real-time quantitative PCR (EvaGreen™, Hayward, CA, USA).
2.11.5. Library Sequencing
Library sequencing was conducted by pair end on MiSeq System, with sequencing strategy
PE250 (PE251 + 8 + 8 + 251) (MiSeq Reagent Kit, Illumina Hong Kong Limited, Hong Kong, China).
Mothur pipeline and QIIME pipeline were used to analyze the data.
2.12. Statistical Analysis
Data are presented as the mean ˘ standard deviation (SD), and significant difference among
groups was analyzed by one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc
test (SPSS 21.0, IBM, New York, NY, USA). Significant difference of the body weight among groups
was analyzed by repeated measures analysis of variance (SPSS 21.0). Statistical significance was set
at p < 0.05.
3. Results
3.1. Apple-Derived Pectin Protected Rats from High Fat Diet Induced Obesity
In the intervention stage, rats in the high fat diet (HF) group gained more body weight than
rats in the Chow group (283.63 ˘ 10.17 g vs. 161.00 ˘ 2.88 g, p < 0.01). Importantly, rats in the HF
supplemented with pectin (HF-P) group gained significantly less weight than rats in the HF group
(207.38 ˘ 7.96 g vs. 283.63 ˘ 10.17 g, p < 0.01) (Figure 1). Rats in the HF group developed adipose
tissue more rapidly than the Chow group (epididymal, 23.44 ˘ 2.36 g vs. 14.86 ˘ 2.04 g, p < 0.01;
subcutaneous, 18.44 ˘ 2.36 g vs. 11.99 ˘ 1.21 g, p < 0.01) (Figure 1). Pectin supplementation significantly
suppressed the development of adipose tissue in the HF-P group as compared with the HF group
(epididymal, 17.90 ˘ 1.55 g vs. 23.44 ˘ 2.36 g, p < 0.01; subcutaneous, 15.02 ˘ 1.44 g vs. 18.44 ˘ 2.36 g,
p < 0.01) (Figure 1).
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Figure 1. Apple-derived pectin suppresses body weight gain and development of adipose tissue in
rats fed a high fat diet. (a–c) Growth curves; (d) body weight gain; (e) weight of epididymal adipose
tissue; and (f) weight of subcutaneous adipose tissue of rats in Chow, high fat diet (HF), and high fat
diet supplemented with pectin (HF-P) groups (** p < 0.01 vs. Chow, ## p < 0.01 vs. HF, one way analysis
of variance (ANOVA)).
3.2. Apple-Derived Pectin Alleviated High Fat Diet Induced Hypercholesterolemia
Rats in the HF group exhibited higher levels of serum total cholesterol, triglycerides, glucose, and
insulin than those in the Chow group (total cholesterol, 2.06 ˘ 0.26 mmol/L vs. 1.43 ˘ 0.16 mmol/L,
p < 0.01; triglycerides, 1.31 ˘ 0.41 mmol/L vs. 0.57 ˘ 0.294 mmol/L, p < 0.01; glucose,
15.14 ˘ 3.85 mmol/L vs. 10.18 ˘ 0.35 mmol/L, p < 0.01; insulin, 6.49 ˘ 1.82 mmol/L vs.
3.07 ˘ 1.14 mmol/L, p < 0.01). Total cholesterol levels were significantly decreased in rats of the
HF-P group as compared with those in the HF group (1.46 ˘ 0.13 mmol/L, p < 0.01), while serum
triglycerides, fasting serum glucose, and insulin levels showed only a trend of decrease within
the duration of the study (triglycerides, 1.02 ˘ 0.65 mmol/L vs. 1.31 ˘ 0.41 mmol/L, p = 0.669;
glucose, 13.37 ˘ 1.32 mmol/L vs. 15.14 ˘ 3.85 mmol/L, p = 0.607; insulin, 3.75˘ 3.00 mmol/L vs.
6.49 ˘ 1.82 mmol/L, p = 0.167) (Figure 2).
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Figure 2. Effects of apple-derived pectin on HFD-induced changes in blood chemistry: (a) serum total
cholesterol; (b) triglycerides; (c) glucose; and (d) insulin in Chow, HF, and HF-P groups. (** p < 0.01 vs.
Chow, * p < 0.05 vs. Chow, ## p < 0.01 vs. HF, one way ANOVA).
3.3. Apple-Derived Pectin Prevented HFD-Induced Alterations of Gut Microbiota
Gut microbiota was analyzed by 16S rDNA pyrosequencing at the levels of phylum, class, order,
family, genus and species (Figure 3). The number of reads per sample and raw data can be found in
Supplementary Materials (Table S1).
Figure 3. Cont.
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Figure 3. Composition analysis of gut microbiota at the: (a,b) phylum; (c,d) class; (e,f) order; (g,h)
family; (i,j) genus; and (k,l) species level in Chow, HF, and HF-P groups; (m) Principal component
analysis (PCA) and (n) clustering analysis of gut microbiota in Chow, HF, and HF-P groups (** p < 0.01
vs. Chow, * p < 0.05 vs. Chow, ## p < 0.01 vs. HF, # p < 0.05 vs. HF, one way ANOVA).
At the phylum level, rats in the HF group had a significantly lower level of Bacteroidetes and
a higher level of Firmicutes than the Chow group. However, in the HF-P groups, these changes
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were restored to similar levels as the Chow group. There was no significant difference in the level of
Proteobacteria among the three groups.
At the class level, rats in the HF group presented a significantly higher level of Bacilli (a class
of Firmicutes phylum) and Gammaproteobacteria (a class of Proteobacteria phylum) as well as a
significantly lower level of Bacteroidia (a class of Bacteroidetes phylum) and Deltaproteobacteria
(a class of Proteobacteria phylum). The percentage levels of the above four classes of bacteria were
reverted to normal in the HF-P group (Chow group as reference).
At the order level, we observed a significantly lower level of Bacteroidales (an order of Bacteroidia
class, Bacteroidetes phylum) and a higher level of Lactobacillales (an order of Bacilli class, Firmicutes
phylum) in the HF group than in the Chow group. After pectin supplementation for six weeks, the
levels of the above two orders of bacteria in the HF-P group were similar to those in the Chow group.
At the family level, we observed a significantly lower level of Bacteroidaceae (a family of
Bacteroidales order, Bacteroidia class, Bacteroidetes phylum) in the HF group than in the Chow
group, and these decreases were restored to normal levels in the HF-P group.
At the genus level, we observed a dramatically lower level of Bacteroides (a genus of Bacteroidaceae
family, Bacteroidales order, Bacteroidia class, Bacteroidetes phylum) and a higher level of Lactococcus
(a genus of Streptococcaceae Family, Lactobacillales Order, Bacilli Class, Firmicutes Phylum) in the HF
group than in the Chow group. Again, pectin supplementation prevented these changes induced by
high fat diet.
At the species level, Clostridium ruminantium (a species of Clostridium Genus, Clostridiaceae
Family, Clostridiales Order, Clostridia Class, Firmicutes Phylum) was the only species that displayed
a significant increase upon high fat diet and became normal with pectin supplementation.
Accordingly, principal component analysis (PCA, Figure 3m) and clustering analysis (Figure 3n)
illustrated both similarity and variance among the Chow, HF, and HF-P groups, where the first three
components explained 62.28% of the total variance (36.36%, 17.65%, and 8.27% for PC1, PC2, and PC3,
respectively). The score plot showed that diversity of gut microbiota was similar between the Chow
and HF-P groups but different from the HF group.
Taken together, these data indicated that rats in the HF group exhibited a lower level of
Bacteroidetes phylum and a higher level of Firmicutes phylum than those in the Chow group.
Importantly, both of these changes were restored to normal levels in the HF-P group. At the
downstream level, we found some changes consistent with the phylum level, such as higher levels
in the HF group of the Bacilli class, Lactobacillales order, Lactococcus genus, Clostridium ruminantium
species (belonging to the Firmicutes phylum), and a significantly lower level of Bacteroidia class,
Bacteroidales order, Bacteroidaceae family, and Bacteroides genus (belonging to Bacteroidetes phylum).
Supplementation of apple-derived pectin brought these changes back to normal levels (Chow group
as reference).
3.4. Apple-Derived Pectin Restored the Expression of Intestinal Alkaline Phosphatase (IAP) in the Ileal Tissueof
Rats on High Fat Diet
We measured the protein levels of IAP via immunoblotting and found that the expression of
IAP in the ileal tissue of rats in the HF group was significantly lower than that in the Chow group
(0.30 ˘ 0.19 vs. 1.00 ˘ 0.25, p < 0.01). Supplementation of pectin significantly increased the level of
IAP in the ileal tissue of rats as compared with high fat diet alone (0.57 ˘ 0.20 vs. 0.30 ˘ 0.19, p < 0.05)
(Figure 4).
Consist with the immunoblotting analysis of IAP, IHC analysis of IAP in the ileum also revealed
that high fat diet reduced the expression of IAP in comparison with chow diet while supplementation
of pectin could attenuate this reduction.
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Figure 4. Expression of intestinal alkaline phosphatase (IAP) in the ileum of rats: (a) representative
immunoblots for IAP and β-actin; (b) quantitation of IAP in the Chow, HF, and HF-P groups (** p < 0.01
vs. Chow, # p < 0.05 vs. HF, one way ANOVA); and (c) immunological histological chemistry analysis
of IAP in Chow, HF, and HF-P groups. Original magnification: 20ˆ.
3.5. Apple-Derived Pectin Prevented the High Fat Diet Induced mRNA Expression of TLR4 in the Ileal Issue
TLR4 mRNA levels in the ileal tissue of rats in the HF group were higher than those in the Chow
group (2.04 ˘ 0.89 vs. 1.00 ˘ 0.49, p < 0.05). Pectin supplementation blunted this high fat diet induced
increase of TLR4 mRNA in the HF-P group (0.76 ˘ 0.58 vs. 2.04 ˘ 0.89, p < 0.01) (Figure 5).
Figure 5. TLR4 mRNA expression in the ileal tissue of rats in the Chow, HF, and HF-P groups (* p < 0.05
vs. Chow, ## p < 0.01 vs. HF, one way ANOVA).
3.6. Apple-Derived Pectin Alleviated High Fat Diet Induced Ileal Inflammation in Rats
The levels of pro-inflammation markers were significantly higher in the ileal issue of the HF group
than in the Chow group (tumor necrosis factor alpha (TNFα), 3.48 ˘ 0.71 vs. 1.00 ˘ 0.27, p < 0.01;
interleukin (IL)-6, 2.59 ˘ 0.45 vs. 1.00 ˘ 0.25, p < 0.01). The level of anti-inflammation cytokine IL-10 in
the ileal issue was significantly lower in the HF group than that in the Chow group (IL-10, 0.25 ˘ 0.04
vs. 1.00 ˘ 0.20, p < 0.01) (Figure 6). The levels of TNFα and IL-6 were significantly decreased in
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the HF-P group as compared with the HF group (TNFα, 1.55 ˘ 0.37 vs. 3.48 ˘ 0.71, p < 0.01; IL-6,
1.02 ˘ 0.17 vs. 2.59 ˘ 0.45, p < 0.01), and the level of IL-10 in the ileal tissue was significantly increased
in the HF-P group as compared with the HF group (0.60 ˘ 0.054 vs. 0.25 ˘ 0.04, p < 0.01) (Figure 6).
Figure 6. The mRNA levels of (a) tumor necrosis factor alpha (TNFα); (b) interleukin (IL)-6 and
(c) IL-10 in the ileal tissue in Chow, HF, and HF-P groups (** p < 0.01 vs. Chow, ## p < 0.01 vs. HF, one
way ANOVA).
3.7. Apple-Derived Pectin Preserved Gut Barrier (Tight Junction) Function in Rats
The expression levels of claudin1, occludin and zonula occludens-1 (ZO-1) proteins in rats of the
HF group were significantly lower than those in the Chow group (claudin1, 0.55 ˘ 0.18 vs. 1.00 ˘ 0.22,
p < 0.01; occludin, 0.36 ˘ 0.11 vs. 1.00 ˘ 0.23, p < 0.01; ZO-1, 0.24 ˘ 0.15 vs. 1.00 ˘ 0.40, p < 0.05).
Supplementation of pectin significantly improved the level of claudin1 but only caused a tendency
of increase in the levels of occludin and ZO-1 as compared with the high fat diet alone (claudin1,
0.76 ˘ 0.14 vs. 0.55 ˘ 0.18, p < 0.05; occludin, 0.57 ˘ 0.21 vs. 0.36 ˘ 0.11, p = 0.060; ZO-1, 0.52 ˘ 0.25 vs.
0.24 ˘ 0.15, p = 0.172) (Figure 7).
Figure 7. Cont.
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Figure 7. Expression levels of the tight junction proteins claudin1, occludin, and ZO-1.
(a) Representative Western blots of claudin 1, occludin, and ZO1 with β-actin as a loading control;
Quantitation of: (b) claudin 1; (c) occludin; and (d) ZO1 (** p < 0.01 vs. Chow, * p < 0.05 vs. Chow,
# p < 0.05 vs. HF, one way ANOVA).
3.8. Apple-Derived Pectin Decreased High Fat Diet Induced Metabolic Endotoxemia
High fat diet caused a significant increase in the serum level of LPS as compared with chow
diet (HF 2.83 ˘ 0.42 EU/mL vs. Chow 0.68 ˘ 0.14 EU/mL, p < 0.01) while supplementation of
apple-derived pectin significantly decreased high fat diet induced LPS appearance in the serum (HF-P
2.09 ˘ 0.24 EU/mL vs. HF 2.83 ˘ 0.42 EU/mL, p < 0.01) (Figure 8).
Figure 8. Serum LPS concentration (EU/mL) in Chow, HF, and HF-P groups. (** p < 0.01 vs. Chow,
## p < 0.01 vs. HF, one way ANOVA).
3.9. Apple-Derived Pectin Alleviated High Fat Diet Induced Systemic Inflammation in Rats
The levels of pro-inflammation cytokines (TNFα and IL-6) in the portal serum of rats in the HF
group were higher than those in the Chow group (TNFα: 355.59 ˘ 8.10 EU/mL vs. 283.16 ˘ 7.28
EU/mL, p < 0.01; IL-6: 58.98 ˘ 2.59 EU/mL vs. 44.56 ˘ 3.67 EU/mL, p < 0.01). Serum TNFα and IL-6 in
the HF-P group were decreased compared with those in the HF group (TNFα: 316.13 ˘ 7.62 EU/mL vs.
355.59 ˘ 8.10 EU/mL, p < 0.01; IL-6: 51.78 ˘ 2.35 EU/mL vs. 58.98 ˘ 2.59 EU/mL, p < 0.01) (Figure 9).
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Figure 9. Portal serum levels of (a) TNFα and (b) IL-6 in Chow, HF, and HF-P groups (** p < 0.01 vs.
Chow, ## p < 0.01 vs. HF, one way ANOVA).
4. Discussion
In this study, we found that rats fed with a high fat diet exhibited obvious increases of body
weight and adipose tissue, disturbance of gut microbiota, gut barrier dysfunction, systemic chronic
inflammation, and metabolic endotoxemia. However, these changes could be restored to normal
levels by dietary supplementation with pectin. To the best of our knowledge, no previous study
has investigated the potential effects of apple-derived pectin on obesity and how apple-derived
pectin could modulate gut microbiota, gut barrier function, metabolic endotoxemia, and systemic
inflammation in diet-induced obese rats.
Many studies have demonstrated that various types of dietary fiber play roles in anti-obesity
and have hypoglycemic and hypolipidemic effects [31–35]. Similarly, we found in this study that
supplementation with apple-derived pectin could significantly suppress weight gain and fat deposition
in HFD fed rats. In addition, dyslipidemia, hyperglycemia, and hyperinsulinism caused by HFD were
also alleviated with pectin supplementation to different extents.
In 2004, Gordon et al. first reported that gut microbiota modulated lipid metabolism, suppressed
activity of genes involved in fat consumption, and improved the activity of genes involved in fat
synthesis, which led to excessive fat synthesis and fat accumulation in mice. They also found that
the presence of gut microbiota was necessary for obesity occurrence, as germ free animals did not get
obese even when fed a HFD [37]. Since then, additional studies have demonstrated that gut microbiota
is an important factor when assessing risk factors associated with obesity and related disorders, such
as dyslipidemia, hyperglycemia, inflammation and diabetes. Thus, modulation of gut microbiota
might be a novel approach to manage body weight and metabolic disorders [35,38–44].
Here, we found that Bacteroidetes phylum, a principal component of gut microbiota, as
well as subordinate Bacteroidia class, Bacteroidales order, Bacteroidaceae family, and Bacteroides
genus, decreased sharply in rats fed with a high fat diet as compared to rats fed a normal diet.
However, Firmicutes phylum, another principal component of gut microbiota, as well as subordinate
Bacilli class, Lactobacillales order, Lactococcus genus and Clostridium ruminantium species, increased
significantly in the HF group. Supplementation with apple-derived pectin in HFD fed rats restored
bacteria levels to normal ranges (Chow group as reference).
Interestingly, Gammaproteobacteria and Deltaproteobacteria, two classes from the Proteobacteria
phylum, presented different alteration trends, where the former increased and the latter decreased
in the HF group as compared to the Chow group. As a result, the total level of Proteobacteria at the
phylum level was similar among the three groups. Nevertheless, both Gammaproteobacteria and
Deltaproteobacteria were restored to normal levels after supplementation with pectin.
Although not unanimously recognized, obesity is generally characterized by an increased ratio of
Firmicutes to Bacteroidetes [45,46]. Similarly, we found here an increased level of Firmicutes and a
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lower level of Bacteroidetes. A previous study showed that some Lactobacillus species were associated
with normal weight (Bifidobacterium animalis (B. animalis)) while others (Lactobacillus reuteri (L. reuteri))
were associated with obesity [47]. In this study, we observed changes in the level of L. reuteri in Bacilli
class, Lactobacillales order and Lactococcus genus, which were restored with pectin supplementation.
In addition, we report here for the first time changes in Clostridium ruminantium species in rats fed
with HFD and attenuation with pectin supplementation. This finding needs to be investigated further
for verification.
In previous studies, the expression of IAP and the activation of TLR4 were increased in the ileal
tissue of obese rats, showing that activation of TLR4 could alter tight junctions and increase intestinal
permeability [48]. IAP is a type of glycoprotein anchored in the apical membrane of intestine by a
glycosyl-phosphatidyl-inositol linkage, which plays an important role in gut barrier function, including
detoxification of bacterial LPS and free nucleotides [49,50], remission of intestinal inflammation [27,51],
and modulation of gut microbiota [52–55]. Intercellular tight junctions play an important role in
the permeability properties of the gut barrier [17,26]. Tight junctions consist of transmembrane
proteins (occludin, claudins, and junctional adhesion molecule (JAM)), junctional complex proteins
(such as ZO-1, zonula occludens-2 (ZO-2), Symplekin, and cingulin), and actin cytoskeleton [56].
Transmembrane proteins act as a mediator in adhesion, gut barrier formation, selective paracellular
diffusion, interaction with junctional complex proteins, and actin cytoskeleton, which is significant for
the regulation of the permeability of gut barrier [26].
In this study, we observed that increased expression of TLR4 mRNA in the ileum tissue of HFD
fed rats was blunted upon pectin supplementation (Figure 5). We also observed that expression of
IAP as well as the tight junction proteins claudin 1, occludin, and ZO-1 were significantly reduced in
comparison with the chow group (Figure 4). Notably, supplementation with pectin restored claudin 1
and IAP to normal levels, and caused a tendency of increase in the levels of occludin and ZO-1. One
possible explanation for this ineffectiveness of pectin to restore occludin and ZO-1 is that the duration
of HFD was too long so that the damage was irreversible. Taken together, our data suggest that
apple-derived pectin improves gut barrier function and maintains the integrity of intestine.
In previous studies, inulin-type fructan and wheat-derived arabinoxylan oligosaccharides were
shown to modulate gut microbiota in cecal content and increase integrated gut barrier function,
leading to improvements in metabolic endotoxemia and inflammation [9,35,57]. In the present study,
we observed that the level of endotoxin in the portal serum was significantly reduced with pectin
supplementation (Figure 3). In addition, we observed that two pro-inflammatory factors, namely TNFα
and IL-6, were downregulated in the portal serum upon pectin supplementation. The HFD-induced
increase in TNFα and IL-6 mRNA in the ileal tissue was also blunted with pectin. Meanwhile, pectin
upregulated the mRNA expression of the anti-inflammatory factor IL-10 in the ileal tissue of obese
rats, increasing the anti-inflammatory effect. In accordance with a decrease in metabolic endotoxemia,
we propose that the lower inflammatory tone observed upon pectin supplementation was due to
modulation of inflammatory factors.
It is well known that inflammatory cytokines TNFα and IL-6 could cause insulin resistance [58–60].
Consist with the effects on TNFα and IL-6, pectin supplementation could mildly alleviate insulin
resistance in HFD fed rats as evidenced by changes in serum total cholesterol, triglycerides, glucose
and insulin (p < 0.01 for total cholesterol, however, only a trend for triglycerides, glucose, and insulin).
These findings are consistent with other studies that showed consumption of different kinds of dietary
fiber, such as fractionated yellow pea fiber, oligofructose, and grape skin extract could lower blood
glucose levels in human subjects and rodents [33,34,61–63].
It is known that insulin functions to promote fat synthesis, transfer glucose into cells, and promote
glycogen synthesis. In a state of hyperinsulinism and glycemia, more fat deposition occurs, leading to
obesity. In accordance with our hypothesis, the increases in body weight and fat pad weight in the HF
group were blunted with pectin supplementation.
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This study demonstrated a complex link between obesity and gut microbiota, gut barrier,
inflammation, and metabolic endotoxemia. The sequence of events could possibly occur as follows:
modulation of gut microbiota, expression of IAP and TLR4, intestinal inflammation, altered gut barrier
function (especially tight junction), change in serum LPS concentration, and, finally, increases in weight
gain and development of adipose tissue (see Figure 10).
Figure 10. (a) Proposed model by which HFD leads to weight gain and adipose development. HFD
leads to disturbance of gut microbiota, possibly by decreasing IAP expression and increasing TLR4
expression, which may result in metabolic endotoxemia and intestinal and systemic inflammation.
Intestinal inflammation results in altered gut barrier function and promotes penetration of LPS from the
lumen to the lamina propria. The precise mechanism by which metabolic endotoxemia leads to weight
gain and adipose tissue development is not clear; (b) Proposed model by which supplementation
of apple-derived pectin suppresses weight gain and adipose development. Pectin supplementation
maintains gut microbiota, promoting recovery of IAP and TLR4 levels, which may alleviate metabolic
endotoxemia and intestinal and systemic inflammation. Thus, gut barrier function is protected and
penetration of LPS from the lumen to the lamina propria is suppressed. These events lead to suppression
of weight gain and adipose development.
However, there are some limitations associated with our study, which warrants precautions in
interpretation of the data. For instance, gut microbiota are different in human and rats, and our
conclusion in rats may not be readily translatable into human. Given our positive results in rats, it
is worthwhile to carry out clinical trials to properly address whether apple-derived pectin also has
such beneficial effects in human. Moreover, since we did not transplant the possible “obesity-causing”
microbiota to sterile rats for further verification, we could not establish causality between gut
microbiota and obesity development. We also realize the potential limitation of our method for
measurement of serum LPS. This method determines the bio-reactivity of LPS rather than its absolute
quantity. Although the bio-reactivity of LPS in different groups of rats correlated with the changes in
gut barrier function, we cannot rule out the possibility that changes in gut microbiota might directly
cause the differences in the bio-reactivity of LPS in serum. Nevertheless, apple-derived pectin could
alleviate HFD-induced metabolic endotoxemia.
5. Conclusions
In conclusion, this study demonstrated that apple-derived pectin could modulate gut microbiota,
as previously shown for inulin-type fructan and wheat-derived arabinoxylan oligosaccharides [35,64].
Concomitantly, pectin supplementation alleviated HFD-induced body weight gain, fat mass
development, dyslipidemia, hyperglycemia, hyperinsulinism, metabolic endotoxemia, and systemic
inflammation in obese rats. In addition, expression of IAP and gut barrier function (tight junctions)
were improved with pectin supplementation. These results indicate that apple-derived pectin might
play a protective role with prebiotic properties in the prevention of obesity and associated metabolic
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and inflammatory disorders. Prospectively, it might become a useful tool for clinical management of
patients with metabolic disorders.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/3/126/s1,
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Abstract: Recent evidence has suggested that the Korean horn beetle (Allomyrina dichotoma) has
anti-hepatofibrotic, anti-neoplastic, and antibiotic effects and is recognized as a traditional medicine.
In our previous works, Allomyrina dichotoma larvae (ADL) inhibited differentiation of adipocytes
both in vitro and in vivo. However, the anorexigenic and endoplasmic reticulum(ER) stress-reducing
effects of ADL in obesity has not been examined. In this study, we investigated the anorexigenic
and ER stress-reducing effects of ADL in the hypothalamus of diet-induced obese (DIO) mice.
Intracerebroventricular (ICV) administration of ethanol extract of ADL (ADE) suggested that an
antagonizing effect on ghrelin-induced feeding behavior through the mTOR and MAPK signaling
pathways. Especially, ADE resulted in strong reduction of ER stress both in vitro and in vivo.
These findings strongly suggest that ADE and its constituent bioactive compounds are available and
valuable to use for treatment of various diseases driven by prolonged ER stress.
Keywords: Allomyrina dichotoma larvae; diet-induced obesity; ER stress; hypothalamus; appetite
1. Introduction
Obesity is widely recognized as the largest and fastest growing public health problem in the
world. Obesity is caused by an imbalance between energy intake and expenditure and results in
major comorbidities, including metabolic syndrome, hypertension, type 2 diabetes, stroke, cancer, and
dyslipidemia [1–3]. Although anti-obesity drugs were heralded as an answer to the obesity problem
in the past, they have demonstrated inconsistency and side effects. Therefore, new treatments for
obesity that are both better tolerated and more efficacious are urgently needed. For decades, bioactive
products have been identified and isolated from a variety of sources such as living organisms and are
widely used in traditional medicine and the food industry [4,5]. Among them, insects have gained
attention as a source of effective bioactive products [6]. Although there is a lack of scientific evidence
regarding the safety and beneficial effects of insects, numerous insect species are used as a traditional
food or medicine in many countries.
Allomyrinal dichotoma (A. dichotoma) is a species of rhinoceros beetle and widely used in traditional
medicine for its anti-diabetic, anti-hepatofibrotic, anti-neoplastic, and anti-obesity effects [4,5,7,8].
The Food and Agriculture Organization of the United Nations (FAO) reported the possibility
of using edible insects in human dietary supplements in the future. Despite growing interest
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in insect-based bioactive products, the biological activities of insect-based products have rarely
been studied. In previous studies, we reported that A. dichotoma larvae (ADL) inhibit in vitro
and in vivo differentiation of adipocytes via downregulation of transcription factors, peroxisome
proliferator-activated receptor-γ (PPARγ), and CCAAT/enhancer binding protein-α (C/EBPα) [7,9].
The hypothalamus plays a central role in the regulation of feeding behavior and energy balance
by controlling appetite regulatory neuropeptides and specific neuronal excitations [10,11]. However,
disruption of these physiological functions of the hypothalamus has been implicated in various
diseases, such as diabetes mellitus, neurodegenerative disease, ischemia, prion disease, and cystic
fibrosis [12,13]. In particular, hypothalamic ER stress has been suggested to cause feeding behavior
disorder and glucose dysregulation for promotion of obesity and diabetes [14–16]. Therefore, sustaining
the functional roles of hypothalamic neurons may be beneficial for hypothalamic regulation of
energy balance.
In the present study, we investigated the appetite regulatory effect of natural products extracted
from A. dichotoma larvae (ADE) on the hypothalamus, a section of the brain responsible for homeostasis,
of high-fat-induced obese mice since there has been no study elucidating the direct effect of ADE on
appetite control in the hypothalamus. We determined food intake, body weight, appetite regulatory
neuropeptides, and ER stress in mice fed high-fat diets with or without ADE. Our results demonstrate
the potential of ADE as a novel treatment option for anorexigenic function in high-fat-induced obese
mice via reduction of ER stress.
2. Materials and Methods
2.1. Reagents and Cells
DMSO was purchased from Sigma-Aldrich (Sigma-Aldrich, St Louis, MO, USA). QGreenTM
2X SybrGreen qPCR Master Mix was purchased from CellSafe (CellSafe, Suwon, Korea). Mouse
hypothalamic GT1-7 cells were maintained in Dulbecco’s modified Eagle’s media (Gibco, Rockville,
MD, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco, Grand Island,
NY, USA), 100 U/mL of penicillin, and 100 μg/mL of streptomycin (Gibco, Grand Island, NY, USA).
2.2. Preparation of Allomyrina Dichotoma Larvae Extract (ADE)
Freeze-dried ADL (fdADL), ground to a powder and sterilized, was provided by World Way
Co. (Yeongi, Korea). fdADL was mixed with ethanol (1 g of fdADL/mL of ethanol) and incubated
at RT for 30 min after ultrasonication (250 J, 10 s, two times). After incubation, the supernatant was
filtered and completely dried using a rotary evaporator. Dried ethanol extract of ADL was dissolved
in 20% DMSO.
2.3. MTT Assay
Cell viability was determined by 3-(4,5-dimet hylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Hypothalamic neuronal GT1-7 cells were seeded in triplicate at a density of 1 ˆ 104
cells per well on a 96-well plate. After treatment, culture media were removed and MTT (0.5 mg/mL)
added, followed by incubation at 37 ˝C for 2 h in a CO2 incubator. After dissolving the insoluble
crystals that formed in DMSO, absorbance was measured at 570 nm using a microplate reader (Anthos
Labtec Instruments, Wals, Austria).
2.4. Mice
Male C57BL/6J mice (7 weeks of age) were obtained from Japan SLC (Hamamatsu, Japan). Mice
were allowed free access to standard chow diet and water for 1 week. To generate diet-induced obesity
(DIO), 8-week-old mice were fed a high-fat diet (HFD, 60% fat, D12492; Research Diets, New Brunswick,
NJ, USA) for 8 weeks. Lean control mice were fed a low-fat diet (LFD, 10% fat, D12450B; Research
Diets) for the same period. The mice were placed in a controlled temperature room (23 ˝C) with a 12-h
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light/12-h dark cycle with free access to food and water. All procedures followed the Principles of
Laboratory Animal Care (NIH, Washington, DC, USA) and were approved by the Institution Animal
Care and Use Committee of College of Medicine, Dongguk University.
2.5. Intracerebro-Ventricular Cannulation and ADE Administration
Mice were implanted with a 26-gauge stainless guide cannular (5 mm bellow pedestal; C315G,
Plastics one, Roanoke, VA, USA) into the third ventricle under stereotaxic control using a stereotaxic
apparatus (coordinates from Bregma: anteroventral, ´1.8 mm; lateral, 0.0 mm; dorsoventral, 5.0 mm)
through a hole created in the skull with a micro driller. The cannula was secured to the skull with
dental cement and capped with a dummy cannular (C315DC, Plastic one) that extended 0.5 mm below
the guide cannular. Animals were weighed daily, and any animal showing signs of illness or weight
loss was removed from the study and euthanized. At 7 days after ICV cannulation, HFD (n = 20)
and LFD (n = 20) mice were divided into two groups. The first group of HFD (n = 10) and LFD mice
(n = 10) was infused with 1 μL of 20% DMSO as a vehicle, whereas the second group of HFD (n = 10)
and LFD (n = 10) mice was infused with 1 μL of ADE (10 mg/mL). All ICV injections were made
using a 33-gauge internal cannular (C315I, Plastic one) that extended 0.5 mm below the guide cannular,
connected by a cannular connector to a 5 μL Hamilton syringe and infused over 5 min. At 12 h after
ADE infusion, hypothalamus were dissected and flash frozen in liquid nitrogen and kept in ´80 ˝C
until further processing.
2.6. Western Blot Analysis
Tissue or cells were lysed in RIPA lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.02%
sodium azide, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, and 1 mM phenylmethylsulfonyl
fluoride). Protein concentrations of cell lysates were measured using a Bio-Rad protein assay kit
(Bio-Rad, Hercules, CA, USA). Equal amounts of protein were separated by 8% or 12% SDS-PAGE
and transferred to PVDF membranes (Bio-rad, Hercules, CA, USA). Membranes were blocked with
5% skim milk and sequentially incubated with primary antibodies (mouse monoclonal anti-CHOP
antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA); rabbit polyclonal anti-phospho-eIF2α
antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA); rabbit polyclonal anti-eIF2α antibody
(1:1000; Cell Signaling Technology, Danvers, MA, USA); mouse monoclonal anti-Ero1L antibody
(1:1000; Abnova, Taipei, Taiwan); mouse monoclonal anti-PDI antibody (1:1000; Enzo Life Sciences,
Inc., Plymouth Meeting, PA, USA); rabbit monoclonal anti-phospho-Stat3 (Tyr705) (1:1000; Cell
Signaling Technology, Danvers, MA, USA); mouse monoclonal anti-Stat3 (1:1000; Cell Signaling
Technology, Danvers, MA, USA); rabbit polyclonal anti-SOCS3 antibody (1:1000; Cell Signaling
Technology, Danvers, MA, USA); α-tubulin antibody (1:2000; Sigma-Aldrich, St Louis, MO, USA),
and HRP-conjugated secondary antibody (1:10,000; anti-mouse and rabbit-IgG antibody; Amersham
Biosceinces, Piscataway, NJ, USA )), followed by detection using an ECL detection kit (Invitrogen,
Waltham, MA, USA).
2.7. Reverse Transcription-PCR
Total RNA was extracted from tissue or cells with an RNeasy Mini Kit (Qiagen, Hilden, Germany),
according to the manufacturer’s instructions. An aliquot of RNA was subjected to 1% agarose gel
electrophoresis to confirm integrity. cDNA was synthetized with M-MLV Reverse Transcriptase
(Promega, Madison, WI, USA) and oligo(dT) primers after DNase I treatment (Invitrogen, Life
Technologies). Real-time PCR was performed using the specific primer set in Table 1. Traditional PCR
amplification was carried out at an annealing temperature of 60 ˝C for 27 cycles using the specific
primer set in Table 1. For analysis of PCR products, 10 μL of each PCR product was electrophoresed
on a 1%–2.5% agarose gel and detected under UV light. Gapdh was used as an internal control.
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Table 1. DNA primers for PCR.














































All data are presented as the means ˘ SDs. Comparisons between two groups were performed
using the Student’s t-test. Comparisons between three or more groups were analyzed using one-way
ANOVA with Dunnett experiments. SPSS version 18.0 K (SPSS Inc., Chicago, IL, USA) was used for
the analysis, and p value differences of < 0.05 were considered statistically significant.
3. Results
3.1. High Fat Diet-Induced Obesity Induces Hypothalamic Endoplasmic Reticulum Stress
To examine whether obesity induces ER stress in hypothalamus, we fed male C57BL/6J mice a
high-fat diet (HFD; 60% kcal from fat) and low-fat diet (LFD; 10% kcal from fat) for 8 weeks (Figure 1A).
Body weight significantly increased in high-fat-diet-induced mice during the study period compared
with low-fat-diet-induced mice (Figure 1B). We then performed quantitative PCR analysis of ER
stress responsive markers, such as spliced X-box binding protein 1 (Xbp-1s), activating transcription
factor 4 (Atf4), c/EBP-homologous protein (Chop), 78 kDa glucose-regulated protein (Grp78), and ER
DnaJ homolog 4 (Erdj4), after mRNA isolation from the hypothalamus of mice fed a high-fat diet or
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low-fat diet for 8 weeks. The expression levels of ER stress responsive markers were dramatically
upregulated in high-fat-diet-induced mice (Figure 1C). Taken together, these results indicate that
the persistence of obesity gradually induces ER stress, followed by activation of the UPR signaling
pathway in the hypothalamus.
3.2. Central Administration of ADE Reduces Food Intake and Body Weight through Regulation of
Appetite-Related Neuropeptides in High Fat Diet-Induced Mice
To examine the possibility that ADE as a natural food supplement can regulate appetite, we
tested cytotoxicity of ADE before central administration using hypothalamic neuronal GT1-7 cells.
The cytotoxicity of ADE was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay after treatment with various concentrations of ADE (0.01–5 mg/mL). As a
result, up to 5 mg/mL of ADE showed no cytotoxic effect on hypothalamic neuronal GT1-7 cells [17].
To determine whether or not central administration of ADE regulates food intake and body weight
in high-fat-diet-induced mice, we administrated a single dose of ADE (1 μL of 10 mg/mL ADE) into
the third ventricle. Administration of ADE significantly reduced food intake and body weight during
24 h compared to the vehicle control, which was evident 2 h after infusion and was consistent after
24 h (Figure 2A,B, Supplementary Figure S1A,B). Next, we evaluated whether or not the anorexigenic
action of ADE is associated with changes in ARC-derived neuropeptides. As shown in Figure 2C,
central administration of ADE decreased the mRNA expression levels of Agrp and Npy, whereas Pomc
expression increased in high-fat-diet-induced mice. However, low-fat-diet-induced mice showed no
changes (Supplementary Figure S1C).
Figure 1. Increased hypothalamic ER stress in mice fed a high-fat diet. (A) Experimental timeline of
the experimental procedure; (B) Time dependence of body weight in low fat and high-fat-diet-induced
mice. At 8 weeks of age, mice fed a high-fat diet showed a 43% increase in body weight compared with
those fed a low-fat diet. The results are means ˘ SDs (n = 10); * p values of < 0.05 indicate significant
difference from low-fat diet-induced mice; (C) mRNA expression levels of ER stress responsive markers
in low fat and high-fat-diet-induced mice. mRNA expression levels of ER stress responsive markers
were dramatically upregulated in high-fat-diet-induced obese mice. The results are means ˘ SDs
(n = 10); * p values of < 0.05 indicate significant difference from low-fat-diet-induced mice. LF, low-fat
diet. HF, high-fat diet.
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Figure 2. Effects of central administration of ADE on food intake and body weight. The average
cumulative food intake (A) and body weight (B) were measured in high-fat-diet-induced mice ICV
administration with ADE (1 μL of 10 mg/mL) or DMSO (1 μL of 20% DMSO) during the experimental
period. The results are means ˘ SDs (n = 10 per group); * p values of < 0.05 indicate significant
difference from administration with DMSO (1 μL of 20% DMSO). (C) Effects of ICV administration of
ADE (1 μL of 10 mg/mL) on hypothalamic mRNA expression levels of neuropeptides. The results are
means ˘ SDs (n = 10 per group); * p values of < 0.05 indicate significant difference from administration
with DMSO (1 μL of 20% DMSO). ADE, ethanol extract of Allomyrina dichotoma larvae. HF, high-fat
diet with DMSO. HFA, high-fat diet with ADE.
3.3. Central Administration of ADE Reduces Hypothalamic Endoplasmic Reticulum Stress
In previous works, under diet-induced obesity (DIO) conditions, orexigenic neuropeptides
(AgRP and NPY) were induced while anorexigenic neuropeptides (α-MSH) were reduced by
hypothalamic ER stress [18–20]. To examine whether or not ADE can regulate hypothalamic ER
stress in high-fat-diet-induced mice, we administrated ADE and vehicle control into the third ventricle
of high fat or low-fat-diet-induced obese mice. Expression levels of ER stress responsive markers
(phosphor-eIF2a and CHOP) and ER chaperone/foldases (Bip, Ero1L, and PDI) were dramatically
reduced in the hypothalamus in high fat diet-induced obese mice (Figure 3A). Furthermore, mRNA
expression levels of ER stress responsive genes (Xbp-1s, Atf4, Chop, Grp78, and Erdj4) were significantly
reduced in ADE-administrated high fat diet-induced obese mice compared with vehicle control
(Figure 3B). However, low-fat-diet-induced mice showed no changes due to lack of ER stress
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(Supplementary Figures S2A,B and S3). These results indicate that ADE can forcefully reduce ER stress
induced by a high-fat diet in the hypothalamus.
Figure 3. Effects of central administration of ADE on ER stress responsive markers and ER
chaperone/foldases expression. (A) Effects of ICV administration of ADE (1 μL of 10 mg/mL) on
hypothalamic ER stress responsive markers and ER chaperone/foldases. The results of densitometric
analysis (lower) are means ˘ SDs (n = 10); * p values of < 0.05 indicate significant difference from
administration with DMSO (1 μL of 20% DMSO); (B) Effects of ICV administration of ADE (1 μL of
10 mg/mL) on hypothalamic mRNA expression levels of hypothalamic ER stress responsive markers.
The results are means ˘ SDs (n = 10 per group); * p values of < 0.05 indicate significant difference from
administration with DMSO (1 μL of 20% DMSO). HF, high-fat diet with DMSO. HFA, high-fat diet
with ADE.
3.4. Central Administration of ADE Regulates Appetite through MAPK and mTOR Signaling
Recent evidence has demonstrated that hypothalamic mammalian target of rapamycin (mTOR), a
highly conserved serine-threonine kinase, signaling plays a role in modulation of feeding behavior by
acting as a cellular sensor of changes in energy balance, nutrients, and growth factors [21,22]. Leptin
and ghrelin seem to be powerful factors in the regulation of food intake and body weight. In the
hypothalamus, activation of leptin or ghrelin receptor initiates different signaling cascades regulating
food intake [23–26]. mTOR and MAPKs (ERK and p38) signaling has been previously associated with
ghrelin [27–31]. For example, central administration of ghrelin has been reported to activate mTOR and
ERK signaling to induce food intake. Therefore, we determined which signaling cascades are linked
to appetite control after central administration of ADE. Firstly, we investigated leptin signaling with
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phospho-Stat3, -JAK2, and SOCS3 antibody. However, phosphorylation or expression of these proteins
was unchanged. Secondly, we determined ghrelin signaling downstream of mTOR (phospho-S6K1
and -S6) and MAPKs (phospho-ERK and -p38) (Figure 4 and Supplementary Figure S4). As shown in
Figure 4, S6K1, S6, and ERK phosphorylation levels were significantly reduced after administration
of ADE compared with vehicle control. However, phosphorylation of p38MAPK was elevated after
ADE administration in mice fed a high-fat diet. These results assume that ADE reduces appetite by
antagonizing ghrelin signaling cascades rather than leptin signaling, and mTOR and MAPK signaling
pathways were necessary for appetite regulation of ADE in the hypothalamus.
Figure 4. Central administration of ADE reduces ghrelin signaling through mTOR and ERK signaling
pathways in mice fed a high-fat diet. (A) Effects of ICV administration of ADE (1 μL of 10 mg/mL)
on mTOR signaling pathways. The results of densitometric analysis (right) are means ˘ SDs (n = 10
per group); * p values of < 0.05 indicate significant difference from administration with DMSO (1 μL
of 20% DMSO); (B) Effects of ICV administration of ADE (1 μL of 10 mg/mL) on MAPK signaling
pathways. The results of densitometric analysis (right) are means ˘ SDs (n = 10); * p values of < 0.05
indicate significant difference from administration with DMSO (1 μL of 20% DMSO). HF, high-fat diet
with DMSO. HFA, high-fat diet with ADE.
4. Discussion
The hypothalamus is considered a key player in the regulation of food intake and body weight,
although hypothalamic dysfunction may occur in a chronic energy excess state [20,32]. Under
obese conditions induced by pharmacologic or genetic causes, endoplasmic reticulum (ER) stress
in the hypothalamus causes central leptin and insulin resistance, resulting in increased food intake,
hypertension, and glucose intolerance, whereas reduction of ER stress significantly attenuates these
metabolic derangements [33,34]. Beetle species, a very well-known insect, is widely used in Oriental
medicine to treat various diseases such as diabetes and hepatofibrosis in Asian countries [8,35]. Insects
can be used as a health food supplement or functional food, as they are rich in protein, vitamins,
minerals, fiber, and unsaturated fatty acids [36–38]. Previous works reported that several kinds of
insect extracts could be used as anti-obesity and liver disease treatment agents [7,9,39].
In this study, we demonstrated the functional effects of ADE on ER stress and appetite
regulatory neuropeptide processing in obesity. In diet-induced obesity (DIO), the appetite
regulatory α-melanocyte-stimulating hormone (α-MSH) is downregulated, whereas appetite-inducing
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neuropeptide Y (NPY) and aqouti-related protein (AgRP) are induced [18–20]. To study the effects
of ADE on appetite control, ADE was injected with ICV, and food intake and body weight changes
were measured (Figure 2A,B). As a result, food intake and body weight were markedly reduced after
ADE administration compared with vehicle control, which was evident 2 h after infusion and was
consistent after 24 h. Furthermore, we quantified the mRNA expression levels of Npy, Agrp, and Pomc
by quantitative PCR. As shown in Figure 2C, Npy and Agrp mRNA expression levels were reduced,
whereas Pomc mRNA level increased after ADE administration. From these results, we assume that
the appetite reducing effect of ADE is mediated by restoration of DIO-induced leptin resistance
accompanied by reduction of ER stress on the hypothalamus. Thus, we investigated expression levels
of ER stress markers and chaperones using Western blot analysis or quantitative PCR. As shown in
Figure 3, ER stress markers and chaperones were dramatically downregulated upon ADE infusion,
whereas leptin resistance was not restored.
Ghrelin expression was elevated upon fasting and reduced upon feeding in normal and genetically
obese rodents [40–42]. Based on these findings, we speculate that reduction of food intake and body
weight by ADE may be due to antagonization of ghrelin function. In previous works, ICV injection
of ghrelin induced orexigenic action by increasing mTOR and ERK signaling pathways [27,28,43,44].
Additionally, ghrelin was shown to inhibit p38 MAPK activation in oligodendrocytes and other types of
cells [30,31]. Therefore, we determined levels of S6K1 and S6 phosphorylation, downstream signaling
cascades of mTOR, and phosphorylation of MAPKs (ERK and p38) (Figure 4). Central administration
of ADE significantly downregulated phosphorylation of S6K1, S6, and ERK as well as upregulation
of p38 MAPK in mice fed a high-fat diet. However, low-fat-diet-induced mice showed no changes
(Supplementary Figure S4). These result indicate that ADE reduces appetite by antagonizing ghrelin
signaling cascades rather than leptin signaling, and mTOR and ERK signaling are necessary for appetite
regulation of ADE in the hypothalamus in mice fed a high-fat diet.
In summary, our most significant finding is that ethanol extract of Allomyrina dichotoma larvae
(ADE) has an anorexigenic effect through regulation of mTOR and MAPK pathways, resulting in
reduced food intake and body weight changes accompanied by reduced ER stress. We speculate
that the anorexigenic effect of ADE is due to antagonization of ghrelin-induced feeding behavior.
Furthermore, ADE showed the strongest reducing effect on ER stress both in vitro and in vivo (Figure 3
and Supplementary Figure S2). Accumulating evidence suggests that chronic activation of ER stress
contributes to the pathogenesis of many diseases, including neurodegenerative diseases, bipolar
disorder, diabetes mellitus, atherosclerosis, inflammation, ischemia, heart diseases, liver and kidney
disease, and cancer [45,46]. As research on ER stress-related diseases has recently increased, these
results strongly suggest that ADE is available and valuable to use for treatment of various diseases
driven by prolonged ER stress. This study demonstrates the anorexigenic and ER stress-reducing
effects of ADE in the central nervous system and provides a strong possibility for the implications of
insect-derived multiple compounds for the therapeutic purposes in patients. However, this study was
limited to the administration of ADE, an anti-obesity drug, via the third ventricle, which grants further
investigation to validate the effects via other routes of administration including oral. Furthermore,
fractionation of ADE is also warranted to examine the proper components of the ADE responsible for
these effects, as well as to provide strong evidence of the anorexigenic and ER stress-reducing effects
of ADE on hypothalamic ER stress-driven metabolic disorders.
5. Conclusions
Intracerebroventricular (ICV) administration of the ADE had an antagonizing effect on
ghrelin-induced feeding behavior through mTOR and MAPK signaling pathways. These findings
strongly suggest that ADE and its constituent bioactive compounds are available and valuable to use
for treatment of various diseases driven by prolonged ER stress
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/2/100/s1:
Figure S1: Effects of central administration of ADE on food intake and body, Figure S2: Effects of ADE on ER
stress responsive marker expression, Figure S3: Effects of central administration of ADE on ER stress responsive
markers and ER chaperone/foldases expression in mice fed a low-fat diet, Figure S4: Central administration of
ADE reduces ghrelin signaling through mTOR and ERK signaling pathways in mice fed a low-fat diet.
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Abstract: Obesity, which is characterized by excessive fat accumulation, is associated with several
pathological disorders, including metabolic diseases. In this study, the anti-obesity effect of
6,8-diprenylgenistein (DPG), a major isoflavonoid of Cudrania tricuspidata fruits was investigated
using high fat-diet (HFD)-induced obese mice at the doses of 10 and 30 mg/kg for six week. The body
weight of the DPG-treated groups was significantly lower compared to the HFD-treated group.
In addition, fat accumulation in epididymal adipose tissue and liver was dramatically decreased
in the HFD + DPG groups. The food efficiency ratios of the HFD + DPG groups were also lower
compared to the HFD group with the same food intake. Metabolic parameters that had increased
in the HFD group were decreased in the HFD + DPG groups. Further studies demonstrate that
DPG efficiently reduces lipogenic genes by regulation of transcription factors, such as peroxisome
proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein α (C/EBPα), and
hormones, such as leptin and adiponection. DPG also regulates acetyl-CoA carboxylase (ACC)
and hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) by AMP-activated protein kinase
(AMPK) activation. Taken together, DPG is beneficial for the regulation of obesity, especially resulting
from high fat intake.
Keywords: 6,8-Diprenylgenistein (DPG); Cudrania tricuspidata; high-fat diet-induced obesity; lipid
profile; AMPK
1. Introduction
The prevalence of obesity has increased continuously and became one of the major threats to global
health due to the association with several pathological disorders, including diabetes, hypertension,
atherosclerosis and cancer [1,2]. In the development of obesity, genetic and environmental factors are
known to play important roles. In particular, a diet high in saturated fats is considered to be one of
main contributors to obesity, particularly in the Western diet. Fat is digested into monoglycerides
and fatty acids by lipase and absorbed fat is accumulated in adipose tissue through excessive
adipocyte differentiation [3]. Adipocyte differentiation is an organized process regulated by various
transcriptional factors depending on differentiation stages. CCAAT/enhancer-binding protein (C/EBP)
β and δ are expressed in early stages of adipocyte differentiation. C/EBPs β and δ regulate the
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expression of peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding
protein α (C/EBPα), the most crucial transcriptional factors in adipogenesis [4]. Obesity is also
closely related to the levels of leptin and adiponectin, adipose specific hormones. Leptin amount is
proportionally correlated with obesity, while adiponection amount is inversely related to obesity [5].
Therefore, inhibition of adipogenesis by the regulation of transcription factors and hormones are one
of the targets of anti-obesity strategies. AMPK is another regulator of cellular energy homeostasis.
Phosphorylation by AMPK inactivates metabolic enzymes, such as acetyl CoA carboxylase (ACC) and
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which results in fatty acid oxidation and
reduced biosynthesis of fatty acid and cholesterol [6,7].
Phytochemicals are defined as the substances found in edible fruits and vegetables. Various
phytochemicals are known to exhibit a potential for human health. In addition, favorable role of
phytochemicals on the prevention and treatment of obesity have been reported. Epigallocatechin
gallate of green tea is well known for its beneficial effect on obesity [8]. Xanthigen, a mixture of
brown seaweed and pomegranate seed extract, showed anti-obesity activity in animal model [9].
Sulforaphane, an isothicyanate of broccoli and alkaloids of lotus leaves, showed beneficial effects on
obesity [10,11].
Fruits are good sources of diverse phytochemicals. Especially, polyphenols, such as flavonoids,
are considered as major functional components of fruit. They possess diverse biological activities (e.g.,
antioxidant, estrogenic, anti-inflammatory and anti-cancer activity [12–14]. As a result, the utility of
this fruit as an ingredient in dietary supplements and functional foods ingredients is being actively
investigated in many fields.
Cudrania tricuspidata, which belongs to the Moraceae family, is a thorny tree cultivated in East
Asia including Korea. The fruits of C. tricuspidata are widely consumed as fresh fruits, jams, and
processed products, such as wine and vinegar. They are known for its diverse biological activities
such as antioxidant, anti-inflammatory and immunomodulatory activity [15–17]. We previously
reported the pancreatic lipase inhibitory activity of C. tricuspidata fruits. 6,8-diprenylgenistein (DPG),
a major isoflavonoid of C. tricuspidata fruits (Figure 1) was suggested as an active constituent [18].
Moreover, the inhibitory activity of DPG on diacylglycerol acyltransferase (DGAT), a key enzyme
in triglyceride synthesis, has been reported [19]. Therefore, further studies have been attempted to
elucidate anti-obesity effect in high fat diet (HFD)-induced animal model and its potential mechanisms,
to verify the anti-obesity activity of DPG.
Figure 1. (a) Structure of 6,8-diprenylgenistein (DPG) from C. tricuspidata fruits; (b) High performance
liquid chromatography (HPLC) chromatogram of the extract of C. tricuspidata fruits.
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2. Experimental Section
2.1. Chemicals
Antibodies against peroxisome proliferator-activated receptor γ (PPARγ) and hydroxy-3-
methylglutaryl coenzyme A reductase (HMGCR) were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, USA). Antibodies against CCAAT/enhancer-binding protein α (C/EBPα),
adiponectin, phospho-AMP-activated protein kinase alpha (p-AMPKα), phospho-AMP-activated
protein kinase β1 (p-AMPKβ), phospho-acetyl-CoA carboxylase (p-ACC), and β-actin were obtained
from Cell Signaling Technology (Beverly, MA, USA). The antibody against leptin was obtained from
GeneTex, Inc. (Irvine, CA, USA).
2.2. Preparation of DPG
DPG, a major isoflavonoid of C. tricuspidata fruits was isolated, as previously reported [18]
(Figure 1a,b). The purity was higher than 95%, as measured HPLC analysis.
2.3. Animal Treatment
Male C57BL/6J mice (n = 60, 4 weeks old, 15% ˘ 10% g) were purchased from Central Lab.
Animal Inc., Seoul, Korea. All mice were housed in a room with controlled temperature (21–23 ˝C),
humidity (55%–60%), and lighting (12-h light/dark cycle) and given water ad libitum. After acclimation
for 1 week, the mice were randomly divided into the following four groups (n = 15/group): ND
(normal diet), HFD, HFD + DPG10 (10 mg DPG/kg mice) and HFD + DPG30 (30 mg DPG/kg mice).
ND group was fed with a normal diet (4.3% fat of diet, 7% of kcal from fat). The HFD, HFD + DPG10
and HFD + DPG30 groups were fed HFD (24% fat including 0.5% cholesterol of diet, 45% of kcal
from fat) (Table S1). DPG samples were prepared in distilled water (DW) at the concentrations of
10 mg/mL or 30 mg/mL. DPG samples were administered orally (10 mL/kg) to HFD + DPG groups,
and DW (10 mL/kg) was administered orally to the ND and HFD groups for 6 weeks. At the end
of experiment, the mice were sacrificed and their blood and organs were collected. The protocol for
this study was approved by the Animal Care and Use Committee of Chungbuk National University
(Approval No. CBNUA-644-13-01).
2.4. Serum Biochemical Parameters
All mice were fasted for 12 h before they were sacrificed. Blood was collected and serum was
obtained by the centrifugation at 3500 g for 10 min at 4 ˝C. The content of triglyceride, total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, alanine
transaminase (ALT) and aspartate transaminase (AST) were determined using Hitachi7080 analyzer.
2.5. Histopathology
Histological photograph of adipose tissue was analyzed based on the paraffin method using
a light microscope. Epididymal adipose tissue was fixed with 10% neutral buffered formalin and
embedded in paraffin block. Six μm sections were cut and mounted on glass slide. Paraffin was
removed with xylen and alcohol. The sections were then stained with hematoxylin and eosin (H&E).
After dehydration by alcohol, the photograph was taken with light microscope. The size of epididymal
adipocyte was calculated by Image analysis system (IPKR-1003, Saramsoft Co., Ltd., Seoul, Korea).
For the detection of lipid deposition in liver, liver section were prepared from frozen liver and stained
with Oil Red O, as previously reported [20].
2.6. Western Blot Analysis
Epididymal adipose tissues were homogenized in lysis buffer containing 50 mM Tris-HCl (pH 7.4),
1% Triton X-100, 0.2% sodium deoxycholate, 0.2% sodium dodecylsulfate, 1 mM phenylmethylsulfonyl
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fluoride, and a protease inhibitor cocktail tablet. The homogenate was centrifuged at 18,300 g for 30 min
at 4 ˝C, and the supernatant was collected. The total protein concentration of each lysate was measured
using bicinchoninic acid (BCA) Protein Assay Reagent. Proteins in the lysates were electrophoretically
separated in 7.5% to 15% SDS polyacrylamide gel and then transferred to polyvinylidene difluoride
membranes. The membranes were blocked in 5% bovine serum albumin overnight at 4 ˝C and
then incubated overnight at 4 ˝C with the following primary antibodies: PPARγ, C/EBPα, leptin,
adiponectin, p-AMPKα, p-AMPKβ, p-ACC, HMGCR, and β-actin. Membranes were next incubated
with horseradish peroxidase-conjugated secondary antibodies overnight at 4 ˝C. Bands were visualized
with enhanced chemiluminescence, and the intensities of the bands were quantified in WCIF Image J
(University Health Network Research, Toronto, ON, Canada) for Windows.
2.7. Statistical Analysis
Values are expressed as the mean ˘ standard error (SE). The evaluation of statistical significance
was determined by Levene’s test followed by one-way ANOVA or Turkey HSD-test with a value of
p < 0.05 considered to be statistically significant.
3. Results
3.1. Effects of DPG on Body Weight and Food Efficiency Ratio
The effect of DPG on obesity was investigated using HFD-induced male C58BL/6J mice. DPG was
administered to HFD-induced obese mice at doses of 10 mg/kg (DPG10) and 30 mg/kg (DPG30),
respectively, for 6 weeks. In our study, the body weights was increased in the HFD group, whereas
the body weight of HFD + DPG10 and HFD + DPG30 groups were significantly lower compared to
HFD groups (Figure 2). On day 42, at the end of the experiment, the body-weight gains of the ND and
HFD group were 3.39 g and 7.81 g, respectively. However, the body weight gains of HFD + DPG10
and HFD + DPG30-treated group were significantly lower compared to the HFD group as 5.25 g and
5.13 g, respectively (Table 1).
The food efficiency ratio (FER) of HFD was much higher compared to that of ND group. The FERs
of the HFD + DPG10 and HFD + DPG30 groups were also significantly lower compared to the HFD
group with no differences in food intake (Table 1).
Figure 2. Effect of DPG10 and DPG30 on body weight in high fat-diet (HFD)-induced obese mice.
Results are expressed as the mean ˘ SE (n = 12–15). # p < 0.05 compared with ND (normal diet) group,
* p < 0.05, ** p < 0.01 compared with HFD group.
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Table 1. Effect of DPG on body weight gain, food intake and FER.
Group Body Weight Gain (g/Mice/6 Weeks) Food Intake (g/Day/Mice) FER 1
ND 3.39 ˘ 0.48 3.49 ˘ 0.03 0.023 ˘ 0.003
HFD 7.81 ˘ 0.98 ## 2.71 ˘ 0.03 ## 0.069 ˘ 0.008 ##
HFD + DPG10 5.25 ˘ 0.65 #,* 2.73 ˘ 0.04 ## 0.046 ˘ 0.005 ##,*
HFD + DPG30 5.13 ˘ 0.50 # * 2.74 ˘ 0.09 ## 0.044 ˘ 0.004 ##,*
DPG: 6,8-Diprenylgenistein; FER: the food efficiency ratio; ND: normal diet; HFD: high fat diet. 1 Food efficiency
ratio was calculated as the body weight gain/food intake. # p < 0.05, ## p < 0.01 compared with ND group,
* p < 0.05 compared with HFD group.
3.2. Effect of DPG on Fat Accumulation
The effect of DPG on fat accumulation was examined. The relative ratio of epididymal fat per
body weight was significantly higher in the HFD group compared to the ND group. The amount of
epididymal fat was significantly lower in the HFD + DPG10 and HFD + DPG30 groups (Figure 3a).
The epididymal adipocyte size in HFD group was markedly enlarged compared to that in ND groups.
However, adipocyte sizes of HFD + DPG10 and HFD + DPG30 groups were significantly smaller than
those of HFD group (Figure 3b). Fat accumulation in liver was increased in HFD group, whereas
decreased in HFD + DPG10 and HFD + DPG30 groups (Figure 4a). In addition, the increase of liver
weight in HFD group was also significantly reduced in HFD + DPG10 and HFD + DPG30 groups
(Figure 4b).
Figure 3. Effect of DPG10 and DPG30 on weight and size of adipocyte tissues in HFD-induced obese
mice. (a) Epididymal adipose tissue; (b) sections of epididymal adipose tissue stained with hematoxylin
and eosin (H&E). ## p < 0.01 compared with ND group, * p < 0.05 compared with HFD group.
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(a) (b)
Figure 4. Effect of DPG10 and DPG30 on fat accumulation in liver and liver weight in HFD-induced
obese mice. (a) Liver sections stained with Oil Red O; (b) liver weight per mouse. # p < 0.05 compared
with ND group, * p < 0.05 compared with HFD group.
3.3. Effect of DPG on Serum Lipid Profiles
Regular high fat and high cholesterol diet leads to the changes in enzyme and lipid profiles.
The HFD caused elevation of the serum levels of ALT and AST which were lower in the HFD + DPG10
and HFD + DPG30 groups. Administration of DPG also significantly reduced the levels of lipid
metabolic parameters including LDL, HDL and total cholesterol, and triglyceride. In particular, the
HFD-induced increase of triglyceride was markedly decreased in the DPG-treated groups (Table 2).
Table 2. Effect of DPG on biochemical parameters of serum in HFD-induced obese mice.
Group ND HFD HFD + DPG10 HFD + DPG30
AST 1 46.54 ˘ 5.55 58.85 ˘ 8.83 53.22 ˘ 5.21 50.48 ˘ 4.02 **
ALT 1 20.13 ˘ 2.85 24.25 ˘ 3.35 21.18 ˘ 2.14 * 20.54 ˘ 2.98 **
Total cholesterol 2 101.95 ˘ 10.46 151.25 ˘ 14.02 135.78 ˘ 13.44 * 130.15 ˘ 15.20 **
HDL cholesterol 2 62.61 ˘ 7.41 83.03 ˘ 6.63 76.19 ˘ 6.75 * 75.75 ˘ 6.87 *
LDL cholesterol 2 4.60 ˘ 0.82 8.17 ˘ 1.31 6.77 ˘ 1.41 * 6.45 ˘ 1.38 *
Triglyceride 2 30.71 ˘ 10.13 50.55 ˘ 13.71 35.19 ˘ 10.65 * 33.72 ˘ 7.48 **
AST: aspartate transaminase; ALT: alanine transaminase. 1 IU/L, 2 mg/dL. * p < 0.05, ** p <0.01 compared with
HFD group.
3.4. Effect of DPG on Adipogenesis in Adipose Tissue
Adipogenesis includes increase in expression transcription factors such as PPARγ and
C/EBPα [4,21]. As shown in Figure 5, the expression of PPARγ and C/EBPα in epididymal adipose
tissue of HFD group was elevated up to 2-fold and 5-fold, respectively, compared to ND group.
DPG markedly suppressed the HFD-induced elevation in the expression of PPARγ and C/EBPα as
comparable to ND group (Figure 5a).
Adipose tissue secretes adipokines such as leptin and adiponectin. HFD cause differential effects
on these adipokines [22,23]. The leptin expression was increased in HFD group, whereas adiponection
expression was decreased in HFD group. DPG reversed the HFD-induced increase in leptin expression
and decrease in adiponection expression (Figure 5b).
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Figure 5. Effect of DPG on the expression of adipogenesis-related proteins in adipose tissue. (a) PPARγ
and C/EBP α; (b) leptin and adiponectin; (c) p-AMPKα, p-AMPKβ, p-ACC, and HMBCR. Values
are expressed as mean ˘ SE. # p < 0.05, ## p < 0.01 compared with ND group, * p < 0.05, ** p < 0.01
compared with HFD group.
3.5. Effect of DPG on AMPK Pathway
AMPK is a heterotrimer consisting of a catalytic subunit (α) and 2 regulatory subunits (β and γ).
AMPK, a regulator of energy homeostasis, plays a major role in lipid metabolism. AMPK activation via
phosphorylation promotes phosphorylation and inactivation of acetyl CoA carboxylase (ACC), which
results in reduced biosynthesis of fatty acids and stimulation of fatty acid oxidation [6,7]. As expected,
phosphorylation of AMPK and ACC was reduced in HFD group and DPG promoted phorphorylation
of AMPK and ACC (Figure 5c).
HMG-CoA reductase (HMGCR) is another key enzyme that control cholesterol synthesis [24].
The expression of HMGCR was increased in epididymal adipose tissue of HFD groups and was lower
in HFD + DPG groups compared to that of HFD controls (Figure 5c).
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4. Discussion
Due to the harmful effect of obesity on human health, investigations for anti-obesity therapeutics
have been actively conducted in many fields. Especially, food and food ingredients are considered as
good targets for anti-obesity agents to prevent obesity and obesity-associated disorders [4,25–28]. In our
previous study, we suggested anti-obesity activity of C. tricuspidata fruits and its major isoflavonoid,
DPG [18]. In this study, we investigated the anti-obesity potential of DPG in HFD-induced obese mice.
Diet-induced obesity in rodents has been used as an animal model to investigate environmental
effect. Rodents fed HFD become obese and show distinctive symptoms such as increase of adipose
tissue, disturbance of lipid metabolism, hyperinsulinemia and fatty liver, which are typically associated
with human obesity [29]. In our present study, HFD-induced obesity was clearly confirmed by many
factors such as increase of body weight, adipocyte size, fat accumulation and liver weight, and
disturbance of lipid metabolism. However, oral administration of DPG, at doses of 10 and 30 mg/kg,
dramatically improved HFD-induced obesity in many parameters.
First, the body weight in HFD + DPG groups were significantly lower than HFD groups (Figure 2).
Food intake was higher in the ND group than in HFD groups, but did not significantly differ among the
HFD, HFD + DPG10 and HFD + DPG30 groups. However, FERs of HFD + DPG10 and HFD + DPG30
groups were significantly reduced compared to HFD group (Table 1). Therefore, decrease of body
weight in HFD + DPG10 and HFD +DPG30 group was achieved partially by decrease of FER not by
loss of appetite. Consistent with FER, DPG inhibits pancreatic lipase, which plays key roles in fat
digestion [18]. Therefore, DPG inhibited fat absorption by pancreatic lipase inhibition without any
effect on appetite, which leaded the reduction of body weight gain.
Increase of fat accumulation and abnormal lipid metabolism were also observed in HFD group,
which was improved in HFD + DPG10 and HFD + DPG30 groups. Especially, the epididymal fat weight
and adipocyte size were greatly increased in HFD groups, which were reduced in HFD + DPG10 and
HFD + DPG30 (Figure 3a,b). HFD-induced increase of the liver weight and fat accumulation in liver
also improved in HFD + DPG10 and HFD + DPG30 groups (Figure 4a,b). Therefore, DPG inhibited
fat accumulation into liver, which resulted in decrease of liver weight. In addition, biochemical
parameters related to lipid metabolism, such as HDL, LDL, total cholesterol and triglyceride were
also recovered in HFD + DPG10 and HFD + DPG30 (Table 2). Taken together, DPG mainly act on
inhibition of fat accumulation, which further resulted in decrease in liver weight and lipid profiles in
blood. Therefore, DPG might be effective in liver dysfunction induced by HFD, which was supported
by the improvement of ALT and AST parameters in HFD + DPG10 and HFD + DPG30 groups.
Excessively absorbed fat is accumulated as adipose tissue through adipocyte differentiation.
Adipogenic differentiation is a well-organized process tightly regulated by sequential activation of
many transcriptional factors. PPARγ and C/EBPα play pivotal roles in adipogenesis by regulating
gene expression for fat accumulation [30,31]. Adipogenesis is also regulated by leptin and adiponection,
specific hormones secreted from adipose tissue [32,33]. Leptin amount is proportionally correlated
with obesity, while adiponection amount is inversely related to obesity [29]. DPG effectively reduced
the expression of PPARγ and C/EBPα, which were increased by HFD (Figure 5a). In addition, DPG
significantly reduced leptin expression increased by HFD and restored the adiponection expression
reduced by HFD (Figure 5b). Therefore, DPG efficiently reduced lipogenic genes by regulation of
transcription factors and hormones, eventually leading to the suppression of lipogenesis.
To better understand the signal pathway for lipogenesis, effect of DPG on AMPK signaling was
investigated. AMPK acts as an energy sensor and maintain energy homeostasis [34]. AMPK regulates
fatty acid oxidation and cholesterol synthesis via ACC and HMGCR, thus has become an attractive
therapeutic target in the treatment of metabolic disorders including obesity [35]. Consistent with
reduced parameters of fat in epididymal, liver and serum, the levels of phosphorylation of AMPKs
and ACC were higher in HFD + DPG group compared to those of HFD group. DPG also reduced
expression of HMGCR (Figure 5c). In addition, DPG is a pancreatic lipase inhibitor [18]. Taken together,
it is persuasive that DPG inhibited fat absorption by the inhibition of pancreatic lipase, and reduced
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lipogenesis via AMPK activation and followed by fatty acid oxidation and inhibition of cholesterol
synthesis, which might contribute the improvement of metabolic parameters and eventually leading
to the anti-obesity effect in vivo.
DPG is 6,8-diprenylgenistein, which means that the chemical structure of DPG is similar to
genistein except for two additional prenyl moieties. Genestein, is also reported to be efficient for
metabolic diseases including obesity [36]. However, DPG showed stronger inhibition on pancreatic
lipase than genistein in our assay system [18], which suggested the importance of prenyl moieties of
DPG. HPLC analysis showed the high content of DPG in C. tricuspidata fruits (Figure 1b). The extract
of C. tricuspidata fruits contains as much as 5.4% of DPG when extracted with 70% ethanol [18].
Our present study shows that administration of 10 mg/kg is sufficient for maximum efficacy of DPG in
HFD-induced obesity. Therefore, daily intake of 10–15 g C. tricuspidata fruits corresponds to 10 mg/kg
DPG for man, which will be beneficial in regulation of obesity. In addition, C. tricuspidata fruits also
contain diverse isoflavonoids including DPG and genistein [16,18]. Therefore, we suggest that DPG
and C. tricuspidata fruits might be beneficial for the regulation of obesity, especially obesity resulting
from high fat intake.
5. Conclusions
DPG, a major isoflavonoid of C. tricuspidata fruits improved many parameters of HFD-induced
obesity. In particular, DPG significantly reduced epididymal fat and the serum triglyceride content,
which had increased due to the HFD. Administration of DPG also improved liver dysfunction as
suggested by reduced fat accumulation and the levels of ALT and AST increased by HFD. Further
study suggests that DPG efficiently reduces lipogenic genes by regulation of transcription factors and
hormones, and regulates ACC and HMGCR by AMPK activation. Taken together, DPG are beneficial
for the regulation of obesity, especially obesity resulting from high fat intake.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/7/12/
5544/s1, Table S1: Composition of experimental diets.
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Abstract: The physical and biochemical changes resulting from moderately low magnesium (Mg)
intake are not fully understood. Obesity and associated co-morbidities affect Mg metabolism and
may exacerbate Mg deficiency and physiological effects. Male rats selectively bred for diet-induced
obesity (OP, obese-prone) or resistance (OR, obese-resistant) were fed a high-fat, high-energy diet
containing moderately low (LMg, 0.116 ˘ 0.001 g/kg) or normal (NMg, 0.516 ˘ 0.007 g/kg) Mg for
13 weeks. The growth, body composition, mineral homeostasis, bone development, and glucose
metabolism of the rats were examined. OP and OR rats showed differences (p < 0.05) in many physical
and biochemical measures regardless of diet. OP and OR rats fed the LMg diet had decreased body
weight, lean body mass, decreased femoral size (width, weight, and volume), and serum Mg and
potassium concentrations compared to rats fed the NMg diet. The LMg diet increased serum
calcium (Ca) concentration in both rat strains with a concomitant decrease in serum parathyroid
hormone concentration only in the OR strain. In the femur, Mg concentration was reduced, whereas
concentrations of Ca and sodium were increased in both strains fed the LMg diet. Plasma glucose
and insulin concentrations in an oral glucose tolerance test were similar in rats fed the LMg or NMg
diets. These results show that a moderately low Mg diet impairs the growth of lean body mass and
alters femoral geometry and mineral metabolism in OP and OR rats fed a high-energy diet.
Keywords: bone; diet; glucose; growth; lean body mass; magnesium deficiency; obesity; rat
1. Introduction
Magnesium (Mg) is an essential nutrient and co-factor in hundreds of metabolic reactions in
the body. Mg is required for cell proliferation, cellular energy production, mineral metabolism,
bone development, and glucose homeostasis [1–4]. Nutrition surveys in North America indicate
that Mg consumption is below recommended intakes for a large segment of the population [5,6].
Furthermore, diseases such as type 2 diabetes [7] and use of certain medications [8] can increase
Mg loss and predispose individuals to Mg deficiency. The low Mg intakes in comparison to
current recommendations combined with the high prevalence of factors that can increase Mg
requirements raise concern about widespread Mg deficiency. Biochemical data lend further support.
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Hypomagnesemia (low serum Mg) exists in the general population and the incidence is high in certain
subpopulations [7,9,10].
Despite evidence suggesting Mg deficiency in the general population, the health implications are
unclear. Several factors account for this, including concerns that dietary recommendations for Mg [11]
may be set too high [12] and that much of the evidence relating lower Mg intake or serum Mg with
diseases and health conditions is based on observational studies. In addition, overt symptoms of Mg
deficiency (e.g., hypocalcemia) are rarely observed in the general population and there is uncertainty
regarding the serum Mg concentration needed for optimal health.
Since Mg is required for many enzymatic reactions, Mg deficiency can presumably affect numerous
physiological processes. Some studies have reported changes in body composition with dietary Mg
restriction. In rats, maternal and postnatal feeding of a Mg-deficient diet decreased body weight, lean
body mass, and fat free mass and increased percentage body fat in the offspring [13,14]. In contrast,
body weight, fat mass, and lean mass were similar in rats fed a high-fat diet containing normal or low
Mg beginning after weaning [15].
Studies in rats and mice have shown that dietary Mg restriction impairs bone growth, changes
bone architecture, and increases bone fragility [16–21]. An uncoupling of bone formation and bone
resorption was observed in rats fed a very low Mg diet [22]. Mg-depleted rats showed greater bone
resorption with an increase in the number of tartrate-resistant acid phosphatase-positive osteoclasts
and a decrease in the number of osteoblasts per area of bone surface [22]. With less severe dietary Mg
restriction (diets containing 10%–50% of nutritional requirement), the number of osteoblasts per bone
surface were not affected in the distal femur of rats [16–18,23]. However, rats fed a Mg-deficient diet
containing as high as 50% of nutritional requirement showed a greater number of osteoclasts per bone
surface, reduced bone mineral content, and lower percentage of trabecular bone volume in the distal
femur [16].
The effects of Mg deficiency on parathyroid hormone (PTH) secretion/action and calcium (Ca)
homeostasis may partly account for the observed effects on bone [23]. In humans, severe Mg deficiency
impairs PTH secretion, causing hypocalcemia [24]. In rats, severe Mg deficiency increases serum Ca
and decreases serum PTH [18,20]. With severe dietary Mg restriction, competition between Mg and Ca
for intestinal absorption and reabsorption in the kidney may be diminished in rats, causing a rise in
serum Ca concentration [23]. The observed decrease in serum PTH may be a consequence of the rise in
serum Ca or direct impairment of PTH secretion [23]. Under conditions of milder dietary Mg restriction,
a decrease in serum Ca and an increase in serum PTH have been reported in rats [16]. With less severe
Mg restriction, competition between Mg and Ca may still exist and the small reduction in serum Mg
may affect the Ca-sensing receptor in a similar way as Ca, thus increasing PTH secretion [23]. It is only
when the degree of Mg deficiency becomes more pronounced that PTH secretion is reduced.
There is evidence to suggest that Mg deficiency may contribute to insulin resistance and glucose
intolerance [13]. Maternal and perinatal Mg restriction in rats induced insulin resistance and decreased
insulin response to a glucose challenge [13]. A recent study showed decreased phosphorylation of
proteins involved in the insulin-signaling pathway in rats fed a Mg-deficient, high-fat diet, suggesting
decreased insulin sensitivity, but blood glucose and insulin concentrations did not differ compared to
rats fed a normal Mg diet [15]. In human studies, lower Mg intakes or serum Mg concentrations have
been associated with reduced bone mineral density [25], type 2 diabetes [26–29], and poorer insulin
sensitivity and glucose control [9,30].
At present the physiological effects of moderately low Mg intakes are incompletely understood.
The objective of this study was to examine physical and biochemical changes in rats fed moderately low
Mg in the context of a high-fat, high-energy diet. Effects on body weight, body composition, mineral
metabolism, bone development, and glucose homeostasis were investigated. Given that obesity and
associated co-morbidities (e.g., type 2 diabetes) can affect Mg metabolism, effects were examined in
rat strains selectively bred for susceptibility or resistance to diet-induced obesity. We report that a
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moderate decrease in dietary Mg impairs growth of lean body mass, alters femoral geometry, and
induces changes in serum and bone mineral concentrations in these rat strains.
2. Materials and Methods
2.1. Animal Protocol and Diets
Fifty Crl:OP (CD) (OP, obese-prone) and 50 Crl:OR (CD) (OR, obese-resistant) male rats (Charles
River Canada, St. Constant, QC, Canada) of six weeks of age were used in this study. OP (n = 25/diet
group) and OR (n = 25/diet group) rats were fed high-fat, high-energy diets (Dyets, Inc., Bethlehem, PA,
USA) containing moderately low (LMg, 0.116 ˘ 0.001 g/kg diet) or normal (NMg, 0.516 ˘ 0.007 g/kg
diet) Mg. Compositions and energy densities of the diets are shown in Table S1. Diets were formulated
using the AIN-93G mineral mix [31] without Mg and supplemented with either 0.100 (LMg) or
0.500 (NMg) g of Mg (as Mg oxide) per kg diet. Mg concentrations in the final diets were slightly
higher than expected based on the amount of Mg oxide added. The additional Mg comes from other
diet ingredients. Diets were a modified version of the Research Diets, Inc. D12266B formulation used
previously to induce obesity in rats [32–34]. Diets were pelleted for more accurate measurement of
food consumption.
OP and OR rats were assigned to diet groups based on initial body weight so that mean body
weights in each diet group were similar at the start of the study. Rats were housed individually in
solid-bottom cages held in vented racks. Cages had a wire-grille insert on the bottom and contained a
stainless steel platform and shelter. Rats were put on a 12:12-h light-dark cycle and had free access to
food and demineralized water throughout the study. Food consumption and body weight for each rat
was measured twice a week. Food consumption was determined by measuring food missing from
the feeder. Results for body weight measurements and parameters related to food consumption were
not reported between days 46–64 and 78–81 because some rats were fasted on the selected days of
measurements. The body composition of each rat was measured at the beginning (week 0), middle
(weeks 8 and 9), and end (week 14) of the study using an EchoMRI-4in1™ system (EchoMRI, Houston,
TX, USA).
After 13 weeks of feeding the diets, rats were fasted overnight (~12 h) in metabolic cages for
collection of urine. Rats were then killed by exsanguination under general isoflurane anesthesia. Blood
was collected from the abdominal aorta by syringe and dispensed into a Trace Element Serum tube
(14-816-154, Thermo Fisher Scientific, Ottawa, ON, Canada) for isolation of serum. Hind legs and
adipose depots were extracted and immediately frozen on dry ice and then stored at ´80 ˝C until
analysis. The experimental protocol was approved by the Health Products and Food Branch Animal
Care Committee of Health Canada (Protocol No.: 2014-007).
During the study, five OR rats fed the LMg diet and two OR rats fed the NMg diet died
unexpectedly without symptoms. The number of deaths did not differ (p ě 0.05, Fisher’s exact test)
among diet groups. Serology reports from sentinel rats were negative, suggesting that an infectious
agent was not responsible. Post-mortem examination did not reveal significant lesions suggestive of
infection, toxicity, or lymphoma and the final judgment was sudden death of undetermined cause.
Results from an additional four rats were excluded from the analyses. These rats were euthanized
following unintentional gavage of solution into the lungs during a practice (n = 3) and the experimental
(n = 1) oral glucose tolerance test (OGTT).
2.2. OGTT
During week 13 of the study an OGTT was performed on subgroups (n = 10/group) of OP and
OR rats with the highest and lowest percentage body fat measurements at weeks 8–9 of the study,
respectively. Following an overnight fast (~12 h), a 0.4 g/mL dextrose solution was orally administered
to the rats by gavage (2 g dextrose/kg body weight). Blood samples (~250 μL) were drawn from the
tail vein before dextrose dosing (0 min) and 30, 60, and 120 min after dosing. Blood samples were
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dispensed into BD Microtainer™ tubes with lithium heparin (13-680-62, Thermo Fisher Scientific) for
isolation of plasma. Plasma samples were immediately frozen at ´80 ˝C until analysis.
2.3. Femur Isolation and Physical Measurements
Femurs were isolated from the right leg. Skin and flesh was removed using a scalpel and forceps.
Wet and dry femur weights were measured using a Mettler Toledo AT261 delta range analytical balance
(Mettler Toledo, Mississauga, ON, Canada). Femur length and width were measured using a dial
caliper (Mitutoyo Canada Inc., Toronto, ON, Canada). Femur length corresponds to the distance from
the greater trochanter to the lateral condyle. Femur width was the distance between medial and lateral
surfaces at midshaft. Femur volume was determined using a PYREX™ specific gravity bottle (01-716,
Thermo Fisher Scientific). Femur volume was calculated as the mass of water displaced by the femur
in grams divided by the density of water (0.99997 g/cm3). Femur density was calculated as the wet
weight in grams divided by the volume in cubic centimeters.
2.4. Mineral Analyses
Diets (~1 g samples) and femurs were placed in preweighted quartz beakers and dried overnight
at 100 ˝C in an Isotemp® oven (Thermo Fisher Scientific). Samples were cooled, placed in a desiccator
for 1 h and then weighed to obtain dry weights. Diets and femurs were ashed using a combination
of dry ashing using an Isotemp® Programmable Forced Draft Furnace (Thermo Fisher Scientific)
and wet ashing using concentrated trace metal grade nitric acid (Thermo Fisher Scientific). Ashes
were solubilized in dilute nitric acid. Solubilized ashes and urine samples were analyzed for mineral
concentrations using a 700 Series inductively coupled plasma optical emission spectrometer (Agilent
Technologies Canada Inc., Mississauga, ON, Canada). Operating conditions have been described
previously [35]. Concentrations of minerals were derived from a standard calibration curve prepared
using the CALEDON-88 multi-element standard (Inorganic Ventures, Christiansburg, VA, USA).
Analytical accuracy was verified using National Institute of Standards and Technology traceable
reference material™ (SCP Science, Baie D’Urfé, QC, Canada).
2.5. Assays
Mineral concentrations in serum and urine creatinine were measured using the ABX Pentra
400 chemistry analyzer (HORIBA Instruments Inc., Irvine, CA, USA). Plasma insulin and glucose
were measure using the Rat Ultrasensitive Insulin ELISA (80-INSRTU-E01, Alpco Diagnostics, Salem,
NH, USA) and Glucose Colorimetric Assay Kit (10009582, Cayman Chemical, Ann Arbor, MI, USA),
respectively. Serum PTH and osteocalcin were measured using the Rat BioActive Intact PTH ELISA
Kit (60-2700, Immutopics, Inc., San Clemente, CA, USA) and Osteocalcin Rat Enzyme Immunoassay
Kit (BT-490, Alfa Aesar, Ward Hill, MA, USA), respectively. Urine deoxypyridinoline (DPD) was
determined using the MicroVue™ DPD EIA Kit (8007, Quidel Corporation®, San Diego, CA, USA).
2.6. Statistical Analyses
Results are reported as means ˘ SD. Two-way ANOVA was used for analysis of parameters
measured at a single time point to examine the overall effects of strain and diet. Fisher’s least significant
difference post hoc test was performed for parameters with a significant (p < 0.05) strain ˆ diet
interaction. Mixed-design ANOVA was used for analysis of parameters measured at multiple time
points to determine the effects and interactions of time, strain, and diet. For parameters with a
significant time ˆ strain or time ˆ diet interaction, univariate results are presented for the effect of
strain or diet at each time point, respectively. Homogeneity of variances was assessed using Levene’s
test. Data that showed unequal variances were transformed prior to analysis. Fisher’s exact test was
used to determine differences in proportions. The area under the glucose and insulin curves was
calculated using the trapezoidal rule with the Area below Curves function in SigmaPlot 12.5 (Systat
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Software Inc., Chicago, IL, USA). Statistical analyses were performed using Statistica 7 (StatSoft, Tulsa,
OK, USA). Statistical significance was set at p < 0.05.
3. Results
This study examined the effects of a moderately low Mg diet high in fat and energy on growth,
body composition, energy intake, energy efficiency, mineral homeostasis, bone development, and glucose
metabolism in OP and OR rats. The effect of rat strain and diet on each parameter is presented. Body
weights differed between rat strains and between rats fed the low or normal Mg diets (Figure 1). Body
weights at the start of the study were higher for OR than OP rats. From day 25 to the end of the study, OP
rats were heavier than OR rats and rats fed the low Mg diet were lighter than rats fed the normal Mg diet.
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Strain, F1,85 = 33.7, p < .001
Diet, F1,85 = 5.78, p < .05




















Figure 1. Body weights of rats. Results are presented as means ˘ SD, n = 18–25. Results were analyzed
by mixed-design ANOVA to determine effects and interactions of time, strain, and diet. Time ˆ strain
and time ˆ diet interactions (p < 0.05) were observed and univariate results are shown for effects of
strain (*, p < 0.05; **, p < 0.001) and diet (#, p < 0.05; ##, p < 0.01). ns, p ě 0.05.
Percentage lean body mass was higher, but total lean body mass was lower in OR compared to OP
rats at weeks 8–9 and week 14 (Table 1). Rats fed the low Mg diet had lower total lean body mass at weeks
8–9 and week 14. Percentage body fat, total body fat, and weight of four distinct fat depots were higher in
OP compared to OR rats at week 14 (Table 1). Percentage and total body fat did not differ between rats fed
the low or normal Mg diets. Weight of mesenteric fat was lower in rats fed the low Mg diet.
Energy intakes did not differ between rat strains (Figure 2A). Rats fed the low Mg diet had lower
energy intakes compared to rats fed the normal Mg diet. OP rats had superior energy efficiency
compared to OR rats (Figure 2B). Energy efficiency was similar for rats fed the low or normal Mg
diets. Food consumption did not differ between rat strains, but was lower for rats fed the low Mg diet
(Figure S1). Similarly, Mg intake was comparable between rat strains, but was lower for rats fed the
low Mg diet (Figure S2).
Concentrations of minerals and markers of bone metabolism were examined in the serum (Table 2)
and urine (Table 3) of the rats. Concentrations of minerals and bone markers in serum and urine
differed between rat strains. Serum and urine Mg concentrations were lower in rats fed the low Mg
diet. Serum Ca concentrations were higher and serum potassium (K) concentrations were lower in rats
fed the low Mg diet. The low Mg diet decreased serum PTH concentration only in OR rats (Table 2).
Serum osteocalcin and urine DPD concentrations were similar in rats fed the low or normal Mg diets
(Tables 2 and 3).
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Figure 2. Energy intake and energy efficiency of rats. Results are presented as means ˘ SD, n = 17–25.
Results for energy intake (A); and energy efficiency (B) were analyzed by mixed-design ANOVA to
determine effects and interactions of time, strain, and diet. Univariate results are shown for effects
of strain (*, p < 0.05; **, p < 0.01; ***, p < 0.001) or diet (#, p < 0.05) when a significant (p < 0.05)
time ˆ strain or time ˆ diet interaction was observed, respectively. Energy efficiency = (body weight
gain (g/day)/energy intake (kcal/day)). ns, p ě 0.05.
Femoral mineral concentrations and physical measurements were assessed in the rats. OP and OR
rats showed differences in Mg, K, and sodium (Na) concentrations in femur (Table 4). Concentration
of Mg was lower and concentrations of Ca and Na were higher in femurs of rats fed the low Mg diet.
Measurements for femur width, dry weight, and density were higher, whereas femur length:width
ratio was lower in OP compared to OR rats (Table 5). Measurements for femur width, wet weight,
dry weight, and volume were lower in rats fed the low Mg diet. The low Mg diet increased femur
length:width ratio only in OR rats.
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An OGTT was performed on a subgroup of rats in each group to investigate the effect of the
low Mg diet on glucose homeostasis. Mean percentage body fat for these rats at the end of the study
were 25.9% ˘ 2.5% (OP-LMg), 26.6% ˘ 2.1% (OP-NMg), 16.7% ˘ 1.4% (OR-LMg), and 17.3% ˘ 1.6%
(OR-NMg). At the 30 min time point, plasma glucose concentration was higher in OR rats compared to
OP rats regardless of diet (Figure 3A). Plasma glucose concentrations were similar for OP and OR rats
fed the low or normal Mg diets at each time point (Figure 3A). The area under the glucose curve did
not differ between rat strains or rats fed the low or normal Mg diets (Figure 3C). OP rats had higher
plasma insulin concentrations at each time point compared to OR rats (Figure 3B). Area under the
insulin curve was also greater for OP rats (Figure 3D). Plasma insulin concentrations at each time point
and area under the insulin curve were similar in OP and OR rats fed the low or normal Mg diets.
Figure 3. Plasma glucose and insulin during an oral glucose tolerance test conducted at week 13 of
the study. Plasma glucose and insulin concentrations (A,B) and the respective area under the curve
(AUC) (C,D); Dextrose solution (0.4 g/mL) was orally administered to the rats (2 g dextrose/kg body
weight) after an overnight fast. Blood was collected from the tail vein before dosing (0 min) and 30,
60, and 120 min after dosing. Results are displayed as means ˘ SD, n = 9–10. Results were analyzed
by mixed-design ANOVA to determine the effects and interactions of time, strain, and diet (A,B); For
glucose a significant (p < 0.05) time ˆ strain interaction was observed and univariate results are shown
for effect of strain (*, p < 0.001). AUC results were analyzed by two-way ANOVA (C,D). ns, p ě 0.05.
4. Discussion
This study examined physical and biochemical changes in rats fed a moderately low Mg diet
with the aim of identifying physiological processes sensitive to reduction in Mg intake. Obesity
and associated co-morbidities such as type 2 diabetes affect Mg metabolism [7] and may increase
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vulnerability to Mg deficiency and adverse health outcomes. For this reason effects were investigated
in rats selectively bred for susceptibility or resistance to diet-induced obesity. The high-fat, high-energy
diets used in this study induced differences in adiposity between OP and OR rats validating our
experimental model. OP rats had greater fat mass and percentage body fat at weeks 8–9 and at the end
of the study.
The low Mg diet contained 23% of nutritional requirement for growing rats [31]. This degree of
deficiency may exist in some individuals in the extreme lower percentiles of usual Mg intakes [11]
(pp. 392–393). The low Mg diet depressed Mg status in both rat strains as evidenced by reductions in
Mg concentrations in serum, urine, and femur.
Some evidence suggests that Mg status may affect body composition. In a placebo-controlled,
randomized trial, supplementation of overweight women with 250 mg of Mg daily for eight weeks
resulted in an increase in lean body mass and decrease in fat mass compared to baseline values [36].
In rats, maternal and postnatal Mg restriction caused a decrease in lean body mass and increase in
percentage body fat in the offspring [13,14]. In the present study the low Mg diet decreased body
weight and lean body mass in both rat strains, demonstrating that dietary Mg restriction after weaning
impairs the growth of lean body mass. The low Mg diet did not affect percentage or total fat mass,
indicating a greater effect on growth of lean mass as opposed to accumulation of fat. Energy efficiency
of rats fed the low or normal Mg diets was similar, meaning that rats consumed a similar amount
of energy from food for a similar amount of body weight gain. These results indicate that metabolic
inefficiency was not the cause of the lower body weight and lean mass. The data also do not support a
repartitioning of dietary energy from lean body mass to adipose tissue in rats fed low Mg since fat
mass did not increase. The lower energy intake (and food consumption) observed for rats fed the low
Mg diet is likely explained by the impaired growth and smaller size of the rats. Together, these results
demonstrate that growth of lean body mass is sensitive to decreases in Mg intake and a moderately
low Mg diet does not promote adiposity in rats selectively bred for susceptibility or resistance to
diet-induced obesity.
There is compelling evidence indicating that Mg plays an important role in the control of cell
proliferation [3,4] and protein synthesis [37]. Impaired cell growth and/or downregulation of protein
synthesis may have contributed to the observed decrease in growth of lean body mass of rats fed the
low Mg diet. Effects on the secretion or action of anabolic hormones such as insulin-like growth factor
1 or testosterone could also explain the impaired growth of lean body mass [38,39].
The low Mg diet reduced femur size (width, weight, and volume) in both rat strains and increased
femoral length:width ratio in OR rats. These findings are noteworthy since the physical characteristics
of a bone (shape and size) influence its mechanical strength [40]. Femoral structural geometry has been
shown to adapt to mechanical loading [41], and therefore these femoral changes may be a consequence
of a lesser mechanical load because of the lower body weight of rats fed the low Mg diet. Even though
bone density and markers of bone formation (serum osteocalcin) and resorption (urine DPD:creatinine
ratio) were unaffected by diet, specific effects on processes that influence bone development cannot
be excluded. Bone development in rats is sensitive to reduction in Mg intake [16–19]. A low Mg
diet containing 50% of nutritional requirement decreased the percentage of trabecular bone volume
and bone mineral content of the distal femur in rats [16]. It has been proposed that increased release
of substance P and inflammatory cytokines in response to Mg depletion may contribute to bone
loss [16,17]. The increase in femur Ca and Na concentrations observed in this study for rats fed the
low Mg diet may be a result of the lower amount of Mg incorporated into the bone.
Serum Ca has been shown to increase in rats and mice in response to moderate or severe Mg
deficiency [18,20,21]. Serum Ca increased in both rat strains fed the low Mg diet. In OR rats there
was an associated decrease in serum PTH, which excludes hyperactivity of the parathyroid gland
as the cause. Ca and Mg compete for intestinal absorption and reabsorption in the kidney [42,43].
Increased Ca absorption and/or reabsorption resulting from diminished Mg antagonism may account
for the observed rise in serum Ca. The associated decrease in PTH in OR rats may be explained
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by hypoactivity of the parathyroid gland in response to the rise in serum Ca. This is supported by
experiments in Mg-deficient rats demonstrating increased blood Ca and hypoactivity of the parathyroid
gland determined by histologic and morphometric analyses [20]. OP rats fed the low Mg diet did not
show a reduction in PTH despite a rise in serum Ca. The higher basal serum Ca (and perhaps PTH) in
OR rats may have sensitized the parathyroid gland to an additional rise in serum Ca.
A decrease in serum K concentration was observed for rats fed the low Mg diet. A reduction in
serum K is often associated with Mg deficiency [44]. It has been proposed that Mg deficiency causes K
wasting by increasing renal K excretion [44]. In this study, urine K concentration was not elevated in
rats fed low Mg; however, urine minerals were only measured at the end of the study and thus we
cannot comment on urinary excretion of minerals at earlier time points in the study.
Lower Mg intakes and serum Mg concentrations have been associated with type 2 diabetes [26–29].
A number of mechanisms have been proposed to explain the negative effect of diabetes on Mg status
including increased renal Mg loss from glycosuria [7]. Whether moderately low Mg intakes adversely
affect glucose homeostasis is less clear. In this study, the effects of the low Mg diet on plasma insulin
and glucose concentrations were examined during an OGTT. OP rats with the highest percentage body
fat and OR rats with the lowest percentage body fat were selected to allow for investigation of any
modifying effect of adiposity. Plasma insulin concentrations were higher in OP than OR rats, which
is in agreement with the greater insulin resistance previously described for obese-prone rats [45–47].
Plasma glucose and insulin concentrations were unaffected by diet, indicating that any effects of the
low Mg diet on glucose control and insulin resistance were minor. The results also indicate that the
differences in adiposity and insulin resistance between OP and OR rats did not influence the outcome.
At the 30 min time point, OR rats showed higher plasma glucose compared to OP rats, irrespective
of diet. This may be explained by slower intestinal glucose absorption and reduced entry of glucose
into the bloodstream in OP rats. Delayed and lower glucose absorption has been reported for obese
compared to lean rats [48]. The results of this study differ from the results of an earlier study that
showed greater insulin resistance, impaired glucose tolerance, and lower insulin response to a glucose
challenge in Mg-restricted rats [13]. An important distinction, however, is that rats in that study were
born to dams that were deprived of Mg before conception and during pregnancy.
OP and OR rats showed differences in body composition, femoral physical measurements,
markers of bone metabolism, plasma insulin, and serum and femur mineral concentrations. Despite
these differences, for most parameters examined, an interaction between diet and strain was not
observed, indicating that the low Mg diet had a similar effect in both rat strains. The exceptions were a
decrease in serum PTH concentration and an increase in the femur length:width ratio, which was only
observed in OR rats fed the low Mg diet. These results indicate that the greater adiposity in OP rats
did not exacerbate the physical and biochemical changes induced by the low Mg diet.
The results from this study should be interpreted in the context of the experimental design.
Rats were fed low Mg in the background of a high-fat, high-energy diet and therefore the effects may
not be generalizable to lower fat and energy diets. It should be noted, however, that the low and normal
Mg diets only differed in Mg content and therefore the reported physical and biochemical differences
can be attributed to differences in Mg intake. It should also be mentioned that rats in this study
were selectively bred for susceptibility or resistance to diet-induced obesity. Peculiarities in genetic
makeup may have predisposed these rats to the effects of a low Mg diet. Caution is also warranted
when extending these findings to humans, in particular effects on the Ca–PTH axis. Rats develop
hypercalcemia in response to a moderate Mg deficiency, whereas humans develop hypocalcemia
secondary to hypoparathyroidism and reduced circulating PTH concentration [24,49–51].
5. Conclusions
This study has shown that moderately low Mg intake when consuming a high-fat, high-energy
diet causes prominent physiological changes in both OP and OR rats. The low Mg diet reduced body
weight gain and growth of lean body mass and bone (femur) of the rats. In addition, serum and bone
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mineral concentrations were altered. These results underscore the importance of evaluating these
physiological parameters in future studies exploring the public health risks from low Mg consumption.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/5/253/s1.
Acknowledgments: We thank Dominique Patry for help with the serum mineral and urine creatinine
measurements. We are also grateful to Julie Todd, Cina Aghazadeh Sanaei, Kevin Kittle, Karine Chamberland,
Don Caldwell, Martha Navarro, and Philip Griffin for care of the rats and assistance with the necropsies.
This research was funded by the Bureau of Nutritional Sciences, Health Canada.
Author Contributions: J.B. conceived and designed the experiments; C.L., S.R., H.R., N.A.V., and L.J.P. performed
the experiments; J.B., C.L., S.R., H.R., and E.S. analyzed the data; J.B. wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript, and in the
decision to publish the results.
References
1. Volpe, S.L. Magnesium in disease prevention and overall health. Adv. Nutr. 2013, 4, 378S–383S. [CrossRef]
[PubMed]
2. Elin, R.J. Magnesium: The fifth but forgotten electrolyte. Am. J. Clin. Pathol. 1994, 102, 616–622. [CrossRef]
[PubMed]
3. Wolf, F.I.; Cittadini, A. Magnesium in cell proliferation and differentiation. Front. Biosci. 1999, 4, D607–D617.
[CrossRef] [PubMed]
4. Cittadini, A.; Wolf, F.I.; Bossi, D.; Calviello, G. Magnesium in normal and neoplastic cell proliferation: State
of the art on in vitro data. Magnes. Res. 1991, 4, 23–33. [PubMed]
5. Ford, E.S.; Mokdad, A.H. Dietary magnesium intake in a national sample of US adults. J. Nutr. 2003, 133,
2879–2882. [PubMed]
6. Health Canada. Do Canadian Adults Meet Their Nutrient Requirements through Food Intake Alone?
Available online: http://www.hc-sc.gc.ca/fn-an/surveill/nutrition/commun/art-nutr-adult-eng.php
(accessed on 23 September 2015).
7. Pham, P.C.; Pham, P.M.; Pham, S.V.; Miller, J.M.; Pham, P.T. Hypomagnesemia in patients with type 2
diabetes. Clin. J. Am. Soc. Nephrol. 2007, 2, 366–373. [CrossRef] [PubMed]
8. De Baaij, J.H.; Hoenderop, J.G.; Bindels, R.J. Magnesium in man: Implications for health and disease.
Physiol. Rev. 2015, 95, 1–46. [CrossRef] [PubMed]
9. Bertinato, J.; Xiao, C.W.; Ratnayake, W.M.; Fernandez, L.; Lavergne, C.; Wood, C.; Swist, E. Lower serum
magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and
white Canadian women but not men. Food Nutr. Res. 2015, 59, 25974. [CrossRef] [PubMed]
10. Whang, R.; Hampton, E.M.; Whang, D.D. Magnesium homeostasis and clinical disorders of magnesium
deficiency. Ann. Pharmacother. 1994, 28, 220–226. [PubMed]
11. Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride;
National Academy Press: Washington, DC, USA, 1997; pp. 190–249.
12. Hunt, C.D.; Johnson, L.K. Magnesium requirements: New estimations for men and women by cross-sectional
statistical analyses of metabolic magnesium balance data. Am. J. Clin. Nutr. 2006, 84, 843–852. [PubMed]
13. Venu, L.; Kishore, Y.D.; Raghunath, M. Maternal and perinatal magnesium restriction predisposes rat pups
to insulin resistance and glucose intolerance. J. Nutr. 2005, 135, 1353–1358. [PubMed]
14. Venu, L.; Padmavathi, I.J.; Kishore, Y.D.; Bhanu, N.V.; Rao, K.R.; Sainath, P.B.; Ganeshan, M.; Raghunath, M.
Long-term effects of maternal magnesium restriction on adiposity and insulin resistance in rat pups. Obesity
2008, 16, 1270–1276. [CrossRef] [PubMed]
15. Sales, C.H.; Santos, A.R.; Cintra, D.E.; Colli, C. Magnesium-deficient high-fat diet: Effects on adiposity, lipid
profile and insulin sensitivity in growing rats. Clin. Nutr. 2014, 33, 879–888. [CrossRef] [PubMed]
16. Rude, R.K.; Gruber, H.E.; Norton, H.J.; Wei, L.Y.; Frausto, A.; Kilburn, J. Reduction of dietary magnesium by
only 50% in the rat disrupts bone and mineral metabolism. Osteoporos. Int. 2006, 17, 1022–1032. [CrossRef]
[PubMed]
235
Nutrients 2016, 8, 253
17. Rude, R.K.; Gruber, H.E.; Norton, H.J.; Wei, L.Y.; Frausto, A.; Kilburn, J. Dietary magnesium reduction to 25%
of nutrient requirement disrupts bone and mineral metabolism in the rat. Bone 2005, 37, 211–219. [CrossRef]
[PubMed]
18. Rude, R.K.; Gruber, H.E.; Norton, H.J.; Wei, L.Y.; Frausto, A.; Mills, B.G. Bone loss induced by dietary
magnesium reduction to 10% of the nutrient requirement in rats is associated with increased release of
substance P and tumor necrosis factor-alpha. J. Nutr. 2004, 134, 79–85. [PubMed]
19. Stendig-Lindberg, G.; Koeller, W.; Bauer, A.; Rob, P.M. Experimentally induced prolonged magnesium
deficiency causes osteoporosis in the rat. Eur. J. Intern. Med. 2004, 15, 97–107. [CrossRef] [PubMed]
20. Jones, J.E.; Schwartz, R.; Krook, L. Calcium homeostasis and bone pathology in magnesium deficient rats.
Calcif. Tissue Int. 1980, 31, 231–238. [CrossRef] [PubMed]
21. Rude, R.K.; Gruber, H.E.; Wei, L.Y.; Frausto, A.; Mills, B.G. Magnesium deficiency: Effect on bone and
mineral metabolism in the mouse. Calcif. Tissue Int. 2003, 72, 32–41. [CrossRef] [PubMed]
22. Rude, R.K.; Kirchen, M.E.; Gruber, H.E.; Meyer, M.H.; Luck, J.S.; Crawford, D.L. Magnesium
deficiency-induced osteoporosis in the rat: Uncoupling of bone formation and bone resorption. Magnes. Res.
1999, 12, 257–267. [PubMed]
23. Rude, R.K.; Singer, F.R.; Gruber, H.E. Skeletal and hormonal effects of magnesium deficiency. J. Am. Coll. Nutr.
2009, 28, 131–141. [CrossRef] [PubMed]
24. Rude, R.K.; Oldham, S.B.; Sharp, C.F., Jr.; Singer, F.R. Parathyroid hormone secretion in magnesium deficiency.
J. Clin. Endocrinol. Metab. 1978, 47, 800–806. [CrossRef] [PubMed]
25. Orchard, T.S.; Larson, J.C.; Alghothani, N.; Bout-Tabaku, S.; Cauley, J.A.; Chen, Z.; LaCroix, A.Z.;
Wactawski-Wende, J.; Jackson, R.D. Magnesium intake, bone mineral density, and fractures: Results from the
women’s health initiative observational study. Am. J. Clin. Nutr. 2014, 99, 926–933. [CrossRef] [PubMed]
26. Kao, W.H.; Folsom, A.R.; Nieto, F.J.; Mo, J.P.; Watson, R.L.; Brancati, F.L. Serum and dietary magnesium and
the risk for type 2 diabetes mellitus: The atherosclerosis risk in communities study. Arch. Intern. Med. 1999,
159, 2151–2159. [CrossRef] [PubMed]
27. Larsson, S.C.; Wolk, A. Magnesium intake and risk of type 2 diabetes: A meta-analysis. J. Intern. Med. 2007,
262, 208–214. [CrossRef] [PubMed]
28. Ma, J.; Folsom, A.R.; Melnick, S.L.; Eckfeldt, J.H.; Sharrett, A.R.; Nabulsi, A.A.; Hutchinson, R.G.;
Metcalf, P.A. Associations of serum and dietary magnesium with cardiovascular disease, hypertension,
diabetes, insulin, and carotid arterial wall thickness: The ARIC study. Atherosclerosis risk in communities
study. J. Clin. Epidemiol. 1995, 48, 927–940. [CrossRef]
29. Villegas, R.; Gao, Y.T.; Dai, Q.; Yang, G.; Cai, H.; Li, H.; Zheng, W.; Shu, X.O. Dietary calcium and magnesium
intakes and the risk of type 2 diabetes: The Shanghai women’s health study. Am. J. Clin. Nutr. 2009, 89,
1059–1067. [CrossRef] [PubMed]
30. Cahill, F.; Shahidi, M.; Shea, J.; Wadden, D.; Gulliver, W.; Randell, E.; Vasdev, S.; Sun, G. High dietary
magnesium intake is associated with low insulin resistance in the Newfoundland population. PLoS ONE
2013, 8, e58278. [CrossRef] [PubMed]
31. Reeves, P.G.; Nielsen, F.H.; Fahey, G.C., Jr. AIN-93 purified diets for laboratory rodents: Final report of the
American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet.
J. Nutr. 1993, 123, 1939–1951. [PubMed]
32. Aziz, A.A.; Kenney, L.S.; Goulet, B.; Abdel-Aal, E. Dietary starch type affects body weight and glycemic
control in freely fed but not energy-restricted obese rats. J. Nutr. 2009, 139, 1881–1889. [CrossRef] [PubMed]
33. Boustany, C.M.; Bharadwaj, K.; Daugherty, A.; Brown, D.R.; Randall, D.C.; Cassis, L.A. Activation of the
systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 2004, 287, R943–R949. [CrossRef] [PubMed]
34. Bertinato, J.; Aroche, C.; Plouffe, L.J.; Lee, M.; Murtaza, Z.; Kenney, L.; Lavergne, C.; Aziz, A. Diet-induced
obese rats have higher iron requirements and are more vulnerable to iron deficiency. Eur. J. Nutr. 2014, 53,
885–895. [CrossRef] [PubMed]
35. Bertinato, J.; Lavergne, C.; Vu, N.A.; Plouffe, L.J.; Wood, C.; Griffin, P.; Xiao, C.W. l-Lysine supplementation
does not affect the bioavailability of copper or iron in rats. J. Trace Elem. Med. Biol. 2016. [CrossRef] [PubMed]
36. Moslehi, N.; Vafa, M.; Sarrafzadeh, J.; Rahimi-Foroushani, A. Does magnesium supplementation
improve body composition and muscle strength in middle-aged overweight women? A double-blind,
placebo-controlled, randomized clinical trial. Biol. Trace Elem. Res. 2013, 153, 111–118. [CrossRef] [PubMed]
236
Nutrients 2016, 8, 253
37. Dørup, I.; Clausen, T. Effects of magnesium and zinc deficiencies on growth and protein synthesis in skeletal
muscle and the heart. Br. J. Nutr. 1991, 66, 493–504. [CrossRef] [PubMed]
38. Dørup, I.; Flyvbjerg, A.; Everts, M.E.; Clausen, T. Role of insulin-like growth factor-1 and growth hormone in
growth inhibition induced by magnesium and zinc deficiencies. Br. J. Nutr. 1991, 66, 505–521. [CrossRef]
[PubMed]
39. Maggio, M.; Ceda, G.P.; Lauretani, F.; Cattabiani, C.; Avantaggiato, E.; Morganti, S.; Ablondi, F.; Bandinelli, S.;
Dominguez, L.J.; Barbagallo, M.; et al. Magnesium and anabolic hormones in older men. Int. J. Androl. 2011,
34, e594–e600. [CrossRef] [PubMed]
40. Bouxsein, M.L.; Karasik, D. Bone geometry and skeletal fragility. Curr. Osteoporos. Rep. 2006, 4, 49–56.
[CrossRef] [PubMed]
41. Petit, M.A.; Beck, T.J.; Lin, H.M.; Bentley, C.; Legro, R.S.; Lloyd, T. Femoral bone structural geometry adapts
to mechanical loading and is influenced by sex steroids: The Penn State young women’s health study. Bone
2004, 35, 750–759. [CrossRef] [PubMed]
42. Alcock, N.; Macintyre, I. Inter-relation of calcium and magnesium absorption. Clin. Sci. 1962, 22, 185–193.
[PubMed]
43. Bertinato, J.; Lavergne, C.; Plouffe, L.J.; El Niaj, H.A. Small increases in dietary calcium above normal
requirements exacerbate magnesium deficiency in rats fed a low magnesium diet. Mag. Res. 2014, 27, 35–47.
44. Huang, C.-L.; Kuo, E. Mechanism of hypokalemia in magnesium deficiency. J. Am. Soc. Nephrol. 2007, 18,
2649–2652. [CrossRef] [PubMed]
45. Chang, S.; Graham, B.; Yakubu, F.; Lin, D.; Peters, J.C.; Hill, J.O. Metabolic differences between obesity-prone
and obesity-resistant rats. Am. J. Physiol. 1990, 259, R1103–R1110. [PubMed]
46. Madsen, A.N.; Hansen, G.; Paulsen, S.J.; Lykkegaard, K.; Tang-Christensen, M.; Hansen, H.S.; Levin, B.E.;
Larsen, P.J.; Knudsen, L.B.; Fosgerau, K.; et al. Long-term characterization of the diet-induced obese and
diet-resistant rat model: A polygenetic rat model mimicking the human obesity syndrome. J. Endocrinol.
2010, 206, 287–296. [CrossRef] [PubMed]
47. Paulsen, S.J.; Jelsing, J.; Madsen, A.N.; Hansen, G.; Lykkegaard, K.; Larsen, L.K.; Larsen, P.J.; Levin, B.E.;
Vrang, N. Characterization of beta-cell mass and insulin resistance in diet-induced obese and diet-resistant
rats. Obesity 2010, 18, 266–273. [CrossRef] [PubMed]
48. Garcia-Martinez, C.; Lopez-Soriano, F.J.; Argiles, J.M. Intestinal glucose absorption is lower in obese than in
lean zucker rats. J. Nutr. 1993, 123, 1062–1067. [PubMed]
49. Chiba, T.; Okimura, Y.; Inatome, T.; Inoh, T.; Watanabe, M.; Fujita, T. Hypocalcemic crisis in alcoholic fatty
liver: Transient hypoparathyroidism due to magnesium deficiency. Am. J. Gastroenterol. 1987, 82, 1084–1087.
[PubMed]
50. Mukai, A.; Yamamoto, S.; Matsumura, K. Hypocalcemia secondary to hypomagnesemia in a patient with
Crohn’s disease. Clin. J. Gastroenterol. 2015, 8, 22–25. [CrossRef] [PubMed]
51. Shah, B.R.; Santucci, K.; Finberg, L. Magnesium deficiency as a cause of hypocalcemia in the CHARGE
association. Arch. Pediatr. Adolesc. Med. 1994, 148, 486–489. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access





















St. Alban-Anlage 66  
4052 Basel, Switzerland 
Tel. +41 61 683 77 34 
Fax +41 61 302 89 18 
http://www.mdpi.com 









St. Alban-Anlage 66 
4052 Basel 
Switzerland
Tel: +41 61 683 77 34 
Fax: +41 61 302 89 18
www.mdpi.com ISBN 978-3-03842-323-2
